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Abstract 
Correct regulation of synaptic function is essential for normal brain activity. 
Disrupted synaptic signalling can result in a loss of neuronal contacts and altered 
morphology, leading to deficits in network activity and transmission; features of 
neuropsychiatric disorders. Indeed, defects in neuronal and synapse morphology are 
detected in autism and schizophrenia and thought to contribute to the characteristic 
behavioural abnormalities observed in these conditions. In this thesis the role of two 
neuropsychiatric disease associated proteins, CYFIP1 and Ahi1, in the regulation of 
synaptic function and neuronal morphology were investigated. First, this study 
revealed that CYFIP1 and CYFIP2 were enriched at excitatory synapses. Altering 
CYFIP1 gene dosage to model disease states showed that CYFIP1 affected dendritic 
complexity, spine morphology and spine actin dynamics. Inhibitory synapse integrity 
was also disrupted with increased CYFIP1 or CYFIP2 dosage. Secondly, genetic 
studies revealed a significant association of CYFIP1 with schizophrenia, contributing 
to the evidence that CYFIP1 is a risk locus for this condition. However, CYFIP1 
schizophrenia-associated mutations identified here did not interfere with CYFIP1 
localisation or protein interactions. Novel CYFIP1 knockout (KO) systems were 
characterised to further understand CYFIP1 function. Initial observations revealed 
CYFIP1 KO reduced viability and impaired F-actin levels in fast dividing cells while 
conditional KO of CYFIP1 in adult CA1 neurons disrupted dendritic complexity. 
Lastly, a novel Ahi1/HAP1/KIF5 trafficking complex was identified in brain. However, 
the trafficking of GABAARs, known HAP1/KIF5 cargo, was unaffected by altered Ahi1 
expression. Nevertheless, Ahi1 was localised to synapses and Ahi1 knockdown 
enhanced dendritic complexity. In summary, this thesis provides evidence that 
altered expression or disease associated mutations in CYFIP1 and Ahi1 led to changes 
in synapse integrity and dendritic complexity, both of which may contribute to the 
development of the neurological symptoms observed in autism and schizophrenia.  
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Chapter 1 
Introduction 
1.1 Neurons, synapses and transmission 
Early studies of neuronal anatomy over 200 years ago proposed that the brain was 
not a continuous entity, as previously thought, and was in fact composed of many 
individual neurons capable of communicating with each other. Many years of research 
later and it is now known that the human brain is made up of a complex network of 
an estimated 100 billion neurons. In order for our brains to function in memory 
processing, decision-making and learning these neurons have had to evolve to become 
highly sophisticated signalling units. They are adapted for long-range intracellular 
signalling within the cell and short-range intercellular signalling between neurons. A 
typical neuron consists of a complex architecture of dendrites designed to receive 
signals from neighbouring cells, a cell soma, which contains the nucleus, and an axon, 
which in large mammals can extend up to meters in length to reach its target.  
 
Neurons communicate by generating an electrical signal, known as an action 
potential, which can be propagated along the length of one cell and transmitted to the 
next at specialised sites.  These sites of communication are known as synapses. There 
are two classes of synapses within the central nervous system (CNS), the chemical 
synapse, which is the major type of synapse in the brain, and the electrical synapse. 
In the electrical synapse ion channels, called gap junctions, connect the membranes 
between two neighbouring cells allowing the passing of ions between cells for fast 
bidirectional signalling. In a chemical synapse the signal transmission is directional. 
The electrical impulse from the transmitting cell is converted into a chemical signal 
at axonal presynaptic boutons which then activates the postsynaptic site on the 
dendrites of the receiving cell. Upon reaching the presynapse the electrical action 
potential activates voltage-gated calcium channels, which results in a local rise in 
intracellular Ca2+. This triggers the fusion of chemical neurotransmitter filled vesicles 
with the plasma membrane resulting in the release of neurotransmitter into the 
synaptic cleft. The synaptic cleft is a 20-40nm gap between the pre and postsynapse.  
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Figure 1.1: Excitatory and inhibitory chemical synapses. 
The arrival of an action potential at an axon terminal allows the inﬂux of calcium through 
voltage-dependent calcium channels, which triggers synaptic vesicle fusion with the plasma 
membrane releasing neurotransmitter into the synaptic cleft. The main excitatory 
neurotransmitter is glutamate, which binds to and activates the glutamate ligand-gated ion 
channel receptors such as NMDA and AMPA receptors that are permeable to sodium and 
calcium. The main inhibitory neurotransmitter is GABA, which binds to and activates GABAA 
receptors which are permeable to chloride ions.   
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Neurotransmitter diffuses across the cleft and binds to ionotrophic receptors 
anchored in the membrane of the postsynaptic cell. When stimulated by 
neurotransmitter these receptors allow the flow of ions into the postsynaptic cell, 
which either promote or inhibit the firing of a new action potential.  
 
Early electron microscopy studies discovered key differences in the structure of 
chemical synapses within the vertebrate CNS. Synapses were classified as type 1 
(asymmetric) and type 2 (symmetric) based on the width of their electron dense 
postsynaptic density (PSD) (Gray, 1959). Later, with the identification of synapse type 
specific neurotransmitters combined with immunohistochemistry, the different 
structures were labelled excitatory and inhibitory synapses respectively. In mature 
neurons, excitatory synapses contain ionotropic receptors that are activated by the 
binding of excitatory neurotransmitters such as glutamate. Upon activation the 
receptor channels open allowing the fast influx of positively charged ions, such as 
sodium (Na+) and calcium (Ca2+) ions, into the postsynaptic cell. This lowers the 
membrane potential of the cell making it more excitable and increases the likelihood 
of an action potential firing. In comparison, upon activation of inhibitory synapses, 
mediated predominantly by the neurotransmitter GABA (γ-aminobutyric acid) in the 
CNS, ionotropic GABA type A receptors (GABAARs) open and allow the flow of 
negatively charged chloride (Cl-) ions into the cell. In mature neurons, where 
intracellular chloride is generally low, this increases the membrane potential in the 
postsynaptic cell, leaving it in a hyperpolarised state, decreasing the chances of an 
action potential firing. Conversely, in immature neurons in which GABAergic 
synapses are the ﬁrst functional synapses to be formed, GABA acts as an excitatory 
neurotransmitter eliciting membrane depolarisation. This is because young neurons 
express the Na-K-Cl cotransporter (NKCC1). This enables Cl- ions to accumulate 
intracellularly so that when GABAARs are activated, Cl- ions ﬂow out of the cell and 
cause subsequent membrane depolarisation (Lu et al., 1999; Vardi et al., 2000). It is 
not until later in development (post-natal days 3-12) that GABA elicits inhibitory 
eﬀects due to a switch in the transmembrane Cl- gradient during the maturation of 
the neurons caused by the expression of the K-Cl cotransporter (KCC2) (Ben-Ari, 
2002, 2014). Excitatory and inhibitory synapses act together to modulate neuronal 
communication and any disruption or damage to this signalling system can impact 
detrimentally on normal brain function (Figure 1.1).  
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1.2 The excitatory synapse  
Excitatory synapses bring about the depolarisation of the postsynaptic cell, if the 
appropriate threshold is met, resulting in a new action potential and the transmission 
of a nerve impulse from one neuron to another. This is the fundamental mechanism 
of neuronal connectivity and is essential for normal brain function. The main 
excitatory neurotransmitter within the CNS is glutamate, thus making glutamatergic 
synapses the main excitatory synapse within the brain. Glutamate binds and activates 
the ionotropic NMDA, kainate and AMPA receptors and the metabotropic mGluR 
receptors. NMDA and AMPA receptors have been most intensely studied due to their 
abundance at glutamatergic synapses and their roles in synaptic plasticity. Synaptic 
plasticity is the ability of synapses to strengthen or weaken over time in response to 
increases or decreases in their activity. This strengthening or weakening in synaptic 
transmission effects response to future stimuli and is thought to underlie learning and 
memory.  
1.2.1 Dendritic spines and excitatory synaptic structure 
1.2.1.1 Structure and composition of dendritic spines 
Dendritic spines are actin rich, dynamic, membrane protrusions that decorate the 
shafts of neuronal dendrites. These structures were first described over 100 years ago 
by Ramón y Cajal in his beautiful descriptive drawings of neuronal architecture 
(Ramón y Cajal, 1888; Yuste, 2015). He proposed that dendritic spines could serve as 
the contact sites between neurons. This proposal was later confirmed with the 
emergence of electron microscopy (Gray, 1959). Dendritic spines are now known to 
compartmentalise the excitatory postsynaptic density (PSD) and spatially confine 
biochemical signals for efficient neuronal transmission (Bourne and Harris, 2008; 
Kennedy et al., 2005). The PSD is the term given to the vast collection of proteins that 
make up the post excitatory synapse discussed in more detail below. By electron 
microscopy the PSD appears as an electron dense thickening on spine heads opposed 
to the presynaptic active zone (Gray, 1959; Sheng and Kim, 2011). Packaging of the 
PSD into spines allows ions and signalling molecules to become concentrated 
following synaptic activation for the efficient propagation of neuronal inputs. 
 
During development dendrites produce numerous filopodia, thin actin dependent 
membrane extensions. Many of these filopodia will develop into spines, thought to be  
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Figure 1.2: Spine morphology classification.  
Dendritic spines come in a wide variety of shapes and sizes, with a volume ranging from 0.01 
to 0.8µm3.  On the basis of detailed anatomical studies of fixed brain tissue, dendritic spines 
have been classified by shape as long thin, stubby, mushroom and cup-shaped. Spines begin 
as actin based protrusions called filopodia, then throughout development progress from 
immature long, thin spines to mature mushroom, branched, stubby or cup-shaped spines. 
This maturation process relies on network activity to strengthen the synapse and induce 
mature spine formation. Spine morphology is stabilised by expression of structural proteins 
and actin dynamics. However, the speed in which spine structure can change is calling this 
static view of spine morphology into question. Adapted from (Hering and Sheng, 2001). 
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stabilised by the formation of synapses, while others will retract and form synapses 
on the dendritic shaft.  These shaft synapses may eventually re-emerge on spines or 
may be eliminated during synaptic pruning later in development (Bourne and Harris, 
2008). Due to their actin rich nature, dendritic spines are highly dynamic structures 
and can continuously adapt their morphology, even throughout adulthood (Ebrahimi 
and Okabe, 2014; Sala and Segal, 2014). In particular, their shape varies dramatically 
during development from an immature spine with weak synaptic connections to a    
mature spine with stronger stable connections. During development increased 
sensory inputs will strengthen a synapse and influence progression to a mature spine 
structure (Alvarez and Sabatini, 2007; Fischer et al., 2000). Additionally, recent work 
using 2 photon microscopy and glutamate uncaging has revealed that glutamate alone 
is sufficient to induce de novo spine formation in the mouse cortex (Kwon and 
Sabatini, 2011). Considerable literature addressing spine morphology has risen with 
advancements in imaging techniques, and has resulted in the formation of common 
spine classifications used to describe the different spine morphologies observed 
(Figure 1.2) (Bellot et al., 2014; Bourne and Harris, 2008). However, this static view 
of spine classification is being reconsidered as more recent live imaging studies 
demonstrate in vivo spines can change size and shape within minutes (Sala and Segal, 
2014). Importantly, the correct modulation of these small membrane protrusions is 
critical as defects in spine morphology and regulation are hallmarks of neurological 
disorders (Penzes et al., 2011). 
1.2.1.2 Dendritic spine plasticity 
An essential adaptation of dendritic spines is their ability to undergo structural and 
functional changes in response to synaptic plasticity. One form of synaptic plasticity 
is long-term potentiation (LTP), the persistent, long lasting strengthening of synapses 
in response to recent patterns of high-frequency stimulation. At excitatory 
postsynapses this form of plasticity is characterised by increased spine volume as well 
as alterations in PSD size and increased AMPAR surface expression. Conversely, 
during long-term depression (LTD), the long-lasting weakening of synapses following 
low-frequency stimulation, there is a reduction in spine volume, PSD size and a 
decrease in AMPARs (Kasai et al., 2010; Matsuzaki, 2007; Sala and Segal, 2014; 
Shepherd and Huganir, 2007). Advanced live cell imaging has demonstrated these 
alterations in spine morphology in response to LTP and LTD stimulation protocols 
(Hill and Zito, 2013; Oh et al., 2013; Zito et al., 2009). Enhancing or reducing synaptic 
strength in this way requires numerous cellular processes such as changes in the 
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composition of surface receptors and the PSD (Chater and Goda, 2014; Makino and 
Malinow, 2009; Sheng and Kim, 2011), changes in actin dynamics (Hanley, 2014; 
Hotulainen and Hoogenraad, 2010), altered exocytosis and endocytosis and 
regulation of protein turnover including the redistribution of polyribosomes and 
proteasomes (Bourne and Harris, 2008). Indeed, recycling endosomes, exocytosis 
and endocytosis are critical for the regulation of spine shape as these processes add 
or remove membrane from the spine during activity-dependent growth or shrinkage 
(Park et al., 2006). Blocking the recycling endosome trafficking pathway abolishes 
LTP-induced spine formation (Park et al., 2006). Likewise, local protein translation 
at spines is upregulated during LTP to provide the necessary proteins for PSD 
expansion and spine growth while, proteosomes are redirected to spines to regulate 
protein turnover (Bourne et al., 2007; Kelleher et al., 2004). 
1.2.1.3 The actin cytoskeleton and its regulation 
Regulation of the actin cytoskeleton is fundamental to dendritic spine development 
and plasticity (Bellot et al., 2014; Hotulainen and Hoogenraad, 2010). Actin filaments 
are capable of extending and retracting in a process known as actin treadmilling. This 
process generates forces within the cell necessary for changes in cell morphology, 
membrane curvature and movement of organelles within the cytoplasm (Pollard and 
Cooper, 2009). Dendritic spines undergo all these actin driven processes which is 
reflected in the highly actin-rich nature of spines. 
 
A description of the actin assembly machinery and the main proteins involved will 
therefore be given prior to a discussion of the evidence that actin is vital for dendrite 
spine formation and maintenance. 
 
Actin assembly: The actin structure is highly dynamic and made up of monomeric 
globular (G)-actin that polymerises to form filamentous actin (F-actin). In response 
to appropriate signalling new actin filaments are generated by proteins including the 
actin related protein (Arp2/3) complex and formins (Pollard, 2007). Proteins are 
required for this process because G-actin polymerisation is unfavourable due to the 
incredibly unstable nature of actin oligomers. Filament elongation however, is much 
more stable. During elongation actin monomers bind to filaments at the fast growing 
plus (barbed) end whereas depolymerisation of actin involves the loss of actin 
monomers from the minus (pointed) end of filaments (Lee and Dominguez, 2010). G-
actin binds to ATP and ATP can regulate actin formation. ADP-bound actin 
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dissociates from filaments more rapidly than ATP-bound actin suggesting that ATP 
hydrolysis promotes actin disassembly (Pollard, 1986).  
 
Rho GTPases: Rho GTPases are found in all eukaryotic cells and are best 
documented for their important signalling roles in regulating the actin cytoskeleton, 
which implicate the proteins in many cellular processes such as cell polarity, motility 
and trafficking (Jaffe and Hall, 2005). The family comprises of 20 molecules however, 
the most well described members of the family are RhoA, Rac1 and cdc42. In the 
mammalian system both Rac1 and cdc42 have been shown to induce the formation of 
membrane protrusions known as lamellopodia and filopodia, while RhoA is more 
critical for cellular trafficking (Heasman and Ridley, 2008; Ridley et al., 1992). 
 
Rho family proteins can bind to both GTP and GDP and have intrinsic GTPase activity.  
These proteins are often called molecular switches because in their active GTP-bound 
forms they can activate downstream effector proteins and drive cellular mechanisms. 
The activity of Rho proteins is regulated by two classes of proteins known as the 
guanine exchange factors (GEFs) and the GTPase activating proteins (GAPs). GEFs 
promote the exchange of GDP to GTP by stimulating GDP release and therefore 
regulate the activation of Rho GTPases while GAPs stimulate the intrinsic GTPase 
activity of the proteins leading to hydrolysis of GTP back to GDP and deactivation 
(Jaffe and Hall, 2005).  
 
Rho GTPases bring about changes at the plasma membrane by activating actin 
polymerisation. They are often recruited and consequently locally activated by GEFs 
(Rossman et al., 2005). Indeed, post-translational modifications of the Rho GTPases 
at basic regions within the C-terminus of Rho proteins allow the molecules to directly 
interact with the plasma membrane. An intriguing class of proteins known as the 
guanine-nucleotide dissociation inhibitors (GDIs) can bind to Rho GTPases and are 
capable of masking their interaction with the membrane and downstream effectors 
adding another level of regulation to these critical global regulatory molecules 
(Heasman and Ridley, 2008; Jaffe and Hall, 2005). 
 
Formins: Formins are a major group of actin nucleators known to produce 
unbranched filaments and are present in almost all eukaryotes. These proteins play 
critical roles in many aspects of cell function including, cytokinesis, cell polarity, 
migration and morphogenesis (Breitsprecher and Goode, 2013). The defining feature 
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of all formins is the presence of the C-terminal formin homology domains 1 and 2 
(FH1 and FH2). These domains are capable of binding to actin and are thought to 
bring about nucleation in vivo by capturing and stabilising G-actin monomers 
(Breitsprecher and Goode, 2013). Indeed, FH2 domains are sufficient to trigger 
nucleation of purified actin (Chesarone et al., 2010). During elongation, FH2 domains 
are active as a homodimer and bind processively to the elongating barbed end of actin 
filaments to protect against capping proteins attempting to terminate elongation. The 
FH1 domain is proline rich and recruits profilin-actin complexes. This recruitment 
dramatically accelerates actin elongation; thought to be due to a rise in local G-actin 
concentration. The N-terminus of formins are more variable, functioning mainly to 
direct protein localisation via signalling and protein interactions. It is this sequence 
diversity that primarily leads to the different biochemical and cellular activities of 
individual formins (Campellone and Welch, 2010). 
 
Arp2/3 complex: The Arp2/3 complex initiates the formation of branched daughter 
actin filaments on the side of existing mother filaments. It functions by anchoring the 
pointed end of the daughter filament to the mother filament as the free barbed end 
grows away from the complex (Pollard, 2007). This intrinsically inactive seven 
subunit complex contains two actin related proteins, Arp2 and Arp3 and 5 other 
subunit proteins: ARPC1-5. An actin monomer, as well as an actin regulatory molecule 
known as a nucleation promoting factor (NPF) and actin filaments come together to 
cooperatively activate the Arp2/3 complex.  
 
Nucleation promoting factors (NPFs): These proteins have been identified as 
scaffolding molecules that act upstream of the Arp2/3 complex and bring about its 
activation. NPFs all share a common C-terminus and have been classified into four 
different families based on their different N-terminal domains. The WASP and WAVE 
families are the most described and more recently the WHAMM/JMY and WASH 
families have also been identified (Derivery and Gautreau, 2010; Padrick and Rosen, 
2010; Pollitt and Insall, 2009; Takenawa and Suetsugu, 2007). The common C-
terminal region of NPFs contains a VCA domain that consists of the verprolin-
homology domain (V; also known as the WASP-homology-2-domain (WH2)) the 
cofilin-homology domain (C; also known as the central domain) and the acidic 
domain (A). The V domain binds to the actin monomer while the CA domain interacts 
with Arp2/3 resulting in Arp2/3 complex activation and actin polymerisation. The 
initiation of a new actin branch requires the nucleation of three actin monomers. The 
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Arp2/3 complex provides two actin related molecules, therefore the binding of 
another actin monomer to the V domain mimics the three actin molecules necessary 
for de novo filament formation (Machesky and Insall; Machesky et al., 1999; Pollard, 
2007; Takenawa and Suetsugu, 2007).  
 
The VCA domain alone can activate the Arp2/3 complex however; full-length WASP 
with a partial deletion of an internal basic region has been shown to activate Arp2/3 
with higher efficiency in pure systems (Suetsugu et al., 2001). This demonstrates how 
other regions beyond the VCA domain of NPFs are important in contributing to 
Arp2/3 activation and regulation. Indeed, the N-terminal regions of NPFs either 
contain regulatory domains that are important for the autoinhibition of the VCA 
domain or interact with other proteins and in this way provide inhibition of the VCA 
domain. This tight control of actin nucleation is necessary for normal cellular 
function. One class of proteins known to regulate NPFs are the Rho GTPases. 
 
 WASP: WASP (Wiskott-Aldrich syndrome protein) was originally identified as the 
gene mutated in Wiskott-Aldrich syndrome, an immunodeficiency disease (Derry et 
al., 1994). Later N-WASP was identified to interact with growth factor receptor-bound 
protein 2 (GRB2) and was named neural-WASP due to its enriched expression in 
neuronal tissue but the protein has since been shown to be expressed in other tissue 
types (Miki et al., 1996). WASP and N-WASP are both NPFs and share very similar 
protein structure. Both proteins contain an N-terminal WI domain followed by a basic 
region, a GTPase binding domain (GBD) and a proline-rich domain before the C-
terminal VCA region. Early experiments demonstrated that under resting conditions 
WASP proteins were retained in an autoinhibited state, an intramolecular interaction 
between the N-terminal GBD and C region of the C-terminal VCA domain occluded 
the VCA domain from binding Arp2/3 and initiating actin polymerisation rendering 
the protein inactive.   
 
Cdc42, among other Cdc42 related GTPases, in its GTP-bound form has been shown 
to competitively interact with the GBD, relieving WASP autoinhibition and regulating 
its activity (Derivery and Gautreau, 2010; Padrick and Rosen, 2010; Takenawa and 
Suetsugu, 2007). WASP proteins are also known to be activated by phosphorylation 
or by the binding of SH3 domain containing proteins to their proline rich region (Ho 
et al., 2004; Suetsugu et al., 2002). Additionally, the autoinhibited conformation of 
WASP is reasonably weak and binding of WASP interacting proteins (WIP) proteins 
 
Introduction 
 
 
 25 
to the WI domain of WASP has been shown to intensify its autoinhibition (Martinez-
Quiles et al., 2001). Importantly, most of the mutations associated with WASP are 
found within the WI domain, highlighting the significance of the WIP interactions for 
normal WASP regulation and function. Lastly, phosphinositides have been shown to 
interact with the basic region of WASPs and are thought to target them to the 
membrane to locally regulate actin dynamics. Taken together, the activation of WASP 
proteins and hence Arp2/3 is tightly modulated by various types of signalling 
molecules (Takenawa and Suetsugu, 2007). 
 
WAVE: On the other hand, WASP family Verprolin-homologous proteins (WAVE), 
another large class of NPFs, are structurally distinct from WASP proteins and behave 
differently with regards to their activation and native complex formation. Indeed, 
unlike the WASP family WAVE proteins are constitutively active (Machesky et al., 
1999). WAVE1 was identified from a screen of proteins that shared sequence 
homology with the VCA domain of WASP (Miki et al., 1998). Further screening 
identified the mammalian homologs WAVE2 and WAVE3 (Suetsugu et al., 1999). 
WAVE proteins have a different N-terminal structure to WASP and N-WASP, they 
contain a WAVE homology domain (WHD) and a basic region. The basic region can 
interact with phosphoinosides and is important for the localisation of WAVE proteins 
while the WHD is important for WAVE complex formation. The WAVE complex was 
first identified by purifying WAVE1 from bovine brain lysate (Eden et al., 2002). Four 
other proteins were found in a complex with WAVE1 in a 1:1:1:1:1 stoichiometry. The 
complex was later confirmed by the purification of WAVE2 from HeLa cells (Gautreau 
et al., 2004; Innocenti et al., 2004). Since then, all three WAVE proteins have been 
identified in the same pentameric heterocomplex complex with Nap1, CYFIP1 (also 
known as Sra1 or the closely related CYFIP2/PIR121), Abi (Abelson-interacting 
protein) and HSPC300 (also known as BRICK). The pentameric heterocomplex is 
known as the WAVE regulatory complex (WRC) and like WASP proteins has been 
implicated in many actin regulatory functions due to its ability to activate Arp2/3 and 
promote actin polymerisation. 
 
WAVE Regulatory Complex (WRC): Although the interactions between 
members of the WRC have been known for many years, there has been much debate 
about how the WRC is regulated and the role it plays in activating the Arp2/3 complex. 
WAVE is known to bind to Abi1/2 in a 1:1 protein complex. HSPC300 also interacts 
directly with WAVE. Nap1 and CYFIP1 form a homodimer, which interacts with  
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Figure 1.3: Schematic representation of WAVE regulatory complex 
regulation. 
The WAVE regulatory complex (WRC) consists in five components, CYFIP1 or CYFIP2 (blue), 
NAP1 (green), Abi (purple), HSPC300 (orange) and WAVE (pink). Under steady-state 
conditions CYFIP1 maintains the WRC in an inactive state by binding and occluding the active 
VCA domain of WAVE. Following Rac1 activation, where GDP is exchanged for GTP, active 
GTP-bound Rac1 interacts with CYFIP1 causing a conformational change in the protein which 
relieves its repression of the VCA domain. The VCA domain can then interact with Arp2/3 and 
bring about actin polymerisation and branching. 
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WAVE via a Nap1 Abi interaction (Innocenti et al., 2004). Nap1 can interact with the 
membrane anchor Nck (Kitamura et al., 1996) and CYFIP1 is known for its specific 
binding to activated Rac1 (Kobayashi et al., 1998), both of these interactions are 
thought to contribute to the regulation of the WRC. In addition, the WRC has been 
reported to be activated by phospholipids cooperatively at the membrane and can 
undergo phosphorylation at many sites of which some have been shown to enhance 
signalling activity (Takenawa and Suetsugu, 2007).  
 
It was initially suggested that the WRC maintains WAVE in an inactive state and that 
GTP-Rac1 binding to CYFIP1 could stimulate the dissociation of WAVE and HSPC300 
from the complex resulting in WAVE activation (Eden et al., 2002). However, this was 
followed by the suggestion that Rac1 can bind to the WRC without promoting its 
dissociation and that WAVE was active and could stimulate Arp2/3 within the 
complex with or without Rac1 binding (Innocenti et al., 2004). More recent structural  
experiments and the publication of the 2.3-angstrom WRC crystal structure have 
revealed the true mechanism of WRC regulation (Chen et al., 2010b; Ismail et al., 
2009). CYFIP1 and Nap1 share homologous structures and were described to interact 
extensively and form a pseudo-symetric dimer that provides a platform for binding of  
the trimer consisting of WAVE:Abi:HSPC300. Importantly, the C-terminus of WAVE 
including the VCA domain interacts with CYFIP1; an interaction that is central to the 
regulation of the complex activity. As previously described the V domain is critical for 
actin binding. In the WRC, the helical region of the V domain which would normally 
recruit an actin monomer is buried in the CYFIP1 interface making it inaccessible to 
actin. Furthermore, the C domain, which is necessary for Arp2/3 binding, is also 
masked by its interaction with CYFIP1. When amino acid residues of these 
interactions are mutated, the WRC becomes constitutively active, highlighting that 
these interactions are critical for WRC inhibition. Studies into the affinity of the WRC 
for Rac1 revealed that active Rac1 interacts with the WRC competitively with the VCA 
domain. Therefore, active Rac1 is thought to bind to the WRC via CYFIP1 resulting in 
conformational changes allowing the VCA domain to be accessible to recruit 
monomeric actin and activate Arp2/3 (Figure 1.3) (Chen et al., 2010b; Ismail et al., 
2009). 
1.2.1.4 The actin cytoskeleton and dendritic spines 
Within dendritic spines both F-actin and G-actin have been detected. The actin 
network within the head of the spine is branched whereas in the spine neck the actin 
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forms long tight bundles (Hotulainen and Hoogenraad, 2010). Compared to other 
cellular regions, actin turnover in the spine is extremely high with actin filaments in 
the head being replaced every minute (Honkura et al., 2008; Star et al., 2002). This 
property of spine actin is consistent with the knowledge that spine morphology can 
change in a time scale of seconds to minutes. Indeed, actin polymerisation has been 
shown to be associated with spine enlargement while actin depolymerisation is linked 
with spine shrinkage (Sala and Segal, 2014). Furthermore, synaptic activity has been 
shown to modulate spine head size via actin mechanisms (Star et al., 2002). Evidence 
for a role of actin in spine stability was provided by Allison and colleagues who 
demonstrated that acute depolymerisation of actin filaments with the drug 
latrunculin A resulted in loss of AMPA receptor positive dendritic spines in primary 
hippocampal neurons (Allison et al., 1998). The observations that actin dynamics are 
intimately linked to spine morphology and synapse activity has driven research into 
this field. 
 
More recently, as well as being shown to alter spine shape, changes in spine actin 
dynamics have been shown to contribute to the organisation of the PSD. PSDs 
fluorescently labelled with GFP-tagged PSD-95 have been shown to undergo rapid 
dynamic structural changes driven by actin dynamics both under steady-state 
conditions and in response to synaptic activity (Blanpied et al., 2008). Furthermore, 
super-resolution imaging studies have shown that the PSD is more complex than just 
one protein rich domain. It is in fact made up of smaller subsynaptic domains that 
rearrange during plasticity (MacGillavry et al., 2013; Nair et al., 2013) in response to 
actin redistribution (Kerr and Blanpied, 2012). Indeed, it has been proposed that actin 
filaments contact the PSD at its interior face and perisynaptically (Burette et al., 2012; 
Frost et al., 2010a) and that this contact is critical for structural and functional 
synaptic plasticity (Kerr and Blanpied, 2012). Interestingly, upon closer inspection 
using photoactivation localisation microscopy (PALM), movements of individual 
actin molecules within the spine have been measured. These experiments revealed 
that actin has heterogeneous polymerisation rates within the spine. The molecular 
velocity of the actin varied between different subdomains of the spine head and neck 
demonstrating the diverse functions of actin within the spine (Frost et al., 2010a). 
 
Another role for actin within spines is in the trafficking of AMPARs, particularly 
during synaptic plasticity. Actin is necessary to propel recycling endosomes towards 
the membrane for insertion of receptors during LTP, but is also critical for the 
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generation of membrane curvature during the endocytosis and exocytosis of AMPARs 
following LTD or LTP respectively (Hanley, 2014). Manipulating actin dynamics with 
drugs has demonstrated a role for actin in the AMPA trafficking process. Treatment 
of cultured neurons with the actin stabilising drug jasplakinolide blocked glutamate-
induced AMPAR internalisation (Zhou et al., 2001). Furthermore, both the 
depolymerising drug latrunculin B and phalloidin (another actin-stabilising drug) 
were shown to block LTP (Kim and Lisman, 1999). These finding indicate dynamic F-
actin is necessary for LTP and the stabilisation of AMPARs at synapses while 
depolymerisation of actin is required for AMPAR endocytosis. There are numerous 
actin associated proteins and actin binding proteins (ABPs) that have been implicated 
in the regulation of AMPAR trafficking within the synapse such as RIL, cofilin, PICK1 
and ARC (Hanley, 2014). Many of these molecules interact with the intracellular tail 
of AMPAR subunits and couple them directly or via associated proteins to the actin 
cytoskeleton. Indeed, PICK1 has been shown to interact with the GluA2 subunit and 
regulate actin dynamics through inhibition of Arp2/3 during AMPAR internalisation. 
Upstream of PICK1, the GTPase Arf1 in its active form was shown to limit PICK1-
mediated inhibition of Arp2/3. Loss of Arf1 resulted in increased PICK1 inhibition, 
AMPAR internalisation and spine shrinkage. Interestingly, NMDA-induced LTD 
down-regulated Arf1 activation and GluA2-PICK1 binding (Rocca et al., 2013). Of 
note, others have reported depolymerising actin with drugs has little or no effect on 
the synaptic stability of all, or a subpopulation, of synaptic AMPARs. This suggests 
that instead the role of actin on AMPAR trafficking may be more important at 
extrasynaptic sites (Kerr and Blanpied, 2012; Kim and Lisman, 2001). Additionally, 
conditional knockout of the actin filament disassembly protein n-cofilin in the 
forebrain of postnatal mice reduced the lateral mobility of AMPARs within the 
membrane  extrasynaptically but not at synaptic sites (Rust et al., 2010). 
 
As well as regulating receptor trafficking, ABPs are known to influence dendritic spine 
structure, function and plasticity. The Arp2/3 complex is an ABP that brings about de 
novo actin branch formation by acting as a catalyst to nucleate free G-actin (Pollard, 
2007). Upstream actin regulators such as Rac1, WASP and WAVE, which themselves 
are tightly regulated, control both spatially and temporally the activation of this 
complex. Indeed, altered expression of Rac1 and WAVE impact on spine morphology, 
highlighting how critical these signalling pathways are for the maintenance of 
dendritic spines (Corbetta et al., 2009; Kim et al., 2006). In the context of dendritic 
spines, conditional KO of Arp2/3 in mouse forebrain results in a defect in spine 
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structural plasticity, significant loss of dendritic spines and behavioural abnormalities 
demonstrating the importance for this protein in spine structure and function (Kim 
et al., 2013). Furthermore, inhibition of the Arp2/3 complex by PICK1 is required for 
AMPAR internalisation (Rocca et al., 2008) and a mutant version of PICK1, that 
cannot bind and inhibit Arp2/3, was shown to block CA1 LTD in hippocampal slices 
(Nakamura et al., 2011) indicating how Arp2/3 regulation is critical for synaptic 
plasticity. In addition to Arp2/3, the formin ABPs promote unbranched actin filament 
formation (Breitsprecher and Goode, 2013) and are critical to the establishment of 
filopodia (Mellor, 2010) and hence dendritic spine formation. Furthermore, electron 
microscopy studies demonstrate that the spine neck contains bundles of unbranched 
actin filaments (Landis and Reese, 1983) therefore, formins are thought to have a role 
in spine neck formation and maintenance. Indeed, it has been shown that filopodia 
elongation at both the root and tip is regulated by the small GTPase Rif acting on the 
formin mDia2 during spinogenesis (Hotulainen et al., 2009). 
 
On the other hand, cofilin is a ubiquitous ABP that reorganises actin filaments by 
causing minus end depolymerisation and F-actin severing. This reduces the ratio of F 
to G-actin, therefore increasing F-actin turnover. Cofilin is deactivated by LIM kinase 
mediated phosphorylation and activated by the slingshot phosphatases (SSH1) 
(Sarmiere and Bamburg, 2004). Pontrello et al. demonstrated a role for cofilin in 
synaptic plasticity. They showed upon NMDAR activation, active calcineurin causes 
dephosphorylation of cofilin, active cofilin is then translocated into spines and brings 
about remodelling (Pontrello et al., 2012). Additionally, conditional loss of cofilin in 
neurons results in a greater proportion of F-actin, increased spine density and area 
resulting in altered synaptic plasticity and impaired associative learning (Rust et al., 
2010).  
 
Many other actin regulatory proteins have been shown to be important in spine 
morphology and synaptic receptor trafficking. The Rho GTPases are all fundamental 
regulators of actin dynamics and impact on spine morphology (Negishi and Katoh, 
2005; Newey et al., 2004). Furthermore, Rho GTPase GAPs and GEFs have also been 
implicated in spine structure. Altered expression of the Rac1 GEFs PIX and Kalirin7 
are both associated with defects in spine morphology (Penzes et al., 2001; Zhang, 
2005). Other synaptically localised ABPs such as α-actinin, calponin, profilin, 
neurabin1 and VASP are involved in the building of F-actin (reviewed by (Bellot et al., 
2014)). Additionally, actin capping proteins, which bind plus ends and inhibit F-actin 
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extension, impact spine morphology. Indeed, loss of the capping protein Eps8 results 
in increased filopodia and immature spines as well as impaired synaptic plasticity 
(Menna et al., 2013; Stamatakou et al., 2013). Taken together, these finding have 
illustrated the critical role for ABPs and actin regulatory proteins in spine structural 
and functional maintenance and plasticity. 
1.2.2 The postsynaptic density and glutamate receptors 
The excitatory PSD is a dynamic structure containing hundreds of proteins, many of 
which have been identified to be critical for brain function. The PSD is a 
morphological specialisation of the postsynaptic membrane located largely at the tips 
of dendritic spines. However, certain spines have been described to contain more than 
one synapse and therefore PSD, and in some cases PSDs have also been identified on 
dendritic shafts. Functionally, the PSD spatially localises postsynaptic elements 
directly opposed to the presynaptic active zone. The principal functional components 
of the PSD are the ionotropic glutamate receptors, which are embedded in a vast, 
dense protein network of scaffolding proteins, signalling molecules, cytoskeletal 
elements and membrane proteins. Importantly, this network couples activation of 
glutamate receptors to biochemical signals within the postsynaptic cell (Figure 1.4) 
(Sheng and Kim, 2011).  
 
Research into the PSD began in the 1970s when detergents were used to purify the 
PSD. Changes in conformation and concentration of proteins were correlated with 
learning and memory; evidence for the importance of the plastic PSD in neurological 
function (Davis and Bloom, 1973; Siekevitz, 1985). It was not until the 1990s and the 
emergence of peptide sequencing that the first PSD proteins, CAMKII and PSD95 
were identified and cloned. However, it was much later when these proteins were 
shown to be the most abundant molecules of the PSD (Cheng et al., 2006; Cho et al., 
1992; Peng et al., 2004). Yeast two-hybrid (Y2H) screens were also popular in the 90s 
with researchers using known molecules of the PSD, such as receptor subunits as ‘bait’ 
to identify novel PSD proteins. 
 
More recently, mass spectrometry has allowed further characterisation of novel PSD 
proteins. An estimate for the number of PSD proteins now ranges from a few hundred 
to 2000. False positives can be identified in all these methods, plus rare or loosely 
bound PSD proteins can go undetected indicating the need for caution when 
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interpreting the great number of screens available in this field. Nevertheless, many 
PSD proteins have now been robustly characterised and classified into functional 
categories (Sheng and Kim, 2011). 
1.2.2.1 Glutamate receptors 
The vast majority of excitatory transmission in the CNS is mediated by the ubiquitous 
amino acid glutamate. This neurotransmitter is packed into presynaptic vesicles by 
specialised vesicular transporters (vGLUTs). Following presynaptic stimulation 
glutamate is released and diffuses across the synaptic cleft to activate glutamate 
receptors (GluRs) positioned in the postsynaptic membrane. GluRs are the most 
functionally critical membrane proteins of the PSD consisting of ionotropic (iGluR) 
and metabotropic (mGluR) glutamate receptors.  The fast-acting iGluRs open upon 
ligand binding, resulting in an influx of cations, membrane depolarisation and 
production of a subsequent action potential. mGluRs on the other hand, are G-
protein-coupled receptors and have a slower response to glutamate. In particular, 
goup I mGluRs (mGluR-I) including mGluR1 and 5 are enriched postsynaptically at 
glutamatergic synapses and localise to perisynaptic zones on the periphery of the PSD 
(Luján et al., 1997).  They signal though G-proteins to produce a canonical signalling 
cascade which triggers the mobilisation of Ca2+ and the activation of various 
downstream effector pathways (Bellone and Mameli, 2012). mGluR-I are known to 
modulate NMDAR activity and are often found in close proximity to these receptors 
via scaffolding proteins of the PSD (Tu et al., 1999). Additionally, they are important 
in the regulation of protein translation and can modulate synaptic strength by 
inducing LTP and LTD in various brain regions (Lüscher and Huber, 2010). 
Conversely, mGluR-II are predominantly found presynaptically and have different 
signalling properties. Mammalian iGluRs are encoded by 18 genes and form four 
receptor families: AMPA, NMDA, kainate and delta receptors (AMPARs, NMDAs, 
kainateR and deltaRs). AMPARs and NMDARs typically mediate excitatory post 
synaptic currents and are vital in the production of synaptic plasticity and therefore 
will be discussed in more detail. 
 
Both AMPA and NMDARs are made up of four subunits which form a tetrameric 
complex within the membrane. Four genes encode the AMPAR subunits (GluA1-4) 
while 7 genes are known to encode the NMDAR subunits (GluN1, GluN2A-D, 
GluN3A-B). AMPAR subunits can form homo and heteromers however, the latter are 
more prominent in vivo. Indeed, AMPARs are said to be a product of a dimer of 
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Figure 1.4: Molecular composition of the excitatory postsynaptic density. 
A schematic diagram depicting proteins know to localise or function within the postsynaptic 
density (PSD) contained within a dendritic spine discussed in this introduction. Protein 
interactions indicated by direct contacts or overlaps between the proteins. Adapted from 
(Sheng and Kim, 2011).  
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dimers formed during transit through the secretory pathway (Ayalon and Stern-Bach, 
2001). NMDARs are made up of two GluN1 subunits and either two GluN2 subunits 
or a combination of GluN2 and GluN3 subunits.  
 
AMPA receptors are activated by glutamate alone with one ligand binding to each 
subunit. Two ligand bound subunits is sufficient to allow ion influx through the 
channel and flux is increased as more binding sites are occupied. Interestingly, 
subunits can undergo splicing, post-translational modifications and RNA editing to 
alter the channel properties adding diversity to the receptor properties (Smart and 
Paoletti, 2012). For instance, RNA editing of the GluA2 subunit mRNA results in an 
amino acid change at residue 607 from a neutral glutamine to a positively charged 
arginine within the channel pore (Sommer et al., 1991). This positive charge renders 
the channel impermeable to calcium (Ca2+). AMPAR permeability to cations is 
therefore governed by the GluA2 subunit which is the most abundant subunit in the 
CNS and is required for proper receptor conformation (Sans et al., 2003).  GluA2 is 
commonly found in its edited form hence, the principle ions gated by AMPARs are 
sodium and potassium, distinguishing AMPARs from NMDARs which also permit 
calcium influx. NMDARs have a more complicated activation process. Efficient 
channel opening requires glutamate and the co-agonist glycine or D-serine to interact 
with the GluN2 and GluN1/3 subunits respectively. This has to occur simultaneously 
with membrane depolarisation to relieve the Mg2+ block from within the channel pore 
that exists at resting potential (Smart and Paoletti, 2012). More often than not 
NMDARs and AMPARs are found together within excitatory PSDs. In response to 
glutamate NMDAR activation will occur following AMPAR activation and membrane 
depolarisation. Indeed, synapses only containing NMDARs are considered ‘silent’ 
synapses as they do not response to glutamate due to the Mg2+ block not being 
removed. 
Numerous intracellular proteins within the PSD, such as scaffolding and cytoskeletal 
molecules, can interact with the GluRs via their intracellular regions. These 
interactions have been shown to control the transport and clustering of GluRs as well 
as the recruitment of multiple signalling molecules (Smart and Paoletti, 2012). Both 
AMPARs and NMDARs contain C-terminal PDZ-binding domains which allow 
binding with many core PSD PDZ-containing proteins. For example AMPARs can 
bind GRIP and PICK1 while NMDARs interact with PSD95, SAP102, SAP97, and 
PSD93 (also known as chapsyn110). These scaffold molecules play key roles in the 
structural and functional changes that excitatory synapses experience during 
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development, plasticity, and disease (Elias and Nicoll, 2007; Montgomery et al., 
2004). Interestingly, AMPARs do not directly interact with PSD95, the most 
abundant scaffold within the PSD but bind to it indirectly via the AMPA receptor 
auxiliary subunits (TARPs) (Bats et al., 2007). TARPs are membrane proteins which 
modulate AMPAR activity and are important in the trafficking and stabilisation of the 
receptor. GluR trafficking, mediated by intracellular protein interactions, is thought 
to be one of the major underlying mechanisms of synaptic plasticity. Indeed, rapid 
insertion or removal of AMPARs from the post synaptic membrane resulting in 
synaptic strengthening or weakening correlate with LTP and LTD respectively 
(Shepherd and Huganir, 2007).  
1.2.2.2 Adhesion molecules 
Adhesion molecules are another class of PSD membrane proteins, which function 
mainly by interacting with presynaptic binding partners to align and stabilise the 
synapse. Adhesion molecules form a trans-synaptic link across the cleft allowing 
signals to be propagated from intracellular contacts on one side of the synapse to the 
other. The best described example of a trans-synaptic link is between the presynaptic 
neurexins (Nrxns) and the postsynaptic neuroligins (NLs). Nrxns are a highly diverse 
family of type-I membrane proteins. The human genome has three Nrxn genes each 
of which encodes an α- and β-Nxrn from different promoters. These transcripts can 
also undergo extensive alternative splicing resulting in thousands of Nrxn isoforms 
(Südhof, 2008). Neuroligins (NLs) were first identified as endogenous Nrxn ligands 
and are also type-I membrane proteins. There are 4 known NL proteins in mammals 
each containing a large extracellular domain, a transmembrane region and a short 
intracellular tail, interactions with cytosolic proteins via this tail region are critical for 
synapse formation and stability. Intriguingly, NL1 and NL2 have been shown to be 
synapse specific and are detected at glutamatergic and GABAergic/glycinergic 
synapses respectively. NL1 binds to the excitatory scaffold molecule PSD95 through 
its C-terminal intracellular PDZ domain-binding motif targeting it to excitatory 
synapses (Irie et al., 1997). By contrast, NL3 has been reported to be present at both 
excitatory and inhibitory synapses, while NL4 has been detected to a lesser extent at 
glycinergic synapses (Südhof, 2008). NLs have recently been shown to form 
constitutive dimers, including homomers and heteromers. This finding raises the 
question as to the distinct roles of different NL heteromers (Poulopoulos et al., 2012). 
Other trans-synaptic complexes such as EphB-EphrinB binding and N-cadherin 
homophilic contacts are also found in the PSD (Sheng and Kim, 2011).  
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Different expression patterns of these adhesion molecules, many of which have 
numerous family members and splice forms, are thought to contribute to synapse 
diversity (Shen and Scheiffele, 2010; Sheng and Kim, 2011). It is clear that a large 
number of Nxrn and NL variants are generated from the many genes and complex 
alternative splicing processes. Researchers are now trying to understand the 
importance of such a varied family of proteins. It has been proposed that a 
combinational interaction code generated by these variants may determine synapse 
identity and network connectivity (Krueger et al., 2012). Indeed, different Nrxn3 
splice isoforms deferentially regulate AMPA receptor trafficking, while loss of Nrxn3 
from different brains regions reveal distinct circuit-dependent functions for the 
protein (Aoto et al., 2013, 2015). 
 
Many synaptic adhesion molecules have synaptogenic properties (Craig and Kang, 
2007). Over expression of NL1 in cultured neurons promotes excitatory synapse 
formation, whereas, silencing NL1 reduced synapse number (Chen et al., 2010a; Chih 
et al., 2005). Furthermore, expression of either Nrxn1β or NL1 in heterologous cells 
cocultured with dissociated neurons led to the induction of post and presynapses 
respectively on neighbouring neurons and the formation of hemisynapses (Graf et al., 
2004; Scheiffele et al., 2000). An interesting experiment using microspheres coated 
with antibodies against NL1 or Nrxn1β protein showed that these beads could induce 
clustering of NL1 and hemisynapase formation. This suggests the clustering of NL1 is 
important for its synaptogenic properties and the recruitment of scaffold proteins 
(Barrow et al., 2009). 
1.2.2.3 Scaffold proteins 
Scaffold proteins are characterised by highly conserved, multiple protein-protein 
interacting domains that are important for the facilitation of protein binding and the 
formation of complex protein networks. These proteins can interact with multiple 
binding partners simultaneously to link different components of the PSD. 
 
PSD95: PSD95 is the most abundant and most widely-studied scaffold protein of the 
PSD (Cheng et al., 2006; Peng et al., 2004). The main function of PSD95 and its family 
members (PSD93/Chapsyn110, SAP97 and SAP102) is to bind and tether membrane 
proteins and signalling molecules in the PSD. Like many PSD proteins PSD95 and its 
family proteins contains PDZ binding domains. PDZ domains were named after their 
occurrence in three related scaffold proteins PSD95/Dlg/ZO-1. These domains 
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commonly interact with short peptide motifs often found at the very C-terminus of 
proteins. PSD95 was notably shown to interact with the GluN2 subunit of the NMDAR 
and stabilise these receptors at the surface (Kornau et al., 1995; Roche et al., 2001). 
However, these experiments were mostly carried out using an overexpression system 
in heterologous cells and it is still unclear if the same mechanism occurs in vivo. A 
clearer role for PSD95 is in the coupling of receptor activity with downstream 
signalling molecules. PSD95 can bind to a variety of signalling molecules such as 
Kalirin7, SynGAP and AKAP97 recruiting them to membrane-tethered receptors for 
localised signalling (Kim and Sheng, 2004). Furthermore, PSD95 can interact with 
TARPs to recruit AMPARs to synapses and regulate AMPAR surface trafficking, 
thereby regulating synaptic strength (Bats et al., 2007). Indeed, overexpression of 
PSD95 increases excitatory synaptic transmission while RNAi knockdown of PSD95 
decreases it (El-Husseini et al., 2000; Elias et al., 2006). It has been shown that 
PSD95 is intimately linked with synaptic plasticity too as overexpression of PSD95 
occludes increased AMPAR LTP in slice culture and LTD is impaired in PSD95 mutant 
mice (Ehrlich et al., 2007; Migaud et al., 1998; Stein et al., 2003). PSD95 can also 
interact with adhesion molecules within the synapse such as the neuroligins (Irie et 
al., 1997). Taken together, this diverse molecule acts as a synaptic hub by interacting 
simultaneously with glutamate receptors, signalling proteins and adhesion molecules 
for efficient synaptic function. 
 
Shank, Homer and GKAP: These three proteins form another abundant 
scaffolding complex deep within the PSD. Shank interacts with Homer via its PDZ 
domain while GKAP binds on the one hand to Shank and on the other to PSD95 acting 
as a bridge between this tripartite complex and membrane proteins via PSD95. There 
are three Shank proteins (1-3), which are large with many protein interacting 
partners. Shank proteins have been shown to promote spine growth and synaptic 
transmission (Sala et al., 2001). Furthermore, mutations in Shank proteins have been 
strongly associated with autism spectrum disorders (ASD) and KO mice show 
synaptic and spine defects highlighting the importance of Shank function in the PSD 
(Durand et al., 2012; Peça et al., 2011; Sato et al., 2012). The Homer family of proteins 
(Homer1-3) couple Shanks to group I mGluRs which indirectly creates an interaction 
between NMDARs and mGluRs via Shank, GKAP and PSD-95 (Tu et al., 1999). Homer 
also interact with dynamin3 linking the PSD with endocytic zones, specialised regions 
for endocytosis located proximal to the PSD for plasticity induced receptor trafficking 
(Lu et al., 2007). 
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Other scaffolding components: IRSp53 has been identified in the PSD and 
interacts with both PSD95 and Shank. This molecule acts as a Rac1 effector to regulate 
actin dynamics in spines (Choi et al., 2005; Soltau et al., 2004). AKAP79 binds to 
PSD95 and recruits AKAP associated enzymes to the PSD such as PKA and 
calcineurin. AKAP proteins are thought to bring these kinases and phosphatases 
closer to their specific substrates within the synapse (Bhattacharyya et al., 2009; 
Tavalin et al., 2002). Other scaffolding proteins have been shown to be important in 
the targeted transport of AMPARs within the synapse such as GRIP1 and PICK1 
(Hanley and Henley, 2005; Mao et al., 2010; Setou et al., 2002). These trafficking 
molecules are present throughout the cell and are not selectively enriched in the PSD 
suggesting they function elsewhere within the trafficking pathway as well. 
Cytoplasmic signalling molecules such as kinases (CAMKIIα and β, PKA) and 
phosphatases (calcineurin, PP1) are recruited by scaffold proteins and enriched 
within the PSD for downstream regulation. CAMKIIα interacts with NMDARs and is 
activated by Ca2+ influx when NMDARs are stimulated. Active CAMKIIα brings about 
synaptic AMPAR delivery and is critical for LTP (Sheng and Kim, 2011).  
1.3 The inhibitory synapse 
GABA mediated inhibitory neurotransmission is the main form of inhibition in the 
brain, is critical for maintaining the correct balance between neuronal excitation and 
inhibition and is necessary for normal brain function (Smith and Kittler, 2010). GABA 
neurotransmitter largely acts through GABAARs within the CNS. In addition, to the 
fast action of GABA on ionotropic GABAARs, GABA also activates metabotropic 
GABABRs that alter neuronal activity on a slower scale (Gassmann and Bettler, 2012). 
The inhibitory neurotransmitter glycine acts on a different subset of inhibitory 
synapses, via glycine receptors (GlyRs), which are important for mediating inhibition 
in the spinal cord, brainstem and retina (Betz et al., 1999; Dutertre et al., 2012). 
GABAAR expression, trafficking and function modulate the strength of GABAergic 
synapses, implicating GABAARs in the regulation of virtually all aspects of neuronal 
information processing and brain development. 
1.3.1 GABA and GABAA receptors 
GABAARs are expressed ubiquitously throughout the whole CNS. They are 
heteropentameric GABA-gated chloride channels that belong to the Cys-loop ligand 
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gated ion channel family and respond to the neurotransmitter GABA. GABA was first 
identified in 1950 (Awapara et al., 1950; Roberts and Frankel, 1950). This 
identification lead to a large body of research suggesting GABA was acting as an 
inhibitory neurotransmitter (Bloom and Iversen, 1971). This data accumulated in the 
discovery that GABA localised to inhibitory nerve terminals in the brain. GABA is 
derived from glutamate by two glutamic acid decarboxylase isoforms found 
presynaptically, GAD65 and GAD67 (Erlander et al., 1991) and is loaded into synaptic 
vesicles by the vesicular GABA transporter (vGAT).  
 
There are 19 GABAAR subunits, which have been classed into 8 different groups based 
on sequence homology (α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3). Each individual subunit 
consists of an N-terminal extracellular region, four transmembrane (TM) domains 
and a large cytoplasmic loop between TM3 and TM4. This loop is the site of most 
intracellular interactions between the subunit and cytosolic proteins important in 
signalling and trafficking. GABAARs with different subunit compositions give rise to 
different receptor subtypes that are structurally and functionally distinct (Luscher et 
al., 2011a; Möhler, 2006). Recently, the first 3D X-ray structure for the GABAAR was 
described using a human β3 homopentamer. The structure revealed architectural 
elements unique to eukaryotic Cys-loop receptors and is vital for a complete 
understanding of the GABAAR and of the consequences of human disease mutations 
(Miller and Aricescu, 2014). 
 
The most common subtypes that are found enriched in at least one area of the brain 
are made up of 2α and 2β subunits as well as a single γ2 or δ subunit. Other subunit 
combinations exist leading to less common subtypes with more limited distribution 
within the brain (Olsen and Sieghart, 2008). The major GABAAR subtypes that 
localise to the synapse are made up of two α1, α2 or α3 subunits, together with two β2 
or β3 subunits and one γ2 subunit. Indeed, the γ2 subunit is essential for the 
postsynaptic clustering of these subtypes (Essrich et al., 1998). Within the synapse γ2 
subunit-containing receptors characteristically have a lower affinity for GABA than 
extrasynaptic receptors and hence respond selectively to high levels of GABA released 
into the synaptic cleft during inhibitory synaptic transmission resulting in transient 
rapidly-desensitising postsynaptic responses (Perrais and Ropert, 1999).  
 
GABAARs also exist extrasynaptically and are known to be important in mediating 
tonic inhibition. This persistent form of GABAergic conductance is thought to shape 
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neuronal excitability and synaptic plasticity (Brickley and Mody, 2012). The most 
common nonsynaptic GABAAR subtypes consist of α4βδ in the forebrain and α6βδ in 
the cerebellum while α1βδ is important for tonic inhibition in the hippocampus. The 
δ-containing receptor subtypes have a high affinity for GABA allowing activation even 
in the presence of ambient GABA concentrations, often the result of residual GABA 
overspill from the synapse (Lee and Maguire, 2014; Luscher et al., 2011a). The 
necessity of δ-containing receptors for normal regulation of neuronal circuits is 
highlighted by the fact that changes in expression patterns and levels of δ-subunit 
containing receptors are associated with neurological disease phenotypes (Whissell et 
al., 2014). Interestingly, GABAARs made up of specific subunit compositions are also 
detected along axons and within the axon initial segment (AIS) where they play a role 
in modulating action potential conductance and neurotransmitter release (Kullmann 
et al., 2005; Luscher et al., 2011a; Nusser et al., 1996). 
1.3.2 Inhibitory synaptic structure 
For efficient inhibitory synaptic transmission to take place it is vital that inhibitory 
neurotransmitter receptors are targeted to synapses opposing GABA or glycine 
releasing presynaptic terminals. Synaptic targeting and clustering of both GABAA and 
glycine receptors is mediated by the interaction of the intracellular domains of these 
receptor subunits with the cytoskeleton and the inhibitory PSD (Moss and Smart, 
2001). Within the inhibitory PSD the proteins organise around one critical scaffold 
molecule, gephyrin. Gephyrin forms multimeric complexes by auto-aggregation and 
becomes the core of the PSD onto which other key proteins can interact. GABAARs, 
GlyRs, NLs and collybistin (Cb) are all known to interact with gephyrin and contribute 
to the integrity of the PSD (Figure 1.5) (Sheng and Kim, 2011; Tyagarajan and 
Fritschy, 2014). 
 
How the inhibitory PSD forms and is maintained is still not well understood. Unlike, 
the excitatory PSD which is compartmentalised within dendritic spines, GABAergic 
synapses are found on the cell soma, dendritic shafts and within the AIS. Therefore, 
association of inhibitory PSD proteins with cytoskeletal components and extracellular 
molecules probably contribute to the formation and stabilisation of these synapses 
(Tyagarajan and Fritschy, 2014). Indeed, the inhibitory PSD interacts with the 
presynapse via trans-synaptic protein complexes, which implies a presynaptic 
contribution to the formation and maintenance of inhibitory synapses (Craig and 
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Kang, 2007; Zhang et al., 2010). The formation of hemisynapses on neurons co-
cultured with heterologous cells overexpressing proteins of interest has provided an 
elegant method for determining the synaptogenic properties of a protein. Currently, 
presynaptic Nrxns and postsynaptic NL2, Slitrk3 and GABAARs themselves have all 
been shown to promote inhibitory synapse formation in this way (Chih et al., 2006; 
Fuchs et al., 2013; Kang et al., 2008; Siddiqui and Craig, 2011; Takahashi et al., 2012). 
1.3.2.1 Gephyrin 
Gephyrin is considered to be the principle inhibitory postsynaptic scaffold protein 
which can auto-aggregate and form a lattice-like structure. The 93kDa molecule was 
the first identified protein to localise at inhibitory synapses (Triller et al., 1985) and 
was known to interact directly with GlyRs via the β-subunit (Pfeiffer et al., 1982). 
Since these early findings work has focused on characterising the role of gephyrin at 
inhibitory synapses and how the protein impacts on inhibitory synaptic structure and 
function (Tyagarajan and Fritschy, 2014). Gephyrin has two functional domains, G 
and E, joined by an unstructured linker region that contains most gephyrin regulatory 
sites and protein binding sites. The crystal structures of the G and E domains have 
been solved which has allowed models to be developed regarding the aggregated 
structure of gephyrin. Through the formation of trimers and dimers, gephyrin is 
thought to generate a hexagonal structural network capable of anchoring GlyRs and 
GABAARs within the inhibitory synapse (Xiang et al., 2001). However, recently these 
models have been called into question following structural analysis of gephyrin and 
super-resolution imaging of gephyrin and GlyRs. Quantitative single molecule 
imaging has revealed endogenous gephyrin clusters at a density of 5,000-10,000 
molecules/μm2 and molecules are in approximately a 1:1 stoichiometry with GlyRs 
consistent with a model whereby all gephyrin molecules can bind receptors rather 
than binding as dimers and trimers (Specht et al., 2013). The inability to solve the 
structure of the linker region of gephyrin means accurately determining the 
mechanism of gephyrin auto-aggregation remains an obstacle within the field (Sander 
et al., 2013; Tyagarajan and Fritschy, 2014).  
 
Although a robust interaction between gephyrin and GlyRs has been described an 
interaction between GABAARs and gephyrin has been difficult to obtain (Meyer et al., 
1995; Pfeiffer et al., 1982). It was not until more recently that a detergent-sensitive 
interaction between gephyrin and the α2 subunit was described, which was later 
shown for the α1 and α3 subunits (Maric et al., 2011; Saiepour et al., 2010; Tretter et 
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al., 2008, 2011). Others have shown using in vitro assays that gephyrin is capable of 
binding the intracellular loop of GABAAR β2 and β3 subunits too (Kowalczyk et al., 
2013). Interestingly, the binding sites of the α-subunits on gephyrin overlap and 
compete with the binding of the GlyR β-subunit within the E domain, however, the 
affinity of the GABAAR subunits are ~500 fold less than the GlyR subunits (Maric et 
al., 2011). Of note, the α-subunits, together with the γ2 and δ subunits have been 
shown to play a direct role in the synaptic versus extrasynaptic localisation of 
GABAARs. Indeed, expression of α2β3γ2 receptors in HEK cells co-cultured with 
neurons produced fast GABAergic events consistent with synaptic localisation. 
Substitution of the α2 subunit for α6 resulted in very slow events that could not be 
explained by changes in receptor kinetics but instead were due to the loss of synaptic 
targeting potentially due to lack of gephyrin binding (Wu et al., 2012). Recently, the 
synaptic localisation of α5 subunit containing GABAARs, through an interaction with 
gephyrin, has been reported. The levels of these receptors, commonly known to be 
extrasynaptic, within the synapse have been shown to regulate dendritic outgrowth 
and spine maturation (Brady and Jacob, 2015). Although the interaction between 
gephyrin and GABAARs appears to be subunit specific, gephyrin still serves as a 
reliable postsynaptic marker for all GABAergic synapses.  
 
Gephyrin has been shown to be required for the synaptic clustering of GABAARs in a 
subtype specific manner. In the absence of gephyrin α2βγ2 and α3βγ2 receptors no 
longer cluster at synapses (Essrich et al., 1998; Kneussel et al., 1999). However, α1βγ2 
receptors have been shown to cluster at synapses independently of gephyrin. This is 
interesting as gephyrin has been shown to be essential for GlyR clustering (Lévi et al., 
2004). Furthermore, this finding points towards other, potentially unknown 
inhibitory PSD scaffold proteins being sufficient to stabilise synapses independent of 
gephyrin. Intriguingly, the relationship between the GABAARs and gephyrin appears 
to be bi-directional. Loss of postsynaptic receptor clustering in GABAAR subunit KO 
mice results in  synaptic gephyrin declustering and the formation of large gephyrin 
aggregates within the soma, coupled with these cells failing to produce GABAergic 
currents (Peden et al., 2008). Taken together, these data indicate that the exact role 
of gephyrin at synapses is receptor and receptor subtype specific. 
 
Recent biochemical studies have revealed that post-translational modifications of 
gephyrin are integral to its role in regulating GABAAR clustering and inhibitory 
synaptic transmission. Phosphorylation of gephyrin at serine 270 and serine 268 by 
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GSK3β and ERK respectively was shown to regulate the density of GABAergic 
synapses and the frequency of GABAergic postsynaptic currents (Tyagarajan et al., 
2011a, 2013). Furthermore, a homeostatic increase in perisomatic inhibitory synapses 
and spontaneous GABAergic currents following NMDA-receptor dependent LTP was 
shown to be dependent on CamKII phosphorylation of gephyrin at serine 305 in slices 
(Flores et al., 2015). Additionally, in dissociated neuronal culture palmitoylation of 
gephyrin at cysteine 212 and cystine 284 has been shown to enhance gephyrin 
clustering and potentiate GABAergic transmission (Dejanovic et al., 2014). Lastly, 
gephyrin has been reported to interact with neuronal nitric oxide synthase (nNOS) 
and be S-nitrosylated in vivo. S-nitrosylation had a negative effect on gephyrin 
clustering as inhibition of nNOS resulted in larger gephyrin clusters and more surface 
GABAARs (Dejanovic and Schwarz, 2014). It remains to be fully determined what the 
upstream regulators of these modifications are. However, Wuchter and colleagues 
carried out a screen to identify kinases required for gephyrin clustering and identified 
12 hits including FGFR1, TrkB, TrkC, MAPK and mTOR pathways (Wuchter et al., 
2012). 
1.3.2.2 Neuroligin 2 
Neuroligins (NLs) have already been discussed with respect to the excitatory synapse, 
however, the synapse specificity of NL2 has led to it being intensely studied as a 
potential molecular determinant for GABAergic synapse formation (Krueger et al., 
2012; Varoqueaux et al., 2004). Co-culture experiments have revealed that 
heterologous cells overexpressing NL2 can induce presynaptic development of 
GABAergic synapses on neighbouring neurons (Chih et al., 2005; Scheiffele et al., 
2000). NL2 has also been shown to interact with gephyrin (Poulopoulos et al., 2009), 
therefore, can drive the clustering of gephyrin and GABAARs at new postsynaptic sites. 
Recently, binding of Nrxn1β to NL1 was shown to stimulate the interaction between 
NL1 and PSD95 and promote phosphorylation of NL1 at tyrosine 782 in its 
intracellular domain. This phosphorylation prevented gephyrin binding to NL1 
suggesting that ligand-dependent tyrosine 782 phosphorylation provides a 
mechanism to control the balance between excitatory and inhibitory scaffold 
assembly (Giannone et al., 2013). The corresponding residue in NL2, tyrosine 770, 
when mutated to a phospho-null residue abolished the interaction between NL2 and 
gephyrin (Poulopoulos et al., 2009). However, physiological phosphorylation of this 
site or the signalling molecules involved have not been identified for NL2. It remains 
to be determined if tyrosine 770 phosphorylation could provide a mechanism for 
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modulating inhibitory synapse formation. In line with this notion, NL2 was recently 
shown to undergo proline-directed phosphorylation which led to the recruitment of 
the peptidyl-proline cis-trans isomerase Pin1 and a loss of gephyrin binding. Indeed, 
in Pin1 KO mice, NL2, gephyrin and GABAAR accumulation was enhanced at 
inhibitory synapses and amplitude of spontaneous GABAergic currents were 
increased (Antonelli et al., 2014). 
 
Interestingly, NL2 knock-out mice can still form GABAergic synapses although the 
animals show region specific alterations in GABAergic synapse distribution and 
function. This implies that NL2 is not essential for GABAergic synapse formation and 
that there are likely compensatory mechanisms in place using other adhesion 
molecules or NL family members. Nevertheless, NL2 KO mice show selective loss of 
gephyrin and GABAAR clusters, a decrease in inhibitory transmission in the cerebral 
cortex and exhibit increased-anxiety behaviour demonstrating the importance of NL2 
at inhibitory synapses (Blundell et al., 2009; Gibson et al., 2009; Hoon et al., 2009). 
Furthermore, conditional NL2 KO in the medial prefrontal cortex of mice has shown 
that local disruption of synaptic inhibition by loss of NL2 can also lead to cognitive 
impairments. These mice displayed complete loss of NL2 in the medial prefrontal 
cortex within 2-3 weeks and by 6-7 weeks showed major reductions in inhibitory 
synaptic transmission along with impaired anxiety, fear memory and social 
interactions (Liang et al., 2015). Triple NL1, NL2 and NL3 KO mice showed severely 
altered GABAergic and glycinergic synapses in the brainstem but not a total lack of 
inhibitory synapses suggesting that other so far unknown inhibitory synaptogenic 
complexes probably exist (Tyagarajan and Fritschy, 2014). 
1.3.2.3 Collybistin 
Collybistin (Cb), encoded by the gene Arhgef9, is another protein localised to the 
inhibitory synaptic PSD in rodent brain. It was first identified to bind to gephyrin in 
a Y2H screen and can modulate gephyrin clustering. When overexpressed in non-
neuronal cells gephyrin appears diffuse in the cytoplasm, however, coexpression of 
Cb induces the translocation of gephyrin to the cell surface and drives the formation 
of gephyrin clusters (Kins et al., 2000). In neurons, endogenous Cb colocalises with 
gephyrin and GABAAR clusters and is recruited to synapses early in development. 
Intriguingly, Cb is only detected at a subset of gephyrin positive puncta within the 
cerebellar cortex (Patrizi et al., 2012). Mutations in Arhgef9, are a rare cause of 
intellectual disability (ID), with associated features such as seizures, increased anxiety 
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and aggressive behaviour, thought to be caused, at least in part, by mislocalised 
gephyrin and altered inhibitory synapse formation (Harvey et al., 2004, 2008).  
 
Cb is a specific Rho GTPase GEF and its crystal structure revealed it to be selective for 
Cdc42 (Xiang et al., 2006). The protein has an N-terminal SH3 domain as well as a 
catalytic DBL homology (DH) domain and a pleckstrin homology (PH) domain. There 
are three known isoforms of Cb (Cb1-3) and numerous splice variants of each. By 
studying Cb splice variants with and without the SH3 domain (SH3+, SH3-), this 
motif was shown to negatively regulate the translocation and submembrane 
clustering of gephyrin (Harvey et al., 2004). More recently Cb splice variants were 
shown to differentially interact with Cdc42 and gephyrin to regulate gephyrin 
clustering. Cdc42, gephyrin and Cb2SH3- but not Cb2SH3+ could form a ternary complex 
and explained the increased gephyrin clustering in neurons observed with Cb2SH3- 
compared to Cb2SH3+ overexpression (Tyagarajan et al., 2011b). That said, shRNA 
mediated knockdown of Cb in hippocampal cultures impaired GABAergic signalling 
which could be rescued by any of the Cb isoforms (Körber et al., 2012). Therefore, the 
relevance for these numerous splice isoforms still remains unclear (Papadopoulos and 
Soykan, 2011). 
 
Cb has been shown to drive gephyrin clustering and inhibitory synapse stability via 
interactions with GABAARs and NL2, as well as its interaction with Cdc42. Indeed, 
gephyrin and Cb both interact with the α2 GABAAR subunit forming a trimeric 
complex. This complex can be disrupted by a disease associated mutation in Cb 
(G55A), highlighting the importance for Cb in α2 subunit-containing GABAAR 
clustering (Saiepour et al., 2010). Interestingly, a recently discovered epilepsy and 
intellectual disability (ID) associated mutation in Cb (R290H) was shown to alter the 
strength of an intramolecular interaction in Cb between the DH and PH domains. This 
mutation reduced the phosphatidylinositol 3-phosphate lipid-binding affinity of Cb 
and consequently affected inhibitory synapse formation (Papadopoulos et al., 2015). 
NL2 has been shown to specifically activate Cb and drive the cell autonomous 
clustering of GABAARs in the presence of gephyrin and Cb2SH3+. This mechanism has 
been suggested to be more physiological as only Cb isoforms containing the SH3 
domain have been detected in vivo (Poulopoulos et al., 2009). KO mouse studies 
provide more evidence for the role of Cb in gephyrin clustering and GABAergic 
synapse formation. Arhgef9 KO mice show Cb is not essential for gephyrin and GlyR 
clustering at glycinergic synapses, however, alterations were seen at GABAergic 
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synapses. Furthermore, the animals showed reduced GABAergic transmission in the 
hippocampus. Behaviourally, they were more anxious than WT animals and had 
impaired spatial learning, consistent with reduced inhibitory transmission 
(Papadopoulos et al., 2007). These defects in inhibitory transmission could also be 
induced upon conditional postnatal KO of Cb in mice demonstrating that Cb in 
required for GABAergic maintenance as well as development (Papadopoulos et al., 
2008).  
1.3.2.4 Other scaffolding components 
Including, gephyrin, NL2, Cb and GABAARs themselves, there have been a number of 
other inhibitory synaptic molecules identified however the function of many of these 
proteins remain largely unknown (Tyagarajan and Fritschy, 2014). The scaffold 
molecule S-CAM is known to be enriched at inhibitory synapses and although an 
interaction with gephyrin has not yet been described it can bind to NL2 via its protein 
interacting domains (Sumita et al., 2007). Likewise, MAM domain-containing GPI 
anchor proteins MDGA1 and MGDA2 interact in cis with NL2 but not other NLs. Loss 
of these proteins reduce inhibitory synapses in a NL2 dependent manner (Lee et al., 
2013). The large cytoskeletal protein dystrophin has been shown to selectively localise 
to a subset of GABAergic synapses and in dystrophin KO mice GABAAR clustering was 
reduced in dystrophin-positive brain regions independent of gephyrin (Knuesel et al., 
1999). Interestingly, dystroglycan, an adhesion molecule that links dystrophin to the 
extracellular matrix shows similar enrichment at a subset of synapses and is necessary 
for the synaptic targeting of dystrophin (Lévi et al., 2002). Lastly, the adhesion 
molecule neurofacin was shown to stabilise GABAergic terminals at the AIS and 
regulate gephyrin cluster size (Kriebel et al., 2011).  
 
Gephyrin has been shown to interact with tubulin. Intriguingly, tubulin is found in 
very little quantities at inhibitory synapses therefore, the role for this interaction and 
whether it is important for inhibitory synapse structure is still not well understood. 
Gephyrin also interacts with motor proteins and acts as an adaptor in the transport of 
GlyRs and so the interaction between gephyrin and tubulin may be due to a trafficking 
function (Dumoulin et al., 2009). Actin is thought to be the more predominant 
cytoskeletal structure at inhibitory synapses and the actin binding proteins profilin1 
and profilin2, have been shown to interact with gephyrin. Furthermore, this complex 
interacts with the ENA/VASP actin associated protein family, also regulators of actin 
dynamics (Giesemann et al., 2003). Interestingly, the ENA/VASP complex also 
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interact with the WRC (Chen et al., 2014b). In cultured neurons, profilin2A robustly 
colocalises with gephyrin at inhibitory postsynaptic sites. The gephyrin profilin 
interactions have been proposed to regulate changes in the actin cytoskeleton either 
up or downstream of gephyrin anchoring to the PSD (Murk et al., 2012). Recently, the 
scaffold protein GIT1, known to be important in the regulation of excitatory synaptic 
structure, has been identified as a new member of the inhibitory PSD. GIT1 localises 
to inhibitory synapses, interacts with gephyrin and GABAARs and was shown to be 
essential for inhibitory synaptic stability and transmission due to its role in an actin 
regulatory pathway involving βPIX and Rac1 (Smith et al., 2014). 
1.3.3 GABAAR trafficking 
Regulation of GABAAR trafficking may determine inhibitory synaptic strength and 
hence neuronal excitability. Indeed, GABAARs can be rapidly trafficked between 
synaptic and extrasynaptic sites and between surface and intracellular compartments 
(Petrini and Barberis, 2014). These processes are regulated by interactions with 
several GABAAR-associated proteins, and by phosphorylation, palmitoylation and 
ubiquitination of receptors (Figure 1.5) (Luscher et al., 2011a).  
 
Receptors are trafficked to the plasma membrane via the secretory pathway. Newly 
synthesised GABAARs assemble in the endoplasmic reticulum (ER); any unassembled 
receptors are targeted for degradation by ubiquitination. PLIC-1 interacts with 
correctly assembled receptors and inhibits their degradation, which in turn promotes 
translocation of the receptors from the ER to the Golgi (Bedford et al., 2001). The 
palmitoyltransferase GODZ palmityolates the γ2 GABAAR subunit and promotes the 
trafficking of receptors though the Golgi apparatus (Keller et al., 2004). The GEF 
BIG2 is thought to facilitate receptors exiting the Golgi (Charych et al., 2004).  Upon 
exiting the Golgi, GABAARs interact with the kinesin motor KIF5A, via the GABA-
receptor associated protein (GABARAP), which is known to bind to the GABAAR γ2 
subunit (Wang et al., 1999), and are trafficked to the membrane (Nakajima et al., 
2012). The less well characterised kinesin motor KIF21b has also been recently shown 
to drive the surface delivery of γ2 subunit containing GABAARs via an interaction with 
the γ2 subunit (Labonté et al., 2014). At the plasma membrane GABAARs are initially 
inserted extrasynaptically and laterally diffuse into synaptic sites where they become 
anchored by interactions with inhibitory synapse scaffold proteins (Bogdanov et al., 
2006). Extrasynaptic receptors localise to endocytic zones or lipid rafts  
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Figure 1.5: GABAA receptor trafficking and the inhibitory PSD. 
GABAARs are assembled in the endoplasmic reticulum (ER) and trafficked through the ER and 
Golgi via the adaptor proteins PLIC, GODZ and BIG2. Receptors are then coupled to the KIF5A 
kinesin motor and transported to the membrane. At the inhibitory synapse gephyrin, 
collybistin (Cb) and GIT1 tether GABAARs within the PSD. Gephyrin/Cb/GABAAR complexes 
interact with and are stabilised by the adhesion molecule neuroligin2 which in turn binds to 
presynaptic neurexin to aid pre and postsynaptic alignment. GABAARs are endocytosed in a 
phospho-sensitive manner, dephosphorylation promotes AP2 binding and clathrin-
dependent endocytosis. In early endosomes 2 subunit ubiquitination leads to lysosomal 
degradation of internalised receptors. Otherwise, an interaction between HAP1 and the 3 
subunit facilitate KIF5C dependent recycling of GABAARs back to the plasma membrane. 
Adapted from (Luscher et al., 2011a).  
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(Hering et al., 2003; Kittler et al., 2000). A motif within the intracellular loop of the 
GABAAR β3 subunit mediates AP2 binding and stabilisation of receptors at endocytic 
zones (Smith et al., 2012). 
 
Within the plasma membrane GABAARs can be remarkably dynamic. With 
advancements in live cell imaging, receptor lateral diffusion has been analysed. 
Fluorescent recovery after photobleaching (FRAP) experiments of fluorescently 
labelled GABAARs revealed that GABAAR lateral diffusion was confined at synaptic 
sites compared to extrasynaptic locations with the fluorescence recovery rates being 
slower and faster respectively. Recovery was faster at the edges of bleached regions 
consistent with replenishment of GABAARs within the plane of the membrane rather 
than by insertion into the membrane from internal receptor pools. Interestingly, loss 
of gephyrin increased the fluorescence recovery rate at synaptic sites providing 
evidence for the role of gephyrin in GABAAR synaptic confinement (Jacob et al., 
2005). More recently, single-particle tracking of GABAARs with quantum dots has 
demonstrated that receptor diffusion dynamics are modulated by neuronal activity. 
GABAARs were less clustered and more dynamic within the membrane following 
glutamate receptor activation (Bannai et al., 2009; Muir et al., 2010). 
 
Internalisation of extrasynaptic GABAARs occurs mainly via dynamin and clathrin-
mediated mechanisms. Phosphorylation dependent interactions between the 
GABAAR β and γ2 subunits with endocytic proteins such as AP2 modulate this process 
and provide subtype-specific regulation (Kittler et al., 2005, 2008, 2000). Once 
internalised, GABAARs are ubiquitinated and trafficked to the lysosomal pathway for 
degradation or rapidly re-inserted into the surface membrane facilitated by an 
interaction with the Huntingtin-associated protein 1 (HAP1) (Arancibia-Cárcamo et 
al., 2009; Kittler et al., 2004). HAP1 acts as an adaptor molecule coupling GABAARs 
to the kinesin motor KIF5 allowing their recycling back to the synapses after 
internalisation (Kittler et al., 2004; Twelvetrees et al., 2010). Disrupting the HAP1-
KIF5 interaction reduces the number of synaptic GABAARs and physiologically 
decreases mini inhibitory postsynaptic currents (mIPSCs); hence HAP1 can regulate 
the strength of inhibitory synaptic transmission.  
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1.4 Neuropsychiatric disorders 
1.4.1 Genetics 
Neuropsychiatric disorders such as ASD, SCZ, ID and epilepsy are heterogeneous; 
patients present with a wide spectrum of symptoms ranging from mild to very severe. 
The varying disease phenotypes can make diagnosis and treatment challenging, 
therefore understanding the genetic basis of these disorders will help uncover more 
about the human physiology and disease aetiology so that more effective means of 
diagnosis, treatment and prevention can be developed. 
 
Similar to cancer and diabetes, neuropsychiatric disorders are referred to as common 
or complex disorders. They arise from an accumulation of common genomic 
variations with small effect sizes, which are considered to be risk factors for the 
condition, in combination with lifestyle and environmental factors. The huge variety 
in the combination of genetic risk factors a patient may possess is thought to explain 
the large phenotypic heterogeneity observed in these disorders. Such genomic 
variations include, changes to individual nucleotides known as single nucleotide 
polymorphisms (SNPs). These polymorphisms can be common occurring in the 
population at a frequency >5% or can be rare with a frequency of <1-0.5%. Larger 
structural variations such as deletions, insertions, translocations, inversions and copy 
number variations (CNVs) may also contribute to the genetic basis of 
neuropsychiatric disorders (Frazer et al., 2009; Schork et al., 2009). It must be noted, 
that some monogenetic diseases do present with neuropsychiatric phenotypes. The 
defective genes in these diseases are more easily identified due to their large effect 
size allowing a targeted approach to studying the mechanisms of the disease but also 
the associated cognitive phenotypes. 
 
Heritability is the proportion of phenotypic variance in a population attributable to 
additive genetic factors (Manolio et al., 2009). It is measured by estimating the 
relative contributions of genetic verses non-genetic factors to the total phenotypic 
variation. These estimates are important as they outline to what extent genetic factors 
influence disease phenotypes. Estimates of disease heritability are commonly derived 
from familial and twin studies. Familial studies compare the rates of disease in family 
members of an individual with the disease to the prevalence of the disease in the 
general population. As family members share genetic information, higher disease 
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rates within families with an affected member demonstrate an inherited genetic 
contribution to the disease. Twin studies on the other hand, compare the concordance 
rate, i.e. the presence of the same trait in both twins, of monozygotic twins to dizygotic 
twins. For example, if the concordance rate of a disease trait was higher in 
monozygotic twins who share almost 100% of their genetic material compared to 
dizygotic twins who share 50% of their DNA this implicates that genes play an 
important role in this trait. Monozygotic twins also provide a powerful tool to study 
environmental versus genetic contributions to a disease; differences in traits between 
monozygotic twins are most likely due to environmental factors. Early studies of twins 
to estimate ASD heritability showed ~90% concordance in ASD diagnosis in 
monozygotic pairs and ∼10% in dizygotic twins suggesting a heritability of around 
90% (Bailey et al., 1995). However, more recently population-based studies with 
larger sample sizes have resulted in a more refined estimate of ~50%, and suggest half 
of this heritability is due to common variants (Gaugler et al., 2014; De Rubeis and 
Buxbaum, 2015). In the case of SCZ, compiling available twin studies data has led to 
an estimate for heritability of 81% (Bienvenu et al., 2011; Sullivan et al., 2003).  
 
There is a large proportion of heritability in many neuropsychiatric disorders 
(Bienvenu et al., 2011; De Rubeis and Buxbaum, 2015), and to this end identifying 
what genetic variations contribute to this heritability remains an important question. 
In the past, genetic linkage studies were used to identify disease-associated genes in 
affected families. By knowing the location of known genetic markers, this method 
could be used to narrow down the location of the genomic region-associated with 
disease. Genetic linkage has proven useful for single-gene disorders but is more 
challenging and less accurate for complex disorders that may arise from more than 
one alteration in the genome. Originally, to determine the genetics of complex 
disorders, associated SNPs were identified mainly through sequencing projects 
focusing on genes thought to be involved in pathways underlying the disorder. 
However, this candidate gene approach was often based on imperfect biological 
understanding, used small sample sizes and the number of SNPs assayed were 
limited. Over recent years, vast improvements in genomic sequencing has led to the 
emergence of large-scale screening techniques to identify genetic variations 
associated with complex disorders. These screens have been aided by the completion 
of the Human Genome Project and the HapMap Project which have identified regions 
of common genetic variation in the human genome. Genetic research in this way is 
able to shed more light on the contributing genetic risk factors for neuropsychiatric 
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disorders.  
1.4.1.1 Genome-wide association studies 
Genome-wide association studies (GWAS) provide a high throughput method of 
screening whole genomes for common SNPs and are therefore not candidate driven. 
This type of study is a powerful unbiased method of detecting genetic variants that 
contribute to complex disorders. The most common approach of GWAS is the case-
control setup. Microarray chips containing common regions of genomic variation are 
used to screen DNA from a large patient group (cases) with a particular disorder and 
compared to a large group of healthy control individuals (controls). Common genetic 
variants that occur significantly more frequently in cases compared to controls are 
said to be associated with the disorder. For each genotyped SNP, the allele frequency 
is then calculated in the control and case cohort, this is the amount of a particular 
allele represented as a proportion of the total alleles at that particular genetic locus. 
Geneticists look for a significant difference in the allele frequency of a particular SNP 
between the case and control group. The odds ratio is often used to report the size of 
a genetic association in a GWAS. It is a ratio of the odds of having a disease with a 
specific allele verses the odds of having the disease without the specific allele. When 
the allele frequency is much greater in the cases compared to control the odds ratio 
will be higher than 1. Furthermore, a p-value for the significance of the odds ratio is 
often calculated using a chi-squared test. Odds ratios significantly different from 1 
highlight SNPs that are associated with disease and is the main goal for GWAS. This 
type of genetic analysis is very useful in identifying the numerous genetic contributing 
factors to complex disorders such as ASD and SCZ (McCarroll et al., 2014). However, 
as these disorders are thought to arise from an accumulation of many different 
variants with small effect sizes, large sample numbers are needed to identify 
associated variants. 
1.4.1.2 Rare variants studies 
Although GWAS have proved essential in identifying genes and variants associated 
with neuropsychiatric disorders the studies are limited as they only focus on the 
contribution of common genetic variants to the condition in question. Common 
variants individually or in combination typically confer relatively small increments in 
risk explaining only a small proportion of heritability (Frazer et al., 2009), leaving a 
large amount of heritability for neuropsychiatric disorders unexplained. One 
explanation for this missing heritability is that there are a large number of common 
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variants with small effects yet to be found. Increasing the sample size of GWAS will 
improve their power to detect association and may reveal more implicated common 
variants. However, another explanation is that rare variants with larger effect sizes 
that are poorly detected with SNP arrays contribute risk (Manolio et al., 2009; Zuk et 
al., 2014). It is thought that the higher penetrance of these rare variant may result in 
a selective disadvantage and reduced fecundity in the affected individuals 
contributing to the low frequency of these alleles in the population. This idea has 
motivated geneticists to explore the contribution of rare mutations to disease. These 
mutations may infer greater risk but are less frequent in the population therefore 
harder to detect (Manolio et al., 2009).  
 
In contrast to GWAS which mainly uses SNP arrays, rare variant association studies 
employ high-throughput whole genome or exome sequencing. With the 
improvements in the speed and the reduction in costs of such sequencing methods 
these studies are becoming increasingly widespread. Following genotyping, analysis 
is similar to that of GWAS determining whether a variant occurs significantly more 
frequently in cases than controls. Rare variant association studies have the ability to 
detect rare variants occurring in <0.5-1% of the population which are not included in 
common SNP arrays. A caveat to this technique is that the power to detect association 
of rare variants with disease is very low, even in large sample sizes, due to the rarity 
of variants. Strategies are being developed to assess the collective effect of multiple 
rare variants within target genomic regions (Bansal et al., 2010).  As with GWAS the 
need to compile samples from numerous datasets is apparent and will improve the 
power to detect association. 
1.4.1.3 Structural variation: copy number variation 
In addition to the identification of common and rare SNPs contributing to complex 
diseases, there have been a number of studies investigating the contribution of rare 
structural variations, such as copy number variations (CNV), to human disease. CNV 
is the most common form of structural variation in the human genome and can result 
from deletions, duplications, triplications, insertions and translocations of DNA 
stretches ranging from 1 kilobase to several megabases. Depending on the genetic 
location of these structural variations an array of genes can be disrupted resulting in 
alternate gene products or changes in allelic expression. Moreover, disruption of 
genomic regulatory regions can result in dysregulated gene expression. Most CNVs 
are stable and inherited contributing to 13% of human genomic DNA, however, some 
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CNVs arise de novo. Like with SNPs, disease-associated CNVs detected so far include 
rare variants with large associated effect sizes and common variants with more 
modest effects but carried by a large proportion of the population. 
 
As an extension of GWAS specialised SNP arrays have been designed which 
incorporate specific CNV probes so sample DNA can be screened for CNVs 
(McCarroll, 2008). However, many SNP arrays have sufficient information to permit 
CNV analysis already (Frazer et al., 2009; Manolio et al., 2009). Indeed, genetic 
screens have identified de novo CNVs within the genome that are strongly associated 
with neuropsychiatric disorders such as ASD, SCZ and ID (Lee and Lupski, 2006; 
Merikangas et al., 2009; Sebat et al., 2007; Shishido et al., 2014; Tam et al., 2009).  
1.4.2 Molecular mechanisms of neuropsychiatric disorders: synapses 
and dendrites 
Genetic studies as described above have identified numerous neuropsychiatric 
disorder associated SNPs and CNVs. By studying the function of the genes affected by 
these genomic variations it may be possible to elucidate some of the molecular and 
cellular mechanisms which become dysregulated in such conditions. Interestingly, 
genes implicated in the regulation of synaptic function and dendritic development are 
consistently emerging from genetic studies to be associated with disorders such as 
ASD, SCZ and MR. This is perhaps not surprising considering numerous studies 
report that many neuropsychiatric disorders are characterised by dendritic and 
synaptic pathology (Figure 1.6) (Kaufmann and Moser, 2000; Kulkarni and Firestein, 
2012; Penzes et al., 2011). 
 
Correct dendritic development requires the formation of dendritic branches and 
dendritic spines and is necessary for neurons to receive and convey information, is a 
critical step in neurogenesis and vital for normal brain function (Kulkarni and 
Firestein, 2012). Dendrites must satisfy particular physiological requirements to 
function efficiently. Firstly, dendrites need to cover the area (dendritic field) that 
includes the sensory and/or synaptic inputs of that neuron. Secondly, dendrites need 
to be complex and dense enough to sample and process all the signals that converge 
on the dendritic field. Finally, dendrites need to be flexible and capable of adjusting 
during development and in response to experience (Jan and Jan, 2010). In this way, 
dendritic development is a highly complex process and requires a large number of 
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organised and well-coordinated signalling pathways and mechanisms to occur. 
 
Dendritic development occurs in stages. Human dendritic development begins with 
early polarisation, which occurs prenatally. The neurons then progress into a stage of 
dendritic and synapse expansion and growth, this stage occurs both pre and 
postnatally with dendritic complexity and synapse number approaching their 
maximum in early childhood. Following this, dendrites and synapses undergo 
remodelling and pruning during adolescence with the elimination of some processes. 
Finally, the remaining dendrites undergo differentiation and maturation until their 
mature structures are reached (Kaufmann and Moser, 2000). The molecular 
mechanisms that regulate dendritic morphogenesis can be broadly divided into cell- 
extrinsic and cell-intrinsic cues. 
 
Cell extrinsic cues include chemoattractive and chemorepellent molecules such as 
ephrins and neurotrophins. Furthermore, neurotransmitters, growth factors and cell 
adhesion molecules influence dendritic development and guidance to their partner 
synapses (Parrish et al., 2007; Valnegri et al., 2015). Acetylcholine has been shown to 
impact on dendritic expansion while, activation of certain glutamate receptors has 
been implicated in dendritic pruning (Kaufmann and Moser, 2000). In addition, 
neurotrophins such as BDNF and NGF have been shown to modulate dendritic 
arborisation in cortical neurons in a layer specific manner (McAllister et al., 1995, 
1997). These growth cues signal through tyrosine receptor kinases (Trks) (Trks 
reviewed by (Patapoutian and Reichardt, 2001)). Each trophic factor signals through 
a different subset of Trks such that the response of the neuron to neurotrophin 
signalling is determined by the pattern of receptors it expresses (Parrish et al., 2007). 
It is not fully understood how neurotrophins are delivered to growing neurons in vivo, 
however local delivery of BDNF in cultured cortex brain slices has been shown to 
enhance dendritic branching suggesting that where these factors are produced and 
delivered may allow for spatial regulation of dendritic growth (Cohen-Cory et al., 
2010; Horch and Katz, 2002).  
 
As well as secreted proteins and cell adhesion molecules, the expression of surface 
receptors, the formation of synapses and neuronal activity also contribute to 
extracellular growth cues (Valnegri et al., 2015). Live cell imaging has revealed 
dendritic branch formation is not a steady process of growth and extension as 
originally thought but is actually a dynamic process of extension and retraction.  
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Figure 1.6: Dendritic and spine morphology in neuropsychiatric disorders. 
Schematic representation of a neuron and dendritic processes containing spines in brains of 
individuals with neuropsychiatric disorders. Defects in dendritic development and 
morphology including changes in dendritic branching, fragmentation of dendrites, retraction 
or loss of branches and changes in spine morphology and number contribute to many 
neuropsychiatric disorders. In particular, neurons from subjects with autism spectrum 
disorder (ASD) show decreased dendritic complexity and higher spine density than normal. 
Similarly neurons from Rett’s syndrome sufferers have decreased dendritic branching. 
Neurons from schizophrenia patients show reduced dendritic arbour and spine density. 
Finally, aberrant dendritic morphology and a high density of long, thin, immature dendritic 
spines is observed in fragile X syndrome. Down syndrome, stress and anxiety and Azheimer’s 
disease all also impact on dendritic and spine morphology. Adapted from (Kulkarni and 
Firestein, 2012). 
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Dendrite branching begins with filopodia formation; these protrusions rapidly extend 
and contract several times per minute (Dailey and Smith, 1996). Many protrusions 
are lost during retraction while some are stabilised and form nascent branches. 
Synapses form on these newly extended dendritic filopodia and contribute to filopodia 
stabilisation, allowing them to mature into dendritic branches (Niell et al., 2004). 
Indeed, in the juvenile calsyntenin1 KO mouse, a protein important in the trafficking 
of receptors, synapses were less mature due to altered NMDAR subunit composition 
and transmission was depressed. KO neurons showed decreased dendritic 
development, an increased proportion of filopodia-like dendritic protrusions and 
more thin spines (Ster et al., 2014). This highlights the importance of synapse 
formation and maturation in the dendritic development. Synaptic activity is also 
important for dendritic growth. Indeed, two photon imaging of GFP-expressing 
pyramidal CA1 neurons revealed enhanced filopodia extension following high 
frequency stimulation (Maletic-Savatic et al., 1999). As the neuron matures and 
synapses develop, dendritic filopodia become less dynamic and are replaced by the 
formation of dendritic spines (Dailey and Smith, 1996; Kulkarni and Firestein, 2012). 
It is not surprising that due to the intimate relationship between synapse development 
and dendritic stabilisation loss of synapse function or stability can lead to defects in 
connectivity resulting in brain disease. This theory is being considered in the context 
of many neuropsychiatric disorders.  
 
A vital role for cell-intrinsic factors in dendritic growth and development has been 
demonstrated by in vitro studies (Puram and Bonni, 2013). Even within the artificial 
environment of a culture dish, neurons develop different dendritic morphologies. It 
can therefore be assumed that the intrinsic factors within the neurons are influencing 
these differences in morphology (Bartlett and Banker, 1984). The major intracellular 
factors regulating dendritic morphogenesis comprise of transcriptional regulators, 
cytoskeletal mechanisms and regulators of protein trafficking and turnover including 
local protein translation (Puram and Bonni, 2013). Drosophila provide a simple 
system to study dendritic morphogenesis. Indeed, a genome-wide screen of 
transcription factors identified 78 fly genes that regulated different elements of 
dendritic outgrowth, from coverage, to outgrowth versus branching and specification 
of primary or secondary structures (Parrish 2006). It is thought that the different 
expression patterns of these transcription factors between neurons influence their 
dendritic morphology. Many of these genes have been shown to have conserved 
functions in mammals too. Other transcription factors are known to promote activity 
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dependent dendritic development in respond to Ca2+ regulation (Jan and Jan, 2010; 
Kulkarni and Firestein, 2012). 
 
Similarly to the role of actin in dendritic spine morphology, discussed above on page 
27, actin dynamics and actin regulators are vital for normal dendritic development. 
The small GTPases RhoA, Rac1 and Cdc42 are well known for their roles in regulating 
actin extension and retraction and are critical to neuronal development (Auer et al., 
2011; Negishi and Katoh, 2005; Newey et al., 2004). In Drosophila, RhoA mutants 
show excessive dendritic growth while loss of all three Rac1 proteins reduces dendritic 
size and complexity in mushroom bodies (Lee et al., 2000; Ng et al., 2002). 
Furthermore, loss of Cdc42 in the fly visual system results in reduced dendritic 
branching and decreased spine density (Scott et al., 2003). In mouse brain, 
conditional KO of Rac1 impacts on neuronal migration and axonal growth resulting 
in developmental defects. However, Rac2 and Rac3 appear to compensate to some 
degree as the Rac1 KO and Rac3 brain specific conditional KO mouse shows more 
severe developmental effects on hippocampal development and spine morphology 
(Corbetta et al., 2009; Tahirovic et al., 2010). 
  
Lastly, precise protein turnover, including protein formation, delivery and 
degradation is critical for dendritic formation. Without correct dendritic trafficking 
the building blocks required for outgrowth cannot be delivered to sites of extension. 
Indeed, loss of the neuronal motor KIF5 or the KIF5 adaptor protein GRIP1 by RNAi 
in rat hippocampal neurons results in reduced dendritic development due to a 
reduction in the delivery of key trophic signalling receptors to the membrane 
(Hoogenraad et al., 2005). Additionally, mice haploinsufficient for the dynenin 
reterograde motor adaptor protein LIS1 display reduced dendritic length and 
branching compared to WT pyramidal neurons. To enhance the efficiency of protein 
delivery to sites of extension dedicated mechanisms have been identified which target 
elements of the secretory pathway to dendrites. Indeed, Golgi outposts and local zones 
of complex dendritic ER have been identified in dendrites and are essential for 
dendritic development (Cui-Wang et al., 2012; Horton et al., 2005). Finally, 
irrespective of the efficient trafficking pathway in place, due to the high demand for 
proteins during dendritic extension and following neuronal activity there is a 
requirement for rapid local protein synthesis within dendrites. Many RNA binding 
proteins have been implicated in the regulation of local protein synthesis and are 
required for dendritic patterning (Puram and Bonni, 2013). The Fragile X mental 
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retardation protein (FMRP; discussed in detail below, page 62) regulates the 
trafficking and translation of dendritic mRNA and influences dendritic morphology 
however the exact mechanisms are unclear (Bagni and Greenough, 2005). 
 
Consistent with neuropsychiatric disorder association studies highlighting genes 
involved in the regulation of dendritic development, genes vital for synapse formation 
stability and function have also been associated with neuropsychiatric disorders. 
Indeed, dendritic spine defects during development, maintenance and plasticity as 
well as alterations in both excitatory and inhibitory synapse structure and function 
have been implicated in major neurological disorders (Penzes et al., 2011; Smith and 
Kittler, 2010; Ting et al., 2012). A summary of what is understood about the dendritic 
and synaptic mechanisms of pathogenesis for selected neuropsychiatric disorders is 
discussed below. 
1.4.2.1 Autism spectrum disorders 
Autism spectrum disorders (ASD) form a heterogeneous neurodevelopmental 
syndrome characterised by deficits in social interactions, disruptions of verbal 
communication and the presence of repetitive behaviour. ASD effects ~1% of children, 
symptoms appear in early childhood and diagnosis occurs around 2-3 years of age. 
Across the core features there are significant differences in the extent and quality of 
the symptoms. For example, the degree of speech delay or whether the patient will 
present with mental retardation (MR) are variable. Furthermore, social impairments 
are expressed differently, some patients display aloof style behaviour while other 
individuals actively seek social interactions although often in an odd manner. This 
large variability in symptoms explains why the disorder is considered a spectrum. 
ASD research is an expanding field; attempts are being made to understand the 
etiology of ASD and what molecular factors influence the disorder and produce such 
symptom variability (Geschwind and Levitt, 2007). 
 
Altered dendritic morphology is considered a hallmark of ASD. In fact ASD, and 
disorders that are often comorbid with ASD such as Rett’s syndrome (RS) and Fragile 
X syndrome (FXS), are regularly associated with abnormal brain size. It is speculated 
this is due to defects during dendritic development or pruning. The primary 
behavioural abnormalities in ASD patients occur within the first three years of life 
consistent with the idea that defective dendritogenesis could be an underlying cause 
(Jan and Jan, 2010). In one of the first studies to describe the morphological effects 
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of ASD, Golgi staining of CA1 pyramidal neurons from post-mortem brains revealed 
decreased dendritic branching in ASD subjects compared to control samples 
(Raymond et al., 1996). Through similar methods an increase in spine density on 
apical dendrites of cortical pyramidal neurons has also been shown for patients with 
ASD (Hutsler and Zhang, 2010). The authors suggested spine density inversely 
correlated with cognitive function. Others have shown by morphometric analysis that 
the hippocampus and amygdala are enlarged in autistic brains (Schumann et al., 
2004). These observations of reduced dendritic complexity and enhanced synaptic 
connections are consistent with the emerging theory that ASD involves short-range 
hyperconnectivity in local circuits and long-range hypoconnectivity between brain 
regions (Belmonte et al., 2004; Geschwind and Levitt, 2007).  
 
Since the discovery of disrupted dendritic complexity and spine morphology in ASD 
patients, there has been increasing interest in understanding the underlying 
mechanisms of this disorder. Genetics have provided a powerful tool for identifying 
candidate ASD genes. Linkage and association studies have detected mutations in 
genes resulting in monogenic forms of ASD such as tuberous sclerosis (associated 
with TSC1 and TSC2 mutations), Rett’s syndrome (associated with MECP2 
mutations), and FXS (associated with FMR1 mutations). Mutations in FMR1 account 
for ~2% of ASD cases (Huguet et al., 2013). Additionally, genes that possess common 
SNPs, rare variants or CNVs which occur in patients with ASD significantly more 
frequently than in control patients are considered to be associated with ASD. Indeed, 
de novo CNVs are present in 10-20% of patients with ASD compared with 1-2% of the 
general population. The most frequent are located at chromosomal regions 7q11, 
16p11, 22q11-13 and 15q11-13 (Huguet et al., 2013). The latter of which contains the 
gene encoding CYFIP1 and will be discussed in more detail in Chapter 3. Many of these 
ASD-associated genes have defined roles in pathways that regulate synaptic 
stabilisation and function providing evidence for synaptic dysfunction having a role 
in the etiology of ASD.  
 
A number of mutations identified in Nrxns and NLs are associated with ASD and 
result in synaptic and dendritic defects (Südhof, 2008). Internal deletions in Nrxn1 
are observed in patients with ASD and rare ASD-associated mutations in NL3 and 
NL4 have been discovered in individuals with X-linked autism. These mutations were 
shown in cell culture experiments to result in an increase in spine density (Chih et al., 
2004). Chanda and colleagues demonstrated the NL4 ASD-associated mutation 
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R704C significantly impaired normal synaptic function. When the mutation was 
introduced into NL3, surface AMPARs at excitatory synapses were decreased and 
AMPAR mediated synaptic responses were impaired. Intriguingly, the same mutation 
in NL4 had the opposite effect elevating AMPAR-mediated synaptic responses 
(Chanda et al., 2015). Disruptions in NL function could therefore result in destabilised 
synaptic connections, loss of synapses and reduced dendritic complexity (Chen et al., 
2010a). ASD-associated NL deficits also impact on inhibitory synaptic function. NL3 
KO mice, NL3 knock-in mice, containing the autism mutation R451C, and NL2 
overexpression all resulted in increased inhibitory transmission and social deficits in 
the mice (Hines et al., 2008; Radyushkin et al., 2009; Tabuchi et al., 2007). This 
altered inhibitory function due to disrupted GABAAR number and synapse stability 
may be an important factor underlying altered network activity in ASD. Indeed, 
condition knock-out (KO) of the inhibitory synapse specific NL2 in the prefrontal 
cortex of mice resulted in the animals developing behavioural deficits associated with 
neuropsychiatric disorders such as impaired anxiety, fear memory and social 
behaviours (Liang et al., 2015). 
 
Another intensely studied family of ASD-associated proteins are the Shank family 
proteins (Guilmatre et al., 2014; Jiang and Ehlers, 2013). CNVs in the genes encoding 
Shank2 and Shank3 are associated with ASD (Berkel et al., 2010; Durand et al., 2007; 
Pinto et al., 2010). Additionally, patients with ASD have been identified with deletion 
mutations or nonsense point mutations in the genes encoding Shank1 and Shank3 
(Durand et al., 2007; Sato et al., 2012). KO mouse studies have revealed that loss of 
any Shank protein results in spine defects and disrupted excitatory synaptic 
transmission. Moreover, ASD mutations in Shank3 result in modified spine 
morphology via actin mechanisms (Durand et al., 2012). Dendritic complexity is also 
altered in Shank2 knockdown neurons and cannot be rescued by ASD-associated 
Shank2 mutants (Berkel et al., 2012). This demonstrates the importance of Shank 
proteins in synaptic function and dendritic morphology and highlights why Shank 
mutations are so strongly associated with ASD. Indeed, Shank2 and Shank3 KO mice 
demonstrate ASD like behaviour such as deficits in social behaviour, abnormal 
vocalisation and repetitive compulsive actions (Peça et al., 2011; Schmeisser et al., 
2012). Other synaptic molecules such as SAPAP2 and Epac2 have also been 
implicated in the molecular mechanisms of ASD (Srivastava et al., 2012).  
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1.4.2.2 Fragile X syndrome 
Fragile X syndrome is the most common form of inherited intellectual disability (ID), 
severe mental retardation (MR) affects 25% of male cases and it is the most frequent 
known cause of ASD. The disorder is characterised by mild to severe cognitive 
impairment, physical abnormalities, attention deficit, autistic behaviour, childhood 
seizures and importantly abnormal immature dendritic spines within the brain 
(Bardoni et al., 2000; Comery et al., 1997). Most cases of FXS are a result of an 
unstable CGG repeat expansion in the 5’ UTR promoter region of the gene FMR1. 
FMR1 encodes the fragile X mental retardation protein (FMRP). FMR1 expansion 
leads to hypermethylation and transcriptional silencing resulting in loss of FMRP 
expression. In addition, rare cases of FXS have been identified that are associated with 
deletions and point mutations in FMR1. Such as the rare isoleucine to asparagine 
mutation at position 304 (I304N) within the coding region found in a patient with 
severe FXS (Bagni and Greenough, 2005; Bardoni et al., 2000; Feng et al., 1997). 
 
FMRP and its two other family members FXR1P and FXR2P are RNA binding 
proteins (RBPs) that are highly expressed in the brain. FMRP binds polyribosomes 
and mRNAs, although a precise RNA binding motif for FMRP family proteins has not 
been described (Brown et al., 1998; Rubeis and Bagni, 2011). Defects in the mRNA 
binding function of FMRP are important in the pathogenesis of FXS as the I304N 
mutation attenuates the association of FMRP with polyribosomes and mRNA (Feng 
et al., 1997). That said, the exact disease pathogenesis of FXS is still not clear.  
 
Intense research has improved our understanding of FMRP function in an attempt to 
understand how disrupted expression and mutations in the protein result in FXS and 
give rise to neurological symptoms such as ID and ASD. In highly polarised cells such 
as neurons protein translation occurs not only in the soma but also at synapses, along 
the dendrites and in axons too. Indeed, local protein synthesis at synapses is critical 
for synaptic plasticity as protein translation blockers can abolish BDNF-induced LTP 
(Kang and Schuman, 1996). FMRP has been described to play a critical role in the 
stability, localisation, transport and local translation of target mRNA in neurons 
(Abekhoukh and Bardoni, 2014; Bagni and Greenough, 2005; Bassell and Warren, 
2008; Rubeis and Bagni, 2011). When bound to mRNA FMRP has been shown to 
repress protein translation both in vitro and in vivo (Rubeis and Bagni, 2011). Over 
200 FMRP target genes display abnormal distribution on actively transcribing 
polyribosomes in lymphoblastoid cells from FXS patients, suggestive of altered 
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translation (Brown et al., 2001). Furthermore, in FMR1 KO mice, FMRP target 
mRNAs are more localised to polyribosomes due to excessive translation and the 
levels of the translated proteins are increase. This result is also seen in 
synaptoneurosome fractions highlighting the importance of FMRP’s repressive 
function at the synapse (Muddashetty et al., 2007; Zalfa et al., 2003). More recently 
high-throughput screening identified over 100 proteins whose expression was altered 
in purified synaptoneurosomes from FMR1 KO neurons, likely due to the effect of loss 
of FMRP on dendritic mRNA localisation and protein synthesis (Darnell et al., 2011; 
Liao et al., 2008). 
 
Disrupted protein translation upon loss of FMRP has been shown to impact on 
synaptic plasticity, which is critical for normal neuronal function and could contribute 
to the neurological effects of FXS. mGluR5-dependent LTP is reduced in the cortex of 
FMR1 KO mice. In addition, mGluR-dependent LTD is amplified in the absence 
FMRP in the hippocampus whereas, NMDAR LTD is unchanged (Huber et al., 2002). 
The enhanced mGluR5 LTD in FMR1 KO mice was shown to be insensitive to protein 
synthesis inhibitors. It has therefore been suggested that the abnormality in 
expression of synaptic proteins following loss of FMRP is impacting on mGluR5 
receptor activation. Indeed, in these mice mGluR5 receptors are less associated with 
the PSD protein homer, suggesting defects in downstream synaptic signalling 
(Abekhoukh and Bardoni, 2014; Giuffrida et al., 2005). 
 
FMRP was shown by a Y2H screen to interact with CYFIP1 and CYFIP2 (cytoplasmic 
FMRP interacting protein 1 and 2) (Schenck et al., 2001). Unlike FMRP, CYFIP 
proteins do not interact with mRNA; instead these proteins have been suggested to 
regulate the function of FMRP. It is thought that CYFIP proteins may control the 
affinity of FMRP for RNA or regulate the formation of FMRP family protein homo or 
heterodimers since the CYFIP binding site is also the site for FMRP to bind with itself 
or its paralogs FXR1P and FXR2P (Schenck et al., 2001). As CYFIP proteins have been 
suggested to regulate FMRP function there has been great interest in the FXS research 
field to understand more about CYFIP function. 
 
Recently a role for CYFIP1 was described in the translational initiation complex. 
CYFIP1 was identified as a neuronal eukaryotic translation initiation factor (eIF4E)-
binding protein (4E-BP) (Napoli et al., 2008). 4E-BPs function by sequestering eIF4E 
and repressing translation. The 4E-BPs and eIF4G, the scaffolding protein required 
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for the assembly of the active initiation complex, compete for the same binding site 
on e1F4E. Therefore, if a 4E-BP, such as CYFIP1, is bound to eIF4e then eIF4G cannot 
bind to form the initiation complex and translation is repressed. In brain and at 
synapses FMRP recruits CYFIP1 in a complex with eIF4e to its associated mRNA 
resulting in the repression of FMRP target mRNA due to the inability of eIF4G to bind 
(Napoli et al., 2008). The FMRP-CYFIP1-e1F4E complex has been shown to interact 
and regulate a variety of FMRP target transcripts including CamKII, Arc, APP and 
Map1b. Interestingly, the complex also contains BC1 RNA. This non-translated RNA 
enhances the FMRP-CYFIP1 interaction and can act as an adaptor to recruit a 
different subset of mRNAs to the FMRP-CYFIP1-eIF4E complex. Consistent with this, 
downregulation of CYFIP1 in cultured neurons or genetic depletion in mice results in 
a significant increase in the protein levels of FMRP target transcripts (Napoli et al., 
2008; Rubeis and Bagni, 2011). It is of note that the FMRP-CYFIP1-eIF4E complex is 
present along dendrites and at synapses and its repressive function can be regulated 
by neuronal activity. Indeed, upon the stimulation of synaptoneurosomes with either 
BDNF or DHPG, the mGluR I agonist, CYFIP1 is released from e1F4E and the 
translational block is removed (Napoli et al., 2008).  
 
Intriguingly, there has been some controversy as to the formation of the FMRP-
CYFIP1-eIF4E complex. Iacoangeli and colleagues could not detect an interaction 
between FMRP and BC1 mRNA either in vitro or in vivo and interactions between 
BC1 mRNA and FMRP target mRNAs were found to be nonspecific (Iacoangeli et al., 
2008a, 2008b). This data suggests that BC1 and FMRP act independently to regulate 
translation. Furthermore, the majority of the FRMP pool has been described to 
associate with transcribing polyribosomes implying that only a small proportion of 
FMRP functions with CYFIP1 in regulating translational initiation. Indeed, FMRP 
acts as a transcriptional brake and has recently been shown to reversibly stall 
ribosomes specifically on its target mRNA (Darnell et al., 2011). Therefore, as 
suggested when CYFIP1 and CYFIP2 were first identified, CYFIP proteins are also 
likely to interact with this larger pool of polyribosome-associated FMRP and 
contribute to the modulation of FMRP activity during active translation (Abekhoukh 
and Bardoni, 2014; Schenck et al., 2001). 
 
As a final note, like ASD, patients with FXS also develop spine morphology defects. 
Post-mortem studies of Golgi labelled FXS patient brains and research into the FMR1 
KO mice reveal in both cases neurons with long, thin tortuous spines (Comery et al., 
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1997; Irwin et al., 2001; Rudelli et al., 1985). The altered translation of synapse 
specific proteins due to loss of FMRP is hypothesised to cause these spine defects. 
Indeed, changes in the mRNA levels of key PSD scaffold proteins and actin regulatory 
proteins, such as PSD95 and Arc have been shown in models of FXS (Ifrim et al., 2015; 
Napoli et al., 2008). Furthermore, loss of FMRP in KO mice, leads to overactive Rac1. 
Increased activity of this global actin regulator results in abnormal spine and 
dendritic development (Bongmba et al., 2011) suggesting another mechanism for the 
defects in neuronal morphology observed in FXS patients. 
1.4.2.3 Joubert’s syndrome 
Joubert’s syndrome (JS) is an autosomal recessive neurodevelopmental disorder 
characterised by multiple behavioural and neuroanatomical abnormalities, 
development delay and MR. Individuals with JS are considered to have a multisystem 
disease with abnormal breathing and eye movements, ataxia, hypotonia and cognitive 
difficulty as well as extra-neuronal features such as retinal degeneration and cystic 
kidney disease (Doherty, 2009; Ferland et al., 2004; Joubert et al., 1968, 1969; Louie 
and Gleeson, 2005). Physically, the disease is defined by abnormal cerebellar 
development and lack of midline fusion between the two hemispheres resulting in a 
‘molar tooth sign’ on MRI scans. Furthermore, many features of ASD have been 
described in up to 40% of JS patients (Esmailzadeh and Jiang, 2011; Holroyd et al., 
1991; Ozonoff et al., 1999). One study analysed the behaviour of two children with JS, 
both displayed autistic characteristics, one child met diagnostic criteria while the 
other showed autistic features including stereotypic behaviour and impaired social 
interaction and communication (Holroyd et al., 1991).  
 
As JS is a monogenic disorder with neuropsychiatric phenotypes mutations in the 
genes known to cause the disease have been identified due to their high heritability 
and large effect size. The protein products of all 11 genes currently identified are 
localised to primary cilia (Doherty, 2009). Defects in ciliogenesis have been observed 
when proteins associated with cilia are mutated and result in multisystem disorders, 
characterised by brain malformations, retinal degeneration and kidney disease, 
known as ciliopathies (D’Angelo and Franco, 2009; Lee and Gleeson, 2010; Waters 
and Beales, 2011). A comparison of the human symptoms of JS has led to the 
characterisation of this disease as a ciliopathy (Doherty, 2009; Hsiao et al., 2009; 
Lancaster et al., 2009, 2011a; Louie and Gleeson, 2005; Simms et al., 2011; Waters 
and Beales, 2011; Westfall et al., 2010).  
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Cilia are dynamic, specialised membrane bound organelles that project out from the 
cell surface. They consist of a microtubule (MT) cytoskeleton (axoneme), which is 
anchored in the cell by the basal body, a structure composed of a pair of centrioles 
located under the cell surface (Figure 1.7) (Marshall, 2008; Reiter et al., 2012). 
Primary cilia are found on most cell types including renal epithelial cells, retinal 
photoreceptors, chondrocytes, fibroblasts and neurons. The membrane surrounding 
the protruding axoneme is specialised containing specific signalling receptors. The 
most proximal region of the axoneme is termed the transition zone (TZ). The elements 
of the TZ have been reported to act as gatekeepers, regulating the trafficking of 
molecules into the cilia (Figure 1.7) (Reiter et al., 2012). 
 
Of note, loss of function mutations in the gene Ahi1, as a result of frame shifts or 
nonsense mutations, are known to cause JS (Dixon-Salazar et al., 2004; Ferland et 
al., 2004). Studies using Ahi1 KO mice have provided a useful tool for investigating 
Ahi1-mediated JS. Transgenic Ahi1 neuron-specific KO mice showed depressive 
phenotypes and remained significantly more immobile in the tail suspension test and 
the forced swim test compared to wild-type control animals (Xu et al., 2010). 
Furthermore, Ahi1 heterozygous animals (Ahi1+/-) showed anxiolytic characteristics 
across different behavioural paradigms designed to test anxiety. Ahi1+/- mice showed 
a significant decrease in anxiety in the open field, elevated plus maze and light-dark 
box tests as well as during social interaction with other mice (Lotan et al., 2013). MRI 
imaging revealed reduced connectivity between the amygdala and other brain regions 
involved in the processing of antipanic stimuli and inhibitory avoidance learning 
(Lotan et al., 2014). The data suggests Ahi1+/- mice present with relative resistance to 
stress. Moreover, individuals with JS disease causing Ahi1 mutations have the classic 
cerebellar vermis defects and limited involvement of the cerebral cortex. Indeed, MRI 
scans from these patients revealed the typical midbrain ‘molar tooth’ structure 
(Dixon-Salazar et al., 2004; Ferland et al., 2004). Mouse models of JS with mutations 
in Ahi1 also display the malformation (Lancaster et al., 2011a). The evidence suggests 
that Ahi1 could be critical for neuronal development and function. 
 
Mechanistically, primary cilia are vital in developmental signalling pathways and 
neuronal development is known to be impaired when primary cilia are disrupted 
(Waters and Beales, 2011).  Therefore, research into the mechanisms of JS has focused 
on the role of JS causing genes in cilia formation and function. Indeed, Ahi1 has been  
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Figure 1.7: Structure of the primary cilia. 
Cilia are classified into two categories based on their structure. The first, motile cilia, have 
their MTs arranged in a 9 + 2 circular pattern, consisting of a central MT pair surrounded by 
the 9 MT doubles. The second, primary cilia, lack the central 2 MTs (9 + 0 axoneme) and are 
usually non-motile (top panel). The core structure of primary cilia is composed of MT bundles 
forming the axoneme extending from the basal body, a microtubule-based structure derived 
from the mother centriole. The basal body can nucleate the MTs that form the axoneme. The 
transition zone (TZ) sits just above the basal body and contains the ciliary necklace. This is a 
ring structure of membrane proteins that encircles the base of the cilia. The TZ also contains 
Y-shaped linkers that span from the axoneme to the ciliary necklace and a growing number 
of cytosolic proteins. The ciliary membrane is continuous with the plasma membrane, but 
contains a unique protein composition, such as Ca2+ channels and receptors. Thus, primary 
cilia can function as a sensory organelle for receiving and transducing extracellular stimuli 
into cells. Ahi1 has been located at the basal body and TZ. Adapted from (Hsiao et al., 2012).  
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localised to the basal body and TZ (Hsiao et al., 2009; Lee et al., 2014). However, 
much less is known about how these mechanisms might result in neuropsychiatric 
phenotypes. 
1.4.2.4 Schizophrenia 
Schizophrenia (SCZ) is a chronic, severe heterologous brain disorder that effects 
about 0.5-1% of the population and is highly heritable (~80%). SCZ manifests itself 
through positive symptoms including delusions, hallucinations, altered thought and 
negative symptoms such as loss of emotional responses, apathy and social withdrawal. 
Cognitive symptoms include impaired attention, memory and executive functions 
(Andreasen, 1995; Lewis and Lieberman, 2000). 
 
In contrast to mental disorders that develop in early childhood such as ASD discussed 
above, the onset of SCZ is associated with late adolescence and early adulthood. 
Therefore, SCZ could arise from over-pruning or failed maintenance of dendritic 
complexity later in life. Post-mortem studies and non-invasive imaging techniques 
have demonstrated one of the defining features of SCZ is grey matter loss, resulting 
in loss of connectivity (Harvey et al., 1993; Karlsgodt et al., 2008; Ruiz et al., 2013). 
Others have reported that decreased brain volume in SCZ is not due to loss of axons 
or cells bodies (Selemon et al., 1995) strengthening the theory that SCZ arises from a 
loss of dendritic architecture and spines. Consistent with this, decreased spine density 
has been observed in the brain regions most affected by grey matter loss illustrating 
changes in spine density may directly result in the reduced brain volume detected. 
Indeed, reduction of basal dendrites and dendritic spine density was identified in the 
prefrontal cortex (Broadbelt et al., 2002; Garey et al., 1998; Glantz and Lewis, 2000) 
a region of the brain severely affected in SCZ patients (Tan et al., 2007). Interestingly, 
histology and electron microscopy on SCZ post-mortem tissue revealed that 
hippocampal pyramidal neurons were reduced in size with less spines and synaptic 
contacts in the CA3 region (Arnold et al., 1995; Benes et al., 1991; Jönsson et al., 1999; 
Kolomeets et al., 2005).  
 
Consistent with mechanisms thought to underlie ASD, genes encoding synaptic 
proteins appear to be strongly associated with SCZ. This raises an unanswered 
question in the field as to why two disorders that appear to share similar genetic and 
molecular mechanisms of pathogenesis have such different times of disease onsets. 
The synaptically targeted protein DISC1 plays a role in regulating spine morphology 
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and has been implicated in SCZ (Hayashi-Takagi et al., 2010; Penzes et al., 2011). 
Genetically, DISC1 is truncated from intron 8 by a balanced translocation in a large 
Scottish pedigree and cosegregates with major mental illness including SCZ (St Clair 
et al., 1990). Evidence has now been provided for this protein having a role in 
dendritogenesis and maintenance of neuronal complexity too (Duan et al., 2007; 
Kvajo et al., 2011; Lepagnol-Bestel et al., 2013). Altered expression of PSD structural 
proteins have also been implicated in SCZ pathogenesis. PSD95 protein levels are 
reduced in post-mortem cortical samples from SCZ patients while other PSD proteins 
such as Shank3, PSD93 and SAP102 have altered mRNA levels (Föcking et al., 2014; 
Kristiansen et al., 2006). Indeed, Shank3 mutations have been associated with SCZ 
too (Gauthier et al., 2010). Loss or mutated synaptic scaffold proteins could be 
resulting in synapse and dendritic spine loss and defects in neurotransmission 
contributing to the etiology of SCZ.  
 
Actin regulation is critical for synapse stability and spine morphology therefore it is 
not surprising that mutations in key actin regulators are associated with SCZ. Kalirin7 
is a Rac GEF and mutations in conserved regions of the gene have been identified in 
SCZ patients and are thought to be functionally damaging (Kushima et al., 2012). 
Indeed, loss of kalirin7 correlates with cortical spine loss, a feature of SCZ (Hill et al., 
2006). Kalirin7 has also been shown to mediate DISC1 effects on spine morphology 
as DISC1 anchors kalirin7 at spines so it can activate Rac1 (Hayashi-Takagi et al., 
2010).  
1.4.2.5 The excitatory/inhibitory balance 
Neuronal homeostasis refers to the phenomenon where neurons alter their 
excitability to maintain stable levels of electrical activity during development and 
changes in environmental conditions. Neurons can regulate their excitability via 
finely tuned mechanisms that respond to changes in action potential firing and 
network activity. These mechanisms include modulation of synaptic strength, 
alterations in presynaptic release probability and adjustments in intrinsic membrane 
excitability via up- or down-regulation of excitatory and inhibitory receptors 
(Turrigiano, 2011). Too much excitability or inhibition due to defects in these 
mechanisms can result in pathological consequences. In fact, a leading hypothesis for 
ASDs is that they arise from an imbalance in excitation and inhibition in particular 
circuits. Indeed, pathological alterations in the excitatory/inhibitory (E/I) balance 
have been increasingly implicated in neuropsychiatric disorders such as FXS, RS, 
 
Introduction 
 
 
 70 
tuberous sclerosis (TS) and epilepsies (Bateup et al., 2013; Chao et al., 2010; 
Paluszkiewicz et al., 2011; Pizzarelli and Cherubini, 2011).  
 
The mammalian target of rapamycin (mTOR) pathway is strongly implicated in ASD 
and modifications in this pathway have been shown to disrupt the E/I balance. The 
mTOR pathway is activated in response to growth factors and signals through the 
mTOR complex to bring about protein synthesis and the regulation of cell growth and 
metabolism. Upstream of mTOR, mutations in the mTOR negative regulator PTEN 
occur in 1-5% of patients with ASD (Zhou and Parada, 2012). Downstream of mTOR, 
the eIF4e binding protein 2 (4E-BP2) is necessary to maintain the E/I balance. Mice 
lacking 4E-BP2 showed autistic-like behaviours, social interaction deficits and 
developed an increased ratio of excitatory to inhibitory synaptic inputs. The effects 
were shown to be due to disrupted expression of synapse stabilising proteins NL1 and 
NL2 (Gkogkas et al., 2013). Furthermore, neuronal loss of the mTOR negative 
regulator TSC1, a protein mutated in TS and a common target for mutations 
associated with ASD and epilepsy, weakened inhibition. This was caused by 
dysregulation of mTOR and altered the E/I balance leading to hippocampal 
excitability (Bateup et al., 2013). These examples of ASD-associated alterations in the 
E/I balance implicate modulation of mTOR signalling and consequently disrupted 
protein synthesis; emphasising its potential as a converging pathway in some forms 
of ASD.  
 
GABAergic signalling enhances hyperpolarisation and is therefore essential for 
regulating the excitability of a neuron and maintaining the E/I balance of neuronal 
circuits (Smith and Kittler, 2010). Defects in GABAAR trafficking have been shown to 
alter the E/I balance in disorders such as epilepsy and Huntington’s disease 
(Twelvetrees et al., 2010). Loss of surface GABAARs results in a lack of intrinsic 
inhibition and is one of the major pathologies of status epilepticus (SE). During SE, 
the GABAAR β3 subunit was shown to be selectively dephosphorylated resulting in 
rapid internalisation of surface GABAARs due to enhanced AP2 dependent clathrin-
mediated endocytosis (Terunuma et al., 2008). KIF5A KO mice have impaired surface 
GABAAR trafficking and show epileptic phenotypes (Nakajima et al., 2012). 
Additionally, mutations is GABAAR subunits that have been identified in genetic 
epilepsies, rather than modifying channel properties, impair intracellular trafficking 
or impact on receptor degradation (Gallagher et al., 2007). A number of GABAergic 
scaffolding molecules involved in stabilising the synapse and tethering GABAARs have 
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been associated with neuropsychiatric disorders. Mutations in the NLs have been 
identified in ASD patients (Südhof, 2008). Deleting NL3 in mice or overexpression of 
NL2 lead to an increase in inhibitory transmission and impaired social interactions 
(Hines et al., 2008; Tabuchi et al., 2007). While constitutive loss, or condition loss in 
the prefrontal cortex of NL2 in mice causes decreased inhibition and anxiety-like 
behaviour (Blundell et al., 2009; Liang et al., 2015). This behaviour was also observed 
in GABAAR γ2 KO mice or with loss of Cb dependent receptor clustering (Earnheart 
et al., 2007). Altered inhibitory homeostasis, due to disrupted GABAAR trafficking or 
changes in inhibitory synapse number by disrupted scaffolding molecules, may 
therefore be another important factor underlying aberrant network activity in 
psychiatric disorders.    
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1.5 Thesis Aims 
Precise development and maintenance of dendritic complexity and efficient synaptic 
transmission is vital for normal neuronal connectivity and brain function. Alterations 
in these processes are thought to contribute to the etiology of neuropsychiatric 
disorders however, the precise mechanisms are still being understood. Given that the 
genes encoding the proteins CYFIP1 and Ahi1 have been robustly associated with 
neuropsychiatric disorders through genetic studies the aims of this thesis are as 
follows: 
 
1. To investigate the possibility that CYFIP1, and its homologue CYFIP2, regulate 
dendritic morphology and synapse stability in an attempt to elucidate why 
altered dosage of these proteins have been associated with neuropsychiatric 
disorders. 
 
2. To identify novel CYFIP1 SCZ-associated mutations and explore how these 
mutations impact on CYFIP1 function. 
 
3. To characterise CYFIP1 genetic knockout systems to further understand the 
molecular functions of CYFIP1. 
 
4. To investigate the possibility that Ahi1 is important in the trafficking of 
GABAARs at the inhibitory synapse and in the regulation of dendritic 
morphology.  
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Chapter 2 
Materials and Methods 
2.1 Antibodies 
2.1.1 Non-commercial antibodies 
The mouse monoclonal antibodies anti-myc (WB and IF, 1:100), anti-HA (WB and IF, 
1:100), anti-KIF5A-C (WB, 1:100) and anti-GAD6 (IF, 1:100) were obtained from 
9E10, 12CA5, SUK4 and GAD6 hybridoma cells respectively (acquired from the 
Development Studies Hybridoma Brank). All hybridoma antibodies were used 
directly as supernatant and diluted as described for western blotting and 
immunofluorescence. Monoclonal antibodies were produced by growing hybridoma 
cultures in Integra CL350 Bioreactor flasks. Cells were maintained in the cell 
compartment in DMEM with 20% FBS, 1% penicillin-streptomycin and 0.1% 
gentamicin. The nutrient compartment contained serum free DMEM containing 
penicillin-streptomycin and 0.1% gentamicin. Once confluent cells were harvested 
every 3-5 days by removal of 80% of the media from the cell compartment and 
replacement with fresh media. In addition nutrient media was changed with every 
harvest. Cells were spun down and the antibody containing supernatant was filtered 
through a 0.45μm filter and stored at -20°C. 9E10, 12CA5 and SUK4 antibodies were 
produced by Rosalind Norkett, GAD6 antibody was produced by Katharine Smith. 
2.1.2 Commercial antibodies 
For a list of all commercial antibodies and the concentrations at which they were used 
see Table 2.1. All Alexa Fluor fluorescent marker conjugated secondary antibodies 
were from Molecular Probes and used at 1:1000. Anti-rabbit and anti-mouse HRP 
conjugated secondary antibodies were from Rockland and BioRad respectively, used 
at 1:10 000. 
  
7
4
 
Table 2.1: Commercial primary antibodies (dilutions for given experiments are indicated) 
  
Antigen Species Company Product code Western 
blotting 
Immuno-
fluorescence 
Immuno-
precipitation 
Immuno-
histochemistry 
Ahi1 (H-300) rabbit Santa Cruz sc-98623 1:200 - 4μg - 
Ahi1 mouse Abcam ab93386 1:500 1:500 2μg - 
β-tubulin mouse Sigma T5293 1:1000 - - - 
Chapsyn 110 (N18/30) mouse Neuromab 73-057 1:50 - - - 
c-Myc (A-14) rabbit Santa Cruz sc-789 - 1:100 - - 
CYFIP1 rabbit Millipore 07531 1:500 1:200 - - 
CYFIP1/Sra1 mouse Synaptic Systems 309 011 1:500 1:200 - - 
GABAAR γ2 subunit guinea pig Synaptic Systems 224 004 - 1:500 - - 
Gephyrin mouse Synaptic Systems 147 011 - 1:500 - - 
Gephyrin rabbit Synaptic Systems 147 003 1:1000 - - - 
GFP rat Nacalai-Tesque 04404-84 - 1:2000 - 1:500 
GFP (FL) rabbit Santa Cruz sc-8334 1:100 1:100 - - 
GFP (N86/8) mouse Neuromab 73-131 1:100 - - - 
HAP1 mouse BD Transduction 611 302 1:500 - - - 
HAP1 (N18) goat Santa Cruz sc-12556 - - 2μg - 
Homer rabbit Synaptic Systems 160 002 1:500 1:500 - - 
NAP1 rabbit Abcam ab96715 1:500 - - - 
Shank1-3 (N23B/49) mouse Neuromab 73-089 1:50 - - - 
PSD-95  (K28/43) mouse Neuromab 75-028 1:500 1:500 - - 
Rac1 mouse Millipore 23A8 1:500 - - - 
RFP rabbit Abcam 62341 1:500 1:500 - - 
vGAT rabbit Synaptic Systems 131 003 - 1:1000 - - 
vGlut guinea pig Synaptic Systems 135 304 - 1:1000 - - 
WAVE2 (H-110) rabbit Santa Cruz sc-33548 1:200 - - - 
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2.2 Animals 
The Cyfip1 KO mouse line (MDCK; EPD0555_2_B11; Allele: Cyfip1tm2a(EUCOMM)Wtsi) 
was obtained from the Wellcome Trust Sanger Institute as part of the International 
Knockout Mouse Consortium (IKMC). Transgenic animals were generated following 
the Knockout-First strategy on C57BL/6N Taconic USA background (Skarnes et al., 
2011; White et al., 2013). The CreERT line (Feil et al., 1997) (B6N Tac Rosa26 CreERT2 
(MJBA)) was also obtained from the Wellcome Trust Sanger Institute, again 
transgenic mice were bred on C57BL/6N Taconic USA background. The camkcre4 
(CreCAMKIIα) line has been described previously (Mantamadiotis et al., 2002) and the 
YFP Rosa26 reporter line (Ribeiro et al., 2013) was obtained from Prof. Alison Lloyd. 
Animals were maintained under controlled conditions (temperature 20 ± 2°C; 12 hour 
light-dark cycle). Food and water were provided ad libitum. The genotyping was 
carried out following distributors recommended procedures, DNA was extracted from 
ear biopsies and PCR reactions were performed. All experimental procedures were 
carried out in accordance with institutional animal welfare guidelines and the UK 
Animals (Scientific Procedures) Act 1986. 
2.3 Molecular Biology 
2.3.1 Constructs 
Human CYFIP1 and CYFIP2 GFP and mCherry tagged constructs were generated 
using the Gateway Cloning System (Invitrogen) with the expression vectors 
pDEST47GFP (Invitrogen), pDEST-eGFP-N1 and pDEST-mCherry-N1 (Addgene, 
plasmid numbers 31796 and 31907 respectively). CYFIP1 mutant constructs were 
generated by site-directed reverse PCR mutagenesis on the pENTR221-CYFIP1 vector 
and cloned using the Gateway Cloning System into pDEST-eGFP-N1. Primers used 
for mutagenesis are listed in Table 2.6. pCAG-DsRed was purchased from Addgene 
(plasmid number 11151) and actinGFP was a gift from Dr. Jonathan Hanley (University 
of Bristol). 
 
All restriction enzymes used were from New England Biosciences (NEB). The human 
Ahi1 constructs tagged at the N-terminus with either GFP or DsRed were purchased 
from Addgene (plasmid numbers 30494 and 30495 respectively). The N-terminal 
GFP and myc tagged mouse Ahi1 constructs were generated by PCR amplification of 
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the mouse full-length Ahi1 cDNA from an untagged vector pSPORT6_msAhi1 
(available from the Mammalian Gene Collection). The PCR product was cloned into 
pEGFP-C1 (Clontech) and a myc-tagged pRK5 vector using NotI/SalI and BglII/SalI 
restriction sites respectively. Ahi1 mutant constructs were generated by site directed 
reverse PCR mutagenesis on the human Ahi1GFP vector. Primers used for mutagenesis 
are listed in Table 2.6. Full-length rat HAP1a was C-terminally tagged with an HA 
epitope (YPYDVPDYA) in a pRK5 vector and has been described previously (Kittler et 
al., 2004; Li et al., 1998). HAP1aGFP, HAP1bGFP and untagged HAP1b were a gift from 
X. J. Li. Rat HAP1amyc153-599, 215-599, 329-599 and 371-599 were generated in the 
lab by Alison Twelvetrees using PCR to amplify the cDNA and then cloned into an N-
terminal myc tagged pRK5 vector. Full-length mouse KIF5C was N-terminally myc 
tagged and cloned into the pRK5 vector by Mike Lumb. 
2.3.2 Polymerase Chain Reaction (PCR) 
PCR is a process of amplifying DNA in a thermocycler using DNA polymerase 
(Phusion, Finnzymes). The PCR reaction was assembled as described in Table 2.2 and 
subjected to a PCR programme with an appropriate annealing temperature and 
extension time (Table 2.3). The annealing temperature (Tm) is calculated for each set 
of primers using the online Thermoscientific Tm calculator and varies depending on 
GC content and length of the primers. The extension time and the number of repeats 
of the cycle depend on the length of the template DNA. 5μl of the resulting PCR 
product was ran on an agarose gel to confirm amplification and the rest of the product 
was purified using a DNA purification kit (Qiagen) following the manufacturer’s 
instructions. 
 
Primers were designed for PCR using a number of guidelines for efficient downstream 
reactions. Primers should be between 18-22pb long, with a G-C content in the range 
of 40-60%. The primers should have a melting temperature (Tm) between 42-65°C 
and the primer pairs should not differ my more than 5°C. Finally, primers should 
contain a C or G base at the 5’ or 3’ end for efficient binding to the specific DNA 
sequence due to the stronger bonding of G and C bases.  
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Table 2.2: Standard PCR reaction mix. 
Standard PCR reaction Stock conc. Final conc. 
10μl 5X HF buffer 5X 1X 
2.5μl forward primer 10μM 0.5μM 
2.5μl forward primer 10μM 0.5μM 
1μl template DNA - - 
1μl dNTP mix 10mM 200μM 
0.5μl Phusion (DNA polymerase) 2U/μl 0.02U/μl 
32.5μl ddH2O - - 
 
Table 2.3: PCR reaction and protocol. 
Step Temp (°C) Time  
Melting 98 5 minutes  
Melting 98 30 seconds  
Annealing X 30 seconds Repeat x 25-35 
Extension 72 1 minute per Kb  
Extension 72 10 minutes  
Hold 4 ∞  
 
2.3.3 Genotyping by PCR 
DNA was extracted from ear biopsies or tissue samples using the Hot Shot protocol 
(Truett et al., 2000) or from cell samples using the DNeasy Blood and Tissue Kit 
(Qiagen) following manufacturers guidelines. Genotyping PCR was carried out as a 
standard PCR reaction using the appropriate primers, to a final volume of 20μl (Table 
2.4). However, Taq Polymerase (NEB) was used instead of Phusion as high-fidelity 
amplification was not required. Taq buffer (4X) was used which contained dNTPs 
therefore, extra were not added. 5μl of the PCR product was ran on a 1.2% agarose gel 
to determine the size of the PCR products.  
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Table 2.4: Genotyping PCR primers. 
Primer Name Sense Symbol Product Size (bp) Sequence 
Cyfip1_234230 forward 
reverse 
aF 
aR 
259 (WT) 
454 (floxed) 
tggaagtaatggaaccgaaca 
gtaactacctataatgcagacctgaag 
CAS_R1_Term forward 
reverse 
aF 
a’R 
182 tggaagtaatggaaccgaaca 
tcgtggtatcgttatgcgcc 
LacZ_2_small forward 
reverse 
ZF 
ZR 
108 atcacgacgcgctgtatc 
acatcgggcaaataatatcg 
Cre recombinase forward 
reverse 
CF 
CR 
233 catttgggccagctaaacat 
taagcaatccccagaaatgc 
CYFIP1_deletion Forward 
reverse 
dF  
dR 
499 tggtagccctcttcttgtgga 
ctccaagattcccccaaaac 
2.3.4 Site-directed reverse PCR mutagenesis  
Mutagenesis PCR was carried out as a standard PCR reaction using appropriately 
designed primers, care was made to make sure the extension time was adjusted to 
allow for amplification of the whole vector. After PCR and purification, the product 
was then 5’ phosphorylated and ligated. 16μl of the purified PCR product was 
incubated at 65°C for 5 minutes and then on ice for 2 minutes to aid efficient 
phosphorylation. 2μl of T4 polynucleotide kinase (PNK) buffer and 1μl of PNK (NEB) 
was then added to the PCR product and the mixture was incubated at 37°C for 30 
minutes. 1μl of T4 DNA ligase (NEB) was then added to the reaction to ligate the PCR 
product overnight.  
2.3.5 Agarose gels 
0.8-1.2% agarose gels were made by dissolving the appropriate mass of agarose 
(Melfords) in 1X TBE buffer (National Diagnostics). As the gel was poured, 1μl 
ethidium bromide was added to label the DNA bands. Gels were loaded with DNA 
samples diluted with 6X loading dye (Table 2.5), a 10 Kb ladder (Bioline) and were 
run at 90V in 1X TBE. Resolved DNA labelled with ethidium bromide was visualised 
using UV light. 
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2.3.6 Digestion and purification of DNA from agarose gels 
10μl purified PCR product or 1μg plasmid were digested with 1μl restriction enzyme 
(and 1μl of different enzyme for double digests), 2μl 10X enzyme buffer (NEB), 1μl 
20X BSA (NEB), and filtered ddH2O to a 20μl final volume. Digestions were incubated 
at 37°C for 1-2 hours. Digestions were then run on an agarose gel as described above. 
DNA bands of interest were visualised by UV and excised using a scalpel. DNA was 
extracted from the gel using a gel extraction kit (Qiagen) following the manufacturer’s 
instructions. 
2.3.7 Ligations 
Ligation reactions consisted of 2μl T4 DNA ligase buffer (NEB), 1μl T4 DNA ligase 
(NEB), 10μl insert, 2μl vector and 5μl ddH20. An estimated 1:5 ratio of insert to vector 
was used and adjusted if necessary to optimise ligation efficiency. The reaction was 
incubated at 4°C overnight. 
 
Table 2.5: Bacterial culture and molecular biology solutions 
Solutions Components 
Luria-Bertani Broth (LB) 10g NaCl, 10g Tryptone 
5g Yeast extract 
H2O up to 1L 
Luria-Bertani Broth Agar (LB 
Agar) 
10g NaCl, 10g Tryptone 
5g Yeast extract 
10g Agar, H2O up to 1L 
TBE 89 mM Tris 
89mM Boric acid pH 8.3 
8.32mM Na2EDTA 
Loading dye (6X) 40% sucrose 
0.25% bromophenol blue 
H2O 
Ampicillin 100 µg/ml 
Kanamycin 30 µg/ml 
Chloramphenicol 30 µg/ml 
Spectinomycin 100 µg/ml 
 
Materials and Methods 
 
 80 
2.3.8 Bacterial growth media and plates 
Bacteria were grown at 37°C in LB or grown on plates made of LB agar. Each were 
supplemented with appropriate antibiotic depending on the resistance gene present 
on the plasmid being amplified (Table 2.5). 
2.3.9 Production of chemically competent bacterial cells 
Chemically competent TOP10 E. coli (Invitrogen) were produced in the lab by 
Nathalie Higgs. Briefly, cells from a single colony were cultured at 37°C overnight in 
5ml LB. 1.5ml of this preculture was used to inoculate two flasks, each containing 
150ml of LB. Flasks were incubated at 37°C until an OD600 of 0.6 was reached. Cells 
were then cooled on ice for 30 minutes before being harvested by centrifugation. Cells 
were slowly resuspended in 60ml buffer TfBI (a mix of Solution A: 30mM KAc, 
100mM KCl, 10mM CaCl2.2H2O, dH2O to a final volume of 700ml, autoclaved to 
sterilise and Solution B: 50mM MnCl2, 15% glycerol, dH2O to a final volume of 300ml 
and sterilised by filtration using a 0.45 um filter). Cells were harvested once more by 
centrifugation and very gently resuspended in 6ml buffer TfBII (a mix of Solution C: 
10mM NaMOPS, 75mM CaCl2.2H2O, 10mM KCl, dH2O to a final volume of 70ml, 
autoclave to sterilise and Solution D: 15% glycerol, dH2O to a final volume of 30ml 
and sterilised by filtration using a 0.45 um filter). Cells were aliquoted and 
immediately snap frozen in liquid nitrogen and stored at -80°C. 
2.3.10 Transformation of chemically competent bacterial cells 
In house produced chemically competent TOP10 E.coli or commercially available 
OneShot TOP10 E.coli (Invitrogen) were transformed using a heat shock protocol.  
50μl of cells were thawed on ice for each transformation reaction. 2-10μl of ligation 
reaction, 2μl clonase reaction or ~50ng plasmid DNA was added to the cells and 
incubated on ice for 30 minutes. Cells were heat shocked at 42°C for 30 seconds then 
placed back on ice for 2 minutes. 200μl of SOC media (2% glucose in Luria-Bertani 
medium (LB), Table 2.5) was added to the cells and they were incubated at 37°C for 1 
hour at 225 rpm to recover. Finally, cells were spread onto antibiotic selection LB agar 
plates and incubated overnight at 37°C. Bacterial colonies were picked and cultures 
inoculated the next day. For screening ligations, colonies were picked and grown in 
5ml LB plus antibiotic overnight, plasmid DNA was extracted and analysed by 
restriction digest. Positive results were confirmed with DNA sequencing. 
 
Materials and Methods 
 
 81 
2.3.11 Maxi and mini preparation of plasmid DNA 
Plasmid DNA was prepared from 3ml (mini) or 200ml (maxi) overnight bacterial 
cultures using the GelElute Plasmid Mini Prep Kit (Sigma) or the Endotoxin-free 
Maxiprep Kit (Promega), following manufacturer’s protocols. 
2.3.12 LR clonase reaction (Gateway Cloning System) 
Entry vectors (pENTR) (Invitrogen) containing a specific gene of interest were 
purchased from commercial cDNA clone libraries. pENTR vectors contain the cDNA 
flanked by attL recombination sites, which are capable of recombining with attR sites 
present on destination (pDEST) vectors. Therefore, in the presence of the 
recombinase enzyme LR clonase (Invitrogen), the cDNA of a gene of interest in a 
pENTR vector can be easily cloned into a variety of pDEST vectors containing 
different N and C terminal tags to quickly generate many different expression clones. 
300ng of pENTR vector and 150ng of pDEST vector were made up to a total volume 
of 9μl with TE buffer (1mM EDTA, 10mM TRIS pH 8), 1μl of LR clonase was added 
and the reaction was incubated overnight at room temperature. The clonase was then 
denatured with 1μl Proteinase K (Invitrogen) for 10 minutes at 37°C then stored at 
4°C. 2μl of clonase reaction was then transformed into chemically competent OneShot 
TOP10 E. coli (Invitrogen). 
 
pENTR and pDEST vectors commonly contain different antibiotic resistance genes 
therefore, pDEST vectors can be selected for over pENTR vectors following 
recombination by plating transformed bacteria onto the appropriate antibiotic. To 
confirm that the pDEST vectors have undergone recombination, positive colonies 
should die when grown in media containing chloramphenicol. pDEST vectors contain 
a chloramphenicol resistance gene between the attR sites which is lost upon 
recombination with a gene of interest. If the pENTR and pDEST vectors contained the 
same antibiotic resistance gene, following recombination the clonase reaction was 
digested with a specific restriction enzyme chosen to linearise only the pENTR vector 
prior to transformation. The Proteinase K was denatured for 20 minutes at 65°C. 2μl 
enzyme buffer (NEB) 1μl appropriate enzyme and 7μl filtered ddH2O was added to the 
whole 10μl clonase reaction and incubated at 37°C for 2 hours. Restriction enzyme 
was then denatured for 20 minutes at 65°C before 5μl of the digestion was 
transformed into chemically competent OneShot TOP10 E. coli (Invitrogen).  
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Table 2.6: List of primers used for molecular biology. 
Construct Sense Sequence 
msAhi1_eGFP forward 
reverse 
catcatcGCGGCCGCgagccagaaactccagagaag 
catcatGTCGACtcagttggtttgtgacttcgt 
msAhi1_myc forward 
reverse 
catcatAGATCTgagccagaaactccagagaag 
catcatGTCGACtcagttggtttgtgacttcgt 
hAhi1_R351X forward 
reverse 
cacTgaactgatagacttaagt 
aatgtaaactcccaagaca 
hAhi1_R435X forward 
reverse 
cttTgaggctctgatga 
caaatagggaaaattttcat 
hAhi1_V433D forward 
reverse 
aagAcatcctgttctttgag 
taggactctcatcagagcc 
hAhi1_Y933C forward 
reverse 
gctGcaatggaacatttc 
gtttgaacatttcagcctc 
CYFIP1_SNP1(S431N) forward 
reverse 
ccgacaAcgctgaagagtac 
ggcagtccttgttggagtact 
CYFIP1_SNP2(R440C) forward 
reverse 
acgTgctacaactacaccag 
ggcacgctcgtactctt 
CYFIP1_SNP3(R766S) forward 
reverse 
caatAgtctgatcacccagc 
aggtctattgatctgccga 
CYFIP1_SNP4(Y777C) forward 
reverse 
tccctagaactggcgattggac 
cttaCacatggctgctgagac 
CYFIP1_SNP5(R826Q) forward 
reverse 
gttccAggaggccaacca 
atggcgtcgaagccgt 
CYFIP1_SNP2 KASPar forward1 
forward2 
reverse 
gaaggtgaccaagttcatgctgagtacgagcgtgccacgc 
gaaggtcggagtcaacggattaagagtacgagcgtgccacgt 
catcctcacctccactagggcaa 
CYFIP1_SNP3 KASPar forward1 
forward2 
reverse 
gaaggtgaccaagttcatgctcggcagatcaatagacctcaatc 
gaaggtcggagtcaacggattctcggcagatcaatagacctcaata 
tgctgagacgcgctgggtgat 
CYFIP1_SNP4 KASPar forward1 
forward2 
reverse 
gaaggtcggagtcaacggattgcgcgtctcagcagccatgta 
gaaggtgaccaagttcatgctcgcgtctcagcagccatgtg 
cactttcaaatcgtccaatcgccagtt 
CYFIP1_SNP5 KASPar forward1 
forward2 
reverse 
gaaggtgaccaagttcatgctcacgttgtggttggcctccc 
gaaggtcggagtcaacggattacacgttgtggttggcctcct 
tggacggcttcgacgccatgtt 
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2.3.13 Generation of Ahi1 shRNA constructs 
RNA interference (RNAi) enables the specific knockdown of mRNA by the 
introduction of short double stranded RNA molecules that are complementary to the 
gene of interest. These dsRNA molecules are cleaved to short 18-21 bp fragments by 
the enzyme, Dicer, and the resulting small interfering RNAs (siRNAs) are recruited to 
the RNA-Induced Silencing Complex (RISC). This effector complex is able to 
distinguish between the sense and antisense RNA strands, degrade the sense strand 
and utilise the antisense strand to target genes for silencing. Small hairpin RNAi 
(shRNAi) was developed to allow long-term knockdown of target proteins in cells by 
expressing the shRNA from a transfected DNA based vector.  
 
The Ahi1 shRNA construct was made according to the pSUPER manufacturer’s 
protocol (Oligoengine). The oligonucleotides used to create the Ahi1 shRNA construct 
correspond to the nucleotides 2503-2523 of mouse Ahi1 as described in (Hsiao et al., 
2009) (5’-GAAACTGTCACAGAGGTGATA-3’). A scrambled sequence was used as a 
control (5’-GGAATCTTCCTGCTTTGGG-3’).  The oligonucleotides were annealed with 
annealing solution (100 mM NaCl, 50 mM HEPES pH 7.4), digested with BamH1 and 
HindIII and cloned into the BglII and HindIII sites of pSUPERneoGFP (Oligoengine). 
2.4 KASPar Genotyping 
KASPar (KBiosciences Competitive Allele-Specific Polymerase Chain reaction) 
genotyping is a simple, quick and cost effective way to determine the allele frequency 
in a sample and control set. KASPar is a homogeneous, FRET bases, endpoint 
genotyping technology and consists of two main components. The first is the KASPar 
assay mix which is made up of competing, forward primers targeting the variant of 
choice, and one common reverse primer. Each forward primer has a unique tail 
sequence that corresponds with two universal FRET cassettes, one labelled with 
FAMTM dye and the other with HEXTM dye. The second component is the KASPar 
master mix, which contains the universal fluorescent FRET cassettes and Taq 
polymerase in an optimised buffer solution. The two forward competing primers, 
targeting the wild-type allele and variant allele. During PCR one of the allele-specific 
forward primers matches the genomic region and the target region is amplified with 
the common reverse primer. As PCR progresses the level of allele specific tails 
increase and the fluor-labelled part of the complementary FRET cassette gets 
incorporated. This releases the fluor from its 3’ end quencher to produce a fluorescent 
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signal which indicates the genotype of the genomic sample. 
2.4.1 Primer design and PCR optimisation 
KASPar genotyping primers were designed to target the desired mutation by Dr. 
Andrew McQuillin using Primer Picker (K Bioscience, UK). Two almost identical 
primers were designed against the genomic region of each SNP.  The primers differed 
in their last base, one contained the wild-type base while the other contained the rare 
variant base. Normal primer design guidelines were also considered (see page 76). 
Primers listed in Table 2.6. Optimisation of genotyping conditions was done using 
both the specific forward primers and the common reverse primer. The six different 
master mixes tested are outlined in Table 2.7 and the volumes of the allele mixtures 
are described in Table 2.8. The conditions used varied the concentration of MgCl2 
present in the reaction, and the addition or absence of DMSO. The addition of Mg2+ 
ions is essential as they remove phosphates from the dNTPs allowing the reaction to 
continue. The addition of organic additives such as DMSO, inhibit the formation of 
DNA secondary structures and aid amplification in GC-rich regions. DMSO also 
lowers the Tm of DNA by changing its conformation, facilitating the annealing of 
primers to the genomic DNA and enhancing amplification. Optimisation was carried 
out on wild-type DNA. Ideally, a positive sample containing the variant of interest 
would also be used to test the second forward primer however, a positive sample was 
not available in this case. 
 
The optimised conditions were used to carry out case-control genotyping on DNA 
samples. DNA samples were aliquoted onto 384-well PCR plates and dried down prior 
to genotyping. The master mix for the PCR procedure was dispensed into each well of 
the plate using the Epmotion 5075 (Eppendorf, UK). The plate was then mixed and 
spun in a centrifuge at 1500rpm for 1 minute before loading into the LightCycler 480 
(Roche Diagnostics, UK). The thermal cycling conditions for the endpoint genotyping 
are outlined in Table 2.9. For all SNPs genotyped, 17% were duplicated to detect error 
and confirm reproducibility of genotypes on a cross check plate consisting of case and 
control duplicates. All the data was analyses to confirm Hardy-Weinberg equilibrium 
(HWE) where possible i.e. all the variants genotyped occurred normally and were not 
being influenced by natural selection.  
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2.4.2 Endpoint genotyping 
Endpoint genotyping was conducted using LC480 software (Roche Diagnostics, UK). 
Each fluorescent output was measured and samples were differentiated depending on 
the signal recorded (Figure 2.1). Any samples that did not cluster closely in the wild-
type, heterozygous or homozygous mutant regions were manually labelled as 
unknown and regenotyped on the cross check plate. Additionally, samples which 
failed to amplify in the initial genotyping run were plated on the cross check plate 
from the stock genomic DNA sample following dilution to the appropriate 
concentration (33.3ng/µl). 
 
Genotype data was accumulated and complied to confirm no differences were present 
between the original calls and the cross check plate. If such differences were present 
samples were either removed or sequenced to verify calls. As to be expected for each 
SNP genotyped there was a number of samples which failed both the original and 
cross check genotyping, these samples were removed. 
2.4.3 KASPar statistical analysis 
Allelic associations for SNPs were performed using the Chi-square test. A cut-off 
significance of p<0.05 was used. Minor allele frequency was calculated as the number 
of mutant alleles divided by the total number of alleles. 
 
Table 2.7: Optimisation conditions for KASPar genotyping 
Reagents A B C D E F 
 1.8mM 
MgCl2 
2.2mM 
MgCl2 
2.5mM 
MgCl2 
2.8mM 
MgCl2 
5% 
DMSO 
10% 
DMSO 
DNA 1 1 1 1 1 1 
2X Rxn mix (+KTAQ) 2 2 2 2 2 2 
Assay mix ½ 0.11 0.11 0.11 0.11 0.11 0.11 
MgCl2 1:10 0 0.32 0.56 0.8 0 0 
Water 0.89 0.57 0.33 0.09 0.69 0.5 
DMSO 0 0 0 0 0.2 0.4 
Total 4 4 4 4 4 4 
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Table 2.8: Allele mix for KASPar assay. 
Reagents Concentration in 
Assay Mix (µM) 
Volume in 1X 
Assay Mix (µl) 
Allele specific primer 1 (100µM) 12 12 
Allele specific primer 2 (100µM) 12 12 
Common reverse primer (100µM) 30 30 
Water/TrisHCL (10mM, pH8.3)  46 
Total  100 
 
 
 
Table 2.9: Thermocycling conditions for KASPar genotyping. 
Programme Target Temp (°C) Hold Ramp Rate °C/s Cycles 
Hot start activation 94 15 min 4.8 1 
1st amplification 94 
65 
20 sec 
1min 
2.5 
2.5 
10 
2nd amplification 94 
57 
20 sec 
1min 
2.5 
2.5 
26 
Reading 37 
38 
1 sec 
1sec 
2.5 
0.06 
1 
3rd amplification 94 
57 
20 sec 
1min 
2.5 
2.5 
3 
Reading 1 37 
38 
1 sec 
1 sec 
2.5 
0.06 
1 
4th amplification 94 
57 
20 sec 
1min 
2.5 
2.5 
3 
Reading 2 37 
38 
1 sec 
1 sec 
2.5 
0.06 
1 
Cooling 40 1 sec 2.5 1 
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Figure 2.1: Example of KASPar endpoint genotyping. 
An example of the KASPar endpoint genotyping output from one of the case control plates 
genotypes for a single variant of a gene. Wild-type alleles are represented by the blue 
triangles, heterozygous individuals are represented by the red triangles and individuals 
homozygous for the mutation are represented by the green triangles. Both the grey and pink 
circles are samples which have failed or are undefined and were repeated on the cross-check 
plate. 
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2.5 Cell Culture  
2.5.1 Cell culture media and reagents 
Table 2.10: Composition of cell culture solutions 
Solutions Components 
Phosphate buffered saline 
(PBS) 
137 mM NaCl, 2.7 mM KCl  
10 mM Na2HPO4,2 mM KH2PO4 
Trypsin solution 137 mM NaCl, 2.7 mM KCl  
8 mM Na2HPO4, 1.5mM  KH2PO4 
2.5 μg/ml Trypsin (Sgima)  
0.2 μg/ml EDTA, Phenol Red 
Dissection media HBSS (GIBCO) 
10mM HEPES 
Attachment media Minimal Essential Media (GIBCO)  
10% horse serum  
1 mM sodium pyruvate 
0.6% glucose 
Maintenance media Neurobasal (GIBCO) 
2% B27 (GIBCO) 
1% glutaMAX (GIBCO) 
 33 mM glucose 
Cell line culture media Dulbecco’s Modified Eagle Medium 
(GIBCO) 
10% foetal bovine serum (FBS)  
1% penicillin/streptomycin 
MEF culture media Dulbecco’s Modified Eagle Medium 
(GIBCO) 
15% foetal bovine serum (FBS)  
1% penicillin/streptomycin 
Electroporation buffer 15 mM NaH2PO4  
35 mM Na2HPO4, 5 mM KCl  
10 mM MgCl2, 11 mM Glucose  
100 mM NaCl, 20 mM HEPES 
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2.5.2 COS-7, HEK and MEF cell culture 
Cells were cultured in 10cm dishes with 10ml of culture media at 37°C in 5% CO2 
humidified atmosphere. When confluent, cells were briefly washed in PBS then 
detached using 1ml trypsin solution and pelleted at 1000 rpm for 2 minutes. Following 
resuspension cells were plated at an appropriate dilution into fresh dishes and media. 
 
For biochemistry and immunofluorescence cells were transfected using 
Nucleofector® technology (Amaxa) following the manufacturer’s protocol and plated 
into either fresh dishes or dishes containing 13mm glass coverslips. Briefly, cells to be 
nucleofected were detached from their dishes as above and pelleted. The cell pellet 
was resuspended in 100μl per transfection of electroporation buffer. 3-6μg of each 
plasmid required was added to each nucleofection cuvette followed by 100μl of the 
cell suspension. Cells were nucleofected and then immediately plated in complete 
culture media and incubated at 37°C in 5% CO2.  
2.5.3 Generation of transformed MEF lines 
Mouse embryonic fibroblasts (MEFs) were cultured from E10.5 transgenic mouse 
embryos by Prof. Josef Kittler. Briefly, mice were crossed to generate litters of the 
appropriate genotype. Pregnant female mice were killed when embryos were E10.5 
using schedule 1 methods following United Kingdom regulations. The uterus was 
removed and placed onto ice cold dissection media. The embryos within their placenta 
were harvested and placed into separate wells containing dissection media. 
Separately, embryos were carefully dissected from the placenta and the head and 
internal organs were removed. The remaining tissue was roughly cut to increase 
surface area and incubated with 30μl 0.125% trypsin for 10 minutes at 37°C. The 
trypsin was removed and tissue was washed twice with dissection media. Tissue was 
triturated in 1ml of warm MEF culture media by gently pipetting up and down with a 
1ml pipette until a single cell suspension was achieved. Cells were counted using a 
hemocytomer and erythrosine B dye to exclude dead cells before being plated. Media was 
changed after 24 hours. Media was changed every two days in the first week following 
preparation and cells were split if necessary when almost confluent. Following repeated 
splitting cells gained immortal characteristics and spontaneously transformed. After 8-10 
passages of the transformed culture the cells were amplified and frozen down slowly in 
FBS + 10% DMSO and stored at -80°C. 
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2.5.4 Primary neuronal cell cultures 
2.5.4.1 Neuronal culture from E18 Sprague-Dawley rats 
Cortical and hippocampal neurons were cultured from E18 Sprague-Dawley rats as 
previously described (Banker and Goslin, 1998).  Briefly, timed pregnant rats were 
killed by a schedule 1 method following United Kingdom regulations. E18 embryos 
were removed and placed onto ice-cold dissection media. Brains were isolated, 
meninges were removed and hippocampi and cortices were dissected. Dissected tissue 
was then incubated in 0.125% trypsin diluted in dissection media (5 mL) for 15 
minutes at 37°C. Tissue was washed twice in dissection media and triturated to a 
single cell suspension in attachment media using a fire-polished glass pasteur pipette. 
Following trituration, cells were counted using a hemocytomer and erythrosine B dye 
to exclude dead cells before being plated accordingly on pre-prepared poly-L-lysine 
(PLL) coated plates or 13mm glass coverslips in attachment media. PLL was incubated 
for a minimum of 3 hours with coverslips for hippocampal culture and plates for 
cortical culture at 500μg/ml and 50μg/ml respectively. Cells were incubated at 37°C 
in 5% CO2 humidified atmosphere. The media was changed 4-6 hours later to 
neuronal maintenance media.  
2.5.4.2 Neuronal culture from E16 WT or transgenic mice 
Cortical and hippocampal neurons were cultured from wild-type or transgenic E16 
mouse litters using the same protocol as described above for rat cultures. However, 
during transgenic preparations the tissue from individual embryos was dissected, 
triturated and plated separately to ensure no cross contamination of genotypes. A 
sample of remaining tissue from each embryo was retained for genotyping by PCR. To 
obtain mouse transgenic neuronal cultures appropriate animals were crossed to 
produce litters with the desired genotypes.  
2.5.5 Lipofectamine transfection 
Neurons were transfected at the appropriate age using Lipofectamine 2000 
(Invitrogen). For 2 coverslips in individual wells of a 24 well plate, 1μg DNA was 
combined with 100μl unsupplemented Neurobasal (NB) and 2μl Lipofectamine with 
100μl NB in separate tubes. Following 5 minutes incubation at RT the Lipofectaime 
solution was gently combined with the DNA and incubated for 30 minutes at RT to 
complex. 300μl pre-warmed NB + 0.6% glucose was added to the complex solution 
and gently mixed, then 250μl of this was dropped carefully onto each coverslip. 
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Coverslips were incubated at 37°C for 2 hours followed by replacing the transfection 
media with 1ml pre-warmed conditioned maintenance media. Volumes were scaled 
up for additional coverslips or larger dishes.  
2.6 Biochemistry 
2.6.1 Preparation of whole brain and brain region lysates 
Adult rat or mouse whole brains were mechanically homogenised on ice in 10ml and 
5ml HEPES buffer respectively (50mM HEPES pH 7.5, 0.5% Triton X-100, 150mM 
NaCl, 1mM EDTA, 1mM PMSF, 10μg/ml antipain, pepstatin and leupeptin) and 
solubilised for 1 hour rotating at 4°C. Solubilised material was ultracentrifuged at 
38000 rpm for 40 minutes and the supernatant (solubilised protein) was collected 
and quantified using the Bradford assay following the manufacturer’s protocol 
(BioRad).  
 
For brain region lysates, cortex, hippocampus and cerebellum were dissected in 
HEPES buffered HBSS from P16 or P55 mouse brains. Samples were weighed and 
homogenised on ice in the appropriate volume of HEPES buffer (7μl/1mg) and 
solubilised for 1 hour rotating at 4°C. Solubilised material was then centrifuged at 
14000 rpm for 10 minutes. The supernatant was collected and quantified as above. 
2.6.2 Immunoprecipitation from brain lysate or transfected COS-7 cells 
For immunoprecipitation (IP) from whole brain lysate, 2mg of brain lysate in a 
volume of 0.5mL HEPES buffer (see above) was incubated with 2-4μg antibody 
overnight, followed by a 1 hour incubation with 25µl of a 50% slurry of protein A or G 
beads (Generon), depending on the species of antibody. For IP from transfected COS-
7 cells, a 10cm dish of transfected cells was solubilised in 0.5mL TRIS buffer for 1 hour 
(50mM Tris pH 7.5, 0.5% Triton, 150mM NaCl, 1mM EDTA, 1mM PMSF, 10µg/mL 
antipain, leupeptin, pepstatin) and centrifuged at 12 000 rpm for 10 minutes to pellet 
the cell debris. Supernatant was either incubated with 2μg antibody for 2 hours 
followed by 1 hour with 25µl of protein A or G beads (50% slurry), depending on the 
species of antibody, or 10μl of a 50% slurry of GFP TRAP beads (Chromotech) or myc 
agarose beads (SIGMA) for GFP and myc IPs respectively. All incubations were under 
rotation at 4°C. Finally, beads were washed 3-5 times with the appropriate buffer to 
remove any non-specific binding and analysed by SDS-PAGE and western blotting. 
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2.6.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
All samples to be analysed by SDS-PAGE were denatured in 3X sample buffer (150mM 
Tris pH 8, 6% SDS, 0.3M DTT, 0.3% Bromophenol Blue, 30% glycerol) for 6 minutes at 
100°C and either stored at -20°C or immediately loaded onto a polyacrylamide gel. 
Gels were formed of a 10% resolving gel (10% acrylamide mix (ProtoGel, National 
Diagnostics), 0.375M Tris pH 8.8, 1% SDS, 1% ammonium persulphate, 0.04% TEMED) 
and a 5% stacking gel (5% acrylamide mix, 0.125M Tris pH 6.8, 1% SDS, 1% ammonium 
persulphate, 0.1% TEMED) and cast in Novex 1.5mm cassettes (Invitrogen). Gels were 
submerged in running buffer (Table 2.11) (National Diagnostics) in a Novex XCell 
SureLock Mini-Cell system (Invitrogen) and electrophoresis was carried out at 120V 
for ~2 hours until the dye front reached the end of the cassette.  
2.6.4 Transfer of SDS-PAGE gels 
Samples subjected to SDS-PAGE were transferred onto Hybond-ECL nitrocellulose 
membrane (GE Healthcare) using the Novex Blot Module transfer system. The gel and 
pre-wetted membrane were sandwiched between pieces of 3mm filter paper 
(Whatmann) and sponges to fill the Blot Module. The system was run for 2 hours at 
30V in 1X transfer buffer (Table 2.11) (National Diagnostics). Following transfer, the 
membrane was probed with Ponceau stain to reveal protein on the membrane. 
2.6.5 Western blotting 
Membranes were blocked for 1 hour with 4% milk in PBS-0.05% Tween (PBS-T). 
Blocked membranes were incubated over night at 4°C with primary antibodies, then 
washed 3 times with 4% milk PBS-T and incubated for 1 hour with HRP conjugated 
secondary antibodies diluted in blocking solution. After 3 times 10 minute washes 
with 4% milk PBS-T and one final wash with PBS-T the membranes were incubated 
with the Luminata Crescendo substrate (Millipore) for 1 minute. Bands were detected 
using an ImageQuant LAS 4000 CCD camera system (GE Healthcare). For western 
blot quantification densiometric analysis of protein bands was carried out using 
ImageJ (NIH, Bethesda, MD, USA). 
2.6.6 Stripping 
Membranes were washed two times with PBS-T for 10 minutes and then incubated in 
pre-warmed (37°C) stripping buﬀer for 30 minutes (Table 2.11). Membranes were 
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then washed in PBS-T 3 times for 10 minutes and blocked in 4% Milk in PBS-T for 1 
hour before incubation with the primary antibody. 
 
Table 2.11: SDS-PAGE and Western blotting buffers and solutions. 
Solutions Components 
10% resolving gel 10% Protogel (acrylamide solution)  
375 mM Tris pH 8.8  
1% SDS 
1% ammonium persulphate (APS) 
0.04% TEMED 
Stacking gel 5% Protogel (acrylamide solution) 
125 mM Tris pH 6.8  
1% SDS, 1% APS 
0.004% TEMED 
10x Running buﬀer 250 mM Tris  
1.92 M glycine  
1% SDS 
10x Transfer buﬀer 250 mM Tris  
1.92 M glycine  
20% methanol  
0.35% SDS 
Ponceau stain 5% acetic acid  
0.1% Ponceau S 
Membrane blocking 
solution 
4% non fat milk  
0.05% Tween  
in 1x PBS 
Stripping buﬀer 6.25 mM Tris pH 6.8  
2% SDS  
0.7% mercapto-ethanol  
in 1x PBS 
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2.7 Immunofluorescence and Microscopy 
2.7.1 Confocal microscopy 
All imaging was carried out using a Zeiss LSM700 upright confocal microscope unless 
otherwise stated. Objectives used are summarised in Table 2.12. 
 
Table 2.12: Confocal microscope objectives. 
Objective Emersion 
media 
Microscope Numerical Aperture 
63X Oil LSM700 1.4 
40X Oil LSM700 1.3 
63X Water LSM700 1.0 
10X Air LSM700 0.3 
5X Air LSM700 0.16 
20X Air Neurolucida 0.45 
 
2.7.2 Live FRAP imaging of dendritic spines 
Transfected cells grown on 13mm glass coverslips were perfused with ACSF (10mM 
HEPES pH 7.4, 125mM NaCl, 10mM D-Glucose, 5mM KCl, 2mM CaCl2, 1mM MgCl2 
pH7.4) at 37°C and imaged with a 63X water objective. Movies were captured using 
the 488 laser at 2%, a 3.5X optical zoom and a 512x512 pixel resolution for 50 cycles 
(1.94 seconds/cycle). The pixel dwell time was set to 3.15μsec and pinhole size was set 
to 2μm. Bleaching of the spine head with 100% laser intensity for 10 iterations 
occurred after 10 cycles. Spines selected for photobleaching all had a clearly formed 
head. Movies were saved and analysed in ImageJ (NIH, Bethesda, MD, USA).  
2.7.3 Immunocytochemistry 
Neurons or cells lines grown on 13mm coverslips were removed from their media and 
immediately fixed in 4% PFA (PBS, 4% paraformaldehdye, 4% sucrose, pH 7) for 7 
minutes. Coverslips were gently washed in PBS then blocked and permeablised for 10 
minutes in block solution (PBS, 10% horse serum, 0.5% BSA, 0.2% Triton X-100). 
Coverslips were incubated with primary antibody diluted in block solution for 1 hour 
at RT. They were washed 5X in PBS then incubated for another hour with secondary 
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antibody. Finally they were washed 5 times in PBS then mounted onto glass slides 
using ProLong Gold antifade reagent (Invitrogen). Once the mount was set coverslips 
were sealed with nail varnish. For surface staining the protocol was the same however, 
block solution was used without detergent. Cells were visualised using a Zeiss 
LSM700 confocal microscope and a 63X oil immersion objective, images were 
digitally captured using LSM software.  
2.7.4 Immunohistochemistry 
2.7.4.1 Nissl and antibody staining 
Adult mouse brains were dissected whole and fixed in 4% PFA for 24 hours at 4°C. 
Brains were then cryoprotected by incubating in PBS 30% sucrose for 24 hours at 4°C 
and could then be stored at -80°C indefinitely. For Nissl staining, brains were 
embedded in 2% agarose (SIGMA) and the agarose block was glued (Lotite) in place 
for sagittal sectioning on the slicing stage. 30μm slices were made using a vibratome 
(Leica); slices were carefully removed from the agarose and stored at -20°C in 
cryprotect solution (30% polyethylene glycol, 30% glycerol in PBS). Slices were 
washed, blocked and permeablised in PBS 0.5% Triton X-100 during the day. 
Following 2X 5 minute washes in PBS slices were incubated with Neurotrace Green 
Fluorescent Nissl Stain (1:200 with PBS, Molecular Probes) overnight at 4°C. Slices 
were washed for 10 minutes in PBS 0.5% Triton X-100, then twice for 5 minutes in 
PBS, followed by a final 2 hour wash with PBS.  
 
For antibody staining cryoprotected brains were mounted and serially cryosected in a 
Bright OTF-AS Cryostat (Bright Instrument, Co. Ltd) at 30μm thickness. Again slices 
were stored at -20°C in cryoprotect solution (30% polyethylene glycol, 30% glycerol 
in PBS). Slices were washed blocked and permeablised in block buffer during the day 
(10% HRS, 0.2M glycine, 3% BSA, 0.5% Triton X-100). Slices were incubated with 
primary antibody diluted in block buffer overnight at 4°C before being washed 3X 30 
minutes in PBS-0.5% Triton. Secondary antibody was incubated with slices for 4 
hours at RT before 3X 30 minute final washes in PBS-0.5% Triton. All slices were 
carefully floated onto glass coverslips and mounted using ProLong Gold antifade 
reagent (Invitrogen). Slices were imaged using a Zeiss LSM700 confocal microscope 
and a 5X or 10X air objective. A series of overlapping images were taken and merge 
together on PhotoShop (Adobe) using the photomerge tool. 
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2.7.4.2 X-gal staining 
Adult mouse brains were dissected whole and mounted using glue without fixation on 
the slicing stage. Brains were supported with blocks of 2% agarose. 300μm slices were 
made using a vibratome (Leica); slices were carefully transferred to a 12 well plate and 
stored in PBS. Slices were post-fixed in fix buffer (0.1M phosphate buffer pH7.3, 5mM 
EGTA pH 7.3 (Sigma), 2mM MgCl2, 0.2% glutareldahyde, 0.4% PFA, 0.01% 
deoxycholate, 0.02% NP-40) for 15 minutes at RT. Slices were washes 3X 15 minutes 
with gentle rotation in wash buffer (0.1M phosphate buffer pH 7.3, 2mM MgCl2, 
0.01% deoxycholate, 0.02% NP-40). Slices were then incubated with filter sterilised 
staining solution (0.1M phosphate buffer pH 7.3, 2mM MgCl2, 5mM potassium 
ferrocyanide, 5mM potassium ferricyanide, X-gal 1mg/ml added just before use) over 
night at 37°C with gentle rotation. Slices were washed another 3X 15 minutes, then 
dehydrated gradually in 50%, 70% and 100% ethanol. Slices can be stored in 100% 
ethanol until mounting. 
2.8 Image Analysis 
2.8.1 Synaptic enrichment and cluster analysis 
Single confocal images were acquired with the 63X objective for cluster analysis and 
synaptic enrichment experiments. An image of the cell was captured using a 0.5X 
zoom. From this, 3-5 sections of primary or secondary dendrite, ~100μm from the 
soma, were imaged with a 3.5X zoom (equating to a 30μm length of dendrite). 
Acquisition settings and laser power were kept constant within experiments. 
 
Synaptic enrichment and cluster analysis was carried out using Metamorph 
(Molecular Devices, Sunnyvale, CA, USA). Analysis was carried out on the zoomed 
images (3-5 per cell) and then averaged to give a value per cell. To quantify protein 
enrichment at synaptic sites, the length of dendrite was traced to generate the 30μm 
long dendritic region. A user-defined threshold was applied to the synaptic marker 
channel and regions were generated around the thresholded area within the traced 
dendrite. The dendrite and synaptic puncta regions were then transferred to the 
protein of interest channel. The fluorescence enrichment was measured as the average 
fluorescence intensity within the labelled synaptic puncta regions and normalised to 
the average intensity of the total dendritic process region. For cluster analysis, again 
the length of dendrite was traced to generate the 30μm long dendritic region. This 
region was applied to all cluster channels. A user-defined threshold was then applied 
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to all cluster channels and regions were generated around thresholded area within the 
traced dendrite. Number of regions and total area of regions per 30μm of dendrite 
were quantified as a readout for synaptic clusters. Clusters smaller than 0.01μm2 were 
excluded from the number of regions analysis. Thresholds were set individually for 
each cluster channel and kept constant across treatment conditions within an 
experiment. 
2.8.2 Fluorescence intensity analysis 
To quantify fluorescence intensity for shRNA knockdown characterisation, cells were 
imaged in a single plain of focus with the 63X objective and a 0.5X zoom. An 
appropriate threshold was applied to the cell fill channel and a cell region was 
generated. This region was transferred to the channel of interest and average pixel 
intensity within the region was calculated using ImageJ (NIH, Bethesda, MD, USA). 
Data was normalised to the average control value to give a percentage change in 
fluorescence intensity from 100%. Confocal stacks (0.5μm step size) were taken of 
representative cells and max projected for figures. 
 
Line scans used for protein localisation were performed in ImageJ using the 
PlotProfile function (NIH, Bethesda, MD, USA), pixel intensity was calculated as a 
function of distance along a manually drawn line and plotted on a graph. 
2.8.3 Dendritic spine FRAP analysis 
Movies were analysed using ImageJ (NIH, Bethesda, MD, USA). Initially, movies 
were subjected to the StackReg plugin to correct for drift between frames. A 
customised ImageJ plugin was then used to measure the fluorescence intensity of a 
manually selected ROI over the head of the spine normalised to the total fluorescence 
of the image to correct for photobleaching. These values were then normalised to the 
average of the first 10 frames and the lowest value in the data set was subtracted from 
all values to generate a set of data between ~1 and 0.  Finally, the average recovery 
data points across all movies were plotted on a graph against time and fitted to an first 
order exponential recovery curve (y = a*(1-exp(-b*x))) using Mathematica (Wolfram 
Research, Champaign, IL, USA). The average time constant was calculated as τ = 1/b 
where b is the rate constant. The mobile fraction was calculated as an average of the 
plateaued fluorescence level, taken as the last 20 frames, and presented as a 
percentage of the pre-bleached level. 
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2.8.4 Dendritic spine morphology analysis 
Confocal image stacks were acquired for spine morphology analysis with voxel 
dimensions of 0.19m x 0.19m x 0.57m. Spines were manually identified for 
analysis in Imaris software (Bitplane AG, Zurich, Switzerland). For spine 
classification custom parameters were used. Spines were classified into stubby, 
mushroom, long and thin, and filopodia categories using a ratio of spine head and 
neck diameters to spine length (Table 2.13). Classification was entirely automated 
until the final step where errors in classification were removed.  
 
Table 2.13: List of spine classification Matlab parameters. 
Spine 
Classification 
Matlab Plugin Parameters 
Stubby length(spine) < 0.8 and min_width(spine) > 0.1 
Mushroom 3 * max_width(head) > length(spine) and length(spine) > 0.8 
and min_width(spine) > 0.1 
Long, Thin length(spine) >= 1.20 * max_width(head) and length(spine) < 
3.5 and min_width(spine) > 0.1 
Filopodia length(spine) > 3.5 and min_width(spine) > 0.1 
 
2.8.5 Sholl dendrite analysis 
Confocal image stacks were captured using the 63X or the 40X objective for dendritic 
morphological analysis with voxel dimensions of 0.39m x 0.39m x 0.54m and 
0.63m x 0.63m x 1.0m respectively. Neuronal arbors were reconstructed by semi-
manual tracing using NeuronStudio (Wearne et al., 2005). Total dendritic length and 
total number of branch points per cell were calculated from the Sholl analysis output 
from NeuronStudio. To generate number of intersections as a function of distance 
from the soma the .swc trace file from NeuronStudio was imported into ImageJ (NIH, 
Bethesda, MD, USA) and this analysis was generated from the NeuroTracer plugin. 
 
Dendritic morphology in adult mice were analysed using the FD Rapid Golgi Stain kit 
(FD NeuroTechnologies) and Neurolucida (MBF Bioscience). For Golgi-stained Sholl 
analysis, impregnated brains were sliced at 150m using a vibratome (Leica). Well 
isolated hippocampal CA1 neurons were imaged at 20X using the Neurolucida 
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software system and an upright light microscope with a motorized stage (MBF 
Bioscience). The entire extent (apical and basal) of the dendritic tree was traced and 
reconstructed. Total dendritic length, total number of branch points (nodes) and 
intersections as a function of distance from the soma were calculated from the 
Neurolucida output file. Three males were analysed for each condition with a 
minimum of three cells traced per animal. When using animals from separate litters, 
each genotype was equally represented from each litter. 
2.9 Statistics 
All data were obtained using cells from at least three different preparations. Repeats 
for experiments are given in the figure legends as N numbers and refer to number of 
cells unless otherwise stated. All statistical analysis was carried out using GraphPad 
Prism (GraphPad Software, CA, USA) or Microsoft Excel. Data was tested for normal 
distribution with D’Agostino and Person to determine the use of parametric (unpaired 
student’s t-test, one-way ANOVA, two-way ANOVA) or non-parametric (Mann-
Whitney, Kruskal-Wallis) tests. Appropriate post-hoc tests were carried out in 
analyses with multiple comparisons. The Bonferroni’s post hoc test and the Dunn’s 
post hoc test were used to compare the data groups to their reference group or 
compare all the data groups for parametric and non-parametric analysis respectively. 
Data are shown as ± standard error of the mean (SEM). Data was considered 
significant if the p value was < 0.05. Stars represent p values as follows: *p<0.05, 
**p<0.01, ***p<0.001.  
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Chapter 3 
CYFIP1 and CYFIP2 CNVs in neuronal 
morphology and synaptic 
maintenance 
3.1 Introduction 
The 15q11-13 region of the human genome is a common locus for genetic structural 
rearrangement and often results in abnormal neurological phenotypes. In particular, 
CNVs at the 15q11.2 locus have been associated with intellectual disability (ID) 
behavioural abnormalities, epilepsies, autism spectrum disorder (ASD) and 
schizophrenia (SCZ) (Table 3.1). This genetic locus encodes four genes Tubgcp5, 
Cyfip1, Nipa1 and Nipa2 and the non-coding mRNA Whamml1. Of the four genes, 
Cyfip1 is highly expressed within the brain and has been robustly associated with a 
variety of neuropsychiatric disorders independent of its neighbouring genes. 
 
Indeed, there is mounting evidence to suggest that Cyfip1 is the dosage-sensitive gene 
within this genetic locus and that altered expression of this protein could be 
contributing to disease onset. Firstly, CNV of Cyfip1 specifically has been linked to 
ASD and behavioural disturbances (Doornbos et al., 2009; Leblond et al., 2012). 
Genome wide expression profiling of patients with a 15q11-13 duplication has 
specifically demonstrated an up-regulation of Cyfip1 mRNA in those that suffer from 
ASD (Nishimura et al., 2007). Furthermore, a direct deletion of the Cyfip1 gene was 
identified in an autistic patient who also had a SHANK2 deletion (Leblond et al., 
2012). Additionally, a small screen with less than 100 cases and controls found an 
association of CNVs in Cyfip1 with SCZ while genotyping in the Chinese Han 
population revealed a significant SCZ-associated SNP within Cyfip1 (Tam et al., 2010; 
Zhao et al., 2013b). Taken together, Cyfip1 is emerging as a candidate susceptibility 
gene for neuropsychiatric disorders. On the other hand, the homologue of CYFIP1, 
CYFIP2, has no direct association with neuropsychiatric disorders. However, the gene 
is located on chromosome 5 in the q33.3 region which has been identified as a 
susceptibility locus for SCZ and attention-deficit/hyperactive disorder (ADHD) via 
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linkage studies (Arcos-Burgos et al., 2004; Gurling et al., 2001). 
 
Protein analysis has revealed human CYFIP1 and CYFIP2, share 88% amino acid 
sequence homology and the proteins are conserved across species. Mouse CYFIP1 and 
CYFIP2 share 98.7% and 99.9% amino acid sequence homology with human CYFIP1 
and CYFIP2 respectively. Single CYFIP orthologs have also been identified in flies (D. 
melanogaster) and worms (C. elegans) sharing 67% and 51% amino acid identity 
respectively with the human proteins. Zebrafish (D. rerio), like mammalian species 
have two conserved CYFIP proteins (Pittman et al., 2010; Schenck et al., 2001). CYFIP 
proteins are widely expressed and enriched in brain (Schenck et al., 2001). dCYFIP 
mRNA was detected ubiquitously in flies and is present throughout the fly life cycle. 
During development the highest levels of dCYFIP mRNA expression were notably in 
the CNS and gut with expression in the CNS peaking towards the end of 
embryogenesis. This expression was mirrored by the protein levels (Schenck et al., 
2003). Equally, in mice, CYFIP1 mRNA can be detected by native hybridisation 
ubiquitously throughout embryogenesis with most prominent hybridisation 
occurring in brain tissue. This continued into adulthood with the hippocampus and 
olfactory bulb showing higher mRNA expression levels than other brain regions 
(Köster et al., 1998). In addition, CYFIP1 protein can be detected at all ages in mouse 
brain with peak expression in the third post-natal week (Bonaccorso et al., 2015). In 
contrast, CYFIP2 is moderately expressed in 3 day old mice and increases after day 7. 
Interestingly, CYFIP1 has also been identified in synaptosomal fractions (Schenck et 
al., 2001).  
 
Human CYFIP1 and CYFIP2 are both 1253 amino acid residues long and by western 
blot produce bands at ~145KDa (Saller et al., 1999; Schenck et al., 2001). As the whole 
length of CYFIP proteins are species conserved this suggests the proteins must be 
structurally and functionally important. It is then interesting to note that CYFIP 
proteins contain no particular structural domains such as SH3 and coiled-coil 
domains. They have however, been described to interact with several other proteins 
which has implicated them in multiple cellular processes (Figure 3.1). 
3.1.1 Cellular functions of CYFIP proteins 
CYFIP1 was originally identified as a target for the actin regulatory GTPase Rac1. The 
~140KDa protein identified was purified from bovine brain cytosol with GTP-bound 
GST-Rac1, the human cDNA was cloned, characterised and named Sra1 (specific Rac1 
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associated protein) (Kobayashi et al., 1998). Later, the interaction between CYFIP1 
and Rac1 was shown to be vital in modulating the activity of the Wave Regulatory 
Complex (WRC), a heteropentameric complex consisting of CYFIP1, NAP1, Abi, 
WAVE and HSPC300 and critical for actin regulation (see Figure 1.3) (Chen et al., 
2010b; Eden et al., 2002; Ismail et al., 2009). The WRC complex is a downstream 
effector of Rac1 which brings about Arp2/3 activity resulting in actin nucleation, 
branching and polymerisation. In parallel, CYFIP2 was identified in a complex with 
WAVE and Rac1 and due to sequence similarity is considered to regulate the WRC 
similarly to CYFIP1 however, has been less studied (Eden et al., 2002).  
 
This role in actin regulation implicates CYFIP proteins in a number of dynamic 
pathways. CYFIP1 along with other members of the WRC, NAP1 and Abi, are required 
for WAVE stability and localisation during the formation of actin based membrane 
protrusions. During lamellipodia formation, active Rac1 has been shown to 
translocate the WRC to the leading edge of migrating cells and induced actin 
polymerisation. However, following RNAi to CYFIP1 or Nap1 translocation and 
lamellipodia formation was lost (Kunda et al., 2003; Steffen et al., 2004). 
Interestingly, clathrin heavy chain (CHC) was also shown to control lamellipodia 
formation via an interaction with dCYFIP and by regulating the recruitment of the 
WRC to the membrane. Overexpression of CHC reduced the membrane targeting of 
the WRC and decreased cell migration, while membrane targeted CHC enhanced cell 
migration (Gautier et al., 2011). Recently, a small diverse class of membrane proteins 
including G-protein coupled receptors (GPCRs), protocadherins, neuroligins and ion 
channels were found to possess a WRC interacting receptor sequence (WIRS) that 
directly binds to a conserved surface, formed by CYFIP, of the WRC (Chen et al., 
2014a). This motif has also been suggested to be important in recruiting the WRC 
complex to the membrane for actin polymerisation. Indeed, mutant flies expressing a 
form of dCYFIP that could no longer interact with WIRS domain containing 
membrane proteins were shown to have defects in actin organisation and egg 
morphology during oogenesis which led to female sterility (Chen et al., 2014a).   
 
CYFIP1 and CYFIP2 have also been implicated in the regulation of intracellular 
membrane trafficking. During carrier biogenesis from the trans-Golgi network (TGN), 
activation of the GTPase Arf triggers the recruitment of AP1 and CHC. CHC, via its 
interaction with CYFIP1 or CYFIP2, then recruits a CYFIP1 or 2/Abi/Nap1 complex to 
the TGN membrane which, with Rac1 and N-WASP, promotes actin polymerisation 
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and tubule formation (Anitei et al., 2010). Moreover, CYFIP1 has been described to 
interfere with normal epithelial morphogenesis in cancer (Silva et al., 2009) and 
impair bristle development in flies, a process known to be highly dependent on actin 
dynamics (Bogdan et al., 2004). 
3.1.2 CYFIP proteins and FMRP 
Although arguably the most well described function for CYFIP proteins are as 
components of the WRC, CYFIP proteins can also interact with FMRP. Shortly after 
CYFIP1 was first identified, an independent Y2H screen, using FMRP as a bait, 
identified two human homologs, each with a mass of 145KDa, and named them 
CYFIP1 and CYFIP2 (cytoplasmic FMRP interacting protein1 and 2) (Schenck et al., 
2001). Via this interaction, CYFIP1 has been shown to regulate synaptic mRNA 
translation in an activity-dependent manner (see section 1.4.2.2) (Napoli et al., 2008). 
In vitro RNAi to CYFIP1 in cultured mouse neurons demonstrated that reduced 
CYFIP1 expression altered the expression levels of FMRP target proteins such as ARC 
and CamKII. This disruption in protein expression of FMRP target transcripts was 
also observed in CYFIP haploinsufficient animals (Cyfip1+/-) (Napoli et al., 2008; De 
Rubeis et al., 2013). Indeed, the physiology of CYFIP1 heterozygous mice phenocopies 
characteristics of FMRP KO mice (Bozdagi et al., 2012; Huber et al., 2002). The role 
for CYFIP2 and FMRP has been less well described however, CYFIP2 alone interacts 
with the FMRP family members FXR1P and FXR2P (Schenck et al., 2001) (Figure 3.1).  
3.1.3 CYFIP proteins in neuronal development 
The varied functions of CYFIP have implicated the proteins in neurodevelopmental 
processes. Indeed, dCYFIP is enriched in axons and motor terminals. Genetic deletion 
of dCYFIP was lethal and resulted in defects in axonal pathfinding with aberrant 
midline crossings, stalled axonal growth and abnormal branching, which mostly led 
to death during pupal life (Schenck et al., 2003). Furthermore, the organisation of the 
synaptic neuromuscular junction (NMJ) was effected in dCYFIP mutant flies. Schenck 
et al. first described NMJs of dCYFIP mutants to display synaptic undergrowth, 
disturbed bouton structure and supernumerary budding. Supernumerary budding 
describes the phenotype where buds arise from existing boutons and form 
intermediate structures towards the establishment of new boutons (Schenck et al., 
2003, 2004). This finding was later confirmed with electron microscopy images of 
dCYFIP mutant NMJs (Zhao et al., 2013a). NMJs also displayed enlarged synaptic 
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vesicles and more cisternae characteristic of deficient endocytosis. These effects were 
suggested to be due to disrupted F-actin assembly detected at presynaptic NMJ 
terminals (Zhao et al., 2013a).  
 
Others have also reported the involvement of dCYFIP in neuronal development. 
dCYFIP expression was detected in the growth cones of developing photoreceptors as 
well as in the eye imaginal disc cells. When dCYFIP expression was reduced 
photoreceptors exhibited pronounced axonal defects and eyes appeared smaller with 
a rough appearance (Bogdan et al., 2004). A study carried out in zebrafish 
characterised the nevermind (nev) mutant; nev encodes CYFIP2. In retinal ganglion 
cells of nev mutants, positional dorso-ventral information was not maintained by 
axons as they projected from the retina though the optic tract to the tectum during 
development. Interestingly, nev function is specific to retinal axons. This study 
highlights that CYFIP proteins have a conserved role in axonal guidance. Indeed, 
when morpholinos were used against CYFIP1, retinal axon pathfinding defects were 
also observed suggesting CYFIP1 too, is required in early axon development (Pittman 
et al., 2010). Equally, mouse hippocampal studies had previously described a role for 
CYFIP1 with CRMP-2 in axonal development. Knockdown of CYFIP1 by RNAi 
abolished CRMP-2 induced axonal outgrowth and multiple axon formation. CYFIP1 
was found in a complex with CRMP-2 and kinesin-1 light chain (KLC1). When either 
KLC1 or CRMP-2 were knocked down CYFIP1 was mislocalised from the growth cone 
suggesting the importance of these trafficking molecules in targeting CYFIP1 to 
regulate axon formation (Kawano et al., 2005).  
 
A clear role for CYFIP proteins in the regulation of actin dynamics during various 
cellular functions and in axonal development has been established. There is however, 
very little known about the role of CYFIP proteins in the regulation of dendritic 
morphology and synaptic structural stability. Actin cytoskeletal dynamics play a key 
role in the establishment and maintenance of dendritic arborisation and spines. 
Remodelling the actin cytoskeleton is also critical for the structural changes in spine 
shape that occur during synaptic plasticity (Hotulainen and Hoogenraad, 2010). To 
support this, knockout mice of key actin regulators such as Rac1, PAK3 and WAVE1 
display defects in spine dynamics and disrupted neuronal development (Corbetta et 
al., 2009; Kim et al., 2006; Meng, et al., 2005; Soderling et al., 2007; Tahirovic et al., 
2010). Moreover, there are a growing number of mental illness-associated actin 
regulatory molecules including DISC1, dysbindin1, PAK3 and SRGAP2 that have been 
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implicated in the regulation of dendritic development and spine morphology 
(Charrier et al., 2012; Hayashi et al., 2004; Hayashi-Takagi et al., 2010; Ito et al., 
2010). Disrupted expression of these molecules leads to alterations in neuronal 
structure, spine morphology and cognitive function; characteristics of ASD and SCZ. 
This demonstrates that correct regulation of actin dynamics is a critical mechanism 
for neuronal development and normal brain function and defects in modulators of 
this pathway are associated with disease.  
 
It can be hypothesised that CYFIP1, as a candidate ASD and SCZ gene and an actin 
regulator, may also play a role in the regulation of neuronal morphology in this way. 
Therefore, investigating the role of CYFIP1, and its homologue CYFIP2, in dendritic 
morphology and synaptic maintenance may shed light on the neuropsychiatric 
phenotypes associated with CNV at the CYFIP1 region of the genome. Additionally, 
how genomic microdeletions and microduplications affecting CYFIP1 expression, as 
a result of CNV, produce similar neuropsychiatric phenotypes has not yet been 
addressed (Bozdagi et al., 2012; Rubeis and Bagni, 2011). 
 
In this chapter using fixed and live confocal imaging, CYFIP1 and CYFIP2 have been 
shown to localise to dendritic spines and are enriched at excitatory synapses. 
Overexpression of either protein in neurons altered dendritic complexity and spine 
morphology. On the other hand, employing a CYFIP1 haploinsufficient mouse model 
to study loss of CYFIP1 expression, revealed disruptions in neuronal morphology, 
altered synaptic protein expression and impacted on actin dynamics by disrupting F-
actin assembly. Finally, CYFIP1 and CYFIP2 were also identified at inhibitory 
synapses and there, overexpression resulted in a reduction of inhibitory synapses but 
an increase in excitatory synapses. This demonstrates modelling CNV of CYFIP1 or 
CYFIP2 disrupts neuronal morphology and synaptic maintenance, potentially via 
altered actin dynamics, and suggests CYFIP mediated defects in neuronal complexity 
and synaptic function may contribute to the development of the neurological 
symptoms observed in ASD and SCZ.
  
10
6 
Table 3.1: List of references that implicate Cyfip1 in neuropsychiatric disorders. 
Genetic locus Genetic variation Approach Associated disorder Reference 
Cyfip1 CNV CNV project SCZ (Tam et al., 2010) 
Cyfip1 Microduplication mRNA analysis ASD (Nishimura et al., 2007) 
Cyfip1 Deleterious variants whole exome sequencing SCZ (Purcell et al., 2014) 
Cyfip1 
15q11.2 
Rare CNV and SNPs SNP array, CNV analysis, qPCR  SCZ (Zhao et al., 2013b) 
15q11-13 
Cyfip1 
Type I deletion 
reduced mRNA levels 
mRNA analysis PWS (Bittel et al., 2006) 
SHANK2 
Cyfip1 
De novo deletion 
deletion 
Genome wide SNP array ASD (Leblond et al., 2012) 
15q11.2 Microduplication SNP array ASD (van der Zwaag et al., 2010) 
15q11.2 Microdeletion CGH array ASD, ADHD, OCD (Doornbos et al., 2009) 
15q11.2 Microdeletion Genome wide SNP array SCZ (Stefansson et al., 2008) 
15q11.2 Microdeletion  SCZ, ASD (Stefansson et al., 2014) 
15q11.2 CNV CGH array ASD (Levy et al., 2011) 
15q11-13 CNV Dense genotyping arrays ASD (Pinto et al., 2010) 
15q11.2 CNV SNP array and CNV analysis SCZ (Kirov et al., 2012) 
15q11.2 Microdeletion  SNP array, qPCR, CGH  epilepsy (de Kovel et al., 2010) 
15q11.2 Microdeletion CGH array ASD, ID (Madrigal et al., 2012) 
15q11.2 Microdeletion CGH Behavioural problems (von der Lippe et al.) 
15q11.2 CNV SNP array and CGH Developmental delay (Burnside et al., 2011) 
15q11.2 Microduplication SNP array and CNV analysis AD (Ghani et al., 2012) 
15q11.2 Microdeletion SNP array and CNV analysis epilepsy (Lal et al., 2015) 
15q11-13 Microduplication SNP array and CNV analysis Psychotic illness (Ingason et al., 2011) 
15q11-13 Paternal duplication Array CGH, MLPA analysis ID, epilepsy  (Marini et al., 2013) 
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Figure 3.1: A schematic of human CYFIP1 and CYFIP2 
A summary of the protein interacting domains described in the literature for human CYFIP1 
and CYFIP2. Both proteins are equal length and share 88% sequence homology. Proteins 
contain: an N-terminal Rac1 interacting domain (GST) (Kobayashi et al., 1998); a small linker 
region within the N-terminus required for binding to Abi and HSPC300 of the WRC (Struc) 
(Chen et al., 2010b); NAP1 (Struc) and clathrin heavy chain (CHC) (Y2H, IP) binding domains 
although the sites are not defined (Anitei et al., 2010; Chen et al., 2010b); a WAVE interacting 
domain between amino acids 87 and 766 (Struc) (Chen et al., 2010b). CYFIP1 alone has been 
shown to contain a C-terminal CRMP-2 binding domain (GST) (Kawano et al., 2005), a region 
critical for NAP1 binding (N) (IP) (De Rubeis et al., 2013), a conserved 4E-BP binding site 
where e1F4e interacts (GST) (Napoli et al., 2008) and an FMRP interacting domain (416-
1253aa) (GST, Y2H) (Schenck et al., 2001). CYFIP2 alone contains a FMRP/FXR1P/FXR2P 
interacting domain (1-890aa) (Y2H) (Schenck et al., 2001). Putative Rac1 interacting residues 
are labelled (R) (Struc) (Chen et al., 2010b). Interactions identified by: GST=GST fusion 
protein pull down; IP=immunoprecipitation; Struc=structural analysis; Y2H=yeast two-
hybrid screen. 
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3.2 Results 
In order to investigate the effects of manipulating CYFIP1 and CYFIP2 gene 
expression on synaptic maintenance and neuronal morphology it was critical to 
develop and characterise the necessary biological tools. Using the Gateway Cloning 
System, human CYFIP1 and CYFIP2 cDNA were cloned into the pDEST47 or the 
pDESTmCherry-N1 mammalian expression vectors containing a C-terminal GFP tag 
and an N-terminal mCherry tag respectively. To confirm the expression of the tagged 
proteins in a mammalian system, the generated constructs were transfected into 
COS7 cells and the cytosolic localisation of CYFIP1 and CYFIP2 GFP or mCherry-
tagged proteins were observed (Fig. 1A,G). Samples of COS-7 cells transfected with 
CYFIP1GFP or CYFIP2GFP were also subjected to SDS-PAGE and western blotting. 
When the membrane was probed with a GFP antibody, both transfected cell lysates 
showed a clear band between 130 and 250kDa corresponding to the expected 
molecular weight of CYFIP1GFP and CYFIP2GFP ~175kDa. This confirmed that these 
constructs were readily expressed and not subjected to protein cleavage (Figure 
3.2B,E). The 175kDa band was not present in the untransfected control lysate and was 
therefore, considered to be the exogenously expressed CYFIP1GFP or CYFIP2GFP.  
 
Two commercially available CYFIP1 antibodies were characterised for their specificity 
against the human CYFIP constructs. An Upstate antibody (UPST) against CYFIP1 
specifically detected the human CYFIP1 construct by immunofluorescence and 
western blotting (Figure 3.2A,B), whereas a Synaptic Systems antibody (SySy) 
produced against mouse CYFIP1 specifically detected human CYFIP1GFP by 
immunofluorescence but detected both CYFIP1GFP and CYFIP2GFP by western blot 
among other nonspecific bands (Figure 3.2D,E). Both antibodies detected mouse 
CYFIP1 at the expected weight for endogenous rodent CYFIP1 of ~145kDa. However, 
only the UPST antibody detected rat CYFIP1 at ~145kDa (Figure 3.2C,F). Due to the 
CYFIP1 specificity of the Upstate antibody and its ability to detect rat CYFIP1, the 
Upstate antibody was used in all following studies. 
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Figure 3.2: Cloning of GFP and mCherry tagged CYFIP1 and CYFIP2 
constructs and characterisation of a CYFIP1 specific antibody 
(A and D) Transfection of COS-7 cells with human CYFIP1GFP or CYFIP2GFP constructs. Strong 
GFP signal confirms that these fusion proteins are readily expressed. Immunostaining of 
CYFIP1GFP or CYFIP2GFP transfected cells with either (A) an Upsate (UPST) or (D) a Synaptic 
Systems (SySy) commercial anti-CYFIP1 antibody shows that both antibodies for 
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immunocytochemistry are specific to human CYFIP1 alone. Scale bar, 20μm. (B and E) 
Western blotting of untransfected (UT), CYFIP1GFP or CYFIP2GFP transfected COS-7 cell lysates 
and probing for GFP (right panels) confirms that these constructs generate fusion proteins of 
the expected molecular weight ~175 kDa. Probing for CYFIP1 with (B) UPST and (E) SySy 
antibodies (left panels) confirms the specificity of UPST producing a specific band for 
CYFIP1GFP alone at ~175 kDa while SySy recognises both proteins. Probing mouse and rat 
brain lysate on a western blot with (C) UPST or (F) SySy antibodies confirms that the UPST 
antibody reacts to both rat and mouse endogenous CYFIP1 whereas the SySy antibody is 
mouse specific both producing a band at the expected molecular weight ~145 kDa. (G) 
Transfection of COS-7 cells with human CYFIP1mCherry or CYFIP2mCherry constructs. Strong 
mCherry signal confirms that these fusion proteins are readily expressed. Scale bar, 20μm.  
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3.2.1 Neuronal subcellular localisation of CYFIP1 and its homologue 
CYFIP2 
Prior to this work the subcellular localisation of CYFIP1 and its homologue CYFIP2 in 
mammalian neurons had been poorly described (Kawano et al., 2005; Pilpel and 
Segal, 2005). A clear description of the spatial localisation of a protein can shed light 
on how that protein may function within a particular cell type. Therefore, to explore 
in detail the localisation of CYFIP1 and CYFIP2 in neurons CYFIP1GFP or CYFIP2GFP 
were co-expressed in mature hippocampal neurons with DsRed to provide a 
fluorescent cell fill and act as a marker of neuronal morphology. Following three days 
expression neurons were fixed and stained with anti-GFP to enhance the GFP signal 
and analysed using confocal microscopy. CYFIP1GFP and CYFIP2GFP were detected 
throughout the whole neuronal architecture. Their localisation was diffuse within the 
soma. However, both proteins had a more distinct localisation along the dendrites 
(Figure 3.3A). CYFIP1GFP and CYFIP2GFP could also be detected within the axons.  
 
Upon closer inspection using high-resolution zoom images, CYFIP1GFP and CYFIP2GFP 
exhibited a non-uniform distribution along dendrites compared to the localisation of 
DsRed, which uniformly filled both dendritic processes and spines. Indeed, both GFP-
tagged proteins appeared to be selectively targeted to punctate clusters within the 
dendritic shaft and interestingly, localised to dendritic spines (Figure 3.3B,C). A 
similar enrichment at spines was observed for endogenous CYFIP1 using the 
characterised CYFIP1-specific antibody. In neurons transfected with actinGFP to label 
spine and neuronal morphology, endogenous CYFIP1 displayed marked 
colocalisation with actinGFP in spines (Figure 3.3D). The consistency between the 
dendritic localisation of endogenous and GFP-tagged CYFIP1 confirms that the 
overexpression system used does not result in the mislocalisation of CYFIP1 or 
CYFIP2. To graphically represent the colocalisation of CYFIP1GFP, CYFIP2GFP and 
endogenous CYFIP1 at dendritic spines, a line was drawn though a zoom image of the 
dendritic shaft and a single spine head and pixel intensity of the different channels 
were plotted against line length. CYFIP1GFP, CYFIP2GFP and endogenous CYFIP1 all 
showed greater fluorescence intensity in the spine head compared to the dendrite 
(Figure 3.3B-D).  
 
Dendritic spines are small membrane protrusions that extend out from the dendritic  
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Figure 3.3: CYFIP1 and CYFIP2 are localised at dendritic spines.  
(A) CYFIP1GFP and CYFIP2GFP were transfected into mature rat hippocampal neurons. Both 
transgenes were readily expressed with a diffuse staining in the soma and a punctate staining 
along dendrites. Scale bars, 20μm. CYFIP1GFP (B), CYFIP2GFP (C) or endogenous CYFIP1 (D) 
localise to dendritic spines. DsRed (B, C) or actinGFP (D) were used to label processes. A line-
scan through the dendritic shaft and spine head (right graphs) shows the fluorescence 
intensity of the green and red channels depicting the enrichment of CYFIP1GFP, CYFIP2GFP or 
endogenous CYFIP1 in the spine compared to the dendrite. Scale bars, 2μm. 
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Figure 3.4: CYFIP1 and CYFIP2 are enriched at excitatory synapses.  
CYFIP1GFP and CYFIP2GFP were transfected into mature rat hippocampal neurons and stained 
with antibodies against the pre and postsynaptic excitatory markers vGlut and homer 
respectively. CYFIP1GFP and CYFIP2GFP clusters colocalised with the excitatory synaptic 
markers (arrowheads). (B,C) Quantification of CYFIP1GFP and CYFIP2GFP fluorescence 
intensity at excitatory homer puncta shows there is an enrichment of CYFIP1GFP and 
CYFIP2GFP at excitatory synapses compared to the total process (CYFIP1 n=61, CYFIP2 n=54; 
Wilcoxon signed rank test; ***p<0.001). (D) Endogenous CYFIP1 co-localises with the 
excitatory postsynaptic marker PSD95 (arrowheads) in actinGFP expressing cells. (E) 
CYFIP1GFP and CYFIP2mCherry colocalise along dendritic processes at excitatory synapses 
labeled by homer immunostaining. Scale bars, 20μm, 2μm.  
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shaft. They function to spatially compartmentalise the excitatory synapse and are 
critical for normal synaptic function (Bourne and Harris, 2008). Having determined 
that CYFIP1 and CYFIP2 are found at spines, experiments were conducted to further 
investigate their excitatory synaptic localisation using immunofluorescence and 
confocal microscopy. CYFIP1GFP and CYFIP2GFP were transfected into mature 
hippocampal neurons and expressed for 3 days. These neurons were then subjected 
to immunofluorescence labelling with antibodies against the vesicular glutamate 
transporter vGLUT and the PSD structural protein homer, used to label the excitatory 
pre and postsynapse respectively. Both CYFIP constructs colocalised with homer 
puncta at dendritic spines opposed to presynaptic vGLUT clusters (Figure 3.4A).  
 
Quantification of CYFIP1GFP and CYFIP2GFP in dendrites revealed that the 
fluorescence intensity of both proteins was ~90% increased at synaptic homer puncta 
when normalised to the non-synaptic total dendritic process (Figure 3.4B,C) (homer 
puncta: CYFIP1, 191.44 ± 9.77%; CYFIP2, 185.88 ± 12.63%; ***p<0.001). Moreover, 
immunostaining with a CYFIP1 specific antibody demonstrated endogenous CYFIP1 
was also highly enriched at excitatory synapses and colocalised with the postsynaptic 
marker PSD95. Dendritic and spine morphology were labelled with actinGFP (Figure 
3.4D). Finally, to address whether CYFIP1 and CYFIP2 were present together at the 
same locations within dendrites coexpression experiments were performed with 
CYFIP1GFP and CYFIP2mCherry. The majority of CYFIP1GFP colocalised with 
CYFIP2mCherry and overlapping puncta were found both in dendritic processes and 
spines colocalised with the excitatory postsynaptic marker homer (Figure 3.4E). Thus, 
endogenous CYFIP1, along with CYFIP1GFP and CYFIP2GFP are enriched at excitatory 
synapses and exhibit high levels of expression at sites of F-actin accumulation, like 
dendritic spines. 
3.2.2 Modelling the effects of CYFIP1 and CYFIP2 genetic duplication on 
neuronal morphology 
CNV at the CYFIP1-encoding 15q11.2 region of the human genome is associated with 
increased susceptibility to neuropsychiatric diseases. In particular, microduplications 
within this region, which increase the expression levels of CYFIP1, have been 
specifically linked to ASD and SCZ (Tam et al., 2010; van der Zwaag et al., 2010). One 
cellular mechanism thought to contribute to the pathogenesis of these 
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neuropsychiatric disorders is connectivity defects between brain regions. Impaired 
long-range circuits and excessive local connections particularly within the cortex are 
thought to be important contributing factors to ASD, while loss of cortical mass and 
connectivity is more prevalent SCZ (Belmonte et al., 2004; Harvey et al., 1993; 
Karlsgodt et al., 2008). Indeed, advancements in neuronal imaging has provided 
increasing experimental evidence in support of this hypothesis (Minshew and Keller, 
2010; Ruiz et al., 2013). These observations therefore, imply that increased CYFIP1 
expression may impact on CNS connectivity and function.  
 
To investigate whether CYFIP1 and CYFIP2 regulate neuronal morphology and 
connectivity, changes in dendritic complexity were analysed in rat hippocampal 
neurons overexpressing CYFIP1GFP or CYFIP2GFP to model microduplication of the 
genes. Cells were transfected at DIV 10 and transgene expression was allowed for 3-4 
days before cells were fixed for imaging (Figure 3.5A). Neurons were co-transfected 
with DsRed to label morphology. A method known as Sholl analysis was applied to 
quantify dendritic complexity. This method first described in the 1950s requires the 
dendritic arbour of the imaged neuron to be traced. Concentric rings are then plotted 
equal distance apart, beginning at the cell soma and expanding out until all the 
dendrites have been encircled (Sholl, 1953). The dendritic length, number of times a 
dendrite intersects a ring and the number of branch points can then be quantified 
between each ring as indicators of morphological complexity. These values are then 
either plotted as a function of distance from the soma to give a visual representation 
of where the neuron is most complex or can be summed to present the total dendritic 
length, intersections and branch points per cells. 
 
Overexpression of CYFIP1 or CYFIP2 resulted in a significant increase in both the 
number of intersections and the number of branch points as a function of distance 
from the soma compared to control neurons expressing GFP alone (*p<0.05, 
**p<0.01, ***p<0.001) (Figure 3.5B,C). In addition, total dendritic length and the 
total number of branch points per cell were also increased in cells overexpressing 
CYFIP1 or CYFIP2 (Figure 3.5D,E) (dendritic length: GFP, 2098.88 ± 162.99μm; 
CYFIP1, 2875.85 ± 174.46μm; CYFIP2, 2787.38 ± 151.80μm, *p<0.05, **p<0.01; 
branch points: GFP 44.85 ± 4.71; CYFIP1, 66.54 ± 6.98; CYFIP2, 90.08 ± 5.59; 
*p<0.05, ***p<0.001).  
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Figure 3.5: Overexpression of CYFIP1 and CYFIP2 promote increased 
dendritic complexity. 
(A) Overexpression of CYFIP1GFP or CYFIP2GFP for 4 days results in increased dendritic 
complexity compared to expression of control GFP in 14DIV rat hippocampal neurons 
cotransfected with DsRed. Scale bar, 20μm. Quantification by Sholl analysis shows that 
number of intersections (B) and number of branch points (C) are significantly increased with 
distance from the soma in CYFIP1GFP or CYFIP2GFP overexpressing neurons compared to GFP 
control (data points represent an average of 12-13 cells; stars represent points where both 
CYFIP1 and CYFIP2 are significantly different from control; 2-way ANOVA; *p<0.05; **p<0.01, 
***p<0.001). Expression of CYFIP1GFP or CYFIP2GFP increases total dendritic length (D) and 
number of branch points per cell (E) (n=12-13; ANOVA; *p<0.05, **p<0.01, ***p<0.001).  
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Many neuropsychiatric disorders have been coined spineothapies as often these 
disorders present with defects in dendritic spine structure and function as observed 
in post-mortem studies and animal models (Fiala et al., 2002; Hutsler and Zhang, 
2010; Penzes et al., 2011; Purpura, 1974). Furthermore, dendritic spines are actin-rich 
synaptic compartments that undergo many structural changes during neuronal 
transmission and synaptic plasticity. Therefore, it seemed appropriate to investigate 
the effects of CYFIP1 and CYFIP2 on spine morphology due to the key role these 
proteins play in actin regulation and their association with neuropsychiatric 
disorders. 
 
To study the impact of CYFIP1 and CYFIP2 overexpression on dendritic spine 
morphology mature neurons were transfected with either CYFIP1mCherry or 
CYFIP2mCherry and actinGFP to label spine structure (Figure 3.6A). Neurons were fixed 
and high-resolution confocal stacks were taken of cotransfected cells. Images were 
analysed using Imaris software (Bitplane AG). Lengths of dendrite and spines were 
traced and accurate 3D reconstructions of the traced neuronal fragments were 
generated. From this reconstruction, spines were then classified into subtypes based 
on their length, width and volume. The four subtypes were the common spine 
classifications: stubby, mushroom, long thin and filipodia. The former two classes are 
considered more mature and the latter two more immature spine morphologies. 
There was no overall difference in spine density upon overexpression of either 
CYFIP1mCherry or CYFIP2mCherry compared to control neurons expressing DsRed (Figure 
3.6B) (spine density (spines/μm): DsRed, 0.60 ± 0.02; CYFIP1, 0.65 ± 0.02; CYFIP2, 
0.63 ± 0.02; NS). However, when spines were classified into subtypes, neurons 
overexpressing CYFIP1mCherry or CYFIP2mCherry showed altered spine subtype 
distribution (Figure 3.6C). Overexpression of both CYFIP proteins resulted in 
significantly more long, thin spines and a trend towards more filipodia. CYFIP2 
overexpression also resulted in a decrease in stubby spines while increased CYFIP1 
levels produced a slight but significant increase in mushroom spines (Spines/μm, 
stubby: DsRed, 0.23 ± 0.01; CYFIP1, 0.21 ± 0.01; CYFIP2, 0.20 ± 0.01; *p<0.05; 
mushroom: DsRed, 0.25 ± 0.01; CYFIP1, 0.28 ± 0.01; CYFIP2, 0.27 ± 0.01; *p<0.05; 
long,thin: DsRed, 0.12 ± 0.01; CYFIP1, 0.15 ± 0.01; CYFIP2, 0.16 ± 0.01; *p<0.05, 
**p<0.01;  filopodia: DsRed, 0.002 ± 0.001; CYFIP1, 0.007 ± 0.002; CYFIP2, 0.006 
± 0.001). Additionally, the cumulative frequency curve of spine length was shifted to 
the right for cells overexpressing CYFIP1mCherry or CYFIP2mCherry compared to control,  
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Figure 3.6: Overexpression of CYFIP1 and CYFIP2 alter dendritic spine 
structure. 
Spine morphology was analysed at 21DIV in CYFIP1mCherry or CYFIP2mCherry+actinGFP 
expressing rat hippocampal neurons and compared to DsRed+actinGFP expressing cells (A) 
(upper panel: representative image; lower panel: 3D reconstruction). Scale bar, 5m. Colour 
key for spine type in 3D reconstruction: green = mushroom, red = stubby, blue = long thin, 
pink = filipodia. (B) Quantification of total spine density in DsRed control, CYFIP1mCherry or 
CYFIP2mCherry over expressing cells (n=49-66 filaments per condition; ANOVA; NS). (C) 
Quantification of spine subtype density. CYFIP1mCherry and CYFIP2mCherry overexpression 
resulted in increased long, thin spines and filopodia (n=49-66 filaments per condition; 2-way 
ANOVA; *p<0.05, **p<0.01). (D) Cumulative frequency curve of spine length. CYFIP1 and 
CYFIP2 overexpressing neurons have significantly more, longer spines compared to control 
neurons (n=1500-1900 spines per condition; Krustal Wallis test; ***p<0.001).  
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indicating an overall significant shift towards longer more immature spines when 
CYFIP proteins were overexpressed (***p<0.001) (Figure 3.6D). These experiments 
demonstrate that modelling microduplication of CYFIP1 or CYFIP2 effects dendritic 
and spine morphology. This suggests CYFIP1 and CYFIP2 are important regulators of 
neuronal complexity and spine remodelling, mechanisms thought to be important in 
the pathogenesis of neuropsychiatric disorders such as ASD and SCZ. 
3.2.3 CYFIP1 haploinsufficiency provides a model for studying 15q11.2 
microdeletion 
The previous experiments have studied the effect of CYFIP overexpression on 
neuronal morphology and synaptic maintenance to model a form of CNV that 
enhances the expression of a gene, microduplication. However, genetic variation can 
also result in the loss of genetic material, known as microdeletion, leading to a 
decrease in the copy number and expression of a gene. Microdeletion in the 15q11.2 
region of the genome, where CYFIP1 is expressed, is associated with intellectual 
disability, epilepsy as well as ASD and SCZ (Doornbos et al., 2009; Kirov et al., 2012; 
Stefansson et al., 2008; Zhao et al., 2013b). Therefore, in addition to investigating the 
neuronal effects of CYFIP1 overexpression, a CYFIP1 knockout (KO) mouse system 
was characterised. This model was used to explore the effect of reduced CYFIP1 
expression on neuronal architecture, actin dynamics, synaptic content and 
morphology.  
 
The CYFIP1 KO mouse was generated by the Wellcome Trust Sanger Insitute. Briefly, 
a reporter tagged insertion allele was constructed into a targeting vector containing a 
drug resistance selection marker and homologous regions specific to Cyfip1 between 
exons 3 and 4. The insertion allele uses the KO first technique disrupting the 
transcription of Cyfip1 with the inclusion of a LacZ cassette resulting in a non-
functional truncated Cyfip1 mRNA product and the expression of the reporter enzyme 
β-galactosidase (Skarnes et al., 2011; White et al., 2013). The LacZ cassette is flanked 
by FRT sites to allow for the removal of the cassette in the presence of Flip 
recombinase and rescue of the wild-type (WT) gene. The remaining LoxP sites 
flanking exons 4-6 can then be used to conditionally KO Cyfip1 in a cre recombinase 
dependent manner (Figure 3.7A). The vector was electroporated into mouse 
embryonic stem (ES) cells and cells that had undergone correct recombination were  
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Figure 3.7: Generation of Cyfip1 knockout and Cyfip1 happloinsufficient 
mice. 
(A) Design of the knockout (KO)-first allele system showing the wild-type (WT) allele; the 
KO-first Cyfip1 allele (tm2a allele) containing an IRES:lacZ trapping cassette and a floxed 
promoter-driven neo cassette inserted between exons 3 and 4 of Cyfip1, disrupting gene 
function. Both cassettes are bound by frt sites (green triangles). The neo cassette and 3’ frt 
site are flanked by loxP sites with an additional distal loxP site present 3’ of exon 6 (red 
triangles). Cyfip1 KO animals had two KO-first alleles while happloinsufficient animals were 
heterozygous for the KO-first allele (Skarnes et al., 2011; White et al., 2013). (B) PCR analysis 
of F1 progeny from parental mice heterozygous for the KO-first allele. Animals were 
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genotyped with the primers aF and aR to produce a PCR product of 259 base pairs (bp) from 
the WT allele, these primers were too distant from each other to produce a product from the 
KO-first allele. Primers aF and a’R produced a 182 bp product from the KO-first allele with a’R 
annealing at the very 5’ region of the lacZ cassette. Primers ZF and ZR produced a 108 bp 
product from the KO-first allele within the introduced lacZ gene. Lane 1 is a WT mouse (+/+) 
positive for just the WT product, lanes 2 and 3 are heterozygous animals (+/-) positive for 
both the WT allele and the KO-first allele PCR products, lanes 4 and 5 are KO animals with no 
WT PCR product present (-/-). (C) Representative images of Cyfip1 WT and KO embryos at 
E8.5 highlighting the developmental defects seen in KO animals. Scale bar, 0.5mm. Dissection 
and image acquired by Guillermo López-Doménech. (D) Adult WT and Cyfip1+/- sagittal brain 
sections subjected to X-gal staining. Western blot analysis and quantification displaying fold 
change of CYFIP1 protein levels from control (WT) and Cyfip1+/- P55 hippocampal brain 
lysates (E,F) or DIV16 cultured cortical lysates (G,H). Both hippocampal brain lysates and 
cortical neurons from Cyfip1+/- animals had ~40% less CYFIP1 protein compared to WT 
controls (n=3-4; student’s t-test; *p<0.05).   
 
CYFIP1 and CYFIP2 CNVs in neuronal morphology and synaptic maintenance 
 
 
122 
 
selected for and expanded. ES cells were injected into an early mouse embryo and 
implanted into a pseudopregnant mouse. The result of this pregnancy was chimeric 
mice, which were then crossed with WT mice to obtain mice that were exclusively 
derived from the modified ES cells. These mice were heterozygous for the Cyfip1 KO 
first allele and could then be crossed with each other to generate homozygous mutant 
mice. 
 
To study the Cyfip1 KO mouse, heterozygous animals for the KO first allele were 
crossed and the progeny genotyped (Figure 3.7B). CYFIP1 KO mice (Cyfip1-/-) were 
found to be embryonically lethal, as they were never detected at birth. Following this 
observation, pregnancy was disrupted at earlier time points to determine when during 
development Cyfip1-/- embryos were dying. The latest a KO embryo could be detected 
and confirmed by genotyping was embryonic day (E) 8.5 post-coitum. However, it was 
evident even at this early embryonic stage that the KO embryo was reduced in size 
and seriously developmentally delayed, being about a quarter of the length of a WT 
littermate control (Figure 3.7C). Cyfip1 heterozygous animals (Cyfip1+/-) on the other 
hand, were viable until adulthood and fertile. These observations suggest that 
adequate levels of CYFIP1 are critical for proper development through early stages of 
embryogenesis.  
 
Genetic microdeletions often occur on just one allele and the other remains intact and 
fully functioning resulting in reduced gene expression rather than total loss of 
expression. Cyfip1 haploinsufficient mice therefore, provide the ideal model to study 
the effects of decreased Cyfip1 gene dosage. To indicate which brain regions displayed 
reduced Cyfip1 expression the β-galactosidase reporter gene was used. This reporter 
also demonstrates the expression pattern of Cyfip1 in the brain. Adult brains were 
sagittally sliced into 300μm sections, fixed and incubated with X-Gal staining 
solution, which is catalysed into a blue product by β-galactosidase (Figure 3.7D).  
 
Blue product was observed in the dense cell layers of the hippocampus and the 
cerebellum and could also be detected using a microscope more diffusely in the cortex 
of the Cyfip1+/- brain slice. The WT control showed no blue staining as expected. 
Under the conditions used here this assay was not particularly sensitive and the blue 
signal appeared weak. However, the blue product from the X-Gal reaction was still 
detectable, demonstrating β-galactosidase was being expressed in the hippocampus, 
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cortex and cerebellum of Cyfip1+/- brains. This highlights the expression pattern of 
Cyfip1 and that genetic disruption of the allele has occurred in these brain regions. To 
confirm the genetic loss of Cyfip1 expression resulted in a reduction of CYFIP1 
protein, adult hippocampal brain lysate or cultured cortical cells were analysed by 
western blotting for CYFIP1 protein levels. Samples from Cyfip1+/- animals showed a 
~40% reduction in CYFIP1 compared to control samples (Figure 3.7E-H) (brain 
lysate: WT control, 100 ± 15.4%; Cyfip1+/-, 53.2 ± 7.8%; cortical neurons: WT control 
100 ± 11.8%; Cyfip1+/-, 61.1 ± 2.6%; *p<0.05). Taken together these data confirm that 
CYFIP1 is expressed in both the hippocampus and the cortex and that in Cyfip1 
haploinsufficient animals this expression is reduced by ~40%. Therefore, the Cyfip1+/- 
animals provide an ideal model for studying the effect of reduced CYFIP1 expression 
on neuronal function and morphology. 
3.2.4 The impact of CYFIP1 haploinsufficiency on neuronal morphology 
and dendritic spines 
Microdeletion at the 15q11.2 region of the human genome, resulting in CYFIP1 
haploinsufficiency, has been associated with neuropsychiatric disorders (Table 3.1). 
Therefore, investigating the morphological effects of reduced CYFIP1 expression may 
provide insights into how microdeletion at the 15q11.2 region results in disease. With 
this in mind the effects of CYFIP1 haploinsufficiency on dendritic complexity and 
spine morphology were analysed (the work contributing to Figure 3.8 was carried 
out by Dr. Manav Pathania). Cultured hippocampal neurons from Cyfip1+/- and WT 
control animals were transfected with actinGFP to label cell morphology, fixed at DIV14 
and imaged (Figure 3.8A,B). As described previously, imaged neurons were traced 
and subjected to Sholl analysis. Cyfip1+/- neurons showed a decrease in dendritic 
complexity, measured by plotting the number of intersections as a function of distance 
from the soma, compared to WT control neurons (Figure 3.8C) (**p<0.01, 
***p<0.001). In agreement with this, the total dendritic length and total number of 
branch points were also significantly decreased in the Cyfip1+/- neurons compared to 
control (Figure 3.8D,E) (dendritic length: WT, 2704 ± 96.8m; Cyfip1+/-, 2298 ± 
80.2m; branchpoints: WT, 76.7 ± 4.1; Cyfip1+/-, 61.4 ± 3.6; **p<0.01). Interestingly, 
these results illustrate the opposite effect to the enhanced dendritic complexity 
observed in CYFIP1 overexpressing cells. 
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Figure 3.8: Cyfip1+/- effects neuronal morphology and dendritic spines. 
Cyfip1+/- hippocampal neurons had reduced dendritic complexity compared to WT controls at 
14DIV (A,B). Scale bar, 20 μm. Dendritic morphology was examined using Sholl analysis. 
Cyfip1+/- neurons show significantly less complex morphology when compared to WT neurons 
(n=18; 2-way ANOVA; **p<0.01, ***p<0.001) (C). Total dendritic length (D) and total number 
of branch points (E) were also reduced in Cyfip1+/- neurons compared to WT (n=18, student’s 
t-test; **p<0.01). Spine morphology was analysed at 21DIV in Cyfip1+/- neurons and compared 
to WT cells (F,G) (upper panel: representative image; lower panel: 3D reconstruction). Scale 
bar, 5m. Colour key for spine type in 3D reconstruction: green = mushroom, red = stubby, 
blue = long thin, pink = filipodia. (H) Quantification of spine subtype density. Cyfip1+/- neurons 
possessed increased long, thin spines and filopodia (n=27-31; student’s t-test; *p<0.05). (I) 
Cumulative frequency curve of spine length (n=approx. 39000 spines per condition, Mann-
Whitney test, ***p<0.001). Experiments performed and analysed by Dr. Manav Pathania.  
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Dendritic spine morphology analysis revealed that although there was no difference 
in the spine density of Cyfip1+/- neurons there was a change in spine morphology 
compared to WT control neurons. As previously described, when spines were 
classified into subtypes based on structural measurements Cyfip1+/- neurons showed 
more long, thin spines and filopodia compared to control neurons (Figure 3.8H) 
(Spines/m, long,thin: WT: 0.15 ± 0.01, Cyfip1+/-: 0.20 ± 0.01; filopodia: WT, 0.007 
± 0.001, Cyfip1+/-, 0.016 ± 0.003; *p<0.05). Moreover, the cumulative frequency 
curve for spine length was shifted to the right for Cyfip1+/- neurons indicating a 
significant shift towards more long immature spines compared to control (Figure 
3.8I) (***p<0.001). 
3.2.5 CYFIP1 haploinsufficiency dysregulates spine actin dynamics 
Actin rich dendritic spines undergo many structural changes in response to neuronal 
transmission; these structural changes are brought about by tightly controlled local 
modifications to the actin cytoskeleton (Hotulainen and Hoogenraad, 2010; Kasai et 
al., 2010). As both an increase and a decrease of CYFIP1 levels result in a change in 
spine morphology and CYFIP1 is a critical actin regulator, coupling Rac1 signalling to 
WRC regulation (Chen et al., 2010b), it was of interest to investigate whether altered 
CYFIP1 expression levels impacted on actin dynamics at dendritic spines. This may 
help explain the spine morphological phenotypes observed when CYFIP1 expression 
is manipulated. 
 
To study the impact of altered CYFIP1 expression on actin dynamics live fluorescence 
recovery after photobleaching (FRAP) was carried out on the spines of mature 
Cyfip1+/- hippocampal neurons transfected with actinGFP (Figure 3.9A,B). Analysing 
the recorded movies revealed a significant difference in the fluorescence recovery of 
Cyfip1+/- neurons compared to WT controls (Figure 3.9C; *p<0.05, **p<0.01). 
Moreover, the fluorescence recovery of Cyfip1+/- neurons plateaued at a greater 
intensity than WT neurons, which was confirmed by a significant increase in the total 
mobile fraction (Figure 3.9D) (i.e. the amount of final recovered fluorescence as a 
proportion of the total bleached fluorescence; WT, 68.54 ± 5.51%; Cyfip1+/-, 86.45 ± 
4.20%; *p<0.05). However, there was no change in the recovery rate constant, time 
constant or half-life between Cyfip1+/- and WT neurons (Figure 3.9E-G). 
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Figure 3.9: Cyfip1 deficiency dysregulates spine actinGFP dynamics. 
Cyfip1+/- and WT hippocampal neurons were transfected with actinGFP at 17-20DIV and 
subjected to FRAP live-imaging 2 days later. Spines were imaged for 100 seconds and 
bleaching occurred after the first 20 seconds. (A) A schematic of the actin bleaching and 
fluorescence recovery. Scale bar, 20μm. (B) Representative images over time of actinGFP 
fluorescence recovery in WT and Cyfip1+/- spines (sec). The red circles highlight the bleached 
spine. Scale bar, 2μm. (C) Quantification of fluorescence intensity within the spine head 
region of WT or Cyfip1+/- neurons transfected with actinGFP (n=29-33; 2-way ANOVA; *p<0.05, 
**p<0.01). Data are fitted with single exponentials (coloured lines). (D) Mobile fraction is 
significantly increased in Cyfip1+/- neurons expressing actinGFP (n=29-33; student’s t-test; 
*p<0.05). (E) The rate constant, (F) time constant and (G) recovery half life generated from 
fitting a single exponential curve to each data set, revealed no significant difference between 
WT and Cyfip1+/- neurons (n=25-33; Mann-Whitney test; NS). 
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Figure 3.10: Cyfip1 deficiency dysregulates spine Lifeact dynamics. 
Cyfip1+/- and WT hippocampal neurons were transfected with LifeactGFP at 17-20DIV and 
subjected to FRAP live-imaging 2 days later. Spines were imaged for 100 seconds and 
bleaching occurred after the first 20 seconds. (A) Representative images over time of 
LifeactGFP fluorescence recovery in WT and Cyfip1+/- spines (sec). The red circles highlight the 
bleached spine. Scale bar, 2μm. (B) Quantification of fluorescence intensity within the spine 
head region of WT or Cyfip1+/- neurons transfected with LifeactGFP (n=24-29; 2-way ANOVA; 
NS). Data are fitted with single exponentials (coloured lines). (C) Mobile fraction is 
significantly increased in Cyfip1+/- neurons expressing LifeactGFP (n=24-29; student’s t-test; 
*p<0.05). (D) The rate constant, (E) time constant and (F) recovery half-life generated from 
fitting a single exponential curve to each data set, revealed no significant difference between 
the WT and Cyfip1+/- neurons (n=24-29; Mann-Whitney test; NS).  
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To further demonstrate that altered CYFIP1 expression affects actin dynamics within 
dendritic spines, the FRAP experiments were repeated using LifeactGFP, an F-actin 
specific fluorescent probe suitable for FRAP experiments (Rocca et al., 2013), and 
similar results were obtained. Again, a difference in the fluorescence recovery was 
observed between WT and Cyfip1+/- neurons resulting in a significant increase in the 
total mobile fraction (Figure 3.10A-C; WT, 70.01 ± 3.03%, Cyfip1+/-, 79.91 ± 3.12%; 
*p< 0.05). There was no change in the recovery rate constant, time constant or half-
life between Cyfip1+/- and WT neurons (Figure 3.10D-F). Taken together, the 
increased fluorescence recovery of actinGFP and LifeactGFP suggests altered actin 
dynamics in the dendritic spines of CYFIP1 haploinsufficient neurons compared to 
control neurons.  
3.2.6 The effect of reduced CYFIP1 expression in vivo  
The CYFIP1 haploinsufficient mouse provides an in vivo model to study microdeletion 
of CYFIP1. Having determined reduced CYFIP1 levels effect dendritic spines and 
neuronal morphology in vitro, it seemed appropriate to determine whether loss of 
CYFIP1 altered the excitatory synaptic content of dendritic spines or gross brain 
morphology in vivo. To address the effect of reduced CYFIP1 expression on the 
excitatory synaptic content of dendritic spines, brain regions lysates were generated 
from the hippocampus and cortex of Cyfip1+/- and WT brains aged P16 (juvenile) or 
P55 (adult). These samples were then analysed by western blotting and protein levels 
of excitatory structural molecules and CYFIP1 interactors were analysed (Figure 3.11). 
 
To confirm the specificity of the haploinsufficient model the lysates were probed for 
CYFIP1. In the adult cortex and hippocampus a ~40% reduction in CYFIP1 protein 
was observed in Cyfip1+/- animals compared to WT (Figure 3.11D; hippocampus: WT, 
100 ± 10.66%; Cyfip1+/-, 57.27 ± 8.45%; *p<0.05; cortex: WT, 100 ± 21.37%; Cyfip1+/-
, 59.55 ± 6.44%; p=0.09). Unusually, the Cyfip1+/- P16 cortex showed little reduction 
in CYFIP1, most likely due to sample variability however, the Cyfip1+/- P16 
hippocampus showed as expected a ~40% reduction in CYFIP1 although due to large 
error this was not significant (Figure 3.11C; cortex: WT, 100 ± 13.03%; Cyfip1+/-, 86.41 
± 17.63%; NS; hippocampus: WT, 100 ± 25.21%; Cyfip1+/-, 58.17 ± 8.81%; NS). The 
samples were analysed for the expression levels of PSD structural proteins Shank1-3, 
PSD95, chapsyn110 and homer. Only Shank family proteins showed a change in  
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Figure 3.11: The impact of CYFIP1 haploinsufficiency on excitatory synaptic 
protein levels. 
Brain lysates were prepared from the cortex and hippocampus of juvenile (P16) and adult 
(P55) Cyfip1+/- and wild-type (WT) mice. (A) P16 and (B) P55 cortical (left) and hippocampal 
(right) samples were subjected to western blotting and probed for key synaptic proteins. 
Quantification of percentage protein expression from (C) P16 and (D) P55 Cyfip1+/- brain 
lysates normalised to WT control, cortical lysates (left) and hippocampal lysates (right) (n=3-
5; student’s t-test; *p<0.05; #close to significance). 
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Figure 3.12: CYFIP1 haploinsufficiency results in no gross changes in brain 
morphology. 
(A) Nissl staining of WT and Cyfip1+/- adult mouse sagittal brain sections shows no major 
change in gross brain morphology between the two genotypes. Scale bar, 1mm. (B) 
Hematoxylin and eosin staining of WT and Cyfip1+/- adult mouse coronal brain sections shows 
no major change in gross brain morphology between the two genotypes. Hematoxylin is a 
basic, positively charged dye that stains negatively charged structures, such as DNA, blue and 
therefore labels the cell nucleus. Eosin is an acidic, negatively charged dye which stains 
positively charged eosinophilic structures red. The cytoplasm, cell membranes and proteins 
are stained in this way. Staining carried out by the UCL histology service, Institute of Neurology. 
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expression level between Cyfip1+/- and WT animals in the juvenile brain samples, this 
two-fold increase was restricted to the hippocampus (Figure 3.11B) (hippocampus: 
WT, 100 ± 15.06%; Cyfip1+/-, 198.32 ± 32.22%; *p<0.05). In the adult brain samples, 
cortical chapsyn110 was significantly reduced by 50% in Cyfip1+/- animals compared 
to WT, with a similar trend being observed in the hippocampus (cortex: WT, 100 ± 
8.47%; Cyfip1+/-, 50.31 ± 11.53%; *p<0.05; hippocampus: WT, 100 ± 9.48%; Cyfip1+/-
, 59.69 ± 16.11%; NS). PSD95 expression was almost significantly reduced in the adult 
hippocampus tissue, a trend that was also seen in the juvenile hippocampal tissue 
(Figure 3.11C,D; P55 hippocampus: WT, 100 ± 10.84%; Cyfip1+/-, 75.80 ± 5.32%; 
p=0.07; P16 hippocampus: WT, 100 ± 38.52%; Cyfip1+/-, 61.98 ± 7.30%; NS). It was 
interesting to note that in all the brain regions where CYFIP1 was clearly reduced 
homer also appeared to be slightly reduced however, this result was not significant 
(Figure 3.11C,D). Taken together, loss of CYFIP1 could be impacting on PSD protein 
levels as CYFIP1 haploinsufficiency results in disrupted levels of chapsyn110, Shank 
family proteins and PSD95 however, further experiments and repeats will be required 
to confirm this.  
 
To determine whether gross brain morphology was disrupted in Cyfip1+/- animals 
preliminary experiments were carried out to simply compare visually whether there 
were any obvious alterations in brain anatomy between sagittal sections of CYFIP1 
haploinsufficient brains compared to WT. Sections were stained with fluro-Nissl to 
label neuronal cell bodies and brain region architecture. In this experiment, only a 
limited number of sections were stained, small structures such as the olfactory bulb 
were missing and finding equivalent depth sections in the two samples was difficult. 
However, at first glance brains appeared to be of a similar size and no gross structural 
changes were observed between Cyfip1+/- and WT samples (Figure 3.12A). Coronal 
sections of CYFIP1 haploinsufficient and WT brains were also subjected to 
hematoxylin and eosin (H&E) staining to label cellular structures and brain anatomy. 
Due to the difference in anatomical sections presented it was difficult to compare the 
two samples although brain size appeared unchanged between Cyfip1+/- and WT 
animals (Figure 3.12B). This analysis would benefit from further quantification of 
individual brain regions. Taken together this data shows loss of CYFIP1 does not 
appear to alter gross brain morphology, however, it has been suggested to disrupt 
synaptic protein levels. Importantly, additional work carried out in the lab by Dr. 
Manav Pathania showed, by analysing fixed Golgi-stained slices, that CA1 
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hippocampal neurons displayed reduced dendritic complexity (Appendix A). It is 
potentially these more subtle changes in individual neuronal complexity within the 
hippocampus combined with changes in synaptic protein levels that may account for 
the effects on behaviour and neurotransmission observed in CYFIP1 haploinsufficient 
mice (Bozdagi et al., 2012). 
3.2.7 CYFIP1 and CYFIP2 are enriched at inhibitory synapses 
The role of actin at excitatory synapses has been extensively studied over recent years. 
The actin-rich dendritic spine is critical for remodelling the excitatory synapse during 
neuronal transmission and synaptic plasticity (Bourne and Harris, 2008; Hotulainen 
and Hoogenraad, 2010; Matsuzaki, 2007). Furthermore, there is increasing evidence 
to suggest that actin is required for tethering and stabilising synaptic receptors within 
nanostructures at the PSD (Allison et al., 1998; Blanpied et al., 2008; Burette et al., 
2012; Frost et al., 2010a, 2010b). Finally, the role for actin in the rapid trafficking, 
endocytosis and insertion of receptors into the membrane at excitatory synapses has 
been well described (Bellot et al., 2014; Frost et al., 2010b; Hanley, 2014). However, 
how actin functions at the inhibitory synapse, an equally dynamic structure 
undergoing remodelling and receptor trafficking, is only just emerging (Smith et al., 
2014). As CYFIP1 and CYFIP2 are critically involved in regulating actin 
polymerisation and due to the findings presented here suggesting their importance in 
the maintenance of excitatory synaptic structure and morphology it seemed 
important to explore the function of CYFIP proteins at the inhibitory synapse. 
 
Initially, experiments were carried out to determine if CYFIP1 and CYFIP2 were 
localised at inhibitory synapses. Mature hippocampal neurons were transfected with 
CYFIP1GFP or CYFIP2GFP, fixed and stained with antibodies against vGAT and gephyrin 
to label the inhibitory pre and postsynapse respectively. The vesicular GABA 
transporter (vGAT) is frequently used as a marker for the inhibitory presynapse while 
the multifunctional scaffold molecule gephyrin is a common marker of the inhibitory 
postsynapse (Tyagarajan and Fritschy, 2014). Clustered regions of CYFIP1GFP and 
CYFIP2GFP were found to robustly colocalise with gephyrin puncta opposed to 
presynaptic vGAT puncta along the dendritic shafts of transfected neurons (Figure 
3.13A). In addition, when average intensity of CYFIP1GFP or CYFIP2GFP fluorescence 
was analysed, both CYFIP1GFP and CYFIP2GFP were found significantly enriched by  
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Figure 3.13: CYFIP1 and CYFIP2 are enriched at inhibitory synapses. 
(A) CYFIP1GFP and CYFIP2GFP were transfected into mature rat hippocampal neurons and 
stained with antibodies against the inhibitory pre and postsynaptic markers vGAT and 
gephyrin respectively. CYFIP1GFP and CYFIP2GFP clusters colocalised with the inhibitory 
synaptic markers (arrowheads). (B) CYFIP1GFP and CYFIP2GFP transfected neurons stained 
with gephyrin for quantitative analysis. (C) Quantification of CYFIP1GFP and CYFIP2GFP 
fluorescence intensity at inhibitory gephyrin puncta compared to the total process. CYFIP1GFP 
and CYFIP2GFP are significantly enriched at inhibitory synapses (n=33-42; Wilcoxon signed 
rank test; ***p<0.001). (D) Endogenous CYFIP1 co-localises with the inhibitory postsynaptic 
marker gephyrin (arrowheads) in actinGFP expressing cells. Scale bars, 20μm, 2μm.  
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~40% at inhibitory synapses, labelled with gephyrin, compared to the surrounding 
total dendritic process (Figure 3.13B,C; gephyrin puncta: CYFIP1, 142.42 ± 11.16%; 
CYFIP2, 139.67 ± 7.29%; ***p<0.001). By staining neurons, transfected with actinGFP 
to label cell morphology, with an antibody to CYFIP1 it was also observed that 
endogenous CYFIP1 was present at inhibitory synapses and colocalised with gephyrin 
clusters (Figure 3.13D). These data provide evidence that CYFIP1 and CYFIP2 localise 
to inhibitory synapses and are therefore, spatially positioned to have a role in 
inhibitory synaptic maintenance or transmission.  
3.2.8 The effect of CYFIP1 and CYFIP2 overexpression on inhibitory 
synapse stability 
These findings are the first to describe an inhibitory synaptic localisation for CYFIP 
proteins and therefore the role of CYFIP proteins at these synapses is entirely 
unknown. In an attempt to study CYFIP1 and CYFIP2 at the inhibitory synapse an 
overexpression system was used. Observing the effects of altered CYFIP gene 
expression not only allows conclusions to be draw about the functions of CYFIP 
proteins at inhibitory synapses but also provides a good model for studying the effects 
of CYFIP CNV.  
 
Rat hippocampal neurons were transfected with CYFIP1GFP or CYFIP2GFP and allowed 
to express the transgene for 4 days. Neurons were then fixed at DIV14 and subjected 
to immunocytochemistry with a gephyrin antibody before being imaged using 
confocal microscopy. Analysis of the inhibitory synaptic gephyrin clusters along 
dendrites revealed a significant decrease in both total number of gephyrin clusters 
and total gephyrin cluster area upon overexpression of either CYFIP1GFP or CYFIP2GFP 
compared to control GFP expressing cells (Figure 3.14; gephyrin cluster number: 
GFP, 9.87 ± 0.61; CYFIP1, 6.30 ± 0.88; CYFIP2, 6.60 ± 0.57; **p<0.01; gephyrin 
cluster area: GFP, 3.05 ± 0.20μm2; CYFIP1, 2.06 ± 0.31μm2; CYFIP2, 1.94 ± 0.20μm2; 
*p<0.05, **p<0.01).  
 
This study has shown that actin dynamics are disrupted following CYFIP1 
haploinsufficiency at excitatory synapses in dendritic spines. It was therefore 
interesting to determine whether actin dynamics were being altered at inhibitory 
synapses following CYFIP1GFP or CYFIP2GFP overexpression. Disrupted actin  
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Figure 3.14: Overexpression of CYFIP1 or CYFIP2 reduces gephyrin clusters 
at inhibitory synapses. 
(A) Hippocampal neurons were transfected with CYFIP1GFP, CYFIP2GFP or GFP control at 
DIV10 and allowed to express the transgene for 4 days before fixing and staining with an 
antibody to the scaffold molecule gephyrin, a marker of inhibitory synapses. (B) Analysis of 
clusters revealed a decrease in gephyrin cluster number and cluster area upon CYFIP1GFP or 
CYFIP2GFP overexpression compared to control cells. (n=20; ANOVA; *p<0.05, **p<0.01). Scale 
bars, 2μm. 
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Figure 3.15: Overexpression of CYFIP1 and CYFIP2 does not affect 
inhibitory synapse F-actin content. 
(A) Hippocampal neurons were transfected with CYFIP1GFP, CYFIP2GFP or GFP control at 
DIV10 and allowed to express the transgene for 4 days before fixing and staining with an 
antibody to the scaffold molecule gephyrin, a marker of inhibitory synapses, and phalloidin 
conjugated to alexa fluro-647 to label F-actin. (B) Analysis of phalloidin area at inhibitory 
synapses and number of inhibitory synapses positive for phalloidin revealed no difference 
between cells overexpressing CYFIP1GFP and CYFIP2GFP compared to control GFP expressing 
neurons. Gephyrin was used to label inhibitory synapses for the analysis. (n=19-20; ANOVA; 
NS). Scale bars, 2μm.  
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dynamics may have caused the loss of gephyrin clustering observed. Levels of F-actin 
were imaged and analysed using the F-actin binding toxin phalloidin conjugated to 
alexa-647. Neurons were costained with an antibody against gephyrin to label 
inhibitory synapses. Intriguingly, there was no change in the area of phalloidin at 
gephyrin clusters or the percentage of gephyrin clusters positive for phalloidin (Figure 
3.15; phalloidin area: GFP, 54.86 ± 4.48μm2; CYFIP1, 58.90 ± 4.70μm2, CYFIP2 48.46 
± 5.03μm2; NS; phalloidin positive gephyrin clusters: GFP, 86.11 ± 4.52%; CYFIP1  
88.20 ± 3.57%; 86.61 ± 2.51%; NS). This suggests that overexpression of CYFIP1GFP 
or CYFIP2GFP does not dramatically change the amount of F-actin at inhibitory 
synapses. Indeed, unlike at excitatory synapses altered CYFIP expression does not 
appear to impact on inhibitory synapse F-actin content. However, live imaging will be 
required to reveal if there are more subtle spatial and temporal effects of CYFIP 
overexpression on actin regulation at inhibitory synapses. 
3.2.9 CYFIP1 and CYFIP2 and the excitatory/inhibitory balance 
Gephyrin is the major postsynaptic scaffolding protein of GABAergic synapses and is 
critically linked to inhibitory synapse integrity via its role in clustering GABAARs to 
synapses (Kneussel et al., 1999; Tyagarajan and Fritschy, 2014). Therefore, to 
determine whether the observed decrease in gephyrin cluster number and area was 
having an effect on GABAAR synaptic targeting, CYFIP1GFP or CYFIP2GFP 
overexpressing neurons were subjected to a surface stain with an antibody to an 
extracellular epitope of the GABAAR γ2 subunit. This assay identifies synaptic 
GABAAR clusters as the γ2 subunit is only a component of synaptic GABAARs not 
extrasynaptic receptors. In agreement with the initial findings for gephyrin, compared 
to control GFP expressing cells, overexpression of CYFIP1GFP or CYFIP2GFP resulted in 
a significant reduction in number and area of surface GABAAR γ2 subunit clusters 
(Error! Reference source not found.A,B; GABAAR cluster number: GFP, 8.11 ± 
.86; CYFIP1, 5.44 ± 0.77; CYFIP2 5.20 ± 0.73; **p<0.01; GABAAR cluster area: GFP, 
2.83 ± 0.60μm2; CYFIP1, 1.12 ± 0.18μm2; CYFIP2 1.31 ± 0.22μm2; *p<0.05, 
**p<0.01).  
 
Interestingly, when the excitatory synapse was studied under the same conditions the 
opposite effect on synaptic stability was observed. Neurons were stained with an 
antibody to homer, the excitatory PSD structural molecule, to label the excitatory 
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Figure 3.16: The effect of CYFIP1 and CYFIP2 overexpression on GABAAR 
γ2 and homer clusters. 
(A) Hippocampal neurons were transfected with CYFIP1GFP, CYFIP2GFP or GFP control at 
DIV10 and allowed to express the transgene for 4 days before fixing and staining for surface 
GABAAR γ2 inhibitory synaptic clusters and excitatory synaptic homer clusters. (B) Analysis 
of surface GABAAR γ2 clusters revealed a decrease in cluster number and cluster area upon 
CYFIP1GFP or CYFIP2GFP overexpression compared to control cells. (n=21-25; ANOVA; 
*p<0.05, **P<0.01). (C) Analysis of homer clusters revealed an increase in cluster number and 
cluster area upon CYFIP1GFP or CYFIP2GFP overexpression compared to control cells. (n=15-
17; ANOVA; **p<0.01). Scale bars, 2μm.  
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postsynapses. Upon overexpression of CYFIP1GFP or CYFIP2GFP both total number and 
area of homer clusters were significantly increased about 2 fold compared with 
control cells (Error! Reference source not found.A,C; homer cluster number: 
FP, 5.92 ± 1.23; CYFIP1, 12.14 ± 1.51; CYFIP2 12.29 ± 1.06; **p<0.01; homer cluster 
area: GFP, 1.29 ± 0.31μm2; CYFIP1, 3.07 ± 0.51μm2; CYFIP2 3.11 ± 0.33μm2; 
**p<0.01).  
 
Taken together, overexpression of CYFIP1GFP or CYFIP2GFP is negatively impacting on 
inhibitory synaptic structure and receptor content. However, overexpression equally 
appears to be enriching excitatory synaptic number and area. From these results, it 
can be hypothesised that CYFIP overexpression at synapses could somehow be 
disrupting the balance between inhibitory and excitatory transmission. This 
hypothesis highlights another potential contributing factor in the pathogenesis of 
neuropsychiatric disorders associated with CYFIP CNV. However, how 
mechanistically overexpression of CYFIP proteins are causing these effects at 
synapses still remains to be elucidated.  
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3.3 Discussion 
The work presented in this chapter describes the effects of CYFIP1 and CYFIP2 CNVs 
on neuronal morphology and synaptic maintenance in an attempt to understand more 
about how altered CYFIP1 expression might be contributing to neuropsychiatric 
disease. Initially, CYFIP1 and CYFIP2 were shown to be enriched at excitatory 
synapses within dendritic spines. Overexpression techniques were used to model 
genetic microduplication and increased expression of both CYFIP1 and CYFIP2 were 
shown to increase dendritic complexity and alter spine morphology. The effects of 
CYFIP1 microdeletion were studied using a CYFIP1 haploinsufficient mouse model. 
Haploinsufficient neurons developed less complex dendritic arborisation, the 
opposite effect to the increased dendritic complexity observed in CYFIP1 
overexpressing cells. Interestingly, both haploinsufficiency and overexpression 
altered spine morphology in the same way resulting in more long, thin immature 
spines. Live imaging of actin in spines showed that actin dynamics were disrupted in 
Cyfip1+/- neurons (Figure 3.17). CYFIP1 KO mice were found to be embryonically 
lethal illustrating the critical function CYFIP1 must play in development, probably 
through its actin regulatory role. However, reduced CYFIP1 levels must be sufficient 
for development as Cyfip1+/- mice developed normally and presented with no gross 
changes in brain morphology. Finally, CYFIP1 and CYFIP2 were also found to be 
enriched at inhibitory synapses and overexpression of either protein impacted on 
inhibitory synapse integrity. Inhibitory gephyrin and GABAAR clusters were reduced 
while excitatory homer clusters were increased suggesting that CYFIP protein 
overexpression may in some way affect the E/I balance, highlighting another potential 
mechanism of disease pathogenesis for CYFIP CNVs.  
3.3.1 CYFIP proteins, dendritic complexity and development 
Rho GTPases are global actin regulators critical for normal dendritic branch 
dynamics, extension and development (Auer et al., 2011; Jan and Jan, 2010; Newey 
et al., 2004). One downstream effector of the GTPase Rac1 is the WRC, which once 
stimulated by GTP-bound Rac1, brings about Arp2/3 activation resulting in actin 
nucleation and polymerisation. CYFIP proteins form one component of the WRC and 
provide the binding site for active GTP-bound Rac1 making them too, critical actin 
modulators. Indeed, in steady-state conditions CYFIP1 represses the activity of the  
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Figure 3.17: A summary of the morphological effects caused by CYFIP1 CNV 
on dendritic complexity and spine structure. 
Compared to wild-type conditions where dendritic complexity and spine morphology are 
normal, when CYFIP1 is overexpressed in neurons to model CYFIP1 microduplication (left 
panels) dendritic complexity is enhanced and there is a shift towards more long, thin 
immature spines.  Conversely, when CYFIP1 haploinsufficient neurons are studied to model 
CYFIP1 microdeletion dendritic complexity is reduced however, there is still a shift towards 
more long, thin spines. These spines display altered actin dynamics caused by loss of CYFIP1 
which may contribute to this structural phenotype. 
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WRC by inhibiting the active VCA domain of WAVE. Following Rac1 activation, Rac1 
binds to CYFIP1 causing a conformation change in the molecule that leads to removal 
of the WAVE inhibition and consequently actin polymerisation (Chen et al., 2010b; 
Ismail et al., 2009). Disrupted CYFIP protein levels may therefore, effect Rac1 
downstream signalling events to the WRC and impact on dendritic branching. Indeed, 
here it is demonstrated that appropriate CYFIP1 and CYFIP2 levels are important for 
normal dendritic arborisation and neuronal complexity. Increased CYFIP1 or CYFIP2 
dosage led to enhanced dendritic length and branching, while loss of CYFIP1 
expression reduced dendritic complexity.  
 
Active Rac1 often occurs at the membrane where it is spatially localised to bring about 
cytoskeletal rearrangement and membrane extension during cell growth and 
development. CYFIP proteins contain a WIRS motif that has been shown to interact 
with membrane proteins (Chen et al., 2014a). Therefore, one explanation for the 
effects of altered CYFIP dosage on dendritic development could be that CYFIP 
proteins are required to recruit the WRC to the cell membrane where Rac1 can 
subsequently activate it. Greater levels of CYFIP could result in more WRC targeted 
to the membrane where it can be activated to bring about actin polymerisation, 
membrane extension and dendritic development. On the other hand, in conditions 
where CYFIP is decreased, this recruitment is lost and dendritic complexity is 
reduced. Alternatively, microtubule (MT) dynamics are highly important in dendritic 
growth and maintenance (Jan and Jan, 2010); therefore perhaps CYFIP proteins have 
an as yet unidentified role in MT regulation. 
 
Interestingly, a recent study observed similar morphological results to those 
presented here when CYFIP1 was either overexpressed in differentiated 
neuroblastoma cells or in a transgenic mouse. Consistent with the data here, they 
reported a significant increase in total branch number, and also reported an increase 
in cell size and a reduction in neurite length (Oguro-Ando et al., 2014). Furthermore, 
as well as having effects on dendritic morphogenesis, CYFIP1, in an actin regulatory 
complex with WAVE1, has been shown to be necessary for CRMP-2-induced axonal 
outgrowth and axon-dendrite specification (Kawano et al., 2005) while CYFIP2 has 
been identified to be critical in retinal axonal outgrowth (Pittman et al., 2010). Taken 
together, the evidence points towards CYFIP playing a key role in neuron 
development and maintenance particularly impacting on dendritic complexity. 
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Defects in dendritic complexity and hence connectivity have long been considered 
features of ASD and SCZ with impaired long-range connectivity and enhanced local 
connections thought to be contributing factors (Belmonte et al., 2004; Hutsler and 
Zhang, 2010; Karlsgodt et al., 2008). CYFIP proteins, via their regulation of actin 
dynamics, could be impacting on dendritic arborisation and hence cortical 
connectivity, providing one explanation for their neuropsychiatric disease 
association. This suggestion could also explain why there appears to be no change in 
gross brain organisation in CYFIP1 haploinsufficient mice. It is more likely that 
pathogenic changes would occur at the level of neuronal cell architecture. Further 
detailed morphological analysis studying cell number, cortical column density and 
layer thickness may identify local structural changes in Cyfip1+/- animals similar to 
structural defects seen in ASD and SCZ brains (Harvey et al., 1993; Kulkarni and 
Firestein, 2012; Raymond et al., 1996). Interestingly, a recent study investigated 
induced pluripotent stem cell (iPSC)-derived neural progenitors generated from SCZ 
patients carrying the 15q11.2 microdeletion. These reprogrammed neurons displayed 
adherens junction and apical polarity defects and to this date are the only human 
model of CYFIP1 mutations described. The authors demonstrated that CYFIP1 was 
necessary to maintain adherens junctions and apical polarity. In addition, reduced 
CYFIP1 expression in the developing mouse cortex resulted in defects in radial glia 
migration which led to the ectopic localisation of RGCs outside of the ventricular zone. 
This describes another mechanism by which CYFIP1 could impact on cortical 
development and connectivity (Yoon et al., 2014). 
 
CYFIP1 appears not only important in dendritic development but also vital for 
embryonic development. Recent work has highlighted that rare complete gene 
knockouts in humans have a significant role in ASD and major mental illness (Lim et 
al., 2013). Although both deletions and duplication in CYFIP1 have been described in 
humans, it seems unlikely that patients with total loss of CYFIP1 will be described as 
data presented here shows that CYFIP1 KO mice are embryonically lethal. This is 
consistent with previous studies of mice lacking critical actin regulatory genes which 
have been described to display characteristic abnormalities resulting in death during 
developmental progression between E7.5 and E12.5 (Dubielecka et al., 2011). For 
example, inactivation of murine Rac1 and Nap1 are lethal during gastrulation at E7.5 
and 9.5 respectively while n-WASP and WAVE2 are lethal during organogenesis at 
E11 and mid-gestation at E12.5 respectively (Migeotte et al., 2010; Rakeman and 
 
CYFIP1 and CYFIP2 CNVs in neuronal morphology and synaptic maintenance 
 
 
144 
 
Anderson, 2006; Snapper et al., 2001; Yan et al., 2003). Cyfip1-/- embryos do not 
survive beyond E8.5. Thus, CYFIP1 signalling events are likely crucial for gastrulation 
and normal patterning of embryonic structure during developmental progression (Liu 
et al., 2000). CYFIP1 KO embryos were too small to detect specific morphogenic 
defects but one explanation for the severe developmental delay seen in these embryos 
is due to dysregulated cell movement and cell fate during gastrulation as a result of 
disrupted CYFIP1/WAVE-mediated actin regulation similar to what is observed in 
Nap1 KO animals (Rakeman and Anderson, 2006). 
3.3.2 CYFIP proteins regulate spine morphology and actin dynamics 
Tight actin regulation, mediated by Rho GTPases, is critical for normal excitatory 
synaptic functions such as receptor trafficking, endocytosis and spine development 
and maintenance (Bourne and Harris, 2008; Hanley, 2014; Hotulainen and 
Hoogenraad, 2010). The localisation studies shown here strongly reveal the presence 
of CYFIP1 and CYFIP2 at dendritic spines and demonstrate both proteins are enriched 
at excitatory synapses. The restricted localisation of these proteins suggests they 
function within the excitatory postsynaptic compartment. Indeed, as key Rac1 
effectors and regulators of the WRC, both CYFIP1 and CYFIP2 are correctly positioned 
at excitatory synapses to regulate actin dynamics. Thus, altered CYFIP levels may lead 
to changes in actin turnover that could impact on spine morphology and excitatory 
synapse stability. In agreement with this, it is shown here that overexpression of 
CYFIP1, CYFIP2 or CYFIP1 haploinsufficency effect dendritic spine structure, 
resulting in more immature long thin spines and filopodia. Furthermore, recent 
studies from others have also shown reducing CYFIP1 levels using RNAi in cultured 
hippocampal neurons and over expression of CYFIP1 in vivo alter spine morphology 
(Han et al., 2014; Oguro-Ando et al., 2014; De Rubeis et al., 2013). These results are 
consistent with the dysregulated expression of other key actin regulatory molecules 
impacting on spine structure and morphology including WAVE, Arf1 and Arp2/3 
(Kim et al., 2013, 2006; Rocca et al., 2013). 
 
FRAP experiments carried out here were used to study the recovery of fluorescently 
labelled actin in dendritic spines of hippocampal neurons. The greater recovery and 
increased mobile fraction observed in the Cyfip1+/- neurons showed that normal actin 
dynamics within spines were disrupted. These altered actin dynamics could explain 
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the spine morphology defects observed in CYFIP1 haploinsufficient neurons. This 
finding, within a mammalian neuronal system, is consistent with previously 
published in vitro experiments, which show CYFIP1 acts as a negative regulator of 
actin polymerisation due to its inhibitory function over the WRC (Chen et al., 2010b). 
Furthermore, results in line with the findings presented here were observed in 
dCYFIP mutant Drosophila. The neuromuscular junction (NMJ) in mutant flies 
showed dysregulated morphology resulting in shorter NMJs with more satellite 
boutons. In addition, FRAP experiments at the NMJ revealed an increase in actinGFP 
recovery in dCYFIP mutants compared to WT. Interestingly, the actin effect was 
rescued by decreased SCAR expression (the Drosophila homologue of WAVE) (Zhao 
et al., 2013a). This provides evidence that the NMJ defects are caused by an overactive 
WRC due to the lack of inhibition by dCYFIP. It would be interesting to determine if 
knockdown of WAVE, within the CYFIP1 haploinsufficient neurons here, could rescue 
the enhanced fluorescence recovery and the spine phenotype observed in a similar 
way. The NMJ morphology and actin phenotypes observed in mutant Drosophila are 
consistent with the altered spine morphology and actin dynamics illustrated here in 
Cyfip+/- neurons, adding strength to these results. Others have also reported changes 
in phalloidin staining at dendritic spines subjected to CYFIP1 RNAi, again 
demonstrating the critical role of CYFIP1 in F-actin regulation at spines (De Rubeis et 
al., 2013). 
 
It is intriguing that both CYFIP1 overexpression and haploinsufficiency result in more 
immature spines. Mechanistically, reduced CYFIP1 could lead to less WAVE 
inhibition and therefore more Arp2/3 activation and actin polymerisation. While 
CYFIP1 overexpression could be sequestering active Rac1 away from activating PAK 
resulting in less cofilin activity. Active cofilin causes actin depolymerisation (Bellot et 
al., 2014). Interfering with both pathways in this way would result in increased actin 
assembly whether CYFIP1 was up or down regulated possibly leading to the same 
downstream morphological effects. It is furthermore interesting to note, that a 
number of other actin regulatory proteins have been reported to have the same effect 
on spine morphology whether they are up- or down-regulated, including 
VCP/neurofibromin, Abi3 and cofilin (Bae et al., 2012; Hotulainen et al., 2009; Meng 
et al., 2002; Wang et al., 2011). It appears that a critical level of CYFIP1 is required for 
normal spine morphology and shifting its levels either above or below a threshold may 
force spines into an unstable immature state.  
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Long thin, immature spines are a hallmark of many neuropsychiatric disorders. Post-
mortem brains from patients with ID, FXS and ASD present with long thin spines 
while SCZ patients show a reduction in spine density (Fiala et al., 2002; Glantz and 
Lewis, 2000; Hutsler and Zhang, 2010; Purpura, 1974). Both overexpression and 
reduction of CYFIP1 result in an enrichment of immature thin spines demonstrating 
the appropriateness of CYFIP1 CNV as a model for neuropsychiatric disease. Indeed, 
the fact CYFIP1 CNV generates such a strong morphological hallmark of 
neuropsychiatric disorders may help explain why altered CYFIP expression has been 
associated with ASD and SCZ (Doornbos et al., 2009; Leblond et al., 2012; Nishimura 
et al., 2007; Zhao et al., 2013b). Moreover, thin, immature spines are known to form 
weaker synaptic connections and can have a negative impact on network connectivity, 
particularly within the cortex, making this phenotype an important factor in the 
pathogenesis of ASD and SCZ (Penzes et al., 2011).  
3.3.3 CYFIP1, CYFIP2 and protein translation 
It must not be overlooked that CYFIP proteins, together with FMRP and eIF4e, have 
also been described to be involved in a protein translation regulatory complex capable 
of repressing mRNA translation locally at synapses (Napoli et al., 2008). In fact 
recently, the use of CYFIP1 mutants that uncouple its protein translation and actin 
regulation roles demonstrated that both functions were required to rescue the 
immature spine phenotype seen in CYFIP1 knockdown neurons (De Rubeis et al., 
2013). This highlights the importance of both CYFIP functions in dendritic spine 
maintenance and suggests its role in translational regulation may be influencing the 
morphological results observed here too. It would be interesting to use these CYFIP1 
mutants that disrupt its interaction with either eIF4e or the WRC in the CYFIP 
overexpression system to unpick which pathways are required for the increase in 
dendritic complexity observed. 
 
Fmr-1 knockout mice have been intensively studied as a model for FXS and among 
other phenotypes, defects in protein expression due to FMRP’s translational 
repressive role have been characterised (Zalfa et al., 2003). As this repression is 
mediated, at least in part by CYFIP1 (Napoli et al., 2008), CYFIP1-deficient animals 
may also show defects in protein expression. Indeed, here it has been described that 
juvenile Cyfip1+/- mice have increased hippocampal Shank family protein expression 
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compared to WT control. Furthermore, adult Cyfip1+/- mice show decreased levels of 
chapsyn110 and PSD95 in the cortex and hippocampus respectively. Altered 
expression of key synaptic structural molecules have been shown to effect dendritic 
branching and spine dynamics and have been implicated in neuropsychiatric 
disorders (Penzes et al., 2011; Vessey and Karra, 2007). In particular, proteins of the 
PSD, such as PSD95, Shank2 and 3 have been shown to increase spine density and 
size (Roussignol et al., 2005; Steiner et al., 2008). Furthermore, altered expression of 
all three Shank proteins have been implicated in ASD (Arons et al., 2012; Leblond et 
al., 2012; Peça et al., 2011; Sato et al., 2012). Therefore, the defects in expression of 
postsynaptic scaffold proteins seen in CYFIP1 haploinsufficient mice not only mirror 
the phenotypes seen in FXS mice but may also help explain the neuropsychiatric 
defects observed in patients with 15q11.2 microdeletions. Further experiments such 
as quantitative PCR from mRNA samples of the brain regions would add strength to 
these initial findings. 
 
CYFIP1 and CYFIP2 share 98% sequence similarity, have been described in the same 
functional pathways and interact with many of the same proteins. Therefore, due to 
their functional and structural similarities at the protein level it was interesting to 
further explore whether Cyfip2 could be a candidate susceptibility gene for major 
mental illness like Cyfip1. Indeed, with this in mind experiments carried out in this 
chapter were extended to include CYFIP2 in an attempt to shed light on its role in 
neuronal morphology and synaptic maintenance. 
 
The Cyfip2 gene has not been directly associated with any neuropsychiatric disorders, 
however, has been described as a susceptibility locus for SCZ and attention-
deficit/hyperactive disorder (ADHD) (Arcos-Burgos et al., 2004; Gurling et al., 2001). 
Furthermore, increased CYFIP2 protein levels have been identified in brain tissue 
samples of patients with SCZ and FXS (Föcking et al., 2014; Hoeffer et al., 2012). It is 
unclear whether the increased CYFIP2 levels observed in these patients are to 
compensate for reduced CYFIP1 levels or whether CYFIP2 has its own pathogenic 
mechanisms. Intriguingly, the high levels of CYFIP2 in FXS patients did not correlate 
with increased CYFIP2 mRNA and CYFIP2 mRNA is a target of FMRP translational 
regulation (Darnell et al., 2011). Therefore, in FXS patients increased CYFIP2 could 
be a direct result of loss of FMRP and points towards enhanced dosage of CYFIP2 
having its own pathogenic mechanisms. The data in this chapter illustrates that raised 
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CYFIP2 levels cause an increase in dendritic arborisation and defects in spine 
morphology implying that CYFIP2 alone could contribute to neuropsychiatric disease 
pathogenesis. These effects could also be due to the interchangeable role of CYFIP2 
and CYFIP1 in the regulation of the WRC (Takenawa and Suetsugu, 2007). It is yet to 
be revealed whether CNV at the 5q33.3 locus will be found to be associated with 
neuropsychiatric disease. 
 
Few attempts have been made to determine whether CYFIP2 has independent 
functions from CYFIP1. Due to their high sequence similarity often reports assume 
CYFIP2 behaves like CYFIP1 and suggest it may even provide some functional 
compensation should CYFIP1 expression be disrupted. However, CYFIP2 alone has 
been shown to bind the whole FMRP family of proteins including FXR1 and FXR2 
while CYFIP1 is only FMRP specific (Schenck et al., 2001) suggesting CYFIP2 could 
have its own independent function in regulating translation. On the other hand, 
Drosophila only express one FMRP family protein dFMRP and one CYFIP protein 
(dCYFIP) indicating that perhaps CYFIP2 and FXR1/2 contribute to a more complex 
level of translational regulation required for higher order organisms still to be 
elucidated. The shared effects observed with overexpression of both CYFIP1 and 
CYFIP2 seen in this chapter indicate that both proteins are implicated in the 
regulation of dendritic morphology and synapse stability. It would be interesting to 
try and rescue the effects of CYFIP1 haploinsufficient neurons with CYFIP2 
overexpression to determine more about any redundancy between these proteins. 
3.3.4 CYFIP proteins and the excitatory/inhibitory balance 
The final experiments in this chapter place CYFIP1 and CYFIP2 at the inhibitory 
GABAergic synapse and show both proteins are enriched at gephyrin clusters, the 
major scaffolding protein of GABAergic and glycinergic synapses. This is the first time 
CYFIP proteins have been shown to localise to inhibitory synapses and suggests that 
they may be spatially targeted here to carry out specific functions. Indeed, when either 
CYFIP1 or CYFIP2 were overexpressed in neurons, gephyrin cluster number and area 
was reduced as well as GABAAR γ2-subunit cluster number and area. Loss of gephyrin 
clusters have previously been shown to reduced GABAAR clustering (Marchionni et 
al., 2009; Yu et al., 2007) while losing γ2 clusters has reduced presynaptic innervation 
(Li et al., 2005) both resulting in disrupted inhibitory transmission. Interestingly, 
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actin is required for GABAergic synapse integrity, maintenance and postsynaptic 
mobility (Charrier et al., 2006). Moreover, recently Rac1 was described in a novel 
actin signalling pathway critical for inhibitory synaptic stability and function (Smith 
et al., 2014). It could be tempting to suggest that CYFIP1 and CYFIP2, potentially via 
their ability to interact with active Rac1, may be involved in an inhibitory synapse 
specific actin regulatory mechanism that is important for maintaining the stability of 
inhibitory synaptic clusters. However, there was no difference in F-actin levels at 
inhibitory synapses when phalloidin was used to label F-actin in fixed CYFIP 
overexpressing cells. A more sensitive experiment such as actin live-cell imaging will 
be required to determine whether there are effects on actin turnover at inhibitory 
synapses when CYFIP proteins are overexpressed. 
 
Decreased inhibition due to a reduction of surface GABAARs, such as the reduced γ2 
clustering shown here, can upset the E/I balance of neuronal circuits, causing 
disrupted information processing which may result in altered animal behaviour 
(Blundell et al., 2009; Crestani et al., 1999; Tretter et al., 2009; Yizhar et al., 2011). 
Furthermore, defects in inhibitory neurotransmission leading to an altered E/I 
balance have also been implicated in multiple neuropsychiatric disorders including 
ASD (Paluszkiewicz et al., 2011), depression (Luscher et al., 2011b), bipolar disorder 
(Craddock et al., 2010) and SCZ (Charych et al., 2009). Overexpression of CYFIP 
proteins not only reduced inhibitory synaptic clusters but also increased homer 
clusters, a marker of the excitatory postsynapse. This result is an anti-homeostatic 
effect and could point towards disrupted CYFIP1 or CYFIP2 expression impacting on 
the E/I balance. This provides another potential mechanism for why CNV of CYFIP1 
and the CYFIP2 locus have been implicated in neurological dysfunction. These 
intriguing opposite effects of CYFIP overexpression at inhibitory and excitatory 
synapses could be due to the proteins being involved in very different synapse specific 
pathways. Alternatively, perhaps overexpression of CYFIP1 or CYFIP2 enhances the 
translational repression of proteins required for increasing inhibitory synapse size 
and stability and for limiting excitatory synaptic number simultaneously. Further 
investigation is required to understand the mechanism of these synaptic effects. 
 
In summary, this chapter has demonstrated that CYFIP1 and CYFIP2 are enriched 
within dendritic spines, altered CYFIP1 and CYFIP2 expression results in spine and 
dendritic morphology defects, and that CYFIP1 deficiency affects F-actin assembly at 
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spines. Taken together with the previously published findings reporting CYFIP1 and 
CYFIP2 as actin regulators (Chen et al., 2010b; Schenck et al., 2003) it can be 
proposed that CYFIP proteins function to regulate local actin dynamics within spines 
to maintain spine structure and potentially control dendritic morphology through an 
actin regulatory mechanism. Changes in spine size and shape are intimately linked to 
synaptic plasticity and neuronal function (Hotulainen and Hoogenraad, 2010). 
Therefore, disruption of CYFIP1 and CYFIP2 expression, such as in CNV, may result 
in neuropsychiatric phenotypes due to defects in spine and dendritic morphology, a 
form of pathogenesis already associated with neuropsychiatric disorders (Kulkarni 
and Firestein, 2012; Penzes et al., 2011). Additionally, CYFIP1 and CYFIP2 
overexpression has a negative effect on inhibitory synapse stability and increases 
excitatory synaptic sites. This could alter the E/I balance and suggests a new 
mechanism for CYFIP1 and CYFIP2 associated neuropsychiatric disorder 
pathogenesis. 
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Chapter 4 
Identification and characterisation 
of rare Cyfip1 variants in SCZ  
4.1 Introduction 
Our ability to sequence the human genome has led to the identification of many 
disease causing allelic variants and genes. In the last decade, next-generation 
sequencing has revolutionised this field providing fast and efficient genetic 
sequencing technologies with a large fall in costs compared to traditional Sanger 
methods. These new technologies have allowed genome-wide association studies 
(GWAS), CNV analysis and whole exome or genome sequencing of large patient 
cohorts to take place to discern rare mutations associated with disease. In particular, 
the contribution of rare variants to diseases with complex inheritance has been given 
a large amount of attention in an effort to improve our understanding of the disease 
mechanisms and provide new targets for therapeutics. Indeed, there is great interest 
in determining which genomic loci infer risk for SCZ, a highly heritable disorder.  
 
Currently, CNV at the 15q11.2 genomic region, where Cyfip1 is situated, has been 
associated with SCZ. Large genomic screens have implicated both microduplications 
and microdeletions of the 15q11.2 region in SCZ (Consortium, 2008; Kirov et al., 2012; 
Stefansson et al., 2008). However, this genomic region comprises four genes and 
although the neuronal functions of CYFIP1 point towards it being the disease-causing 
gene there is less support for a direct association between Cyfip1 and SCZ (Purcell et 
al., 2014; Tam et al., 2010; Zhao et al., 2013b). Consequently, identification of 
undescribed SCZ-associated variants in Cyfip1 will provide further evidence for the 
gene being a risk factor for SCZ. To address this a genetic analysis approach can be 
used. 
 
The UK10K consortium (The UK10K consortium 2014, a full list of investigators who 
contributed to the generation of this data is available online: http://www.uk10k.org/) 
was developed to sequence 10000 patients between 2010 and 2013 in an attempt to 
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identify rare genetic variants associated with disease. A combination of whole-exome 
analysis and genome-wide sequencing was carried out on different patient groups 
including neurodevelopmental, SCZ, obese and rare disease sample sets. The 
published data is available for scientists to analyse; comparing DNA sequencing from 
case and control groups to identify disease-associated genetic variations. The vast 
scale and depth of the UK10K sequencing records increases the power of the analysis 
and allows for the identification rare SNPs which occur at low frequencies (<0.05%) 
in the population. In this way, uncommon variants associated with SCZ can be 
identified within a gene of interest which would otherwise go undetected in normal 
GWAS. Indeed, it is possible to seek rare variants in Cyfip1 that are linked with SCZ. 
Moreover, functional characterisation of any variants identified is also critical to 
increase our understanding of the molecular mechanisms of SCZ pathogenesis and 
how CYFIP1 might be implicated.  
 
In parallel to unravelling how mutations in CYFIP1 impact its function, there is still 
much to be learned about CYFIP1 from loss of function studies using KO models. It is 
only by combining the findings from all these experimental systems that a bigger, 
clearer picture of CYFIP1 function and how it might be implicated in neuropsychiatric 
disorders will be elucidated. A previous report and data generated here in Chapter 3 
describe constitutive KO CYFIP1 mice to be embryonically lethal. Bozdagi and 
colleagues state CYFIP1 KO embryos generated from heterozygous crosses can be 
detected until embryonic day 3-5 (Bozdagi et al., 2012) whereas it is shown here that 
KO embryos can be identified until day 8.5 in utero. Additionally, loss of CYFIP1 in 
flies was reported to induced lethality during pupal life (Schenck et al., 2003). This 
lethality makes loss of function studies extremely challenging. As an alternative 
approach, RNAi has been used to observe the effects of depleted CYFIP1 levels. In 
human fibroblasts reduced CYFIP1 expression impaired lamellipodia formation, 
decreased membrane ruffling upon growth factor treatment, and abolished the 
establishment of Rac1 induced lamellipodia (Steffen et al., 2004). Furthermore, RNAi 
induced knockdown of CYFIP1 in neurons has been shown to impair dendritic spine 
morphology consistent with data from Chapter 3 and disrupt the regulation of 
adherens junctions and apical polarity (De Rubeis et al., 2013; Yoon et al., 2014). To 
this end however, there have been no loss of function studies carried out with CYFIP1 
KO cells and indeed, the effect of total loss of CYFIP1 on cell function remains an 
interesting question. 
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On the other hand, CYFIP1 haploinsufficient mice are viable and, similarly to RNAi 
approaches, have been used to study the functional effects of reduced CYFIP1 levels. 
In the previous chapter, these mice have been studied as a model for CYFIP1 
microdeletion. CYFIP1 haploinsufficient neurons showed defects in spine and 
dendritic morphology thought to be a result of deregulated actin dynamics. 
Additionally, a recent electrophysiological study revealed CYFIP1 haploinsufficiency 
produced FXS-like characteristics. Hippocampal mGluR induced LTD was enhanced 
in Cyfip1+/- animals compared to WT and was insensitive to protein synthesis 
inhibitors. Furthermore, these mice had a mild behavioural phenotype of enhanced 
extinction in inhibitory avoidance compared to control mice; similar to behaviours 
exhibited by FXS model mice (Bozdagi et al., 2012). Intriguingly, CYFIP2 
haploinsufficient mice showed no morphological or electrophysiological differences 
to WT animals in the hippocampus. However, dendritic spines were altered in the 
cortex of these mice and mGluR induced spine regulation was impaired in cortical 
neurons (Han et al., 2015). The disparate effects of CYFIP1 and CYFIP2 
haploinsufficiency in the hippocampus and cortex suggest that the patterns of 
redundancy and compensatory mechanisms between these two homologues differ 
depending on the brain region in question.  
 
Conditional KO (cKO) mice allow time and region specific deletion of a protein and 
provide a powerful tool for carrying out loss of function studies on a protein that is 
normally essential for viability. Indeed, using this system, KO can be induced 
postnatally which allows the uncoupling of a protein’s function in development from 
its role in maintenance. This idea is specifically relevant for CYFIP1 due to the 
embryonic lethality of constitutive CYFIP1 KO mice. Hence, the generation of CYFIP 
cKO mice would provide the first example of complete CYFIP1 loss of function studies 
and would shed more light on many as yet unanswered aspects of CYFIP1 function. 
 
In this chapter, firstly, genetic analysis of a large cohort of SCZ patient DNA 
sequencing has revealed Cyfip1 as a SCZ-associated gene due to an excess of 
potentially damaging rare variants identified within the gene. Of these variants SNP 
22963816 was found to be significantly associated with SCZ. Furthermore, five of the 
variants, selected based on their potential to disrupt functional CYFIP1 protein 
interactions, were genotyped in an independent SCZ cohort. Again SNP4 (22963816) 
occurred more frequently in cases than controls, however, this association was not 
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significant. Functional characterisation of all five candidate SCZ-associated CYFIP1 
variants revealed they retained their localisation to excitatory and inhibitory 
synapses. Furthermore, the different variants showed no alterations in their 
interaction with a member of the WRC. Secondly, the first example of CYFIP1 
knockout MEFs was characterised. KO cells appeared to show reduced survival rates 
and disrupted actin structure appearing smaller and more rounded. Moreover, 
postnatal deletion of CYFIP1 in the forebrain resulted in a 50% loss of CYFIP1 in the 
hippocampus and an alteration in CA1 pyramidal basal dendrite morphology in six 
month old mice. In summary, this data provides evidence that Cyfip1 is a SCZ-
associated gene. Initial studies show individual variants do not appear to be 
functionally damaging suggesting that an accumulation of variants may have more 
harmful effects. Finally, loss of function studies using novel CYFIP1 cKO models 
revealed CYFIP1 function appears to be critical for viability in fast dividing cells while 
postnatal deletion of CYFIP1 in neurons results in defects in dendritic morphology 
and points towards a role for CYFIP1 in dendritic maintenance as well as 
development. 
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4.2 Results 
4.2.1 Identification of novel CYFIP1 schizophrenia-associated variants 
In order to investigate the functional effects of CYFIP1 SCZ-associated variants, it was 
first important to determine if Cyfip1 was associated with SCZ and if any novel 
variants could be identified within the gene. In collaboration with Dr. Dave Curtis 
from Queen Mary University of London the weighted burden test was applied to data 
produced from the UK10K project to determine if Cyfip1 or Cyfip2 were associated 
with SCZ. The SCZ cohort consisted of 1392 subjects recruited from five British 
centres. These subjects were considered cases and were compared to an unaffected 
control cohort, which in this case was the UK10K obese cohort consisting of 982 
subjects. The weighted burden test provides a rapid method for combined analysis of 
common and rare variants within a gene of interest. Considering all the variants of a 
gene when looking for association with disease can be deemed more appropriate as it 
models the biological reality that a number of different variants may separately 
impact on the function of a gene (Curtis, 2012). 
 
Briefly, the raw data was processed by a custom-built programme developed by Dr. 
Dave Curtis (geneVarAssoc, unpublished). Variants from all SCZ transcripts found in 
either Cyfip1 or Cyfip2 were extracted and the programme generated a prediction 
about the effect of each variant on the protein product. The programme used the 
reference sequence and the coordinates of all the exons, along with transcription start 
and end points of the gene of interest as provided by the online resource RefSeq 
(Pruitt et al., 2014). With this information the programme was then simply able to 
resolve whether each variant was a nonsense, nonsynonymous or synonymous variant 
and was capable of predicting the consequence of each variant on the protein product 
based on the effect the variant had on the amino acid code. Where there were multiple 
transcripts, and hence multiple possible effects, the most severe effect is described. 
 
The weighted burden test was then ran on the input files produced from the 
geneVaAssoc programme using another custom-built software (SCOREASSOC 
(Curtis, 2012)). A narrow category of variants restricted to non-synonymous (NS), 
splice-site or nonsense variants having a minor allele frequency (MAF)<0.1 in either 
cases or control were selected for further analysis. Narrow category variants for Cyfip1 
 
Identification and characterisation of rare Cyfip1 variants in SCZ 
 
 
156 
 
are listed in Appendix B. Each variant was given a weight so that variants deemed 
more likely to have an effect on gene expression or protein function were allocated 
higher weights. Nonsense variants were given a higher weight than NS variants, which 
were given a higher weight than splice-site variants. Likewise, rarer variants were 
given a higher weight than common variants. An overall weight for each variant was 
calculated by multiplying these values together. Each subject was then assigned a 
score consisting of the sum of the weights of all the variants within the gene of interest 
possessed by that subject (Curtis, 2012). The average scores were compared between 
SCZ cases and unaffected controls. This analysis revealed that the average score 
for Cyfip1 was significantly higher in cases compared to controls demonstrating that 
cases had an excess of rare, potentially damaging variants in Cyfip1 (mean score: 
control, 1.904; cases, 2.415; t(2372 df) = 1.658; p<0.05). There was no significant 
difference in the scores for Cyfip2. 
 
To identify if individual Cyfip1 variants were associated with SCZ a compiled list of all 
the NS variants, that had a higher MAF in cases compared to control, were analysed. 
NS variants were studied as any interesting variants could be cloned into expression 
vectors and used for downstream functional analysis in biological systems. Variants 
with a higher occurrence in cases than control had more potential of being pathogenic. 
The genotypes of these variants were studied and compared to the unaffected control 
group. Chi squared tests were carried out to determine if the observed genotyping for 
each variant was significantly different between cases and control.  Interestingly, of 
these variants some stood out. A variant at position 15:22963816 occurred in seven 
cases and was not seen in the unaffected subjects. This variant yielded a significant 
association with SCZ (p<0.05). Variants 15:22963869, 15:22990087 and 15:22993121 
were somewhat commoner among cases but did not individually show significant 
association with SCZ. That said, variant 15:22990087 showed a trend towards 
significance (p=0.078). There was a general excess of singleton variants among SCZ 
cases, which contributed to the overall p value produced by SCOREASSOC (Table 4.1). 
 
To add further strength to these initial findings, the Cyfip1 variants were genotyped 
in an independent SCZ case-control cohort to determine if the results from the UK10K 
analysis could be replicated. SCZ patient DNA and control samples were available 
within the Division of Psychiatry at UCL and genotyped in collaboration with Dr. 
Andrew McQuillin. Screening the UCL cohort for all the identified CYFIP1 variants 
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Table 4.1: Non-synonymous Cyfip1 variants identified from the UK10K whole exome sequencing data analysis. 
Variant 
ID 
Unaffected 
Genotypes 
Case 
Genotypes 
Allele 
Change 
Residue 
Change 
Residue 
Number 
Functional  
prediction p value 
 AA AB BB MAF AA AB BB MAF      
22928169 982 0 0 0 1391 1 0 0.0004 cTg/cCg L/P 83 probably damaging NS 
22933848 982 0 0 0 1391 1 0 0.0004 aCg/aTg T/M 256 possibly damaging NS 
22940807 982 0 0 0 1390 2 0 0.0007 Cgc/Tgc R/C 358 possibly damaging NS 
22947019 982 0 0 0 1390 2 0 0.0007 aGc/aAc S/N 431 benign NS 
22947045 982 0 0 0 1391 1 0 0.0004 Cgc/Tgc R/C 440 probably damaging NS 
22954273 982 0 0 0 1391 1 0 0.0004 Gcc/Acc A/T 475 benign NS 
22954276 982 0 0 0 1391 1 0 0.0004 Atc/Gtc I/V 476 possibly damaging NS 
22956358 982 0 0 0 1391 1 0 0.0004 tCt/tTt S/F - unknown NS 
22963782 982 0 0 0 1391 1 0 0.0004 Cgt/Agt R/S 766 benign NS 
22963816 982 0 0 0 1385 7 0 0.0025 tAt/tGt Y/C 777 benign 0.026 
22963869 976 6 0 0.0031 1377 15 0 0.0054 Ata/Gta I/V 795 probably damaging 0.234 
22969215 982 0 0 0 1391 1 0 0.0004 cGg/cAg R/Q 814 benign NS 
22969251 982 0 0 0 1391 1 0 0.0004 cGg/cAg R/Q 826 possibly damaging NS 
22969353 982 0 0 0 1391 1 0 0.0004 tCt/tGt S/C 860 probably damaging NS 
22990087 975 7 0 0.0036 1371 21 0 0.0075 Ggc/Agc G/S 903 benign 0.078 
22993121 954 27 1 0.0148 1340 51 1 0.019 gCc/gTc A/V 1003 possibly damaging 0.266 
22999403 980 2 0 0.001 1391 1 0 0.0004 aTg/aCg M/T 1092 benign NS 
22999457 982 0 0 0 1391 1 0 0.0004 cGc/cAc R/H 1110 benign NS 
23002888 982 0 0 0 1391 1 0 0.0004 Atg/Gtg M/V 1204 benign NS 
Non-synonymous variants taken from the SCOREASSOC output for the analysis of Cyfip1 treating SCZ subjects from the UK10K project as cases 
and obese subjects as unaffected. The table shows genotype counts, MAF, allelic and residue changes and predicted functional effects. Significant 
association for each variant with SCZ was tested using the chi squared test, *p<0.05. 
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listed in Table 1 was unfeasible due to time constraints therefore, a shortlist of five 
was created based on their likelihood of being functionally damaging. Certain criteria 
were considered when making the shortlist. Firstly, variants which fell within 
functionally interesting domains of the protein were considered. Indeed, Chapter 3 of 
this thesis has suggested that the actin regulatory role of CYFIP1 may be critical for 
its effect on dendritic morphology and synaptic maintenance, both processes which 
when disrupted have been implicated in SCZ pathogenesis (Broadbelt et al., 2002; 
Garey et al., 1998; Glantz and Lewis, 2000). Therefore, using the previously published 
structure of CYFIP1 in the WRC and information about essential residues for binding 
(Figure 4.1A,B) (Chen et al., 2010b), variants which caused an amino acid change in a 
region of CYFIP1 critical for its interaction with other WRC proteins were identified. 
Secondly, the type of amino acid change which was incurred by the genetic variation 
was considered.  
 
Five variants were shortlisted (Figure 4.1C) and from here in are named SNP1-5. Two 
of the variants caused amino acid changes within the Rac1 binding domain of CYFIP1. 
SNP1 results in a serine at residue 431 being mutated to an asparagine (S431N). 
Although this variant does not cause a change in the charge of the residue and was 
predicted to be benign it is in close proximity to a published Rac1 interacting residue  
434 and therefore still of interest. SNP2 was predicted to be probably damaging and 
results in a positively-charged arginine at residue 440 being mutated to a cysteine 
which contains a sulphide group capable of forming disulphide bonds (R440C). Again 
this residue is close to a residue critical for Rac1 binding and could therefore impact 
on active Rac1-dependent CYFIP1 conformational changes. Three of the SNPs caused 
amino acid changes in the WAVE binding domain. SNP3 and SNP5 result in positively 
charged arginine residues being mutated to uncharged serine and glutamine residues 
respectively (R766S, R826Q). SNP4 mutates a tyrosine, capable of undergoing 
phosphorylation, to a cysteine which instead can form disulphide bonds (Y777C). 
SNP3 and SNP4 were predicted to be benign whereas SNP5 was predicted to be 
possibly damaging. By studying the WRC structure all three variants occur at residues 
that fall within close proximity to either a CYFIP1 WAVE interacting residue, or they 
appear to be important in the WAVE binding pocket formed by CYFIP1 (Figure 4.1B).  
 
These five SNPs were then genotyped in the UCL SCZ case-control samples consisting 
of ~1300 control and ~900 case samples. To do this, specific primers to detect both 
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Figure 4.1: Description of the 5 shortlisted SCZ-associated CYFIP1 SNPs. 
(A) The crystal  structure of CYFIP1 in the WRC generated in Pymol (The PyMOL Molecular 
Graphics System, Version 1.7.4 Schrödinger, LLC) using the published 2.3 ångstrom structure 
of the WRC (Chen et al., 2010b). The proteins of the complex are coloured as follows: CYFIP1, 
cyan; NAP1, green; WAVE1, purple; Abi1, orange; HSPC300, yellow. (B) The crystal structure 
of CYFIP1 in the WRC alone with the 5 shortlisted SCZ-associated SNPs highlighted in red, 
selected based on their proximity to previously described predicted Rac1 interacting residues 
and residues critical for WAVE1 binding (inset). (C) A summary of the 5 shortlisted SNPs 
highlighting whether they are predicted to interfere with the Rac1 or WAVE binding 
capability of CYFIP1.   
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the WT allele and the mutant allele were designed and the KASPar endpoint 
genotyping method was carried out (see page 83). Unfortunately, the primers for 
SNP1 could not be suitably optimised for genotyping in the time available and 
therefore only SNP2-5 were genotyped (Table 4.2). Of the four SNPs genotyped, SNP3 
occurred in one case and in no control samples. Genotyping SNP4 revealed there were 
two heterozygous cases and one homozygous case but also two heterozygous controls. 
Although both these SNPs occurred more frequently in cases, these numbers were too 
small to be statistically significant. Interestingly, these genotyping results show 
consistencies with the UK10K data. The MAFs for SNP3 and SNP5 are similar in both 
screens and SNP4 which was the variant closest to being significantly associated with 
SCZ showed a significant association in the UK10K data. SNP2 and SNP5 did not 
occur in the UCL cohort.  
 
Taken together, although incredibly rare, all five candidate variants have been 
identified in a patient with SCZ either in the UCL or the UK10K cohort. Moreover, the 
MAFs of the variants genotyped in the UCL cohort were consistent with the UK10K 
data, thus, validating the UK10K results. Importantly, SNP4 shows a significant 
association with SCZ when a large dataset such as the UK10K is analysed and also 
shows a consistently greater number of affected cases than controls in the UCL cohort 
although this result does not yield a significant association.  
Table 4.2: Genotyping of candidate Cyfip1 variants in the UCL SCZ cohort. 
Name Control 
Genotypes 
Case 
Genotypes 
Odds 
Ratio 
p value 
 AA AB BB MAF AA AB BB MAF   
SNP2 1290 0 0 0 909 0 0 0 - - 
SNP3 1287 0 0 0 910 1 0 0.00055 - 0.444 
SNP4 1312 2 0 0.00076 893 2 1 0.00223 2.937 0.192 
SNP5 1291 0 0 0 923 0 0 0 - - 
 
4.2.2 Generation and neuronal localisation of candidate SCZ-associated 
CYFIP1 variants 
Amino acid mutations at critical residues in a protein can lead to conformational 
changes in the protein structure that have the potential to result in altered protein 
function or inhibit protein-protein interactions. To determine whether the five 
candidate SCZ-associated variants studied in this chapter resulted in any functional 
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consequences the CYFIP1 mutants were generated on the human wild-type CYFIP1 
cDNA backbone.  
 
Site-directed mutagenesis was carried out on the pENTR_CYFIP1 vector to introduce 
the mutations into the cDNA which were then confirmed with sequencing. The 
Gateway Cloning System was then used to clone the wild-type and the CYFIP1 
mutants into the pDESTeGFP-N1 mammalian expression vector which contained a C-
terminal GFP tag. The CYFIP1 constructs were then transfected into COS-7 cells to 
confirm expression of the tagged proteins in a mammalian system. Confocal 
microscopy revealed the GFP tagged proteins were readily expressed and that the 
CYIFP1GFP SNP constructs displayed a cytosolic localisation similar to WT CYFIP1GFP 
(Figure 4.2A). Samples of COS-7 cells transfected with the CYFIP1GFP SNP constructs 
were also subjected to SDS-PAGE and western blotting. When the membrane was 
probed for GFP a band was detected for WT CYFIP1GFP and all five SNPs at ~175kDa 
corresponding to the expected weight of CYFIP1 plus GFP. No band was detected in 
the untransfected control lane indicating that this band was specific to the transfected 
cells. To confirm the band was indeed exogenously expressed CYFIP1 the same 
samples were probed with a CYFIP1 specific antibody. This antibody revealed an 
identical band at ~175kDa for each sample that was not present in the untransfected 
control lane demonstrating that these bands were CYFIP1GFP constructs. Endogenous 
CYFIP1 could also be detected with the CYFIP1 specific antibody in all lanes at 
~145kDa (Figure 4.2B). Interestingly, CYFIP1GFP SNP1 expression was reduced 
compared to the other variants suggesting this point mutation may impact on protein 
expression or stability. 
 
The subcellular localisation of a protein can provide insights into how that protein 
functions. Furthermore, if the normal localisation of a protein is disrupted it is likely 
to indicate that the function of the protein has been altered or the protein can no 
longer be targeted correctly perhaps due to disrupted protein-protein interactions. In 
Chapter 3 the excitatory and inhibitory synaptic enrichment of CYFIP1 was 
demonstrated and CYFIP1 was shown to be important in both excitatory and 
inhibitory synaptic maintenance. Having determined all five CYFIP1 variants are 
readily expressed in mammalian cells it was therefore, interesting to investigate if the 
neuronal subcellular localisation of these CYFIP1 variants was altered.  
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Figure 4.2: Cloning and characterisation of GFP-tagged CYFIP1 SCZ-
associated variants. 
(A) Transfection of COS-7 cells with human WT CYFIP1GFP or CYFIP1GFP SCZ-associated 
variants S431N (SNP1), R440C (SNP2), R766S (SNP3), Y777C (SNP4) and R826Q (SNP5). 
Strong GFP signal confirms that these fusion proteins are readily expressed. Scale bar, 20μm. 
(B) Western blotting of untransfected (UT), WT CYFIP1GFP or CYFIP1GFP SNPs 1-5  transfected 
COS-7 cell lysates and probing for GFP (left panel) confirms that these constructs generate 
fusion proteins of the expected molecular weight ~175 kDa. Probing for CYFIP1 (right panel) 
confirmed the five variants of CYFIP1 could still be detected with a specific anti-CYFIP1 
antibody producing a band for CYFIP1GFP alone at ~175 kDa and a band for endogenous 
CYFIP1 at ~145 kDa (arrow).   
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CYFIP1GFP SNPs were individually transfected into mature hippocampal rat neurons. 
Neurons were fixed after three days transfection and stained with a GFP antibody to 
amplify the GFP signal and either excitatory or inhibitory synaptic markers. All five 
CYFIP1GFP SNP constructs were present in the dendrites, soma and axon of 
hippocampal neurons similarly to WT CYFIP1 (Figure 4.3A; Figure 3.4; Figure 3.13). 
Interestingly, compared to the pDEST47_CYFIP1GFP vector used throughout Chapter 
3 the expression pattern for all the pDESTeGFP-N1_CYFIP1 constructs was more 
diffuse along the dendrites probably due to the increased expression efficiency of this 
vector. Nevertheless, using high-resolution confocal zoom images to look in more 
detail at the dendrites and their synapses all the CYFIP1 variants appeared partially 
clustered with an uneven distribution along the dendritic shaft. Strikingly, all the 
CYFIP1GFP SNPs appeared to be present in dendritic spines and colocalised with the 
post excitatory synaptic marker Homer opposed to the presynaptic marker vGlut in 
the same way as has been described for WT CYFIP1GFP (Figure 4.3B; Figure 3.4). The 
zoom confocal images also revealed that the distribution of CYFIP1 variants 
overlapped with inhibitory synapses. In Chapter 3, a clear enrichment of WT CYFIP1 
was visible at inhibitory synapses (Figure 3.13). However, due to the different vector 
backbone and the more diffuse expression pattern of the CYFIP1GFP SNPs, further 
quantification would be required to conclude an inhibitory synaptic enrichment of 
these variants. Even so, the CYFIP1GFP SNPs were detected at gephyrin positive 
inhibitory postsynaptic sites opposed to the presynaptic marker, vGAT (Figure 4.4). 
Therefore, if not enriched, these variants are at least present at inhibitory synapses. 
Taken together, the CYFIP1 SCZ-associated variants do not appear to modify the 
subcellular localisation of CYFIP1GFP in neurons. This suggests that if the mutations 
are impacting on CYFIP1 function they are most likely having more subtle effects on 
protein function and not disrupting its localisation. 
4.2.3 The effect of candidate SCZ-associated CYFIP1 variants on protein 
interactions 
The candidate SCZ-associated CYFIP1 variants were selected partly because the 
mutation caused an amino acid change within a region of CYFIP1 predicted to be 
important for its interaction with either Rac1 or WAVE in the WRC (Figure 4.5A). To 
directly test whether the CYFIP1 variants altered these protein interactions 
coimmunoprecipitation experiments were carried out in HEK293 cells 
overexpressing the CYFIP1GFP SNP constructs. HEK293 cells are a human embryonic  
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Figure 4.3: CYFIP1 SCZ-associated variants are located at excitatory 
synapses. 
 (A) Five SCZ-associated GFP-tagged variants of CYFIP1 (SNP1-5) were transfected into 
mature rat hippocampal neurons. CYFIP1 variants are detected in the soma, dendrites and 
axon. (B) Neurons were stained with antibodies against the pre and postsynaptic excitatory 
markers vGlut and Homer respectively. CYFIP1 SNP variants show a punctate distribution 
along dendrites and an enrichment in dendritic spines. Each variant colocalised with the 
excitatory synaptic markers within dendritic spines (arrowheads). Scale bars, 20μm, 2μm. 
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Figure 4.4: CYFIP1 SCZ-associated variants are localised at inhibitory 
synapses. 
(A) Five SCZ-associated GFP-tagged variants of CYFIP1 (SNP1-5) were transfected into 
mature rat hippocampal neurons. Neurons were stained with antibodies against the 
inhibitory pre and postsynaptic markers vGAT and gephyrin respectively. CYFIP1 SNP 
variants showed a punctate distribution along dendrites. The variant clusters colocalised 
with the inhibitory synaptic markers along the dendritic shafts (arrowheads). Scale bar, 2μm.  
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kidney cell line. These cells were chosen so interactions between the human CYFIP1GFP 
variants and the endogenous human WRC proteins could be analysed. Furthermore, 
a human cell line system is more physiologically relevant when studying SCZ-
associated mutations identified from patient DNA. WT and all the CYFIP1GFP SNPs 
could be immunoprecipitated from HEK293 cells via their GFP tag using GFP TRAP 
beads. Endogenous NAP1 a large protein within the WRC that forms a pseudo-
symmetric dimer with CYFIP1 could be coimmunoprecipitated with all the CYFIP1GFP 
SNP constructs. Endogenous WAVE2, a ubiquitously expressed form of WAVE, was 
also coimmunoprecipitated with all the CYFIP1 constructs (Figure 4.5B). 
Quantification over repeated experiments revealed that none of the GFP-tagged SNPs 
appear to interact differently with WAVE2 when compared with WT CYFIP1GFP 
(Figure 4.5C). This suggests that the candidate SCZ-associated CYFIP1 variants do not 
interfere with the WAVE interaction. Rac1 could not be coimmunoprecipitated with 
any of the CYFIP1 constructs therefore the effects of the CYFIP1 variants on this 
interaction could not be tested. CYFIP1 interacts specifically with activated GTP-
bound Rac1 (Kobayashi et al., 1998) therefore using drugs to stimulate Rac1 activation 
may push the system enough to observe this interaction by coimmunoprecipitation. 
 
In summary, the five candidate SCZ-associated CYFIP1 variants can still be detected 
in the same synaptic subcellular compartments as WT CYFIP1. However, it cannot be 
concluded that the variants maintain the same enrichment at excitatory and 
inhibitory synaptic puncta without further quantification. Furthermore, the different 
CYFIP1 variants did not affect the interaction between CYFIP1 and WAVE. If the 
mutations are having an effect on CYFIP1 function then, judging by the data presented 
here, they are likely to be quite subtle and will only be unpicked with more sensitive 
assays which will require further investigation.   
4.2.4 Characterisation of a CYFIP1 KO MEF cell line 
The previous experiments in this chapter and those carried out in Chapter 3 have 
modelled CYFIP1 disease-associated genetic alterations to investigated CYFIP1 
function and how it is implicated in neuropsychiatric disorders. However, in addition 
to modelling CYFIP1 disease-associated genetic alterations there is much to be 
learned about a protein by carrying out loss of function experiments using KO model 
systems. Constitutive CYFIP1 KO animals are embryonically lethal therefore, CYFIP1 
loss of function on postnatal or adult animals cannot be studied with this mouse line. 
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Figure 4.5: CYFIP1 SCZ-associated variants interact with WAVE. 
(A) A schematic of CYFIP1 showing important protein interacting domains (N = critical NAP1 
binding region) and depicting the five SCZ-associated CYFIP1 variants identified in this study.   
(B) Western blots of protein complexes coimmunoprecipitated using anti-GFP TRAP beads 
from HEK cells transfected with WT, SNP1, SNP2, SNP3, SNP4 or SNP5 CYFIP1GFP. Input 
samples (Input) represent 5% of the cell lysate included in the immunoprecipitation samples 
(IP). Anti-GFP TRAP beads efficiently coimmunoprecipitated endogenous NAP1 and WAVE2 
from CYFIP1GFP transfected cell lysates but not from GFP only transfected cells. CYFIP1GFP 
constructs were revealed with an anti-GFP antibody while anti-NAP1, anti-WAVE2 and anti-
Rac1 antibodies were used to visualise endogenous NAP1, WAVE2 and Rac1 respectively. (C) 
Quantification of the amount of coimmunoprecipitated WAVE2 protein normalised to the 
amount of CYFIP1GFP pulled down (n=7; ANOVA; NS).  
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Figure 4.6: Generation of CYFIP1 floxed mice. 
(A) A schematic of the knockout (KO)-first allele system, demonstrating the generation of the 
Cyfip1 floxed allele following Flp recombination of the KO-first Cyfip1 allele (tm2a allele). The 
KO-first allele cassettes are described in Figure 3.7. Both cassettes are bound by frt sites 
(green triangles). The neo cassette and 3’ frt site are flanked by loxP sites with an additional 
distal loxP site present 3’ of exon 6 (red triangles). The presence of Flp recombinase extrudes 
the mutant cassettes from the KO-first allele, by recombining the frt sites, reconstituting a 
floxed allele capable of expressing functional CYFIP1 mRNA. (B) Genotyping to distinguish 
between WT, KO-first mutant and floxed alleles (primers: aF aR, aF a’R, ZF ZR). From the left a 
heterozygous WT mutant animal (+/-) produced a wild-type (wt), mutant (mut) and lacZ PCR 
product. A homozygous floxed animal (F/F) produced a shifted floxed (flx) (arrow) and mut 
product but no lacZ as flp recombination had occurred. A heterozygous WT floxed animal 
(F/+) produced a WT and a floxed band from the same primers and a mutant band. (C) A 
schematic of the conditional Cyfip1 KO strategy, depicting the deleted allele following Cre 
recombination of the floxed allele. The presence of Cre recombinase with the floxed allele 
results in the recombination of the LoxP sites (red triangles), the removal of three critical 
Cyfip1 exons (blue boxes) and abolishes gene expression.  
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Indeed, primary neurons cannot even be cultured from constitutive CYFIP1 KO 
embryos as they die too early in development at E8.5. To overcome these problems, 
CYFIP1 can be genetic deleted in a conditional manner either dependent on the 
administration of a drug or the expression of a recombinase enzyme. This approach 
allows the study of CYFIP1 loss of function in a region and temporal specific manner 
thus, avoiding the need of global CYFIP1 KO which results in lethality. 
 
The CYFIP1 transgenic mouse studied in Chapter 3 was generated using the KO-first 
system (Skarnes et al., 2011; White et al., 2013). As previously discussed, a LacZ 
cassette was inserted into the CYFIP1 gene between exons 3 and 4. This cassette 
disrupted the expression of CYFIP1 resulting in non-functional Cyfip1 mRNA and 
expression of the reporter gene. The cassette is flanked by FRT sites which will 
undergo recombination and extrude the flanked mutant cassette, in the presence of 
Flp recombinase, reconstituting a floxed allele (Figure 4.6A). This floxed allele allows 
the expression of function Cyfip1 mRNA but still contains LoxP sites flanking exons 
4-6 of the CYFIP1 gene. Floxed animals were healthy and indistinguishable from WT 
animals. When genotyped floxed animals (F/F) generated a larger floxed product (454 
bp) from the aF and aR primers due to the inclusion of the LoxP site. The mutant band 
was present and the LacZ band was lost confirming Flp recombinase deletion of the 
KO-first cassette had taken place (Figure 4.6B). The presence of the LoxP sites around 
exons 4-6 of Cyfip1 make these floxed CYFIP1 animals KO-ready. With the expression 
of a different enzyme Cre recombinase (Cre) another recombination event can occur 
between the LoxP sites extruding the DNA encoding these three critical exons. The 
result is a deleted allele and loss of functional Cyfip1 mRNA expression in a 
conditional manner dependent on the presence of Cre (Figure 4.6C).  
 
Mouse embryonic fibroblasts (MEFs) are simple to generate from transgenic tissue 
and easy to culture. They can be transformed and passaged many times. Furthermore, 
unlike primary neurons, MEFs divide and undergo migration therefore, they provide 
an ideal system for studying CYFIP1 loss of function effects on cell motility and actin 
dynamics. With this in mind, attempts were made to develop CYFIP1 KO MEFs. 
 
Crossing CYFIP1 floxed mice with Cre expressing mice will result in recombination 
and CYFIP1 conditional KO (cKO) cells. By regulating the expression pattern of Cre  
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Figure 4.7: A schematic of CreERT recombinase function. 
Inducible gene inactivation using CreERT recombinase (CreERT) is based on tamoxifen (TAM)-
inducible excision of a loxP flanked gene in cells expressing TAM-dependent CreERT. CreERT 
consists of Cre fused to a mutated ligand-binding domain (LBD) of the oestrogen receptor. 
(A) Under control conditions, in the absence of TAM, CreERT is retained in the cytoplasm. The 
gene of interest (CYFIP1) is transcribed and expressed as normal (TC). (B) Binding of TAM to 
the LBD induces translocation of CreERT to the nucleus (green oval) where it can recombine 
its loxP flanked (red triangles) DNA substrate (CYFIP1). This results in loss of the gene of 
interest and no transcription or protein expression (no TC). TAM binding regulates the 
localisation of the Cre rather than its enzymatic activity. Spatiotemporal control of DNA 
removal and hence genetic knockout can be achieved by tissue specific expression of CreERT. 
Adapted from (Feil et al., 2009).  
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Figure 4.8: Generation of Cyfip1 conditional knockout MEFs. 
 (A) Western blot showing CYFf/f CreERT+/- MEF cell lysates either untreated (UT) 
or treated with 1μM TAM for 1, 2 or 6 days prior to lysis and probed with a CYFIP1-
specific antibody. (B) Western blot showing CYFf/f CreERT+/- (F/F), CYFf/+ 
CreERT+/- (F/+) and CYFf/f CreERT+/- (cKO) MEF cell lysates after DMSO (F/F) or 
TAM (F/+ and cKO) treatment. Cells were seeded sparsely and treated with 1μM TAM 
or DMSO following three passages before lysis. All CYFIP1 protein is lost from the 
cKO cell line. (C) PCR analysis of F/F (CYFf/f, CreERT+/-, +DMSO) and cKO (CYFf/f, 
CreERT+/-, +TAM) MEF cell DNA. Cells were genotyped with the primers aF and aR to 
produce the shifted floxed (FLX) PCR product and aF and a’R to produce the mutant 
(MT) product. Detection of these bands confirmed the presence of the floxed allele 
originating from the mutant KO-first allele. Primers against Cre produced a product 
if the Cre gene was present (CRE). Primers AF and A’’R produced a product from the 
deleted allele (DEL). F/F control cells were positive for the floxed allele and Cre but 
lacked the deletion allele product due to no TAM induced recombination. cKO cells 
were positive for the deleted allele and Cre but lacked the floxed allele product 
confirming complete recombination had occurred with TAM treatment.
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the population of cells within which CYFIP1 is removed can be controlled. 
Alternatively, CYFIP1 floxed mice can be crossed with mice expressing Cre under a 
germline promoter to induce CYFIP1 loss in all cell types. However, it is known from 
Chapter 3 that constitutive KO of CYFIP1 in mice is embryonically lethal and 
thereforethis cross would not result in any viable KO embryos for the generation of 
MEFs. For that reason, an inducible Cre approach was used (Feil et al., 2009). CYFIP1 
floxed mice were crossed with CreER(T2) recombinase (CreERT) mice. This form of 
Cre is ligand dependent and is only activated in the presence of the drug tamoxifen 
(TAM) (Figure 4.7) (Feil et al., 1997). MEFs were generated from CreERT positive, 
CYFIP1 floxed embryos (CYFf/f, CREERT+/-) and transformed by Prof. Josef Kittler. 
To characterise CYFIP1 protein turnover and determine how long after TAM 
treatment was required for total loss of CYFIP1 protein a time course was carried out. 
Seeded CYFf/f, CREERT+/- MEFs were cultured in 1µM TAM for 1, 2 or 6 days and the 
amount of CYFIP1 present in the cell lysates was assayed by SDS-PAGE and western 
blotting. The time course revealed that after 2 days treatment with TAM almost all 
CYFIP1 had been lost from the cells and by day 6 CYFIP1 could not be detected by 
western blotting. However, treatment for 6 days appeared to cause some cell death 
which can be deduced from the reduction in the β-tubulin band (Figure 4.8A). 
 
CYFIP1 cKO cells may have disrupted actin dynamics and cell division therefore, 
attempts were made to totally eradicated floxed MEFs from the TAM treated cultures. 
Any remaining CYFIP1 expressing floxed cells could be more viable and out compete 
the cKO cells resulting in a mixed population of floxed and cKO cells. To be sure all 
cells underwent recombination in the production of cKO MEFs a different treatment 
approach was tested. CYFf/f, CREERT+/- MEFs were plated at a very low density and 
treated with 1µM TAM or vehicle DMSO control to generate cKO CYFIP1 and floxed 
CYFIP1 expressing MEFs respectively. Plated CYFf/+, CREERT+/- MEFs were treated 
with 1µM TAM to generate CYFIP1 haploinsufficient cells. Cells were passaged three 
times, each time the cells were plated at a low density and retreated. The low density 
plating was used to ensure all cells originated from recombined cells. Following this, 
cells from each of the 3 conditions were lysed in sample buffer, subjected to SDS-
PAGE and western blotting. Western blotting revealed that treatment of CYFf/f, 
CREERT+/- MEFs with TAM in this way resulted in complete eradication of CYFIP1 
levels as expected (cKO). TAM treatment of CYFf/+, CREERT+/- cells (F/+) resulted 
in reduced CYFIP1 levels compared to DMSO-treated floxed cells (F/F) as would be 
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Figure 4.9: F-actin levels and morphology of CYFIP1 cKO MEFs. 
(A) Confocal images of CYFIP1 F/F control (CYFf/f, CreERT+/-, +DMSO) and cKO (CYFf/f, 
CreERT+/-, +TAM) MEFs immunostained with a CYFIP1 specific antibody (green), the F-actin 
binding toxin phalloidin (grey) and DAPI (blue). KO cells appeared sparser, smaller and more 
rounded. (B) Zoom confocal images of the same cells highlighting the reduced phalloidin 
staining in the KO cells. Scale bars, 50μm.  
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expected for cells haploinsufficient for CYFIP1 (Figure 4.8B). For further 
confirmation that cKO cells had been produced DNA was extracted and genotyped by 
PCR. Genotyping the DMSO and TAM treated CYFf/f, CREERT+/- cells confirmed that 
recombination had occurred in all the TAM treated cells. There was total loss of the 
floxed band, demonstrating all floxed alleles had undergone recombination. 
Additionally, a deletion band was present. A PCR product from the deletion primers 
would only be produced if LoxP recombination had occurred (Figure 4.8C). 
 
Following production of CYFIP1 cKO MEFs, cells were plated onto glass coverslips, 
fixed and subjected to confocal microscopy. Cells were stained with a CYFIP1-specific 
antibody (Upstate) with an appropriate fluorescent secondary antibody and the F-
actin binding toxin, phalloidin, conjugated to alexa-647. DAPI was used to label the 
cell nucleus. CYFIP1 cKO cells showed less CYFIP1 antibody staining as expected, 
however, the residual staining observed was unexpected and could be the result of 
nonspecific background staining. Both F/F and cKO cells displayed phalloidin 
labelling. An interesting observation noted was that the density of cKO cells was 
always considerably less than F/F cells suggesting that more cell death may be 
occurring in CYFIP1 cKO cells. cKO cells also appeared smaller and more rounded 
when compared to F/F CYFIP1 expressing cells (Figure 4.9A). Zoom images were 
acquired to analyse the distribution of F-actin more closely. Again cKO cells appeared 
rounder. Furthermore, the phalloidin staining seemed weaker and fewer stress fibres 
were present in cKO cells (Figure 4.9B). These results demonstrate that a novel 
CYFIP1 cKO MEF line has been generated. Initial observations suggest that cell 
morphology and cell viability are effected by loss of CYFIP1 perhaps due to the altered 
F-actin network detected. 
4.2.5 Conditional deletion of CYFIP1 from mouse hippocampus and 
cortex 
In parallel to the generation of CYFIP1 cKO MEFs, floxed mice allowed the study of 
CYFIP1 loss of function in neurons. As constitutive CYFIP1 KO mice died during 
embryogenesis, CYFIP1 must be essential for development. By knocking out CYFIP1 
postnatally and specifically in neurons the function of CYFIP1 can be uncoupled from 
its role in development as it was predicted to overcome the embryonic lethality of 
constitutive CYFIP1 KO mice. In this way, CYFIP1 loss of function in adult neurons 
can be studies to further unpick the neuronal role of CYFIP1 and determine if CYFIP1 
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is important in neuronal maintenance.  
 
To determine the consequences of CYFIP1 loss in postnatal neurons floxed CYFIP1 
mice were crossed with transgenic Camkcre4 (CreCAMKII) mice (Mantamadiotis et al., 
2002). These animals expressed Cre recombinase postnatally under the control of the 
8.5-kb promoter fragment of the calcium/calmodulin-dependent protein kinase II- α 
gene (CAMKIIα). Under this promoter Cre expression has been described to be high 
in the forebrain including the cortex, hippocampus, striatum, thalamus and 
amygdala. Cre-mediated recombination has been shown to be extensive in all areas of 
the brain where the recombinase is expressed (Mantamadiotis et al., 2002). 
 
Cre positive CYFIP1 floxed mice were viable, progressed to adulthood and were 
indistinguishable from control littermates. Observations revealed there was no gross 
difference in brain size between adult floxed (CYFf/f, CRECAMKII-/-), heterozygous 
(CYFf/+, CRECAMKII+/-) and cKO (CYFf/f, CRECAMKII+/-) CYFIP1 animals (Figure 
4.10A). The hemispheres, cerebellum and olfactory bulbs were all of an equivalent size 
when genotypes were compared. Adult floxed and cKO brains were dissected and 
tissue from the cortex and hippocampus was prepared into cell lysates for SDS-PAGE 
and western blotting. DNA was also extracted from floxed and cKO hippocampal 
tissue and genotyped using PCR (Figure 4.10B). As expected the floxed DNA samples 
produced a floxed band and mutant band demonstrating the presence of the floxed 
CYFIP1 alleles containing the LoxP sites. A band for Cre was not detected and 
therefore no deletion band was detected. The cKO sample on the other hand, 
produced a Cre band indicating the presence of Cre in the hippocampal tissue and a 
deletion band demonstrating that recombination and KO of the CYFIP1 gene had 
occurred. However, the floxed band was still present highlighting that the 
hippocampal DNA sample contained a mixed population of cells, some with the 
critical exons deleted and others remaining floxed. This was to be expected due to the 
neuronal specific expression pattern of CAMKIIα promoter which is not expressed in 
non-neuronal cell types.  
 
When western blots of hippocampal and cortical lysates were probed for CYFIP1 a 
reduction in the amount of protein was observed in cKO tissue (Figure 4.10C). 
Quantification revealed a significant 25% reduction in CYFIP1 protein levels in the 
cortex and a 50% reduction of CYFIP1 levels in the hippocampus compared to floxed  
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Figure 4.10: Characterisation of CYFIP1 CreCAMKII cKO mice. 
(A) Example brains from CYFIP1 floxed control (F/F; CYFf/f, CreCAMKII-/-), conditional 
haploinsufficient (F/+; CYFf/+, CreCAMKII+/-) and conditional KO (cKO; CYFf/f, CreCAMKII+/-) 
adult mice. Scale bar, 5mm. (B) Genotyping of hippocampal tissue from control floxed (CYFf/f, 
CreCAMKII-/-, YFP+/-) and cKO (CYFf/f, CreCAMKII+/-, YFP+/-) animals by PCR. DNA was 
genotyped with the primers aF and aR to produce the shifted floxed (FLX) PRC product and aF 
and a’R to produce the mutant (MT) product. Detection of these bands confirmed the presence 
of the floxed allele originating from the mutant KO-first allele. Primers against Cre produced 
a product if the Cre gene was present (CRE). Primers AF and A’’R produced a product from the 
deleted allele (DEL). Floxed control DNA (CYFf/f, CreCAMKII-/-, YFP+/-) was positive for the 
floxed allele but lacked the deletion allele due to the lack of Cre induced recombination. cKO 
DNA (CYFf/f, CreCAMKII+/-, YFP+/-) was positive for Cre and the floxed allele therefore was 
also positive for the deletion allele. (C) Western blot analysis and (D) quantification of CYFf/f 
CreCAMKII-/- YFP+/- (-CRE) and CYFf/f CreCAMKII+/- YFP+/- (+CRE) adult brain region lysates 
probed with antibodies against CYFIP1, the loading control β-tubulin and GFP to detect YFP 
expression as a reporter for Cre recombinase activity. cKO brains had ~30% less CYFIP1 in 
the cortex (CTX) and ~50% less CYFIP1 in the hippocampus (HIP) (n=3; student’s unpaired 
t-test; *p<0.05, ***p<0.001).  
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Figure 4.11: CreCAMKII expression in CYFIP1 floxed mice. 
(A) Schematic of the floxed STOP YFP gene in the Rosa26 locus depicting Cre induced 
expression of YFP and the production of labelled cells. (B) Immunohistochemistry of CYFf/f 
CreCAMKII+/- YFP+/- (cKO) adult mouse sagittal 30μm brain section. Slices were stained with 
a GFP antibody to detect YFP expression as a reporter for Cre recombinase expression and 
activity. YFP expression was detected in the prefrontal brain demonstrating Cre activity in 
the hippocampus (HIP), cortex (CTX), striatum (STR), thalamus (THL), hypothalamus (HYP) 
and midbrain (MID) with less activity in the cerebeluum (CER). (C)  Zoomed images of floxed 
control (CYFf/f CreCAMKII-/- YFP+/-) and cKO (CYFf/f CreCAMKII+/- YFP+/-) adult mouse sagittal 
brains sections stained with anti-GFP. YFP could not be detected in floxed control brains. YFP 
was detected in cKO brains in the hippocampus and cortex with little detection in the 
cerebellum. Scale bars, 500µm. 
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control samples (Figure 4.10D) (cortex: WT, 100%; cKO, 71.18 ± 8.69%; 
hippocampus: WT, 100%; cKO, 49.93 ± 5.69%; *p<0.05, ***p<0.001). These mice 
were also crossed with a YFP Rosa26 reporter mouse line to incorporate a reporter 
allele for Cre expression into their genome (Ribeiro et al., 2013). YFP Rosa26 reporter 
mice contain the gene encoding YFP (yellow fluorescent protein) within the Rosa26 
locus following a LoxP flanked STOP site. Therefore, Cre expression would extrude 
the STOP site and YFP would be expressed (Figure 4.11A). Expression of YFP was 
confirmed by probing the hippocampal and cortical lysate western blots with an 
antibody to GFP (Figure 4.10C). As expected no YFP was detected in the Cre negative 
floxed samples while in the cKO tissue YFP was detected in the cortex and 
hippocampus. 
 
Consistent with this finding, immunohistochemistry on 30µm sagittal sections from 
CYFIP1 cKO brain (CYFf/f, CreCAMKII+/-, YFP+/-) using a GFP antibody revealed the 
expression pattern and recombination efficiency of Cre driven by the CAMKIIα 
promoter. YFP could be detected throughout the hippocampus and cortex as well as 
in the striatum, thalamus and midbrain regions. However, little YFP expression was 
found in the cerebellum (Figure 4.11B,C). Control animals showed no YFP illustrating 
the specificity of the Cre induced YFP expression (Figure 4.11C). This pattern of Cre 
expression is consistent with previous publications using this camkcre4 transgenic 
mouse strain (Mantamadiotis et al., 2002). 
4.2.6 Conditional deletion of CYFIP1 alters hippocampal dendritic 
morphology in vivo 
Here a postnatal neuronal specific CYFIP1 cKO mouse model has been generated and 
characterised. As an extension of the experiments carried out in Chapter 3, it was 
interesting to study the effect complete loss of CYFIP1 in neurons had on hippocampal 
dendritic morphology. Comparisons could then be made between the CYFIP1 
haploinsufficient and cKO models. Analysis of dendritic morphology was carried out 
in Golgi stained 150µm coronal brain slices. Pyramidal CA1 neurons were traced from 
6 month old floxed and CYFIP1 cKO brains using Neurolucida software and traces 
were subjected to Sholl analysis (Sholl, 1953) (Figure 4.12A). Briefly, concentric rings 
were drawn out equal distance apart from the cell soma and the number of dendrites 
that intersect each ring were plotted as a function of distance from the soma. This 
analysis generates a readout for dendritic complexity. The dendritic trace also allowed 
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other parameters such as total dendritic length and total number of branch points to 
be measured. In the CYFIP1 cKO neurons a small effect on morphology was observed 
in basal dendrites, however, when corrections were made for multiple comparisons 
this effect was not significant (Figure 4.12B). That said, when considered alone, cKO 
neurons were significantly more complex 60µm away from the soma (Figure 4.12C) 
(intersections: floxed, 10.78 ± 0.36; cKO, 12.82 ± 0.64; *p<0.05). This effect did not 
translate into an overall change in the total number of branch points or total dendritic 
length per cell (Figure 4.12D,E) (branch points: WT, 32.11 ± 3.32; cKO, 30.64 ± 2.34; 
length: WT, 2921.52 ± 164.84µm; cKO, 3035.95 ± 131.28µm; NS). This experiment 
would benefit from increasing the sample size to more convincingly demonstrate an 
effect on morphology. Intriguingly, CYFIP1 haploinsufficiency resulted in the 
opposite effect and caused a decrease in dendritic complexity, both in cultured 
neurons and in CA1 pyramidal neurons from Golgi-stained adult brains (Figure 3.8; 
Appendix A; work carried out by Dr. Manav Pathania). The contrasting effects on 
dendritic morphology between CYFIP1 postnatal cKO and constitutive 
haploinsufficient neurons suggest a role for CYFIP1 in non-neuronal cells when 
considering the regulation of dendritic morphology or perhaps CYFIP1 plays different 
roles in dendritic development and maintenance. 
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Figure 4.12: cKO of CYFIP1 alters basal dendritic morphology of CA1 
pyramidal neurons. 
Golgi stained CA1 neurons from 6 month old cKO (CYFf/f CreCAMKII+/-) and floxed (CYFf/f 
CreCAMKII-/-) littermate controls were traced to analyse dendritic morphology. (A) Example 
traces of cKO and floxed (F/F) neurons. Scale bar, 35μm. (B) Quantification of dendritic 
complexity using Sholl analysis indicates that there is no significant difference between cKO 
and floxed neurons when data is corrected for multiple comparisons (n=9-11; 2-way ANOVA; 
NS). However, when considered alone the cKO basal dendrites appear more complex at 60µm 
compared with floxed neurons (C) (n=9-11; student’s unpaired t-test; *p<0.05). (D) Total 
number of branch points and (E) total dendritic length per cell was unchanged between cKO 
and floxed (F/F) CA1 neurons (n=9-11; student’s unpaired t-test; NS). 
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4.3 Discussion 
In this chapter, application of the weighted burden test to the UK10K whole-exome 
sequencing database of SCZ patients revealed Cyfip1 as a SCZ-associated gene due to 
an excess of potentially damaging rare variants identified within the gene. 
Furthermore, one individual CYFIP1 variant at position 15:22963816 was shown to be 
significantly associated with SCZ. A shortlist of five candidate CYFIP1 SCZ-associated 
variants were generated for functional characterisation based on the amino acid 
change and the position within the protein of the altered residue brought about by the 
non-synonymous mutation. Four of these five SNPs were genotyped in an 
independent UCL SCZ patient cohort to confirm their association with the disease. 
Although no variants yielded significance SNP4 appeared promising mirroring the 
significant association of this SNP with SCZ observed in the UK10K database. The five 
CYFIP1 rare variants chosen for functional characterisation included potentially two 
Rac1 and three WAVE interacting mutants. However, none of these variants appeared 
to alter CYFIP1’s synaptic localisation or interaction with WAVE. 
 
Finally, two CYFIP1 cKO systems were characterised to further understand the 
neuronal role of CYFIP1 by studying loss of function. Initial observations revealed 
CYFIP1 cKO MEFs showed a decreased cell density compared to floxed control cells 
suggesting altered survival rates. Furthermore, actin subcellular structure appeared 
disrupted in cKO cells resulting in a smaller more rounded cell morphology. CYFIP1 
cKO in forebrain neurons resulted in a 50% reduction in hippocampal CYFIP1 protein 
levels and when dendritic morphology was analysed basal dendritic complexity 
appeared slightly increased in cKO CA1 pyramidal neurons compared to floxed 
animals. Taken together, this data provides more support for Cyfip1 as a 
neuropsychiatric disease-associated gene. Individual CYFIP1 variants did not alter 
CYFIP1 function therefore, speculation can be made that an accumulation of rare 
variations within the gene may be required to render CYFIP1 functionally damaging. 
Lastly, in the first description of cKO CYFIP1 models, loss of CYFIP1 appears to impact 
on viability of fast dividing cells and alters dendritic morphology of CA1 hippocampal 
cell when postnatally deleted from forebrain neurons. 
4.3.1 Cyfip1, a SCZ-associated gene 
Improved sequencing techniques and more cost effective methods have increased the 
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number of patient genome sequencing projects over recent years. This in turn has led 
to an increase in the analysis of such databases to highlight novel genetic risk factors 
for neuropsychiatric disorders. Prior to the work carried out in this chapter Cyfip1, 
has mainly been associated with SCZ through CNV of the 15q11.2 region. Both 
microduplications and microdeletions of 15q11.2 have been implicated in SCZ 
(Consortium, 2008; Kirov et al., 2012; Stefansson et al., 2008; Tam et al., 2010; Zhao 
et al., 2013b). Four genes are located within this genomic region Tubgcp5, Cyfip1, 
Nipa1 and Nipa2. Of these four genes, Tubgcp5 encodes a gamma tubulin complex 
component, NIPA1/2 encode magnesium transporters and Cyfip1 encodes a protein 
enriched in brain tissue known to regulate actin dynamics and control local 
translation of proteins. Due to the important functions of CYFIP1 and their relevance 
to synaptic mechanisms much interest has surrounded this protein (Bozdagi et al., 
2012; Napoli et al., 2008; Oguro-Ando et al., 2014; De Rubeis et al., 2013). It is 
thought Cyfip1 is likely to be the dosage-sensitive gene that results in CNV at the 
15q11.2 locus being associated with SCZ.  
 
That said, compared to the available evidence supporting a role for Cyfip1 in ASD 
pathogenesis (Leblond et al., 2012; Nishimura et al., 2007; van der Zwaag et al., 
2010), there is little evidence of a direct association of Cyfip1 with SCZ (Tam et al., 
2010; Zhao et al., 2013b). Chapter 3 of this thesis and others have shown the 
importance of CYFIP1 in regulating neuronal and synapse morphology both critical 
mechanisms in the etiology of neuropsychiatric disorders, but this finding is not 
specific to SCZ (Oguro-Ando et al., 2014; De Rubeis et al., 2013). In fact, only one very 
recent report addresses whether Cyfip1 is the dosage sensitive gene in 15q11.2 SCZ-
associated CNV. By studying iPSC derived neural progenitors from SCZ patients with 
15q11.2 microdeletions, Yoon and colleagues showed these cells were 
haploinsufficient for CYFIP1, had reduced levels of WAVE and had deficits in 
adherens junctions and apical polarity. They rescued the effects with CYFIP1 
overexpression demonstrating that the 15q11.2 microdeletion cell effects were CYFIP1 
specific (Yoon et al., 2014). The significant association of Cyfip1 with SCZ reported in 
this chapter does not consider CNV and instead shows an association due to an excess 
of rare Cyfip1 variants that occur to a greater extent in cases compared to controls. 
Taken together with previously published work, this finding provides more direct 
evidence for Cyfip1 as a risk factor for SCZ. 
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In the chapter, it is shown that running a weighted burden test on a large cohort of 
exome sequencing from British SCZ patients returned Cyfip1 as a significant SCZ-
associated gene. However, when carrying out automated database analysis such as 
this the results often show weak significance. Furthermore, if other genes are 
investigated during the analysis significant results rarely withstand correction for 
multiple testing. This is in line with previous exome studies and highlights the 
necessity to study very large datasets to produce conclusive results that implicate rare 
variants and genes (Purcell et al., 2014). It is becoming clear that next-generation 
sequencing studies applied to small cohorts, in the low thousands, are hypothesis 
generating and are less likely to produce results which conclusively implicate variants 
or genes. Indeed, this is an issue that is beginning to be addressed. Recently, the SCZ 
consortium compiled the largest set of GWAS data through collaborations and pooling 
smaller databases, the results of the analysis yielded 108 convincing novel SCZ-
associated loci that withstood corrections for multiple comparisons (Ripke et al., 
2014). 
 
Nevertheless, for smaller-scale studies, such as the analysis carried out here, 
interesting variants can still be identified however, carrying out follow up analysis is 
important to seek conclusive evidence of an association before embarking on time 
intensive functional studies. This often involves carrying out genotyping in an 
additional case-control cohort. However, for some genes, the weighted burden 
analysis highlights an association based on an excess of many different variants, each 
occurring in only one or two subjects rather than few variants occurring frequently 
enough in cases over controls to yield significance. In this case it becomes very 
difficult to pinpoint which of the variants are potentially pathogenic. Indeed, 
genotyping the variants in a new cohort is challenging as it is difficult to identify, from 
the excess of variants initially identified, which are the ‘disease causing’ variants that 
should be genotyped again. Furthermore, the variants are extremely rare and to 
validate them would require a very large number of subjects. It has been suggested 
that an alternative approach to follow up identified rare variants is to carry out family 
studies on the individuals possessing the variant (Curtis, 2011). Thus, if there are 
affected relatives who also have the variant one gains confidence that it has an effect 
whereas an affected relative not sharing the variant casts doubt on its relevance.  
 
In this chapter, a shortlist of potentially functionally damaging variants was generated 
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based on biological interest and frequency of appearance in the UK10K dataset for 
confirmation sequencing in an independent SCZ case-control cohort. Unfortunately, 
due to their extremely rare occurrence (MAF ranging from 0.0004-0.0025) 
genotyping the shortlisted variants did not result in a significant association with SCZ. 
Repeating this genotyping in a much larger case-control cohort would generate more 
reliable data. Alternatively as discussed above, access to family DNA of affected 
patients carrying the Cyfip1 variants would be another way of validating the 
importance of these identified rare variants however, these samples were not available 
in this study. To strengthen the data generated here validating the genotyping results 
against the original sample genomic DNA using PCR and sequencing would also be 
appropriate. 
 
One final point to mention is the suitability of the unaffected control group from the 
UK10K project. The obese group was selected as they represented a phenotypically 
homogenous group from similar geographical origins to the SCZ group. However, the 
obese group has been compiled on another trait and this may confound the results 
from the burden analysis. It would have been more appropriate to compare the SCZ 
cohort to a true unaffected group of controls however, this data was not available 
within the UK10K project. This supports the requirement for follow up studies to 
confirm initial findings generated from next-generation sequencing analysis. 
4.3.2 The functional effects of CYFIP1 SCZ-associated variants 
In this chapter experiments were carried out to assay the effects of individual CYFIP1 
variants on CYFIP1 function. None of the five candidate SNPs appeared altered the 
neuronal subcellular localisation of CYFIP1 or its ability to interact with members of 
the WRC. These findings suggest that the variants alone are not particularly 
functionally damaging. They perhaps only result in small, subtle changes to CYFIP1 
function or indeed, possibly one SNP alone does not disrupt CYFIP1 function and that 
an accumulation of CYFIP1 mutations are required for pathogenic effects. 
Interestingly, two of the variants identified in the initial analysis of the UK10K 
database were shown to be in linkage disequilibrium (finding from Dr. D. Curtis) 
suggesting that there is the possibility these SNPs may occur together. 
 
The five candidate SNPs were predicted to interfere with the ability for CYFIP1 to 
interact with Rac1 or WAVE. However, coimmunoprecipitation experiments carried 
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out here under steady-state conditions revealed there was no significant change in 
WAVE binding and a Rac1 interaction could not be detected. CYFIP1 only interacts 
with active GTP-bound Rac1 (Kobayashi et al., 1998), this causes a conformational 
change in CYFIP1, relieving its repression of WAVE allowing active WAVE to activate 
Arp2/3 and bring about branched actin polymerisation (Chen et al., 2010b; Ismail et 
al., 2009). Therefore, the lack of Rac1 interaction detected in these experiments could 
be due to low levels of active Rac1 in the experimental conditions. To generate 
conditions where the Rac1 CYFIP1 interaction could be assayed, Rac1 activators such 
as EGF (Ridley et al., 1992) could be used to stimulate Rac1 activation to generate a 
detectable pool of Rac1-bound CYFIP1. In line with this, another explanation for the 
lack of SNP-dependent functional effects observed here could be because the effects 
are activity dependent. The SNP mutations may interfere with the Rac1-dependent 
regulation of CYFIP1’s repressive function over WAVE or its ability to hold WAVE in 
an inactive state rather than disrupting the interactions completely. To test this, 
coimmunoprecipitation assays could be carried out in the presence of Rac1 activating 
and inhibiting drugs. Furthermore, a read out for downstream actin polymerisation 
activity would be interesting. F-actin/G-actin ratios could be measured by 
biochemistry using appropriate sample fractions and antibodies or in vitro pyrene-
actin assembly assays could be performed using the CYFIP1 mutants (Chen et al., 
2010b; Rocca et al., 2013). 
4.3.3 Total loss of CYFIP1 affects cell survival and dendritic branching 
Findings from Chapter 3 have already revealed that constitutive CYFIP1 KO animals 
are embryonically lethal (undetectable from E8.5). This is probably due to defects in 
embryonic patterning and cell migration during gastrulation, consistent with similar 
effects caused by other WRC KO animals (Dubielecka et al., 2011; Migeotte et al., 
2010; Rakeman and Anderson, 2006). Therefore, generating KO CYFIP1 cells posed 
a biological problem. To conquer this problem CYFIP1 floxed animals were generated 
and crossed with a CreERT(T2) mouse strain. These animals were viable to adulthood 
and the cKO of CYFIP1 was dependent on treatment of the cells with tamoxifen (TAM) 
(see Figure 4.7). MEFs generated from these mice were repeatedly subjected to TAM 
to induce the removal of Cyfip1. Loss of Cyfip1 was confirmed by genotyping and 
western blotting. General observations from the culturing of these cells revealed a 
consistent decreased cell density in the cKO cells when compared to control floxed 
cells. This loss of cell density could be due to a decrease in cell survival or a decrease 
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in cell division. Tight actin regulation is critically required for both these cellular 
functions (Lee and Dominguez, 2010; Pollard and Cooper, 2009). Considering 
CYFIP1 has been previously shown, and demonstrated here, to regulate actin 
dynamics (Chen et al., 2010b; Galy et al., 2011; Ismail et al., 2009; Steffen et al., 2004; 
Zhao et al., 2013a), quite possibly, total loss of CYFIP1 is critically impacting on actin 
dynamics leading to cell death. These suggestions require further investigation. Cell 
survival experiments could be carried out using propidium iodide. Furthermore, time 
lapse live cell imaging and analysis of cell division events could be performed. 
 
Interestingly, preliminary evidence here shows that these cKO cells appear to have 
reduced F-actin labelling by phalloidin. They also appear smaller and more rounded. 
These observation are consistent with an actin polymerisation defect. Indeed, KO cells 
of other actin regulatory molecules show similar cell effects (Dubielecka et al., 2011; 
Steffen et al., 2004). To further explore the precise actin defects taking place in these 
MEFs live FRAP imaging techniques similar to those carried out in Chapter 3 (Figure 
3.9; Figure 3.10) could be implemented to understand more about the dynamics of 
actin turnover following total loss of CYFIP1. Alternatively, actin comet formation 
could be studied in cells infected with Listeria monocytogenes (Lambrechts et al., 
2008). Culturing MEFs on fibronectin patterned dishes will restrict the growth of cells 
to regular shapes so the morphology and F-actin distribution can be quantified in 
fixed cells using a scoring or Sholl analysis type approach (Caesar et al., 2015). Lastly, 
scratch/migration assays could also be used to give a more functional readout for the 
actin defects (Dubielecka et al., 2011). If these experiments were to show loss of 
CYFIP1 alters actin dynamics and cell motility it would provide evidence towards the 
hypothesis that developmental patterning defects due to loss of cell motility cause the 
embryonic lethality of constitutive CYFIP1 KO mice. These assays could be repeated 
with overexpression of the CYFIP1 variants in the KO MEFs to determine how the 
point mutations impact on actin regulation compared to rescuing with WT CYFIP1. 
Indeed, overexpression on a KO background would remove any confounding effects 
of the endogenous protein and allow for a more accurate study of functional effects of 
the mutant constructs. However, if loss of CYFIP1 does indeed effect cell survival as 
predicted from observations here then carrying out these experiments could prove 
challenging especially if drug treatments, transfections or high cell densities are 
necessary for the protocols. Furthermore, in the event that recombination is not 100% 
efficient following TAM treatment cells still expressing CYFIP1 would out compete KO 
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cells leading to a mixed population diluting the effects of any downstream 
experiments.  
 
To generate CYFIP1 cKO neurons floxed animals were crossed with animals 
expressing Cre driven by the CAMKIIα promoter. This resulted in CYFIP1 cKO cells 
predominantly in the hippocampus and prefrontal cortex with little expression in the 
cerebellum (Figure 4.11). This expression pattern was consistent with others who have 
experimented with this mouse strain (Mantamadiotis et al., 2002). Unlike the 
constitutive CYFIP1 KO animals, these animals were viable until adulthood and 
indistinguishable from floxed control littermates, similarly to the inducible cKO 
CYFIP1 mice. Intriguingly, even though Cre recombination efficiency was high in 
adult hippocampal neurons, determined by the YFP reporter expression, western 
blotting revealed here that the reduction in CYFIP1 was only 50%. This discovery was 
surprising and led to the consideration that perhaps non-neuronal cells (that do not 
express CAMKIIα and therefore retain their CYFIP1) express high levels of CYFIP1. 
Indeed, a recent screen studying mRNA levels across the eight major cell classes of 
the brain revealed that CYFIP1 levels were three fold higher in astrocytes than neurons 
and dramatically six fold higher in microglia (Zhang et al., 2014). As the brain region 
lysates generated for the characterisation of this CYFIP1 cKO model contained a 
mixed cell population and not just pure neurons this may explain the incomplete 
knockdown observed. Perhaps the high levels of Cyfip1 expression in these non-
neuronal cells, especially the microglia, is due to their high migratory activity as 
migration is heavily dependent on actin turnover. However, it must be noted a very 
recent publication claims CYFIP1 cannot be detected in astrocytes at the protein level 
(Huang and Chen, 2015), demonstrating that these theories require further 
validation. 
 
The morphology of CYFIP1 cKO neurons was analysed to investigate the impact of 
total loss of CYFIP1 on dendritic complexity compared to CYFIP1 haploinsufficiency 
reported in Chapter 3. Furthermore, the postnatal conditional deletion of CYFIP1 was 
predicted to uncouple its critical role in development from any potential roles in 
neuronal maintenance so they could be studied. cKO CA1 pyramidal neurons showed 
a slight increase in dendritic complexity proximally to the soma in basal dendrites but 
no changes in apical dendrites. Interestingly, this result was opposite to the effects 
observed in constitutive CYFIP1 haploinsufficient mice. One potential explanation for 
these contrasting effects could be that CYFIP1 has a role in non-neuronal cells that 
 
Identification and characterisation of rare Cyfip1 variants in SCZ 
 
 188 
influences dendrite morphology. Indeed, glial cells are emerging as important players 
in orchestrating neuronal development. In particular, defects in astrocyte 
development and function, the most abundant glial cells in the brain, are now 
considered to contribute to the pathogenesis of neurodevelopmental disorders 
(Molofsky et al., 2012; Sloan and Barres, 2014; Yang et al., 2013). Astrocytes derived 
from a mouse model of FXS have been shown to induce developmental delays in 
dendritic maturation of hippocampal neurons in coculture (Jacobs and Doering, 
2010). Perhaps CYFIP1 haploinsufficiency in non-neuronal cells plays a dominant 
role in the reduced dendritic complexity observed in CYFIP1 haploinsufficient 
neurons. For example, disrupted actin dynamics may be altering astrocyte process 
motility. Alternatively, perhaps the postnatal loss of CYFIP1 in cKO neurons 
highlights a specific role for CYFIP1 in dendritic maintenance which is masked in the 
haploinsufficient model due to reduced CYFIP1 levels during development. The CA1 
basal dendrites receive inputs from the CA3 Schaffler collaterals closest to the CA1 
within the hippocampus. This connection forms part of the major hippocampal 
circuitry which is vital for learning and memory (Spruston, 2008). Therefore, it is not 
surprising these dendrites are tightly regulated during neuronal development and 
maintenance. 
 
In conclusion, the work presented in this chapter has provided further evidence that 
Cyfip1 is a SCZ-associated gene and has highlighted a novel variant within CYFIP1 at 
position 15:22963816 (SNP4) which is significantly associated with the disorder. This 
variant did not yield significance when attempts to validate the association in an 
independent cohort were carried out due to the low sample numbers however, did 
show a similar MAF. Functional characterisation of five candidate SCZ-associated 
CYFIP1 variants, including SNP4, did not alter the synaptic localisation or WRC 
interactions of CYFIP1. This suggests an accumulation of variants might be required 
to render CYFIP1 functionally damaging or that the individual variants may be having 
more subtle activity dependent effects on CYFIP1 function. Finally, the generation of 
CYFIP1 cKO systems revealed that cKO MEFs appear smaller, rounder and less dense, 
possibly due to altered F-actin distribution while, CYFIP1 cKO CA1 neurons show 
more proximal neuronal complexity in basal dendrites. These novel cKO systems 
could be used in future rescue experiments to resolve the functional effects of CYFIP1 
SCZ-associated variants. Additionally, they provide the ideal platform to further 
elucidate the spatial and temporal roles of CYFIP1 in neurons.  
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Chapter 5 
The role of Ahi1 in neuronal 
trafficking and morphology 
5.1 Introduction 
Monogenic disorders of the nervous system such as Rett’s syndrome, tuberous 
sclerosis and Fragile X syndrome often present with neuropsychiatric phenotypes 
(Bateup et al., 2013; Moretti and Zoghbi, 2006; Rubeis and Bagni, 2011). Studying the 
cellular function of the individual genes mutated in these diseases provides 
information not only about the mechanisms of disease pathogenesis but also sheds 
light on new pathways implicated in mental illness. One such disorder is the ciliopathy 
Joubert’s syndrome (JS), an autosomal recessive developmental disorder where 
patients often present with depressive and autistic behaviours (see page 65 for a 
detailed description of JS). Loss of function mutations in the gene Abelson helper 
integration site 1 (Ahi1) were the first identified genetic cause of JS (Dixon-Salazar et 
al., 2004; Ferland et al., 2004).  
 
The gene Ahi1 has been genetically linked to various neuropsychiatric disorders. 
Association and linkage studies have identified Ahi1 as a susceptibility gene for SCZ 
(Amann-Zalcenstein et al., 2006; Ingason et al., 2007, 2011; Rivero et al., 2010; Torri 
et al., 2010). Various reports state linkage signals for SCZ map to human chromosome 
6q23.3, the genomic region where Ahi1 is located. More detailed analysis mapped the 
association to single-nucleotide polymorphisms (SNPs) within Ahi1, providing 
evidence for Ahi1 being a SCZ susceptibility gene (Amann-Zalcenstein et al., 2006; 
Rivero et al., 2010; Torri et al., 2010). A study in an Icelandic sample based on original 
findings from a family sample of Israeli-Arabs confirmed two strongly associated SCZ 
markers in a genomic region upstream of Ahi1. A replication study of these findings 
was later carried out in a large European sample (Ingason et al., 2007, 2010). More 
recently, Ahi1 mRNA levels were analysed in immortalised lymphoblasts from 
patients in the Israeli-Arab sample. Patients with early age onset of SCZ had higher 
Ahi1 expression than controls and late-onset patients (Slonimsky et al., 2010).   
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Linkage studies have also associated Ahi1 with ASD (Retuerto et al., 2008). A three-
stage family-based association study demonstrated evidence of an associated 
haplotype in Ahi1 with ASD in a region of the gene known to be a SCZ risk locus 
(Retuerto et al., 2008). More recently, massively parallel sequencing (MPS) has been 
used to investigate the genetic etiology of 8 patients with developmental delay, 
intellectual disability and ASD. Variants in Ahi1 were detected in patients 5 and 7 
(Brett et al., 2014). Interestingly, the Ahi1 variant found in patient 7 (E1086G) is a 
known pathological mutation in a case of JS (Kroes et al., 2008). Indeed, many 
features of ASD have also been described in up to 40% of JS patients (Holroyd et al., 
1991; Ozonoff et al., 1999). Equally, Ahi1 KO animals models of JS show anxiolytic 
and depressed phenotypes (Lotan et al., 2013; Ren et al., 2014; Xu et al., 2010). From 
this perspective Ahi1 is emerging as a promising candidate neuropsychiatric disease-
associated gene. However, despite the strong genetic evidence linking Ahi1 with 
susceptibility to mental illness the role of Ahi1 in normal brain development and 
disease pathogenesis remains poorly understood.  
 
The gene Ahi1 was initially identified as a common helper provirus integration site for 
Abelson leukaemias and lymphomas (Poirier et al., 1988). The encoded protein is 
conserved among mammals and enriched within the brain (Doering et al., 2008; 
Jiang et al., 2002). Protein expression is developmentally regulated peaking in mouse 
during the first postnatal week from E17 through to P7 with lower levels of expression 
persisting into adulthood (Doering et al., 2008; Ferland et al., 2004). Areas of the mid 
and hind mouse brain show the largest amount of Ahi1 expression with the highest 
protein levels detected in the amygdala, hypothalamus and ventral hippocampus 
(Doering et al., 2008; Sheng et al., 2008). Furthermore, in human foetal tissue Ahi1 
mRNA is highly expressed in the brain and kidney and in adult brain tissue expression 
is highest in the cerebellum and cerebral cortex (Ferland et al., 2004). This conserved 
enrichment in brain tissue points towards Ahi1 functioning in neurons. Ahi1 encodes 
a unique 1047 amino acid protein containing 7 WD40 repeats, an SH3 domain, 
potential SH3 binding motifs and, in the human protein, an N-terminal coiled-coil 
domain, all known mediators of protein-protein interactions (Esmailzadeh and Jiang, 
2011; Jiang et al., 2002). The large number of functional domains and signalling 
motifs present in Ahi1 point towards the protein having a critical role in signalling and 
regulation (Figure 5.1). 
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5.1.1 Ahi1 in signalling 
Ahi1 has been localised to the basal body and transition zone (TZ) of the primary 
cilium, a highly conserved organelle central to the regulation of developmental 
signalling pathways, such as the Wnt-β-catenin and sonic hedgehog pathways (turn 
to page 65 for a description of cilia) (D’Angelo and Franco, 2009; Hsiao et al., 2009; 
Lancaster et al., 2011b; Lee et al., 2014). Overexpressed myc-tagged Ahi1 also localises 
to the basal body but this localisation is lost when a JS associated Ahi1 V433D 
mutation is overexpressed (Tuz et al., 2013). More recently, super-resolution 
microscopy has revealed that within the TZ Ahi1 colocalises with CYB1 and OFD1 in a 
ring like structure at the distal end of the centriole. The amount of centriole recruited 
via Ahi1 is reduced in CYB1-/- cells suggesting Ahi1 may contribute to the ciliogenesis 
defects observed in these cells (Lee et al., 2014). Indeed, in vitro experiments in 
IMCD3 cells have shown that Ahi1 knockdown results in a decrease in cells expressing 
cilia, defects in cilia formation and cell polarity (Hsiao et al., 2009; Simms et al., 2011). 
Disrupted formation of primary cilia has also been observed in vivo. Zebrafish 
injected with an Ahi1 morpholino show loss of primary cilia on pronephric ducts while 
Ahi1 knockout mice (Ahi1-/-) show dysregulated photoreceptor cilia formation (Simms 
et al., 2011; Westfall et al., 2010). Furthermore, primary cilia formation and 
localisation of ciliary proteins is defective in fibroblasts from JS syndrome patients 
with Ahi1 mutations (Tuz et al., 2013). Ahi1 is thought to act as a gatekeeper protein 
regulating the trafficking of vesicles and membrane proteins into the cilia (Reiter et 
al., 2012). Taken together, loss of Ahi1 expression or Ahi1 mutations impair cilia 
formation resulting in altered downstream signalling. 
 
In addition to a role in cilia formation, emerging data from Lancaster and colleagues 
has identified Ahi1 as a potential regulator of the canonical Wnt signalling pathway 
and imply defects in this pathway may contribute to JS pathogenesis (Lancaster et al., 
2009, 2011a, 2011b). In their initial study, Ahi1 null mice were shown to have cystic 
kidneys, a common symptom of JS in human subjects. Interestingly, the kidney 
defects in Ahi1 null mice were shown to be owing to decreased Wnt activity (Lancaster 
et al., 2009). Ahi1 was described to interact with β-catenin, a downstream effector of 
Wnt signalling. Wnt activity stimulates the translocation of β-catenin to the nucleus 
where it regulates gene transcription (Willert and Nusse, 1998). More recently, the 
authors investigate the role of Wnt signalling in the neurodevelopmental phenotypes 
of JS (Lancaster et al., 2011a). They demonstrated that both developing Ahi1 KO mice 
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Figure 5.1: A schematic of mouse and human Ahi1 protein isoforms. 
A summary of the structural motifs identified in (A) mouse and (B) human Ahi1 protein 
isoforms. Isoforms contain: seven WD40 repeats (blue circles), an SH3 domain (green 
square), proline rich motifs (P), PEST sequences (dark blue line) and tyrosine 
phosphorylation sites (Y). Human Ahi1 contains an additional coiled-coil domain at the N-
terminus (pink square) that is entirely absent from rodent isoforms. Human isoform 2 is 
shorter and lacks the SH3 domains while isoform 3 still has the SH3 domain but a variable C-
terminus (lined box). SH3 domains are known to bind proline-rich regions and mediate 
specific protein interactions (Shi et al., 2009). Tandem copies of WD40 repeats (repeating 
tryptophan and aspartate residues) often fold together to form a circular protein-protein 
interacting domain called a WD40 domain important in membrane signalling, gene 
transcription and cell cycle regulation (Neer et al., 1994). PEST sites are thought to mediate 
protein degradation. Adapted from (Esmailzadeh and Jiang, 2011). 
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and foetal MRI imaging of human subjects with JS showed the same defects in 
cerebellar midline fusion. By crossing the Ahi1-/- mice with Wnt reporter BATgal 
transgenic mice, Wnt activity at the defective midline fusion site was found to be 
decreased in Ahi1 null mice and could be partially rescued by the Wnt pathway agonist 
lithium (Lancaster et al., 2011a).  
5.1.2 Ahi1 and trafficking 
Importantly, Ahi1 has also been implicated in a number of trafficking functions. Ahi1 
is known to interact with Rab8a and be essential for the correct targeting of Rab8a to 
the cilia basal body (Hsiao et al., 2009, 2012). Knockdown of Ahi1 in IMCD3 cells 
impaired ciliogenesis and resulted in loss of Rab8a from the basal body. These effects 
could not be rescued by overexpression of CA Rab8a showing that Ahi1 is necessary 
for the targeting of Rab8a to cilia (Hsiao et al., 2009). Rab8 is a small GTPase critical 
for polarised membrane trafficking and the formation and function of cilia (Leroux, 
2007). Expression of a dominant negative (DN) or a constitutively active (CA) form of 
Rab8 in Xenopus laevis disrupted trafficking in photoreceptor cells and inhibited and 
promoted ciliogenesis respectively in IMCD3 cells (Follit et al., 2010; Moritz et al., 
2001; Nachury et al., 2007). Additionally, Ahi1 is involved in Rab8a-mediated 
transport in retinal photoreceptor cells (Louie et al., 2010; Westfall et al., 2010). 
Indeed, patients with JS and other ciliopathies often present with retinal degeneration 
(Doherty, 2009; Waters and Beales, 2011). Photoreceptors have modified cilia with a 
basal body, axoneme and outer segment. The outer segment contains stacked 
membrane discs containing opsin and the signalling machinery required for 
phototransduction. This segment is continually replaced and therefore transport of 
opsin to these membrane structures is vital. Ahi1 KO retinal cells resulted in abnormal 
distribution of opsin and cilia specific vesicle targeting was lost due to failed transport 
(Louie et al., 2010; Westfall et al., 2010).  The authors observed a loss of Rab8a 
expression in Ahi1 KO retinal cells and concluded that Ahi1 is critical for the 
trafficking of outer segment proteins and Rab8a-mediated transport in retinal 
photoreceptors (Westfall et al., 2010). 
 
Ahi1 also plays a role in the stabilisation and trafficking of neuronal receptors such as 
the serotonin 2C receptor (5HT2CR) and the neurotrophic receptor tyrosine kinase B 
(TrkB) (Wang et al., 2012; Xu et al., 2010). Ahi1 deficiency has been demonstrated to 
alter TrkB trafficking resulting in depressive phenotypes in mice (Sheng et al., 2008; 
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Xu et al., 2010). Trks are responsible for binding neurotrophins and eliciting effects 
on the cell. TrkB binds to BDNF, and upon activation causes numerous downstream 
signalling events implicated in cell survival, axonal outgrowth, synaptic activity and 
differentiation (Gupta et al., 2013). Often when activated, TrkBs are internalised to 
enhance their interaction with downstream adaptor proteins and facilitate signalling. 
Internalised TrkBs are then either recycled or degraded, but their proper trafficking is 
critical for correct signalling (Patapoutian and Reichardt, 2001). Ahi1 neuronal-specific 
cKO mice show impaired endocytic sorting and increased lysosomal degradation of 
internalised TrkB following BDNF stimulation (Xu et al., 2010). Additionally, Ahi1 
has been proposed to mediate feeding behaviour through an interaction with the 
5HT2CR (Niu et al., 2011, 2012; Wang et al., 2012). Ahi1 was shown to promote the 
degradation of the 5HT2CR through the lysosomal pathway. In neuroblastoma cells 
overexpressing Ahi1 and 5HT2CR, more 5HT2CR was localised to lysosomes compared 
to control cells. Furthermore, in cells transfected with Ahi1, levels of 5HT2CR 
decreased over time, compared to a C-terminal mutant of Ahi1 that could not interact 
with the receptor (Wang et al., 2012). Indeed, Ahi1 levels were shown to be 
upregulated in the hypothalamus of fasted mice while 5HT2CR levels were reduced 
(Niu et al., 2011, 2012; Wang et al., 2012).  
 
Of interest, Ahi1 has been reported to strongly interact with the trafficking adaptor 
huntingtin-associated protein-1 (HAP1), and both proteins are detected in the same 
rodent brain regions (Sheng et al., 2008; Tuz et al., 2013; Xu et al., 2010). Moreover, 
the two proteins have been shown to stabilise each other; levels of HAP1 are 
dramatically decrease in Ahi1 KO brain tissue and in HAP1 KO tissue Ahi1 levels are 
reduced (Sheng et al., 2008; Tuz et al., 2013; Xu et al., 2010). HAP1 is an adaptor 
molecule that has been described to have a myriad of trafficking functions and can 
interact with numerous microtubule motors and non-motor trafficking proteins (Li 
and Li, 2005; Rong et al., 2007a; Wu and Zhou, 2009). In a collection of reports from 
the same group, HAP1 was shown to be involved in the trafficking and stabilisation of 
neurotropic receptors: TrkA, TrkB and EGF receptor (Li et al., 2002; Rong et al., 
2006, 2007b; Sheng et al., 2008). Altered HAP1 expression, disrupted the trafficking 
of these receptors leading to loss of neurite outgrowth. HAP1 has also been linked to 
microtubule-based trafficking. Shortly after HAP1 was first identified, the 
anterograde and retrograde trafficking of HAP1 positive organelles was observed 
(Engelender et al., 1997; Li et al., 1998). Since then HAP1 has been shown to have 
many protein binding domains and interact with multiple components of microtubule  
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Figure 5.2: A schematic of rodent Huntingtin-associated proteins 1 (HAP1) 
isoforms. 
A summary of the structural motifs and binding domains of rodent HAP1A and HAP1B. Both 
proteins are identical over the first 577 residues and then each have a variable C-terminus 
(maroon box) with HAP1B forming a longer protein. The proteins possess three coiled-coil 
(CC) domains (pink box), which together make up the HAP1 N-terminal Homology Domain, 
important for protein-protein interactions. There is an acidic rich amino acid region between 
CC1 and CC2 (purple box) and a C-terminal poly-proline region (orange line). A Y2H screen 
revealed GABAAR β subunits bind to HAP1 at residues 220-520 (Kittler et al., 2004). 
Huntingtin (htt) interacts with HAP1 over residues 371-420 (Li et al., 1995). 
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 motors and other trafficking proteins (Figure 5.2). A Y2H screen identified p150Glued 
as a HAP1 interactor, a vital subunit of the dynactin complex important for dynein 
mediated retrograde transport of vesicles. The same screen revealed that HAP1 also 
interacts with KIF5C, a homologue of human kinesin heavy chain (Engelender et al., 
1997). More recently, HAP1 has been show to bind to kinesin light chain (KLC), a part 
of the conventional anterograde kinesin motor. This study showed anterograde 
trafficking was impaired in HAP1 KO neurons (McGuire et al., 2006).  
 
Other non-motor protein-protein interactions have been described for HAP1 
implicating it in trafficking and cytoskeletal regulation. One study demonstrated that 
HAP1 interacts with the endocytic trafficking protein Hrs (hepatocyte growth factor-
regulated tyrosine kinase substrate) (Li et al., 2002). Hrs is a key substrate of Trks 
and is central for their signal transduction. HAP1 and Hrs together have been shown 
to be important in the stability of internalised neurotrophic receptors (Li et al., 2002; 
Xu et al., 2010). HAP1 also binds 14-3-3. The 14-3-3 family are well conserved 
regulatory proteins that bind a large number of cytoskeletal and trafficking proteins 
and are key to the regulation of many cellular processes (Rong et al., 2007b). Other 
functions of HAP1 include: its ability to interact with the Rac1 GEF Kalirin-7 
(Colomer, 1997); its ability to traffic BDNF containing vesicles and proBDNF 
(Gauthier et al., 2004; Wu et al., 2010); its capacity of binding to other PolyQ proteins 
and its role in regulating transcription (Wu and Zhou, 2009). 
 
Notably, HAP1 has been identified as an adaptor protein necessary for the trafficking 
of GABAARs at inhibitory synapses (Kittler et al., 2004). By linking GABAAR 
containing transport vesicles to the kinesin KIF5, HAP1 was shown to mediate the 
rapid recycling of GABAARs to the synapses. Furthermore, in a model of Huntington’s 
disease (HD) this GABAAR trafficking was disrupted by the strong interaction 
between mutant htt and HAP1 (Li et al., 1995). The result was reduced delivery of 
GABAARs to synapses and reduced inhibitory synaptic transmission (Twelvetrees et 
al., 2010). Altered GABAergic signalling in this way may disrupt the balance between 
neuronal excitation and inhibition. Such an imbalance is thought to be a contributing 
factor in the pathogenesis of neuropsychiatric disorders (Smith and Kittler, 2010).  
The finding that Ahi1 can interact with HAP1 (Sheng et al., 2008) coupled with the 
fact Ahi1 is implicated in numerous trafficking functions make the protein a potential 
candidate GABAAR trafficking molecule. It can be hypothesised that Ahi1, due to its 
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many signalling and protein interacting domains, may provide a level of regulation to 
the GABAAR trafficking function of HAP1. Altered expression or disease mutations in 
Ahi1 may disrupt GABAAR recycling and the number of GABAARs at synapses leading 
to pathological effects on the E/I balance that may explain the prevalence of 
neuropsychiatric phenotypes seen in patients with JS. However, currently the role of 
Ahi1 in GABAAR trafficking is unknown and warrants investigation. 
5.1.3 Ahi and neurite outgrowth 
Lastly, the accurate formation of neuronal networks and synaptic connections is vital 
for normal brain function. Indeed, disrupted neuronal connectivity is one of the key 
prevailing theories in the development of neuropsychiatric dysfunction (Kulkarni and 
Firestein, 2012). The structure and function of primary cilia are known to be crucial 
for the proper development of neurons (D’Angelo and Franco, 2009; Waters and 
Beales, 2011). In fact, malformations of brain anatomy are a feature of many 
ciliopathies, including JS (Ferland et al., 2004; Lee and Gleeson, 2010). Ahi1 has been 
implicated in the mechanisms of neuronal development not only via its roles in cilia 
formation and function but also via its interaction with HAP1 (Sheng et al., 2008). 
HAP1 has been shown to promote neurite outgrowth in PC12 cells through preventing 
degradation of internalised TrkA (Li et al., 2000; Rong et al., 2006). Loss of HAP1 
expression using RNAi led to reduced HAP1 in neurite tips, reduced neurite 
outgrowth and decreased levels of internalised TrkA (Rong et al., 2006). The role of 
Ahi1 in stabilising TrkB also implicates Ahi1 in neuronal development as activation of 
TrkB signalling is known to promote neurogenesis and has also been implicated in the 
maintenance of dendritic complexity and branching (Cohen-Cory et al., 2010). 
Furthermore, a small mass spectrometry screen has revealed Ahi1 can interact and 
stabilise Cend1, a neuronal protein that mediates nerve cell differentiation (Weng et 
al., 2013). Taken together these results illustrate a role for Ahi1 in neurite outgrowth 
however, the impact Ahi1 has on dendritic morphology and synaptic connections has 
not been investigated. 
 
In this chapter, the previously described interaction between Ahi1 and HAP1 was 
confirmed both in an overexpression system and in rodent brain. Furthermore, a 
novel Ahi1/HAP1/KIF5 trafficking complex was identified that could be detected in 
vivo from rodent brain lysate. Ahi1 was shown to be trafficking in this complex by 
KIF5 in a HAP1 dependent manner. The subcellular neuronal localisation of 
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endogenous Ahi1 was investigated and Ahi1 was shown to be localised to excitatory 
and inhibitory synapses pointing towards a synaptic function for Ahi1. The impact of 
both Ahi1 overexpression and knockdown on the surface levels of GABAARs and the 
integrity of inhibitory postsynaptic scaffold molecules were investigated. To further 
explore the role of Ahi1 in the pathogenesis of neuropsychiatric disorders, Ahi1 
autism-associated mutants were generated. These mutants could still interact with 
HAP1 and be trafficked by KIF5 in a HAP1 dependent manner suggesting these 
mutants are likely to be having more subtle effects on Ahi1 signalling and function. 
Finally, knockdown of Ahi1 was shown to significantly impact on dendritic 
morphology a result consistent with the neuronal developmental defects observed in 
JS.  
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Figure 5.3: Ahi1 mRNA expression in adult sagittal mouse brain sections. 
Taken from the Allan Brain Atlas (©2014 Allen Institute for Brain Science. Allen Mouse Brain 
Atlas [Internet]. Available from: http://mouse.brain-map.org/). P56 male WT mouse (strain 
C57BL/6J) sagittal brain sections were generated and subjected to (A) in situ hybridisation 
(ISH) using an Ahi1 mRNA antisense probe to demonstrate where Ahi1 mRNA is expressed. 
Results of ISH were overlaid with hematoxylin and eosin staining to identify brain regions. (B 
and C) A heat map representation of Ahi1 mRNA expression levels in different brain regions 
(hot colours=high expression, cold colours=low expression) (Lein et al., 2007). 
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5.2 Results 
5.2.1 A HAP1 interacting protein Ahi1 and its expression in brain 
In order to investigate the role of Ahi1 in neuronal trafficking and morphology it was 
important to determine the neuronal expression pattern of Ahi1. Previous reports 
have described Ahi1 to be enriched within the brain (Doering et al., 2008; Jiang et al., 
2002) and the often severe neuronal defects seen in JS suggests the function of Ahi1 
in the brain is critical. Indeed, in situ hybridisation data taken from the Allan Mouse 
Brain Atlas (©2014 Allen Institute for Brain Science. Allen Mouse Brain Atlas 
[Internet]. Available from: http://mouse.brain-map.org/ (Lein et al., 2007)) 
demonstrates that Ahi1 mRNA can be detected in specific mouse brain regions, 
principally the hippocampus (Figure 5.3A,B). In fact, the levels of Ahi1 mRNA 
expression are highest in the hippocampus, layers I-III of the cortex, the 
hypothalamus and the amygdala. This can be seen by the red rendering on the heat 
maps of mRNA expression and is consistent with previous findings (Figure 5.3B,C) 
(Doering et al., 2008; Sheng et al., 2008). Ahi1 protein levels could also be detected 
from rodent brain with two commercial antibodies (Figure 5.4A). The Santa Cruz 
antibody detected two protein bands at the expected molecular weight of Ahi1 ~130 
kDa. These bands correspond to the two isoforms of Ahi1 known to be expressed in 
rodent brain with a non-specific band appearing in all lanes at 100 kDa. Interestingly, 
the expression of the smaller isoform is much less pronounced within the rat cortex 
compared to total rat brain lysate.  The commercial Abcam Ahi1 monoclonal antibody 
appears to be species and isoform specific, detecting only one isoform of Ahi1 at the 
expected molecular weight in mouse brain lysate alone.  
 
Mouse Ahi1 cDNA was cloned into myc and GFP vectors which tagged the protein at 
the N-terminus. The constructs were readily expressed when transfected into COS-7 
cells and western blotting against the protein tags revealed bands at the expected 
molecular weights, 130 kDa and 160kDa for msAhi1myc and msAhi1GFP respectively. 
Neither fusion protein could be detected with the mouse specific Abcam antibody 
(Figure 5.4B,C). The cellular localisation of both mouse constructs and an N-
terminally tagged human Ahi1GFP (hAhi1GFP) construct obtained from Addgene could 
be detected via GFP fluorescence or immunostaining with an anti-myc antibody 
(Figure 5.4D). The expression of all three constructs appeared to be cytosolic similar 
to the GFP only control however, there was little Ahi1 present within the nucleus. High  
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Figure 5.4: Ahi1 antibody characterisation and detection in rodent brain 
lysate. 
(A) Characterisation of Ahi1 antibodies. Western blotting of untransfected COS-7 cell lysate, 
rat cultured cortical lysate, rat and mouse brain lysate and probing with a Santa Cruz Ahi1 
antibody (left panel) shows two specific Ahi1 bands at ~130kDa and ~140kDa in rodent 
lysate of which only the larger isoform is present in rat cortical neurons. Probing with a 
monoclonal Abcam antibody (right panel) shows specificity to the smaller mouse isoform of 
Ahi1 at ~130kDa only. Neither antibody detects Ahi1 in COS-7 cell lysate. The Santa Cruz 
antibody (left panel) detected a non-specific band at 100kDa in all samples. Western blots of 
(B) msAhi1myc or (C) msAhi1GFP transfected COS-7 cell lysates and untransfected (UT) control 
lysates were probed for myc and GFP (left panels) to confirm the constructs generated fusion 
proteins of the expected molecular weight ~130kDa and ~160kDa respectively. The Ahi1 
specific Abcam monoclonal antibody did not detect the mouse constructs (right panels). (D) 
Confocal images of COS-7 cells transfected with GFP control, hAhi1GFP, msAhi1GFP or 
msAhi1myc. Immunofluorescence with a myc antibody was used against the msAhi1myc 
construct. Scale bar, 20μm. 
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 Figure 5.5: Ahi1 interacts and colocalises with the trafficking molecule 
HAP1. 
Coimmunoprecipitation and colocalisation experiments demonstrating an interaction 
between Ahi1 and HAP1A or HAP1B. (A) Western blots of protein complexes 
coimmunoprecipitated using anti-GFP TRAP beads from COS-7 cells transfected with Ahi1myc 
and either HAP1AGFP or HAP1BGFP. Input samples (Inputs) represent 5% of the cell lysate 
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included in the immunoprecipitation (IP). Anti-GFP TRAP beads efficiently 
immunoprecipitated Ahi1myc from cotransfected cell lysates but not from Ahi1myc only 
transfected cells. (B) Western blots of endogenous protein complexes coimmunoprecipitated 
from mouse brain lysate with anti-HAP1 antibody. Input represent 5% of the brain lysate 
included in the IP (HAP1 IP). IgG is the non-immune control antibody experiment for non-
specific protein binding. Mouse anti-HAP1 antibody efficiently immunoprecipitated Ahi1 (left 
panel Santa Cruz Ahi1 antibody, right panel Abcam antibody) from mouse brain lysate. 
Confocal images of COS-7 cells (C) singularly transfected or (D) cotransfected with Ahi1GFP 
and HAP1AHA and subjected to immunofluorescence with anti-GFP and anti-HA antibodies 
respectively. Colocalisation appears yellow in the merged image. (E) Graph (above) shows a 
line scan through the merge image of HAP1HA and Ahi1GFP fluorescence, demonstrating the 
cellular distribution and colocalisation of the proteins with the peaks corresponding to 
protein clusters. Scale bar, 20μm.  
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expression of Ahi1 appeared to form aggregates as can be seen with msAhi1GFP, which 
could be due to the ability of Ahi1 to dimerise (Tuz et al., 2013).  
 
To explore the hypothesis that Ahi1 may play a trafficking role with HAP1 at the 
inhibitory synapse, first an interaction between the two proteins needed to be 
confirmed. Immunoprecipitation experiments from COS-7 cell lysates demonstrated 
that mouse Ahi1myc could be coimmunoprecipitated with both isoforms of HAP1, 
HAP1AGFP and HAP1BGFP, when they were pulled down via their GFP tags (Figure 
5.5A). Furthermore, immunoprecipitation experiments from mouse brain lysate 
confirmed that endogenous Ahi1 and HAP1 interact in brain. The interaction is via the 
smaller Ahi1 isoform, as the immunoprecipitated band is detected by the isoform 
specific Abcam antibody and appears as the lower band using the Santa Cruz antibody 
(Figure 5.5B). To study whether Ahi1 and HAP1 colocalise in cells 
immunofluorescence was carried out on COS-7 cells cotransfected with msAhi1GFP and 
HAP1AHA. This experiment revealed a striking recruitment phenotype when the two 
proteins were coexpressed. Alone Ahi1GFP appeared diffuse within the cytosol while 
HAP1AHA was also cytosolic but formed protein clusters that have been previously 
described (Figure 5.5C) (Li et al., 1998). However, when the two proteins are 
coexpressed msAhi1GFP was dramatically recruited to HAP1AHA clusters and the two 
proteins strongly colocalise. This can be seen by the overlapping line scan profile of 
pixel intensity for the two proteins (Figure 5.5D,E). 
 
To further characterise the Ahi1 HAP1 interaction, constructs expressing N-terminal 
truncated versions of HAP1A were used to map the Ahi1 binding site on HAP1. Mouse 
Ahi1GFP was transfected alone as a control into COS-7 cells or cotransfected with 
HAP1Amyc153-599, HAP1Amyc215-599, HAP1Amyc329-599 or HAP1Amyc371-599. The 153-599 
mutant lacked the very N-terminal region of HAP1A, the 215-599 mutant lacked the 
N-terminus plus the first coiled-coil (CC) domain, the 329-599 mutant lacked the N-
terminus and both CC domains 1 and 2, while the 371-599 mutant contained none of 
the CC domains and just expresses the C-terminus of HAP1A (Figure 5.6A). The 
mutants were immunoprecipitated from the transfected cell lysates via their myc tags 
using anti-myc beads and western blotting revealed any coimmunoprecipitation of 
Ahi1GFP. Mouse Ahi1GFP was robustly pulled down by the longest HAP1A truncation 
containing all the CC domains and was partially pulled down with the 215-599 mutant 
lacking only CC domain 1. Mouse Ahi1GFP did not interact with the HAP1A mutants 
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containing only the third CC domain or none of the CC domains (Figure 5.6B). When 
these experiments were repeated with hAhi1GFP a similar result was observed (Figure 
5.6C). hAhi1GFP strongly coimmunoprecipitated with the 152-599 mutant however, 
there was no partial interaction with the 215-599 mutant. These data confirm that 
both rodent and human Ahi1 either directly interact with the first CC domain of 
HAP1A or at least require the presence of this domain for HAP1 to be in the correct 
protein orientation to allow Ahi1 to interact.  
5.2.2 Ahi1 forms a trafficking complex with HAP1 
Previous work has described Ahi1 as a trafficking adaptor molecule involved in the 
transport of cargo along the primary cilia (Hsiao et al., 2009). HAP1 on the other 
hand, is an adaptor protein that couples GABAARs to the KIF5C kinesin motor and is 
required for the recycling of GABAARs within the inhibitory synapse (Twelvetrees et 
al., 2010). Confirming an interaction exists between Ahi1 and HAP1 suggests that 
these two proteins may form a trafficking complex together. Indeed, when HAP1 was 
immunoprecipitated from either rat or mouse brain lysate, using a HAP1 specific 
antibody, both Ahi1 and KIF5 coprecipitated with it, indicating that these three 
proteins can form an endogenous complex in the brain (Figure 5.7A,B). The doublet 
observed for HAP1 in the immunoprecipitation lane corresponds to both isoforms of 
HAP1, which can be enriched for with the HAP1 antibody.  Of note, the stoichiometry 
of the HAP1/Ahi1/KIF5 complex appears to be different between rat and mouse with 
a larger proportion of Ahi1, compared to KIF5, binding HAP1 in mouse verses equal 
proportions of Ahi1 and KIF5 binding HAP1 in rat. These differences could potentially 
be explained by the different Ahi1 isoforms present in rat and mouse and could 
suggest subtle differences in the function of the complex between the two species. 
 
Following the observation that HAP1, KIF5 and Ahi1 can form a protein complex 
together it was interesting to investigate whether this complex was functional and 
whether Ahi1 as well as HAP1 could be trafficked by KIF5. When KIF5Cmyc alone was 
transfected into COS-7 cells and immunofluorescence was used to reveal its 
subcellular localisation, the staining showed a distinct filamentous pattern typical of 
KIF5C decorating the microtubules (Figure 5.8A). When GFP was cotransfected with 
KIF5Cmyc the even distribution of KIF5Cmyc along the microtubules was not disrupted 
(Figure 5.8B). However, when HAP1AHA was cotransfected with KIF5Cmyc both the 
typical distribution of HAP1AHA and KIF5Cmyc was altered. Instead of HAP1AHA  
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Figure 5.6: Mapping the Ahi1 binding site of HAP1. 
Coimmunoprecipitation experiments reveal the first coiled-coil domain of HAP1 is necessary 
for Ahi1 binding. (A) A schematic of HAP1A depicting the 3 coiled-coil domains (CC) the 
glutamine rich region (poly-glu), the proline rich region (poly-pro) and the variable C-
terminus. Grey bars below represent the 4 truncated versions of the protein and red plus and 
minus symbols summerise which trucations can interact with Ahi1 (+: interaction; -: no 
interaction). Western blots of protein complexes coimmunoprecipitated using anti-myc 
beads from COS-7 cells cotransfected with mouse (B) or human (C) Ahi1GFP and either 153-
599, 215-599, 329-599 or 371-599 HAP1Amyc trucations. Input samples (Inputs) represent 
5% of the cell lysate included in the immunoprecipitation samples (IP). Anti-myc beads 
efficiently immunoprecipitated both mouse and human Ahi1GFP from cells coexpressing 153-
599 HAP1Amyc but not from cells coexpressing 215-599, 329-599 or 371-599 HAP1Amyc or 
from Ahi1GFP only expressing cells. 
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 Figure 5.7: Ahi1 forms a trafficking complex with HAP1 and KIF5 in rodent 
brain. 
Western blots of endogenous protein complexes coimmunoprecipitated from mouse (A) or 
rat (B) brain lysates with anti-HAP1 antibody. Input samples (Input) represent 5% of the 
brain lysate included in the immunoprecipitation samples (HAP1 IP). IgG is the non-immune 
control antibody experiment for non-specific protein binding. Mouse anti-HAP1 antibody 
efficiently immunoprecipitated both Ahi1 and KIF5 from mouse and rat brain lysates. 
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Figure 5.8: Ahi1 is trafficked by KIF5C in a HAP1 dependent manner. 
Transfected COS-7 cells were fixed and immunolabelled against the expressed fusion protein 
tags before being imaged using confocal microscopy. (A) Localisation of KIF5Cmyc on 
microtubules in single transfected cells. (B) Coexpression of KIF5Cmyc and GFP does not affect 
the microtubule localisation of KIF5Cmyc. (C) Coexpression of KIF5Cmyc with HAP1AHA results 
in KIF5Cmyc colocalising with HAP1AHA and HAP1AHA clusters being trafficked to the outer-
membrane. (D) Coexpression of KIF5Cmyc with Ahi1GFP does not interfere with KIF5Cmyc 
microtubule staining. Ahi1GFP is not redistributed with KIF5Cmyc. (E) A triple transfection of 
KIF5Cmyc, HAP1AHA and Ahi1GFP results in all three proteins colocalising and HAP1AHA and 
Ahi1GFP positive clusters being trafficking to the cell membrane. Scale bar, 20μm. 
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forming protein clusters evenly throughout the cytoplasm, as previously shown 
(Figure 5.5C), these clusters were trafficked out to the cell periphery. Furthermore, 
KIF5Cmyc, although maintaining some microtubule staining, also showed 
colocalisation with the HAP1AHA clusters (Figure 5.8C). This data demonstrates that 
HAP1AHA clusters can be trafficked along microtubules by KIF5Cmyc in an anterograde 
direction typical of a kinesin motor. Intriguingly, upon cotransfection of Ahi1GFP and 
KIF5Cmyc there was no redistribution of Ahi1GFP to the cell periphery, instead the 
subcellular localisation of Ahi1GFP remained cytosolic (Figure 5.8D). However, when 
all three proteins were transfected into COS-7 cells together both Ahi1GFP and HAP1HA 
could be redistributed to the edge of the cell. In addition, Ahi1GFP, HAP1AHA and 
KIF5Cmyc all colocalised, confirming by immunofluorescence that these three proteins 
interact and form a trafficking complex (Figure 5.8E). Taken together this data shows 
that the Ahi1/HAP1/KIF5C complex identified from brain lysate 
immunoprecipitation experiments can occur within a cell system. Moreover, it shows 
that Ahi1 can be functionally trafficked by KIF5C in a HAP1-dependent manner. 
5.2.3 Subcellular distribution of Ahi1 in neurons 
The identification of an Ahi1/HAP1/KIF5C complex that exists in brain and the 
evidence that Ahi1, in the presence of HAP1, can be trafficked by KIF5C raised the 
question as to what function Ahi1 may play with respect to HAP1 in GABAAR 
trafficking at the inhibitory synapse. In order to determine whether Ahi1 could impact 
on HAP1 function at the inhibitory synapse it was first necessary to determine whether 
Ahi1 could be detected at synapses in neurons. To study the subcellular localisation of 
Ahi1, mature cortical neurons transfected with Ahi1GFP for 3 days, were fixed and 
stained for inhibitory synaptic markers. The presynaptic markers vGAT, or GAD6 
were used. The same neurons were costained for the inhibitory postsynaptic markers, 
gephyrin or the GABAAR synaptic specific subunit γ2. Ahi1GFP displayed an even 
distribution throughout the neuron showing expression in the soma, axon and 
dendrites. Interestingly, Ahi1GFP appeared punctate along the dendrites and Ahi1GFP 
puncta colocalised with inhibitory pre and postsynaptic markers (Figure 5.9A, white 
arrowheads). It was noted that Ahi1GFP appeared to be present in dendritic spine heads 
and therefore the localisation of Ahi1GFP with respect to excitatory synaptic markers 
was also studied. Ahi1GFP colocalised with the PSD scaffold protein homer, an 
excitatory postsynaptic marker, opposed to vGlut, an excitatory presynaptic marker 
(Figure 5.9A). 
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Figure 5.9: Ahi1 is present at inhibitory and excitatory synapses. 
(A) Ahi1GFP was transfected into mature mouse cortical neurons and stained with antibodies 
against the pre and postsynaptic inhibitory markers vGAT or GAD6 and gephyrin or GABAAR-
γ2 respectively (left panel). Ahi1GFP colocalised with the postsynaptic inhibitory markers 
opposed to presynaptic markers (arrowheads).  Transfected neurons were also stained for 
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the excitatory synaptic pre and postsynaptic markers vGlut and homer respectively (right 
panel). Ahi1GFP was present in dendritic spines colocalised with homer and vGlut 
(arrowheads). (B) Endogenous Ahi1 was labelled in neurons using an Ahi1-specific antibody 
and produced clustered staining along dendrites. Endogenous Ahi1 colocalised with the 
inhibitory postsynaptic markers gephyrin and GABAAR-γ2 opposite presynaptic vGAT 
clusters (left panel, arrowheads). Endogenous Ahi1 colocalised with the excitatory pre and 
postsynaptic markers vGlut and homer respectively (right panel, arrowheads). Scale bars, 
whole cell 20μm, zoom 2μm. 
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Interestingly, carrying out the same experiments with a specific Ahi1 antibody, to 
observe the localisation of endogenous Ahi1, enhanced the punctate distribution of 
Ahi1 along dendrites. Endogenous Ahi1 also colocalised with the inhibitory 
presynaptic markers vGAT and GAD6 and the postsynaptic markers gephyrin and 
GABAAR-γ2. In addition, endogenous Ahi1 could be detected in dendritic spines and 
localised with the excitatory pre and postsynaptic markers, vGlut and homer 
respectively (Figure 5.9B). Taken together these data highlight that Ahi1 is detected  
at both inhibitory and excitatory synapses along dendrites. However, due to the 
presence of Ahi1GFP and endogenous Ahi1 throughout the dendrites Ahi1 is not 
enriched at synapses. Nevertheless, Ahi1 could potentially function as a trafficking 
adaptor protein that may play a role at these sites and contribute to the maintenance 
of normal synaptic transmission. 
5.2.4 Ahi1 does not play a role in the GABAAR trafficking function of 
HAP1 
This study has identified Ahi1 as a novel member of the HAP1/KIF5 trafficking 
complex and has furthermore, illustrated that Ahi1 can be detected at inhibitory 
synapses. Previous work has demonstrated that HAP1 functions as an adaptor protein 
coupling GABAARs via the β3 subunit to the KIF5C motor within the inhibitory 
synapse. This interaction promotes the recycling of GABAAR containing vesicles back 
to the membrane to allow insertion of the receptors. Knockdown of HAP1 by RNAi 
results in a decrease in the number of surface GABAARs (Twelvetrees et al., 2010). It 
therefore seemed appropriate to study whether Ahi1 could impact on the GABAAR 
trafficking function of HAP1. To investigate this, DIV10 hippocampal neurons were 
transfected with HAP1GFP, Ahi1GFP or GFP control (Figure 5.10A). The neurons were 
left to overexpress the exogenous proteins for 3-4 days before being fixed and 
subjected to immunofluorescence. A surface stain protocol was used with an antibody 
specific to an extracellular epitope of the synaptic GABAAR-γ2 subunit. This staining 
only labelled surface GABAARs inserted into the membrane; typically the staining 
appeared clustered along the dendrites characteristic of GABAARs tethered within 
synapses. By analysing the number and area of surface clusters information about the 
amount of postsynapses and strength of synapses can be revealed. Following surface 
staining neurons were then permeablised and stained with antibodies against GAD6 
the presynaptic marker and GFP to amplify the fluorescent protein signal. Neurons 
overexpressing HAP1 showed significantly more GABAAR clusters and a significantly  
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Figure 5.10: Overexpression of HAP1 but not Ahi1 effects surface GABAAR 
clusters. 
(A) Rat hippocampal neurons were transfected with Ahi1GFP, HAP1GFP or GFP control at DIV10 
and allowed to express the transgene for 4 days before fixing and staining for surface 
GABAAR-γ2 inhibitory synaptic clusters. Neurons were then permeablised and stained for 
GAD6 inhibitory presynaptic clusters. (B) Analysis of surface GABAAR-γ2 clusters revealed 
both number of clusters and total cluster area increased upon HAP1GFP but not upon Ahi1GFP 
overexpression compared to control cells (n=20-23 cells; one-way ANOVA; *p<0.05, 
**p<0.01). (C) Analysis of GAD6 presynaptic clusters revealed no significant difference in 
cluster number and cluster area upon Ahi1GFP or HAP1GFP overexpression compared to 
control cells (n =18-20 cells; one-way ANOVA; NS). Scale bars, 2μm. 
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Figure 5.11: The effect of Ahi1 and HAP1 coexpression on GABAAR surface 
clusters. 
(A) Rat hippocampal neurons were transfected with either GFP, Ahi1GFP, HAP1GFP, Ahi1GFP + 
HAP1HA or GFP + HAP1HA at DIV10 and allowed to express the transgenes for 4 days before 
fixing and staining for surface GABAAR-γ2 inhibitory synaptic clusters. Neurons were then 
permeablised and expression of the transfected proteins was confirmed by staining with anti-
GFP and/or anti-HA antibodies. (B) Analysis of surface GABAAR-γ2 clusters revealed both 
number and total cluster area increased upon HAP1GFP but not Ahi1GFP overexpression 
compared to control cells. Following coexpression of Ahi1GFP + HAP1HA the HAP1-mediated 
increase in surface clusters could not be observed. Coexpresison of GFP + HAP1HA also 
blocked the HAP1 alone effect (n=19-24 cells; Kruskal-Wallis ANOVA; *p<0.05, **p<0.01). 
Scale bars, 2μm. (C) Analysis of HAP1GFP and HAP1HA overexpressing cells showed no 
significant difference in the effect on surface GABAAR-γ2 cluster number or area. 
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greater total area of GABAAR clusters compared to control GFP expressing neurons 
(Figure 5.10B). However, upon overexpression of Ahi1GFP, the number and total area 
of GABAAR clusters did not differ from control (GABAAR cluster number: GFP, 6.13 ± 
1.06; Ahi1GFP, 8.35 ± 0.65; HAP1GFP, 10.38 ± 1.11; *p<0.05; cluster area: GFP, 2.40 ± 
0.51μm2, Ahi1GFP, 3.32 ± 0.37μm2, HAP1GFP, 5.55 ± 0.85μm2; *p<0.05, **p<0.01). 
Interesting, the postsynaptic effects observed with overexpression of HAP1GFP had no 
impact on the presynapse as the number and total area of GAD6 clusters was not 
significantly different from control cells when either HAP1GFP or Ahi1GFP were 
expressed (Figure 5.10C; cluster number: GFP, 5.11 ± 0.62; Ahi1GFP, 6.38 ± 0.74; 
HAP1GFP, 6.39 ± 0.61; cluster area: GFP, 2.53 ± 0.41μm2, Ahi1GFP, 2.63 ± 0.41μm2, 
HAP1GFP, 3.27 ± 0.48μm2; NS). 
 
Although Ahi1 alone does not appear to influence the number of surface GABAARs it 
was interesting to determine whether Ahi1 as a protein interactor of HAP1 could either 
promote of antagonise HAP1’s GABAAR trafficking function. In a second set of 
experiments, the surface levels of the GABAAR-γ2 subunit were analysed upon 
coexpression of both HAP1 and Ahi1. Neurons expressing HAP1HA and Ahi1GFP were 
compared to single transfected cells, or HAP1HA and GFP expressing cells (Figure 
5.11A). As in the previous set of experiments, overexpression of HAP1GFP alone 
resulted in a significant increase in total number and total area of GABAAR clusters 
compared to GFP control cells (Figure 5.11B). These increases were not seen when 
Ahi1GFP was overexpressed. Initially, it appeared very intriguing that when HAP1HA 
and Ahi1GFP were coexpressed the HAP1-mediated increase in total GABAAR cluster 
number and area could not be observed. This suggested that Ahi1 could have been 
negatively regulating HAP1 function. However, with the addition of a further 
condition, to control for expression changes brought about by plasmid competition in 
cotransfected cells, it was shown that coexpression of HAP1HA and GFP could also 
non-specifically block the HAP1-mediated increase in GABAAR clusters. Taken 
together, this implies the occlusion of a HAP1-mediated increase in surface GABAAR 
clusters upon coexpression of HAP1HA and Ahi1GFP could be non-specific (Figure 
5.11B; GABAAR cluster number: GFP, 6.18 ± 0.69; Ahi1GFP, 6.03 ± 0.73; HAP1GFP, 11.1 
± 1.07; HAP1HA + Ahi1GFP, 6.8 ± 1.09; HAP1HA + GFP, 7.28 ± 1.16; cluster area: GFP, 
2.07 ± 0.26μm2; Ahi1GFP, 2.21 ± 0.48μm2; HAP1GFP, 4.89 ± 0.7μm2; HAP1HA + Ahi1GFP, 
2.27 ± 0.4μm2; HAP1HA + GFP, 2.83 ± 0.59μm2; *p<0.05, **p<0.01). In summary, 
overexpression of HAP1 can induce changes in surface GABAAR levels that result in 
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more and larger GABAAR clusters. In contrast, overexpression of Ahi1 does not 
influence the surface levels of GABAARs. Lastly, it can be concluded that Ahi1 does not 
positively modulate HAP1’s GABAAR trafficking function. 
5.2.5 Characterisation of Ahi1 knockdown and its effect on GABAAR 
trafficking 
It is possible that Ahi1 is expressed at high levels within neurons under steady-state 
conditions. Therefore, the overexpression experiments described above may not alter 
the system to a great extent, resulting in there being little or no effect on the 
experimental readout. With that in mind, an RNA interference (RNAi) approach was 
developed to look at the effects of reduced Ahi1 expression on GABAAR trafficking. 
Short hairpin RNA constructs (shRNA) were developed to target Ahi1 mRNA for 
degradation resulting in knockdown of the protein levels within the transfected cell. 
A previously published shRNA sequence against Ahi1 (Hsiao et al., 2009) was cloned 
into the pSuper vector (Oligoengine), which contained a GFP reporter gene under a 
different promoter to the shRNA to allow for identification of transfected cells. To 
characterise the Ahi1 shRNA in the experimental systems used in this study, mouse 
hippocampal neurons were transfected with Ahi1 shRNA or a scrambled control 
shRNA at DIV10. Neurons were then fixed and stained with the Ahi1 specific Abcam 
antibody at DIV14 allowing 4 days of Ahi1 shRNA expression (Figure 5.12A). 
Quantification revealed that average fluorescence intensity of Ahi1 immunolabelling 
was significantly reduced by 55% in neurons expressing Ahi1 shRNA compared to 
control shRNA expressing neurons (Figure 5.12B; control shRNA: 100 ± 12.75%; Ahi1 
shRNA: 45.45 ± 2.65%; ***p<0.001). This demonstrates the effectiveness of the Ahi1 
specific shRNA at decreasing endogenous levels of Ahi1 protein.  
 
Ahi1 RNAi was then used to explore the effect of Ahi1 knockdown on GABAAR 
trafficking. Mouse hippocampal neurons were transfected with Ahi1 shRNA or control 
shRNA, and fixed after 4 days of expression. The neurons were then surface stained 
using an extracellular GABAAR-γ2 subunit specific antibody to label surface GABAAR 
clusters. Cluster analysis showed that there was no change in total GABAAR cluster 
number or area in Ahi1 knockdown cells compared to control cells (Figure 5.13; 
GABAAR cluster number: control shRNA, 6.98 ± 0.9; Ahi1 shRNA, 6.89 ± 0.7; cluster 
area: control shRNA, 2.13 ± 0.29μm2; Ahi1 shRNA, 2.02 ± 0.21μm2; NS). This result 
demonstrates that reduced levels of Ahi1 have no impact on the levels of GABAARs  
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Figure 5.12: Characterisation of Ahi1 RNAi. 
(A) Mouse hippocampal neurons were transfected with either control or Ahi1 specific short 
hairpin RNA (shRNA) at DIV10 and allowed to express the shRNA for 4 days before fixing and 
staining for endogenous Ahi1 with an Ahi1 specific antibody. Transfected neurons were 
detected by their GFP fluorescence due to a GFP-reporter gene present on the shRNA vector.  
(B) Analysis of endogenous Ahi1 average fluorescence intensity in Ahi shRNA compared to 
control shRNA transfected cells. Expression of Ahi1 specific shRNA produced a significant 
~50% reduction in the endogenous levels of Ahi1 compared to control shRNA expressing 
cells confirming the efficiency of the Ahi1 shRNA (n=24-25; Mann-Whitney U test; 
***p<0.001). Scale bar, 20μm. 
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Figure 5.13: Ahi1 knockdown does not affect surface GABAAR clusters. 
(A) Mouse hippocampal neurons were transfected with control shRNA or Ahi1 shRNA at 
DIV10 and allowed to express the shRNA for 4 days before fixing and staining for surface 
GABAAR-γ2 inhibitory synaptic clusters. (B) Analysis of surface GABAAR-γ2 clusters revealed 
no significant difference in both number of clusters and total cluster area upon expression of 
Ahi1 shRNA compared to control (n=18; Mann-Whitney U test; NS). Scale bars, 2μm. 
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within the membrane. This suggests that although Ahi1 can interact with HAP1, a 
protein known to be important in GABAAR trafficking, Ahi1 itself does not appear to 
be playing a role in this pathway. Hence, these findings suggest that disrupted 
GABAAR trafficking is unlikely to be a pathogenic mechanism of Ahi1 loss of function 
mutations in humans. 
5.2.6 The effect of Ahi1 knockdown on dendritic morphology 
Dysregulated neuronal development and connectivity, particularly within the cortex 
and hippocampus, are long standing hallmarks of brain disorders such as ASD and 
SCZ. Disrupted neuronal morphology has also been associated with other psychiatric  
disorders such as bipolar, anxiety and mental retardation (Kulkarni and Firestein, 
2012). Patients with CNVs or mutations in Ahi1 present with neuropsychiatric 
disorders such as ASD and SCZ (Amann-Zalcenstein et al., 2006; Retuerto et al., 
2008). Therefore, it was interesting to assay whether dendritic development and 
connectivity was affected in cells with reduced Ahi1 expression. To study this, 
dendritic complexity was analysed, using Sholl analysis (Sholl, 1953), in DIV14 mouse 
hippocampal neurons transfected with Ahi1 shRNA or control shRNA for 4 days 
(Figure 5.14A). In brief, the neuronal morphology was traced and concentric rings 
equally spaced apart were created expanding out from the cell soma. The number of 
times a dendrite intersects each ring was plotted as a function of distance from the 
soma and generated an output for dendritic complexity. Ahi1 knockdown resulted in 
a significant increase in both the number of intersections and the number of branch 
points as a function of distance from the soma compared to control shRNA expressing 
neurons (Figure 5.14B; *p<0.05, **p<0.01). In addition, total dendritic length and the 
total number of branch points per cell were also significantly increased, by 28 and 
41% respectively, in Ahi1 knockdown cells compared to control (Figure 5.14C; 
dendritic length: control shRNA, 2175.58 ± 197.87μm; Ahi1 shRNA, 2795.76 ± 
187.53μm; branch points: control shRNA, 47.83 ± 5.21; Ahi1 shRNA, 67.58 ± 5.49; 
*p<0.05). In summary knockdown of Ahi1 impacts on neuronal morphology resulting 
in cells displaying increased dendritic complexity.  
5.2.7 The impact of Ahi1 ASD-associated mutations on Ahi1 function 
Recent genetic studies have associated the gene Ahi1 with ASD (Brett et al., 2014; 
Retuerto et al., 2008). One particular investigation has highlighted that those patients 
with JS, the neurodevelopmental disease brought about by mutations in Ahi1, present  
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Figure 5.14: Ahi1 knockdown affects dendritic morphology. 
(A) Mouse hippocampal neurons were transfected with control shRNA or Ahi1 shRNA at 
DIV10 and allowed to express the shRNA for 4 days before fixing and staining with an anti-
GFP antibody to amplify the shRNA GFP reporter fluorescence for efficient dendritic tracing. 
(B) Quantification by Sholl analysis shows that number of intersections (left panel) and 
number of branch points (right panel) are significantly increased with distance from the soma 
in Ahi1 shRNA expressing neurons compared to control shRNA expressing cells (data points 
represent an average of 12 cells; 2-way ANOVA; *p<0.05, **p<0.01). (C) Expression of Ahi1 
shRNA increases total dendritic length and total number of branch points per cell compared 
to neurons expressing control shRNA (n=12; student’s t-test; *p<0.05). Scale bar 20μm.  
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Table 5.1: Summary of Ahi1 ASD-associated mutations 
Residue 
Change 
Allele 
Change 
Variant Type Disease 
Association 
Reference 
R351X C1051T Nonsense JB, ASD 
 
(Ferland et al., 2004) 
R435X C1303T Nonsense JS, ASD 
 
(Ferland et al., 2004) 
V433D T1328A Missense JS, ASD 
 
(Dixon-Salazar et al., 2004; 
Ferland et al., 2004) 
Y933C A2798G Missense ASD 
 
(Retuerto et al., 2008;  
Yu et al., 2013) 
 
with ASD characteristics (Retuerto et al., 2008). A number of pathogenic point 
mutations in Ahi1 have been described to cause JS (Table 4.2). Therefore, exploring 
how these mutations impact on Ahi1 function may provide some insights not only into 
the mechanisms of JS but why patients display neuropsychiatric behaviours.  
 
Point mutations in the human Ahi1 coding sequence were introduced into hAhi1GFP 
using PCR. All four hAhi1 mutants were confirmed by sequencing and readily 
expressed in COS-7 cells (Figure 5.15A,B). Interestingly, the two C-terminal truncated 
mutants of hAhi1GFP, R351X and R435X, were highly expressed in the nucleus. 
hAhi1GFP(R435X) also showed diffuse cytosolic staining similar to WT hAhi1GFP however,  
hAhi1GFP(R351X) only showed some small puncta within the cytosol with the majority of 
protein retained within the nucleus. It appears the C-terminal truncations may have 
altered the protein folding of Ahi1 and exposed a nuclear localisation signal (NLS) 
targeting these mutants to the nucleus. The distribution of hAhi1GFP(V433D) and 
hAhi1GFP(Y933C) appeared unchanged from WT. Coimmunoprecipitation experiments 
from COS-7 cells transfected with hAhi1GFP mutants and HAP1BHA revealed that all 
the hAhi1GFP mutants could still interact with HAP1BHA despite the disrupted cellular 
localisation of the C-terminal truncated mutants R351X and R435X (Figure 5.15C). 
Quantification of these interactions revealed the hAhi1GFP(R351X) and hAhi1GFP(R435X) 
showed a trend towards less binding with HAP1BHA compared to WT hAhi1GFP. 
Indeed, this could be due to more of the truncated Ahi1 mutants being targeted to the 
nucleus and therefore less able to interact with HAP1  (Figure 5.15D; normalised 
amount of Ahi1GFP binding: WT, 1 ± 0; R351X, 0.59 ± 0.28; R435X, 0.49 ± 0.18; 
V433D, 1.5 ± 0.5; Y933C, 1.39 ± 0.66; NS). In agreement with the biochemical 
coimmunoprecipitation experiment, when hAhi1GFP mutants and HAP1AHA were  
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Figure 5.15: Ahi1 ASD mutants interact with full-length HAP1. 
(A) A schematic depicting four point mutants in hAhi1 that have been found in patients with 
JS and associated with ASD. (B) Confocal images of COS-7 cells transfected with WT human 
Ahi1GFP, or the four mutants R351X, R435X, V433D, Y933C resulting in 2 N-terminal truncated 
proteins, 1 with a mutation in the regions upstream of the WD40 domain and one with a 
mutation in the C-terminal SH3 domain. All proteins were readily expressed. (C) Western 
blots of protein complexes coimmunoprecipitated using anti-GFP TRAP beads from COS-7 
cells transfected with HAP1B and either WT human Ahi1GFP or R351X, R435X, V433D, Y933C 
human Ahi1GFP. Input samples (Inputs) represent 5% of the cell lysate included in the 
immunoprecipitation (IP). Anti-GFP TRAP beads efficiently coimmunoprecipitated HAP1BHA 
from cotransfected cell lysates but not from HAP1BHA only transfected cells. Ahi1GFP 
constructs were revealed with an anti-GFP antibody while an anti-HAP1 antibody was used 
to visualise HAP1B. (D) Quantification of amount of HAP1 coimmunoprecipitation 
normalised to the amount of Ahi1 pulled down (n=4; Kruskal-Wallis ANOVA; NS). 
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Figure 5.16: Ahi1 ASD mutants are recruited to HAP1-positive clusters in 
cells. 
(A) Confocal images of COS-7 cells cotransfected with WT or mutant forms of human Ahi1GFP 
and HAP1AHA and subjected to immunofluorescence with anti-GFP and anti-HA antibodies. 
Colocalisation of Ahi1GFP constructs and HAP1AHA appears yellow in the merged image. (B) 
Line scans through the merged images show the fluorescence intensity of the green (Ahi1 
mutants) and red (HAP1) channels, with overlapping peaks representing colocalisation. All 
four of the ASD associated Ahi1 mutants, like WT Ahi1, are redistributed from their 
cytosolic/nuclear localisation to large HAP1A positive clusters when coexpressed with 
HAP1A. Scale bar, 20μm.  
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cotransfected in COS-7 cells and subjected to immunofluorescence and 
confocalimaging all Ahi1 mutant proteins, in a similar way to WT Ahi1GFP, were 
recruited into HAP1AHA clusters. This can been seen by the yellow puncta in the 
merged image and the overlapping pixel intensity of the green and red channels in the 
line scans. Of note the truncated Ahi1 mutants R351X and R435X are no longer 
targeted to the nucleus in the presence of HAP1 suggesting the interaction with HAP1 
may occlude any uncovered NLS (Figure 5.16).  
 
This chapter has identified a novel Ahi1/HAP1/KIF5 trafficking complex that can be 
detected in brain tissue and demonstrates that Ahi1 can be trafficked by KIF5C in a 
HAP1 dependent manner. To explore the functional effects of the Ahi1 ASD mutants 
further, experiments were carried out to determine whether they too could be 
trafficked in a complex with HAP1 and KIF5C. WT hAhi1GFP is not redistributed when 
coexpressed in COS-7 cells with KIF5Cmyc. However, when HAP1AHA is also expressed 
with WT Ahi1GFP and KIF5Cmyc, Ahi1GFP is recruited to HAP1AHA clusters and these 
clusters are trafficked in an anterograde direction to the cell membrane (Figure 
5.17A). The Ahi1 ASD mutants follow the same pattern of redistribution. When all four 
mutants were coexpressed with KIF5Cmyc alone their cellular localisation was 
unaffected. However, when the mutants were coexpressed with HAP1AHA and 
KIF5Cmyc the mutant Ahi1 proteins colocalised to HAP1AHA clusters and were 
trafficked to the edge of the cell by KIF5Cmyc (Figure 5.17B-E). Taken together this data 
demonstrates that Ahi1 ASD mutant proteins can still interact with HAP1 and be 
recruited to HAP1 clusters within the cell. Furthermore, the Ahi1 mutants can still be 
trafficked by KIF5C in a HAP1 dependent manner suggesting that these mutants must 
have more subtle effects on Ahi1 function and do not interfere with its HAP1 protein 
interactions. 
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Figure 5.17: Ahi1 ASD mutants are trafficked by KIF5C in a HAP1-dependent 
manner. 
Transfected COS-7 cells were fixed and immunostained against the expressed fusion protein 
tags before being imaged using confocal microscopy. (A) Cytosolic localisation of WT hAhi1GFP 
alone (single transfection). Coexpression of WT hAhi1GFP and KIF5Cmyc does not interfere with 
KIF5Cmyc microtubule staining. WT hAhi1GFP is not redistributed and trafficked with KIF5Cmyc 
(upper panels). A triple transfection of KIF5Cmyc, HAP1AHA and WT Ahi1GFP results in all 3 
proteins colocalising and HAP1AHA and Ahi1GFP positive clusters being trafficking to the cell 
membrane (lower panels). (B-E) Cytosolic/nuclear localisation of mutant Ahi1GFP constructs 
alone (single transfections). Coexpression of mutant Ahi1GFP constructs and KIF5Cmyc does not 
interfere with KIF5Cmyc microtubule staining. Mutant Ahi1GFP constructs are not redistributed 
and trafficked with KIF5Cmyc (upper panels). A triple transfection of KIF5Cmyc, HAP1AHA and 
Ahi1GFP mutants results in all 3 proteins colocalising and HAP1AHA and mutant Ahi1GFP positive 
clusters being trafficking to the cell membrane along microtubules by KIF5Cmyc (lower panels). 
Scale bar, 20μm. 
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5.3 Discussion 
The data described in this chapter demonstrates that Ahi1, the protein mutated in the 
neurodevelopmental disorder Joubert syndrome (JS) and associated with 
neuropsychiatric phenotypes, interacts strongly with the trafficking molecule HAP1. 
This chapter reveals that the two proteins form a novel trafficking complex with KIF5 
which exists in vivo in rodent brain. The trafficking of Ahi1 by KIF5C was shown to be 
dependent on HAP1. Irrespective of this trafficking complex, both overexpression and 
knockdown of Ahi1 did not alter surface levels of GABAARs at inhibitory synapses, a 
mechanism known to be regulated by HAP1 and KIF5C (Twelvetrees et al., 2010). 
Nevertheless, endogenous Ahi1 was shown to be present at both inhibitory and 
excitatory synapses suggesting the protein may have an as yet unknown function in 
synaptic trafficking and transmission. Interestingly, Ahi1 ASD associated mutants can 
still interact with HAP1 and be trafficked by KIF5C. This points towards the mutations 
having more subtle effects on Ahi1 signalling and regulation rather than effecting its 
protein-protein interactions. In addition, knockdown of Ahi1 results in altered 
dendritic morphology a finding consistent with the defects in brain development 
observed in patients with JS.  
5.3.1 Dissecting the Ahi1 HAP1 interaction 
Since confirming the interaction between Ahi1 and HAP1 in the experiments 
described here, based on the original findings from Sheng and colleagues (Sheng et 
al., 2008), a number of papers have illustrated a robust interaction between Ahi1 and 
HAP1 (Niu et al., 2011; Tuz et al., 2013; Weng et al., 2013). Experiments carried out 
here have mapped the interaction between Ahi1 and HAP1 using HAP1 N-terminal 
truncations. Ahi1 was found to interact with the first coiled-coil domain (CC1) of HAP1 
(aa169-205), this is consistent with findings from Tuz and colleagues (Tuz et al., 
2013). Ahi1 therefore, either interacts directly with CC1 of HAP1 or the CC1 is required 
to make a HAP1 tertiary structure that allows Ahi1 to bind. Recently, others have 
attempted to map the binding of HAP1 onto Ahi1 using Ahi1 truncations (Sheng et al., 
2008; Tuz et al., 2013; Weng et al., 2013). Sheng and colleagues initially showed a 
truncated version of mAhi1 (aa1-284) could still interact with HAP1 although to a 
lesser extent than WT Ahi1. Furthermore, unlike WT Ahi1, this truncation could not 
stabilise HAP1 protein levels (Sheng et al., 2008). A more recent publication from the 
same research group used GST fusion proteins and demonstrates the same N-
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terminal truncation (aa1-284) bound very weakly to HAP1. This group also reported 
that Ahi1 protein fragments containing just the WD40 domain (aa262-795) or just the 
C-terminus and the SH3 domain (aa651-1047) could still interact with full-length 
HAP1 (Weng et al., 2013). Intriguingly, a yeast two-hybrid (Y2H) study has 
demonstrated that this is not the case for hAhi1. The results from this study clearly 
show that aa141-434 of hAhi1 (corresponding to the mouse aa1-284) robustly interact 
with HAP1. It is also shown that the WD40 domain and the C-terminal SH3 
containing domain protein fragments do not interact with HAP1 (Tuz et al., 2013). 
These results contradict the mAhi1 mapping data. The species discrepancy in how 
Ahi1 interacts with HAP1 implies there could be differences in other Ahi1 protein-
protein interactions between human and mouse. This raises important considerations 
when using mouse systems to study Ahi1 function, especially when studying human 
disease-associated mutations. However, the HAP1 binding site for Ahi1 illustrated 
here remains consistent for both mouse and human Ahi1 proteins.  
 
The Y2H study also showed that the human specific N-terminal CC domain of Ahi1 
alone (aa1-140) could not interact with HAP1 (Tuz et al., 2013). Results presented here 
have shown that the human Ahi1 autism mutant truncations aa1-351 (R351X) and aa1-
455 (R435X) can still interact with HAP1. Taken together with the Y2H data these 
results indirectly map the HAP1 binding site on Ahi1 to aa212-351. It is interesting 
that common JS causing mutations, that are also associated with ASD, generate short 
Ahi1 fragments that still interact with HAP1. Perhaps these mutations encode 
truncated proteins that behave like dominant-negative constructs binding to HAP1 
and disrupting its neuronal function. It would be interesting to carry out further 
experiments to explore this hypothesis.  
5.3.2 Ahi1 in neuronal receptor trafficking and neuropsychiatric 
disorders 
The strong interaction between HAP1 and Ahi1 coupled with their enrichment in the 
same brain regions pointed towards Ahi1 functioning with HAP1 or being implicated 
in the same molecular pathways. Indeed, it was exciting to hypothesise that Ahi1, with 
its many signalling domains, might regulate the GABAAR trafficking function of HAP1 
(Twelvetrees et al., 2010). It could be speculated that defects in Ahi1, as seen in 
patients with JS, might dysregulate HAP1 function leading to disrupted inhibitory 
transmission and a pathological imbalance between neuronal excitation and 
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inhibition (Smith and Kittler, 2010). Demonstrating a regulatory role for Ahi1 in the 
E/I balance could have begun to provide an explanation for why altered Ahi1 
expression results in neuropsychiatric and depressive phenotypes in human patients 
and animal models (Lotan et al., 2013; Ren et al., 2014; Retuerto et al., 2008; Torri et 
al., 2010; Xu et al., 2010). However, from the data presented in this chapter it appears 
this hypothesis is not the case. It can be concluded that Ahi1 does not impact the 
trafficking and recycling of GABAARs at the inhibitory synapse, using the methods 
described here. Neither overexpression nor knockdown of Ahi1, to manipulate Ahi1 
signalling pathways, affected the levels of surface GABAAR-γ2 clusters in hippocampal 
neuronal cultures. 
 
Alternatively, it is possible that the experiments carried out in this chapter did not 
produce dramatic enough changes in Ahi1 protein levels to observe effects on synaptic 
trafficking. Ahi1 and HAP1 have been reported to stabilise each other (Sheng et al., 
2008; Tuz et al., 2013; Xu et al., 2010). In Ahi1 KO tissue HAP1 protein levels are 
reduced compared to control and vice versa. In the RNAi experiments described here, 
perhaps the 55% loss of Ahi1 was not sufficient to disrupt the protein levels or 
regulation of HAP1 and hence, no effect was observed on GABAAR trafficking. 
However, the immunofluorescence assay used to quantify GABAAR trafficking may 
also not have been sensitive enough to detect subtle changes in surface receptors. 
Unfortunately, due to the limitations of neuronal transfection, assays could only be 
designed in this way at the single cell level.  
 
It would be interesting to study how total loss of Ahi1 impacts GABAAR trafficking 
using an Ahi1 KO mouse model. These experiments would hopefully be consistent 
with the results observed here rather than lack of complete knockdown in the RNAi 
system masking an Ahi1 dependent GABAAR trafficking effect. Notably, the finding 
here that Ahi1 overexpression also has no impact on GABAAR trafficking points 
towards GABAAR trafficking being independent of Ahi1 rather than the RNAi system 
being inefficient. The availability of Ahi1 KO neurons would also allow biochemical 
surface biotinylation experiments to be carried out. This protocol purifies surface 
proteins from a total cell population so levels of a particular membrane protein 
between control and sample neurons can be measured. This experiment would 
provide an alternative method for investigating surface GABAARs and support any 
immunofluorescence results. 
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Others have attempted to identify HAP1-dependent mechanisms that are regulated 
by Ahi1 with more success. Indeed, one group have investigated how Ahi1 is 
implicated in the trafficking of the neurotrophic receptor TrkB. When activated, TrkB 
is internalised to bring about signalling events, it is then either recycled or degraded. 
HAP1 and Ahi1 appear to have a role in stabilising these internalised TrkB receptors. 
Sheng and colleagues initially showed that levels of TrkB were destabilised in HAP1 
KO tissue and that RNAi against Ahi1 decreased HAP1 protein levels and hence, TrkB 
levels (Sheng et al., 2008). The group then studied neuronal specific Ahi1 cKO mice 
and revealed both HAP1 and TrkB protein levels were reduced in the hypothalamus. 
Specifically, the level of internalised TrkB protein was decreased in Ahi1 KO brain 
stem cells and was shown to be due to dysregulated endocytic sorting resulting in the 
rapid degradation of TrkB by lysosomes. Loss of Ahi1 was shown to disrupt an 
Ahi1/HAP1/Hrs complex that would normally stabilise internalised TrkB receptors 
for recycling (Xu et al., 2010).  
 
TrkB receptor signalling is known to play a critical role in depressive neuropsychiatric 
disorders; reduced levels of TrkB and its ligands are detected in patients with SCZ and 
mood disorders. In addition, altered BDNF signalling, the neurotrophin ligand for 
TrkB, contributes to the progression of FXS and patients suffering from psychiatric 
disorders respond well to drugs that target TrkB receptors and their signalling 
pathways (Angelucci et al., 2005; Castrén and Castrén, 2014; Gupta et al., 2013; Ray 
et al., 2014). Therefore, the disrupted endocytic trafficking of TrkB in Ahi1 KO tissues 
suggests a mechanism for the neuropsychiatric phenotypes seen in JS patients. 
Importantly, Ahi1 deficiency in these mice lead to depressive and anxiolytic behaviour 
(Lotan et al., 2013; Ren et al., 2014; Xu et al., 2010). In line with this, Ahi1 has been 
shown to interact with the 5-HT2c serotonin receptor (5-HT2cR) and also promote 
degradation of the internalised receptors through the lysosomal pathway (Wang et al., 
2012). Interestingly, serotonin receptors are the target for many antipsychotic drugs. 
Therefore, although a role for Ahi1 in GABAAR trafficking has not been revealed other 
reports suggest that the role of Ahi1 in the trafficking of neuronal receptors may be 
contributing to JS pathogenesis and the neuropsychiatric behaviours observed. 
5.3.3 An excitatory role for Ahi1 
Unravelling a role for Ahi1 in synaptic function and neurotransmission is a tempting 
idea to explain some of the more complex cognitive phenotypes observed in JS 
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(Ferland et al., 2004; Holroyd et al., 1991; Joubert et al., 1969; Ozonoff et al., 1999; 
Xu et al., 2010). If Ahi1 is not impacting on GABAergic synapses at the level of 
trafficking GABAARs then perhaps Ahi1 is playing a role at excitatory synapses. It 
would be interesting to carry out electrophysiological recording on neurons with 
altered Ahi1 expression to see if these neurons have disrupted inhibitory or excitatory 
transmission. Indeed, the data presented here shows that both overexpressed Ahi1GFP 
and endogenous Ahi1 colocalise with excitatory synaptic markers within dendrites. 
Furthermore, endogenous Ahi1 can be seen within dendritic spines. Intriguingly, 
these membrane protrusions, which compartmentalise excitatory synaptic structures 
for enhanced neurotransmission, show many similarities to primary non-motile cilia 
(Nechipurenko et al., 2013). Ahi1 has previously been described to localise and 
function within this protruding cell organelle. Both spines and cilia show parallels in 
their signalling mechanisms, protein composition, structural plasticity and their 
fundamental roles are ultimately similar, to sense and transduce extracellular cues 
into the cell (Nechipurenko et al., 2013). With this in mind, perhaps Ahi1 plays a 
similar role at dendritic spines to its described role at cilia.  
 
The main function of Ahi1 within primary cilia is within the transition zone (TZ) 
(Hsiao et al., 2009; Lancaster et al., 2011b). This is the region at the junction between 
the distal end of the mother centriole, which forms the base of the cilia often known 
as the basal body, and the cilium itself. Super-resolution imaging has recently 
confirmed that Ahi1 is present in the TZ (Lee et al., 2014). Ahi1 is recruited to the TZ 
during ciliogenesis and is thought to function as a molecular component of the ciliary 
gate. The ciliary gate is considered to be a physical barrier that can be seen by electron 
microscopy and blocks the free exchange of soluble and plasma membrane cilia 
components with the rest of the cell. These gatekeeper molecules control the entry 
and exit of proteins into the cilia and regulate intraflagellar transport (Reiter et al., 
2012). A similar diffusion barrier has been proposed for dendritic spines; with the 
constricted spine neck and comparable gatekeeper proteins being required to restrict 
movement of signalling molecules between the spine and the dendrite. Perhaps Ahi1 
could function as a gatekeeper protein at spines as it does in cilia. It would be 
interesting to carry out super-resolution microscopy on Ahi1 in spines to see if it 
localises to the spine neck or forms ring structures. In addition, Ahi1 has been shown 
to interact with the small GTPase Rab8a and be critical in the delivery of vesicles 
targeted to the primary cilia (Hsiao et al., 2009). Rab8a is also required for the 
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synaptic delivery of AMPA receptors during LTP and constitutive receptor recycling, 
therefore, perhaps Ahi1 could be functioning in this trafficking event (Ng and Tang, 
2008). A simple extension of the experiments presented here would be to study the 
role of Ahi1 in AMPA receptor trafficking using similar methods. 
 
Via its interaction with HAP1, Ahi1 could also be implicated in cytoskeletal regulation 
at dendritic spines. HAP1 can bind to the Rac1 GEF kalirin-7 (Colomer, 1997), which 
activates the global actin regulator Rac1. Kalirin-7 is thought to be important in 
regulating the cytoskeleton at excitatory synapses and in dendritic spine morphology 
(Penzes and Jones, 2008) but the significance of its interaction with HAP1 and a 
possible role for Ahi1 in this complex has not been described.  
5.3.4 Ahi1 and neuronal development  
Loss of function mutations in human Ahi1 results in JS. Patients present with brain 
malformations including abnormal cerebellar development and axonal decussation 
highlighting the important of Ahi1 in neuronal development (Ferland et al., 2004). 
Ahi1 KO mice have a reduced cerebellum size due to failure of neuronal proliferation 
and defects in midline fusion consistent with the malformations observed in humans 
(Lancaster et al., 2011a). The use of RNA interference (RNAi) against Ahi1 in IMCD3 
cells resulted in reduced primary cilia formation. Both cells stably expressing or 
transiently transfected with Ahi1 shRNA showed a decrease in the percentage of 
ciliated cells. This result was also confirmed in Ahi1-/- mouse embryonic fibroblasts 
(MEFs) (Hsiao et al., 2009). Defects in ciliogenesis are commonly associated with 
poor cell development as critical developmental signalling pathway such as Hedgehog 
and Wnt signalling required primary cilia (Lee and Gleeson, 2010; Waters and Beales, 
2011). Taken together, this data points towards Ahi1 being required for normal 
neuronal development with loss of Ahi1 resulting in lack of neuronal proliferation and 
growth, probably due to impaired cilia formation. 
 
It is therefore intriguing that Ahi1 knockdown in hippocampal neurons using an RNAi 
approach demonstrated here results in increased neuronal architecture and dendritic 
complexity. Knockdown of Ahi1 in DIV10 neurons for 4 days resulted in neurons being 
significantly more complex, having significantly longer dendrites with more branch 
points. The discrepancies between this data and previously published work, which has 
suggested loss of Ahi1 has a negative impact on neuronal development, could be due 
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to differences in experimental design. Here, an RNAi approach looked at acute 
knockdown of Ahi1 in single cultured neurons. It is not surprising that loss of Ahi1 in 
this way impacted differently on neuronal development when compared to in vivo 
brain studies in humans with Ahi1 mutations and germline Ahi1 KO mice studies 
(Ferland et al., 2004; Lancaster et al., 2011a). A more comparable experiment carried 
out by Weng and colleagues revealed cultured Ahi1 KO hypothalamic neurons had 
significantly reduced dendritic length compared to WT control cells (Weng et al., 
2013). However, these neurons may still have been displaying dendritic defects due 
to total loss of Ahi1 throughout development. Furthermore, the morphology 
experiments carried out here examined the cell autonomous effects of Ahi1 
knockdown at a stage when dendritic structure has already developed. In the 
hypothalamic neuron experiment (Weng et al., 2013) the changes in signalling due to 
loss of Ahi1 in the whole neuronal culture may account for the differences in the 
dendritic length findings. The results presented here show that Ahi1 is required for 
maintenance of dendritic arborisation, a result that has possibly been masked in 
previous studies using Ahi1 KO neurons due to the strong developmental defects 
observed.  
 
To understand more about how acute knockdown of Ahi1 affects dendritic 
morphology it would be interesting to see if primary cilia formation is disrupted 
following RNAi treatment at the time point examined in this chapter. This experiment 
would shed light on whether cilia signalling plays a role in the increased dendritic 
complexity observed. In addition, investigating the dendritic effects of Ahi1 
knockdown in young neurons might provide more information about how loss of Ahi1 
at different time points impacts on dendritic development. 
 
There have been no previous reports of the impact acute Ahi1 knockdown has on 
dendritic morphology. One possible explanation for the increased dendritic 
complexity observed here involves Ahi1 regulating HAP1 trafficking. HAP1A has been 
shown to interact with KLC and be trafficked to neurite tips (McGuire et al., 2006; 
Rong et al., 2006). KLC is part of the conventional anterograde microtubule motor 
kinesin. At neurite tips HAP1A promotes neurite outgrowth by stabilising internalised 
TrkA for downstream signalling. Indeed, loss of HAP1 expression using RNAi lead to 
reduced HAP1 in neurite tips, decreased levels of internalised TrkA and reduced 
neurite outgrowth. Phosphorylation of HAP1A has been shown to decrease its 
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associated with KLC reducing its localisation at neurite tips and inhibiting outgrowth 
(Rong et al., 2006). It could be hypothesised that Ahi1, as a HAP1 adaptor protein, 
promotes the recruitment of a kinase to HAP1A resulting in phosphorylation leading 
to the uncoupling of HAP1A from kinesin as a form of neurite outgrowth regulation. 
Therefore, when Ahi1 expression is reduced following RNAi, the regulation of HAP1 
phosphorylation is lost, leaving HAP1A predominantly dephosphorylated, coupled to 
motors and trafficked to the neurite tip resulting in extension. This model could 
explain the increased dendritic complexity observed here when Ahi1 expression is 
decreased. Indeed, in a more recent study, NGF treatment was shown to induce 
dephosphorylation of HAP1A and reduce the amount of Ahi1 bound to HAP1A (Weng 
et al., 2013). This is consistent with the notion that Ahi1 could negatively regulate 
HAP1 trafficking and neurite outgrowth. 
 
In contrast, the reduction of neurite length and brain volume observed with prolonged 
total loss of Ahi1 function (Ferland et al., 2004; Lancaster et al., 2011a; Weng et al., 
2013) could be due to loss of Ahi1 promoting TrkB degradation (Xu et al., 2010), a 
critical receptor required for dendritic path finding and neuronal development. 
Alternatively, it could be due to the long-term loss of Ahi1 destabilising HAP1 
expression, as previously shown (Sheng et al., 2008), therefore impacting on HAP1’s 
function in TrkA and BDNF trafficking, two other vital pathways in dendritic 
maturation (Rong et al., 2006; Wu et al., 2010). 
 
In summary, the results presented in this chapter explore the neuronal role of Ahi1 in 
an attempt to elucidate how loss of function mutations in Ahi1 can result in the 
neuropsychiatric phenotypes associated with JS. These results demonstrate an 
interaction between Ahi1 and HAP1 and map the Ahi1 binding site to the first CC 
domain of HAP1. This interaction led to the discovery of a novel Ahi1/HAP1/KIF5 
trafficking complex that exists in brain. In light of this complex, the role of Ahi1 in the 
trafficking of GABAARs at inhibitory synapses was investigated, however, although 
Ahi1 is present at inhibitory synapses, it does not appear to impact on GABAAR surface 
stability. All the same, a synaptic role for Ahi1 is an exciting prospect to explain the 
behavioural defects observed in patients with JS. Ahi1 was shown to localise to 
excitatory synapses and be present in dendritic spines; its potential roles at excitatory 
synapses have been discussed. Finally, data reported here illustrates a new role for 
Ahi1 in the maintenance of dendritic complexity and a speculative model of a 
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mechanism involving the regulation of HAP1 phosphorylation has been suggested. 
Taken together, understanding the function of Ahi1 at synapses and in neuronal 
development, two key mechanisms in the pathogenesis of many neuropsychiatric 
disorders, may shed light on why Ahi1 has been associated with ASD, SCZ and 
depressive phenotypes. 
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Chapter 6 
Final Discussion 
6.1 Summary 
Synapses are vital for normal neuronal communication and for many years scientists 
have been attempting to understand their significance in neurological disease 
pathogenesis. Indeed, synapses have been shown to be disrupted in more than 100 
brain disorders (Grant, 2012). Likewise, anatomical studies of post-mortem brains 
and more recently advanced imaging has illuminated an important role for correct 
neuronal connectivity and dendritic morphology in neurological disease (Harvey et 
al., 1993; Karlsgodt et al., 2008; Kulkarni and Firestein, 2012; Raymond et al., 1996; 
Ruiz et al., 2013). Attention has therefore been given to understanding the molecular 
mechanisms of synaptic dysfunction and altered connectivity in pathological 
conditions. Genome-wide genetic screening has identified a multitude of candidate 
disease-associated genes that converge on synaptic or dendritic pathways (Berg and 
Geschwind, 2012; Grant, 2012; Hall et al., 2015; Koleske, 2013). This plethora of 
disease-associated genes has provided scientists with a huge range of targets to 
research in an attempt to illuminate the underlying mechanisms of neuropsychiatric 
disorders. Using a combination of molecular, biochemical and imaging techniques 
this thesis has explored the role of two neuropsychiatric disorder-associated genes in 
an attempt to understand their involvement in such conditions. 
 
Firstly, Chapter 3 described a novel role for CYFIP1 (Schenck et al., 2001) in synaptic 
morphology and dendritic complexity. CYFIP1 is encoded by a gene strongly 
associated with ASD and SCZ through CNV (Table 3.1). CYFIP1 and its homologue 
CYFIP2, a less well studied protein encoded by a genomic region that has also been 
identified as a susceptibility locus for SCZ and ADHD (Arcos-Burgos et al., 2004; 
Gurling et al., 2001), were both shown to be localised to dendritic spines and enriched 
at excitatory synapses. Overexpression of both proteins to model genetic 
microduplication of the genes led to alterations in dendritic complexity and spine 
morphology. Likewise, CYFIP1 haploinsufficiency, a model of microdeletion, resulted 
in more immature spines and reduced dendritic complexity. Interestingly, 
overexpression and haploinsufficiency of CYFIP1 has opposing effects on dendritic 
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complexity but the same effect on spine morphology highlighting the fact that CYFIP1 
must play different roles in the regulation of these vital neuronal structures. Live 
imaging experiments revealed that F-actin assembly was enhanced in 
haploinsufficient neurons implying that altered CYFIP1 levels dysregulate actin 
dynamics and this may contribute to the disrupted spine morphology observed when 
CYFIP1 gene dosage was altered. Overexpression of CYFIP1 was also shown to impact 
on the stability of inhibitory synapses resulting in a loss of gephyrin clusters and 
surface GABAARs. Intriguingly, overexpression of CYFIP1 also resulted in an increase 
in excitatory scaffold clusters suggesting that increased CYFIP1 protein levels could 
be impacting on the E/I balance of neuronal activity. This highlights another novel 
mechanism in which CYFIP1 might be acting on the synapse causing neuronal 
dysfunction.  
 
The second results chapter of this thesis used a genetic approach (Curtis, 2012) to 
identify novel variants in CYFIP1 and determine if they were associated with SCZ. 
CYFIP1 was shown to be significantly associated with SCZ due to an accumulation of 
rare potentially functionally-damaging variants identified within the gene in a cohort 
of SCZ patients compared to unaffected controls. Indeed, one particular SNP in 
CYFIP1 at position 15:22963816 was shown to be significantly associated with SCZ. 
Five candidate CYFIP1 SCZ-associated SNPs were selected on the basis that they may 
disrupt functionally critical CYFIP1 protein interactions. The SNPs were genotyped in 
an independent SCZ case-control cohort, however, none yielded a significant 
association. Functional analysis of these five CYFIP1 variants in cell biological assays 
revealed that individual SNPs did not appear to alter the synaptic localisation of 
CYFIP1 or its interactions with a member of the WRC. CYFIP1 KO models were also 
characterised within Chapter 4 and provide the first description of systems where 
complete loss of CYFIP1 has been studied. Initial observations from these models 
revealed complete loss of CYFIP1 appeared to reduce cell viability in fast dividing MEF 
cells and postnatal deletion of CYFIP1 in CA1 hippocampal neurons altered dendritic 
complexity.   
 
Lastly, in the final results chapter Ahi1, a protein known to be mutated in the 
neurodevelopmental disorder Joubert’s syndrome (JS) and associated with ASD and 
depression, was shown to colocalise with excitatory and inhibitory synaptic markers. 
A novel trafficking complex involving Ahi1 with the inhibitory synaptic trafficking 
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adaptor protein HAP1 and the motor KIF5 was identified in brain. The binding site of 
Ahi1 was mapped to the first coiled-coil domain of HAP1. Although Ahi1 has been 
implicated in a myriad of trafficking pathways, Ahi1 did not appear to alter the 
GABAAR trafficking function of HAP1 (Twelvetrees et al., 2010) and likewise had no 
direct effect on the trafficking of GABAARs to the membrane. However, knockdown of 
Ahi1 resulted in defects in dendritic complexity consistent with disrupted neuronal 
development observed in JS (Ferland et al., 2004). Finally, Ahi1 ASD associated 
mutations (Dixon-Salazar et al., 2004; Ferland et al., 2004; Retuerto et al., 2008; Yu 
et al., 2013) did not alter the ability of Ahi1 to interact with HAP1. That said, the 
synaptic localisation of Ahi1 revealed in Chapter 5 points towards a synaptic role for 
Ahi1 that may be disrupted by ASD associated mutations which requires further 
investigation. 
 
Together, the results presented in this thesis shed more light on the function of two 
neuropsychiatric disease associated proteins and provides increasing evidence of a 
critical role for disrupted synaptic function and altered dendritic complexity in the 
etiology of neuropsychiatric disorders such as ASD and SCZ. 
6.2 Regulation of synapse and dendritic 
morphology 
The formation and maintenance of neuronal connectivity is critical for normal brain 
function. Dendrites and dendritic spines undergo a process of dynamic development 
extending and contracting before finally becoming stabilised in the adult brain.  Loss 
or alterations in dendritic arbour and synapse stability are major contributing factors 
to the pathology of neuropsychiatric disorders. This altered synaptic connectivity is 
thought to contribute to the impaired cognition, memory and social behaviours that 
characterise these disorders (Kulkarni and Firestein, 2012).  
 
Regulation of the cytoskeleton is at the heart of maintaining dendritic and spine 
stability for normal neuronal communication. Dynamic actin turnover within 
dendritic spines is vital for their constantly changing morphology during development 
and plasticity and for maintaining the integrity of the synapse and the stability of 
receptors in the membrane (Bellot et al., 2014; Frost et al., 2010b; Hanley, 2014; 
Hotulainen and Hoogenraad, 2010). As global regulators of the actin cytoskeleton this 
heavily implicates RhoGTPases in the maintenance of spine and dendritic 
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Figure 6.1: CYFIP1 and Ahi1 in the regulation of dendritic morphology and 
synapse stability 
Diagram of the potential roles outlined in this thesis for CYFIP1 and Ahi1 in the regulation of 
dendritic and spine morphology. Protein interactions indicated by direct contacts or overlaps 
between shapes. (1) BDNF signalling via TrkB is known to regulate actin dynamics and 
promote Rac1 activation during spine plasticity changes and dendritic outgrowth. The WRC 
is a downstream effector of active Rac1 which brings about actin branching and 
polymerisation via activating Arp2/3. Rac1 likely signals to the WRC via CYFIP1 in dendritic 
spines and neurite tips to regulate morphology and F-actin turnover. (2) Additionally, CYFIP1 
is known to form complex with FMRP and e1F4e to regulate the local protein translation of 
FMRP target mRNA such as PSD95 and Arc at the base of spines. Correct expression of these 
mRNA is vital for spine stability. (3) Delivery of protein cargo from the soma to distal regions 
is necessary to replenish proteins for dendritic growth and stabilisation. An Ahi1/HAP1/KIF5 
trafficking complex could play a role in this function with Ahi1 being an adaptor for dendrite 
specific cargo. (4) Ahi1 and HAP1 are found in a complex with TrkB while HAP1 is known to 
interact with TrkA. The Ahi1/HAP1/KIF5 trafficking complex may also transport these 
neurotrophic receptors and regulate their membrane expression thus regulating dendritic 
outgrowth. (5) Finally, CYFIP1 is enriched at inhibitory synapses and likely regulates actin 
dynamics here. The WRC is probably tethered to gephyrin via a recently identified interaction 
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with Ena and VASP. Alternatively, CYFIP1 could recruit the WRC to Rac1 which is locally 
activated by the GEF βPIX tethered to the inhibitory synapse by GIT1. Ahi1 is also known to 
be present at excitatory and inhibitory synapses but its function within these compartments 
is still unknown. 
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morphology (Auer et al., 2011). In particular, Rac1 is required for spine stability as 
introduction of a Rac1 DN into hippocampal neurons in slices results in progressive 
spine loss (Nakayama et al., 2000). Among the downstream targets of Rac1 is WAVE, 
which as part of the WRC stimulates Arp2/3 activity bringing about actin nucleation 
and branch formation from existing actin filaments (Eden et al., 2002). WAVE1 
localises to dendritic spines and is critical for spine stability as knockdown or total 
loss of WAVE1 reduced spine density (Kim et al., 2006; Soderling et al., 2007). 
Activated Rac1 signals to the WRC via CYFIP1 placing CYFIP1 right at the centre of 
this vital pathway for spine stability (Chen et al., 2010b). It is not surprising this thesis 
reports that altered CYFIP1 expression levels severely impact on spine morphology. 
Furthermore, recruitment and activation of Rac1 is essential for inhibitory synapse 
stability (Smith et al., 2014). As CYFIP1 and the WRC are downstream effectors of 
active Rac1 it is likely CYFIP1 is playing a key role in actin regulation at the inhibitory 
synapses too. The enrichment of CYFIP1 at the inhibitory synapse and the altered 
gephyrin and GABAAR clusters following CYFIP1 overexpression presented here 
support this idea. 
 
Likewise, although development and maintenance of dendritic morphology relies 
heavily on MT dynamics, actin turnover is essential for membrane outgrowth and 
remodelling during neuronal development (Jan and Jan, 2010). Rac1 is known to play 
a critical role in neuronal outgrowth as Rac1 deficient cerebellar granule cells show 
impaired neurite extension and axon formation. Loss of Rac1 resulted in loss of WAVE 
recruitment to growth cones. This lead to reduced lamellipodia formation and actin 
dynamics which could be partially rescued by membrane targeted WAVE (Tahirovic 
et al., 2010). The presence of CYFIP1 is also necessary for the Rac1 induced membrane 
activity of WAVE (Steffen et al., 2004). It is likely these proteins all play key roles in 
the regulation of actin remodelling required during dendritic extension, thus, 
potentially explaining why altered CYFIP1 levels impact on dendritic morphology as 
described here. Alternatively, as CYFIP1 interacts with Rac1 solely in its active form 
(Kobayashi et al., 1998) then it could be hypothesised that CYFIP1 sequesters active 
Rac1 away from its critical roles in dendrite and spine stability. 
 
Interestingly, BDNF signalling via TrkB is known to have a crucial role in spine and 
dendritic stability (Cohen-Cory et al., 2010; Gupta et al., 2013). Indeed, two-photon 
imaging of transfected cells within the visual cortex showed overexpression of BDNF 
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induced increased dendritic branching in neighbouring cells (Horch and Katz, 2002). 
In the postsynaptic neuron many actin regulatory pathways central to spine 
stabilisation are modulated by BDNF. TrkB signalling increases the localisation of 
cortactin to spines where it can recruit Arp2/3 and bring about actin turnover and 
spine stability (Iki et al., 2005). TrkB signalling can also activate PAK via Rac1. Active 
PAK promotes LIMK1 activity resulting in increased inhibitory phosphorylation of 
cofilin which blocks actin depolymerisation, promotes spine enlargement and 
stabilisation (Dong et al., 2012; Rust et al., 2010). It is likely that CYFIP1 is playing a 
role in these pathways. For example, increased levels of CYFIP1 could be sequestering 
Rac1 away from this BDNF induced cofilin regulation resulting in destabilised 
immature spines as shown here in Chapter 3. Furthermore, others have suggested 
BDNF treatment, shifts CYFIP1 from a protein translation regulatory complex with 
FMRP to the WRC complex where it can bring about actin turnover and regulate spine 
structure (De Rubeis et al., 2013).  
 
Chapter 5 discussed how mutations or disrupted expression of Ahi1 might impact on 
its role with HAP1 in the stabilisation of internalised TrkB (Xu et al., 2010) leading to 
altered TrkB degradation. In this way, Ahi1 could also be implicated in BDNF induced 
spine and dendrite stability. Furthermore, it has been demonstrated here that Ahi1 
and HAP1 form a neuronal trafficking complex with the kinesin motor KIF5. 
Disrupting dendritic trafficking inhibits the ability of neurons to replenish proteins 
and sustain dendritic structure, therefore, has devastating effects on dendritic 
development, maintenance and stability. For example, loss of KIF5 by RNAi in 
hippocampal neurons resulted in reduced dendritic development due to a decline in 
the delivery of key trophic signalling receptors to the membrane (Hoogenraad et al., 
2005). Ahi1 may be involved with HAP1 in the regulation of KIF5 specific cargo 
necessary for synaptic function or dendritic development however, it has been shown 
here not to alter the membrane trafficking of GABAARs, a known cargo of HAP1 and 
KIF5 (Twelvetrees et al., 2010). Perhaps Ahi1 is involved in the HAP1 dependent 
trafficking of TrkA to growing neurite tips or perhaps Ahi1 and HAP1 are implicated 
in the trafficking of TrkB as both proteins are known to regulate its degradation (Rong 
et al., 2006; Xu et al., 2010). Both TrkA and TrkB are important in neuronal 
development. Indeed, ablation of TrkB receptors leads to shrinkage of cortical 
excitatory neuronal dendrites (Xu et al., 2000).  
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Finally, as well as components synthesised in the soma being trafficked to distal 
regions for dendritic growth and maintenance, local protein synthesis is also vital for 
the replenishment of molecular structures to maintain spine and dendritic integrity 
(Jan and Jan, 2010). Loss of local mRNA regulation has been shown to alter the 
expression levels of synaptic proteins and disrupts synapse development (Bassell and 
Warren, 2008). PSD95 mRNA is known to accumulate along dendrites and at 
synapses (Zalfa et al., 2007). PSD95 mRNA translation has been directly visualised 
recently in dendrites and spines at the single molecular level and was shown to be 
disrupted in a mouse model of FXS. The altered expression of such a key PSD protein 
is thought to contribute to the immature spine phenotype observed in FXS (Ifrim et 
al., 2015). Local translation is also necessary to cope with the extra protein synthesis 
burden induced upon neuronal activity and plasticity changes. Arc (activity-regulated 
cytoskeletal associated protein) mRNA is another dendritically targeted mRNA that 
accumulates at activated synapses in response to stimuli such as BDNF (Steward and 
Worley, 2001). Correct Arc expression has been shown to be vital for synaptic 
plasticity and the regulation of actin dynamics (Guzowski et al., 2000; Plath et al., 
2006). Reduced Arc levels occluded BDNF induced LTP and decreases F-actin 
formation in spines (Messaoudi et al., 2007). Interestingly, both PSD95 and Arc are 
FMRP target mRNAs. CYFIP1 is known to regulate the expression of FMRP targets as 
it forms a translational repressor complex with eIF4e (Napoli et al., 2008). Therefore, 
the spine and dendritic morphology defects observed here when CYFIP1 dosage is 
altered could be the result of misregulated local protein translation of genes such as 
PSD95 and Arc. Indeed, others have shown disrupted Arc protein levels in CYFIP1 
haploinsufficient mice (De Rubeis et al., 2013). 
 
Taken together, the data in this thesis supports a role for CYFIP1 and Ahi1 in the 
regulation of dendritic stability and a role for CYFIP1 in regulating spine dynamics. 
The underlying mechanisms are still not fully understood however, the pathways 
suggested to be involved in this discussion are summarised in Figure 6.1. Additionally, 
the data here suggests genetic mutations or alterations in the expression of CYFIP1 or 
Ahi1 may disrupt this normal dendritic and spine morphology which could be 
contributing to the pathogenesis of neuropsychiatric disorders associated with these 
genes. 
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6.3 Genetic risk for psychiatric disorders: 
convergence on synaptic pathways 
The chief motivation for studying psychiatric genetics is to identify the biological 
processes involved in the pathogenesis of these conditions, in an attempt to 
understand more about the disorders and potentially reveal novel therapeutic targets. 
From this type of research, it is emerging that many of the genes associated with 
disorders such as SCZ, ASD, MR and ID are converging on the same pathways; in 
particular the regulation of synapse stability and plasticity (Berg and Geschwind, 
2012; Hall et al., 2015). Numerous synaptic scaffold molecules have been implicated 
in neuropsychiatric disorders such as the SHANK proteins which are integral to the 
excitatory PSD and the NL adhesion proteins which promote synapse formation and 
stability (Guilmatre et al., 2014; Südhof, 2008). Indeed, mutations in over 200 genes 
encoding PSD proteins are known to result in over 130 human brain disorders (Grant, 
2012). Additionally, risk genes are also known to converge on regulators of synaptic 
actin dynamics. Mutations associated with MR are found in PAK3, translocations in 
DISC1 underlie familial SCZ and genetic variations in oligophrenin1 are associated 
with SCZ, all these protein are known to impact on actin dynamics (Hayashi et al., 
2004; Hayashi-Takagi et al., 2010; Ito et al., 2010).  
 
This thesis has shed light on the biological roles of two genes, CYFIP1 and Ahi1, which 
have both been linked to neuropsychiatric disorders via CNVs and rare single 
nucleotide risk variants (Table 3.1) (Amann-Zalcenstein et al., 2006; Brett et al., 2014; 
Ingason et al., 2010; Retuerto et al., 2008; Rivero et al., 2010; Torri et al., 2010). With 
the mounting evidence that synaptic function is intimately connected to the 
pathogenesis of neuropsychiatric disorders it is not surprising that both proteins have 
been shown here to be colocalised with synapses. Indeed, data presented in this thesis 
strongly suggests CYFIP1 is involved in the regulation of actin at dendritic spines and 
is critical for normal spine morphology. Thus, CYFIP1 is another psychiatric disease-
associated gene that can be added to the list converging on regulators of synaptic actin 
dynamics. Furthermore, the effect CYFIP1 overexpression has on inhibitory and 
excitatory synaptic clusters points towards CYFIP1 functioning in the regulation of 
the E/I balance. This is another synaptic regulatory pathway onto which 
neuropsychiatric disease associated genes such as PTEN, TSC1 and CNTNAP2 appear 
to be converging (Bateup et al., 2013; Luikart et al., 2011; Peñagarikano et al., 2011; 
Südhof, 2008). Further work will be required to determine if the synaptic localisation 
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of Ahi1 implicates the protein in synaptic regulation.  
 
Many neuropsychiatric disorders are now being coined synaptopathies due to the vast 
numbers of synaptic genes implicated in these disorders and the observations from 
anatomical studies (Grant, 2012). It is hoped that by grouping disorders in this way, 
based on common molecular pathways, the most significant targets for therapeutic 
intervention will and are beginning to be uncovered. That said, many of the emerging 
pathways appear to be proving challenging drug targets. Indeed, there have been few, 
if any novel drugs developed to target psychiatric disorders in the last 40 years 
(Geschwind and State, 2015). One issue seems to be that modulating pathways such 
as regulators of actin dynamics would have vast off-target effects in other brain and 
bodily regions. However, generating drugs to target one particular pathway could be 
far too simplistic. Data in this thesis reveals that dendritic morphology is also 
disrupted when expression of both Ahi1 and CYFIP1 is altered. Furthermore, Ahi1 may 
also impact trafficking mechanisms although a precise cargo has not been resolved in 
this study. Numerous other factors have been put forward to contribute to the 
pathogenesis of neuropsychiatric disorders such as altered connectivity and 
trafficking defects as suggested here, altered nutrition and oxidative stress, 
inflammation and environmental factors (Compart, 2013). Therefore, like cancer 
treatments, personalised medicine is becoming increasingly popular for the treatment 
of psychiatric disorders in an attempt to combat the combination of pathogenic 
factors involved (Hamilton, 2015). It appears that coupling genetic sequencing to 
reveal affected genes with combination therapies is a more realistic approach. It 
seems clear that research is moving into the era of complexity and that all angles of 
neuronal dysfunction must be considered to fully understand disease pathogenesis 
and design novel therapies. 
 
As a final comment it remains a puzzling question in the field as to why, when there 
is such a lot of genetic and mechanistic overlap in the factors contributing to 
neuropsychiatric disorders, the actual characteristics of the disorders themselves can 
manifest so differently in humans. For example, how is it that disrupted spine and 
dendritic morphology as well as genetic alterations in synaptic proteins are 
considered pathological mechanisms of both ASD and SCZ and yet the onset and 
clinical appearances of these two disorders are very distinct? This question remains 
to be answered. Almost certainly, neuropsychiatric phenotypes are modified by the 
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patient’s genetic background, the time of dysfunction onset and experiences 
throughout life. As mentioned above the answers probably lie within the complexities 
of each individual disorder and with continued research getting to grips with this 
question may become achievable.  
6.4 Future directions 
It is evident that the mechanisms by which CYFIP1 brings about morphological 
changes in neurons still remains to be fully elucidated. Others have attempted to 
investigate this by using CYFIP1 deletion mutants that either disrupt the interaction 
between CYFIP1 and NAP1 or eIF4e. These mutations uncouple the actin regulation 
and translational regulation roles of CYFIP1 respectively. The group showed that both 
pathways were important for CYFIP1’s role in spine formation as neither mutant 
could rescue the immature spine phenotype observed in CYFIP1 knockdown 
conditions (De Rubeis et al., 2013). It would be interesting to carry out similar 
experiments to determine which functions of CYFIP1 are important in maintaining 
dendritic complexity. A recent paper has shown that rapamycin an inhibitor of the 
mTOR pathway can rescue dendritic morphology defects observed in CYFIP1 knock-
in mice (Oguro-Ando et al., 2014). The mTOR pathway promotes protein synthesis 
therefore, this points towards the role of CYFIP1 in the regulation of protein 
translation being important in regulating dendritic morphology but the precise 
mechanism is still to be determined. Importantly, identifying if there is a CYFIP1-
dependent actin involvement in this process would enhance our understanding of this 
pathway. 
 
It is shown here that constitutive haploinsufficiency in CYFIP1 led to a decrease in 
dendritic complexity in DIV14 cultured neurons (experiment carried out by Dr. 
Manav Pathania) while postnatal cKO of CYFIP1 in neurons increased basal dendritic 
complexity in adult CA1 pyramidal cells. These opposing results suggest CYFIP1 may 
play different roles during dendritic development and maintenance. Currently, others 
have profiled CYFIP1 expression during development but not addressed CYFIP1 
function at different developmental time points (Bonaccorso et al., 2015; De Rubeis 
et al., 2013). Using the genetic models characterised here and the power of different 
Cre drivers to conditionally KO CYFIP1 at various developmental time points it would 
be interesting to try and determine whether CYFIP1 has distinct functions during 
neuron development and maintenance. As an alternative hypothesis perhaps the loss 
 
Final Discussion 
 
 247 
of CYFIP1 in non-neuronal cells in the constitutive haploinsufficient model explains 
the differences between the dendritic complexity patterns of the two genotypes. 
Altered astrocyte function is known to impact on dendritic morphology in 
neuropsychiatric disorders (Molofsky et al., 2012; Sloan and Barres, 2014). Therefore, 
exploring the role of CYFIP1 in astrocytes and how altered CYFIP1 expression in these 
cells might impact on dendritic morphology is an intriguing question. 
 
Experiments in Chapter 3 demonstrate that overexpression of CYFIP1 has opposing 
effects on the cluster size of excitatory and inhibitory synaptic structural molecules.  
The role of CYFIP1 in regulating excitatory and inhibitory synaptic size and number 
warrants much further examination. Indeed, the CYFIP mutants that uncouple its role 
in actin and translation could be again used to determine which of CYFIP1’s functions 
cause these effects. The data presented here suggests that CYFIP1 overexpression may 
upset the E/I balance and it would be interesting to confirm this hypothesis 
electrophysiologically. Additionally, looking at how synaptic clusters are effected in 
the haploinsufficient neurons may also help illuminate how CYFIP1 is involved in 
synapse stability. Considerable research has focussed on the role of CYFIP1 in 
dendritic and spine morphology and how this might provide a mechanism for the 
genetic association of Cyfip1 with ASD and SCZ (Bozdagi et al., 2012; Oguro-Ando et 
al., 2014; De Rubeis et al., 2013). Unravelling a role for CYFIP1 in maintaining the E/I 
balance links CYFIP1 to another mechanistic pathway which is increasingly being 
thought to underlie neuropsychiatric disorders such as ASD, epilepsy and TS (Bateup 
et al., 2013; Gkogkas et al., 2013; Luikart et al., 2011; Peñagarikano et al., 2011).  
 
The function of CYFIP1 at the inhibitory synapse is totally unexplored. Does CYFIP1 
play a role in regulating actin dynamics at these synapses? Although actin is known 
be important at the excitatory synapse (Bellot et al., 2014) far less is known about how 
actin dynamics regulate the inhibitory synapse however, this is an emerging field. 
Some studies suggest that actin is involved in both the movements of gephyrin (Hanus 
et al., 2006; Kirsch and Betz, 1995) and the traﬃcking of GABAARs (Graziane et al., 
2009; Meyer et al., 2000). Recently, Rac1 was shown to be recruited to inhibitory 
synapses via a protein complex involving GIT1 and βPIX and this recruitment was 
necessary for synapse stability (Smith et al., 2014). It would be interesting to know if 
CYFIP1 and the WRC can act downstream of Rac1 in this pathway.  Preliminary data 
not discussed in this thesis shows that CYFIP1 can be coimmunoprecipitated with 
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GIT1 and βPIX when overexpressed in cell lines. Furthermore, a Mena/VASP protein 
complex is found at inhibitory synapses (Giesemann et al., 2003) which has recently 
been shown to interact with and cooperatively regulate the WRC (Chen et al., 2014b), 
highlighting that CYFIP1 and the WRC may indeed function at inhibitory synapses. 
Defects in inhibitory synapse structure and function are strongly associated with 
epilepsy which has been shown to be associated with CNV of the CYFIP1 region of the 
genome (de Kovel et al., 2010). Moreover, CYFIP1 mRNA and protein levels have 
recently been shown to be upregulated in temporal lobe tissue of patients with 
temporal lobe epilepsy (Huang and Chen, 2015). These findings support an as yet 
unknown role for CYFIP1 in inhibitory synaptic function. 
 
Attempts have been made in Chapter 4 of this thesis to characterise novel CYFIP1 KO 
systems. These KO models provide an excellent platform to unpick the biological 
functions of CYFIP1. In vitro experiments have shown that CYFIP1 is vital in the 
regulation of WAVE and Arp2/3 activity (Chen et al., 2010b) however, little is known 
about how this regulation impacts on cellular function. In CYFIP1 KO MEFs the role 
of CYFIP1 in cell division and migration could be explored similarly to experiments 
carried out in other WRC protein KO or knockdown cells (Dubielecka et al., 2011; 
Steffen et al., 2004). CYFIP1 KO systems also provide a powerful tool for studying the 
effects of the SCZ-associated CYFIP1 variants identified in this study. Rescue 
experiments comparing the mutant variants to WT could be carried out to determine 
whether the variants alter CYFIP1 function both in neurons and MEFs. Alternatively, 
overexpression experiments with the mutants could be performed to study the impact 
of CYFIP1 disease associated variants on synapses. Similar experiments have recently 
been carried out for novel SHANK2 SCZ-associated variants (Peykov et al., 2015). 
 
Finally, there is still much to be understood about the role of Ahi1 in neurons. The 
finding that Ahi1 forms a novel trafficking complex in brain with HAP1 and KIF5 
raises the possibility of future research opportunities. Although here it is shown that 
Ahi1 is not involved in the trafficking of GABAARs, Chapter 5 has demonstrated this 
protein is localised to excitatory and inhibitory synapses. Perhaps Ahi1 is involved in 
the trafficking of different cargo. A screen for novel of Ahi1 interacting proteins using 
immunoprecipitation from brain lysate and mass spectrometry analysis to reveal the 
interacting proteins would provide new avenues to study. Furthermore, Ahi1 is known 
to impact on cilia stability (Hsiao et al., 2009) and cilia have been compared to spines 
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(Nechipurenko et al., 2013). It would be very interesting to determine if altered Ahi1 
levels or Ahi1 autism mutants could impact on spine morphology, a phenotype widely 
considered in ASD pathology. Finally, here Ahi1 knockdown is shown to disrupt 
dendritic complexity. Determining what role Ahi1 plays in the regulation of dendritic 
complexity and whether this role is developmentally regulated would be an exciting 
prospect. After all, JS, the condition caused by loss of Ahi1, is a neurodevelopmental 
disorder. As previously discussed, validating whether the trafficking of TrkA or TrkB 
receptors are involved would be of great interest. 
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Figure A.1: Dendritic morphology of CA1 hippocampal neurons in adult 
CYFIP1+/- mice. 
Golgi-stained CA1 neurons from Cyfip1+/− and WT littermate controls (P55–60) were traced 
to analyse dendritic morphology. (A) Example traces of Cyfip1+/− and WT neurons. (B) Sholl 
analysis indicates that Cyfip1+/− neurons are significantly less complex within 100μm from 
the soma, in the apical compartment and trending towards significance in the basal 
compartment, compared with WT control neurons (n=9–12 cells per condition, 22-way 
ANOVA, *p<0.05). Experiment carried out by Dr. Manav Pathania. 
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Table B.1: Weighted burden analysis output for Cyfip1 in the UK10K dataset 
Locus 
Unaffected  
Genotypes 
Case  
Genotypes Weight Variant Effect 
Allele 
Change 
Residue 
Change 
Functional 
Prediction 
p 
value 
 AA AB BB MAF AA AB BB MAF       
22928169 982 0 0 0 1391 1 0 0.000359 24.98 
non-
synonymous cTg/cCg L/P 
probably 
damaging 0.401 
22928190 981 1 0 0.000509 1392 0 0 0 24.98 
non-
synonymous tCc/tTc S/F 
probably 
damaging 0.234 
22933663 950 32 0 0.016293 1355 37 0 0.01329 11.78 splice-site   
 
unknown 0.394 
22933749 981 1 0 0.000509 1392 0 0 0 12.49 splice-site   
possibly 
damaging 0.234 
22933848 982 0 0 0 1391 1 0 0.000359 24.98 
non-
synonymous aCg/aTg T/M 
possibly 
damaging 0.401 
22940721 979 3 0 0.001527 1391 1 0 0.000359 12.46 splice-site   
 
unknown 0.172 
22940807 982 0 0 0 1390 2 0 0.000718 24.96 
non-
synonymous Cgc/Tgc R/C 
possibly 
damaging 0.235 
22947019 982 0 0 0 1390 2 0 0.000718 24.96 
non-
synonymous aGc/aAc S/N benign 0.235 
22947045 982 0 0 0 1391 1 0 0.000359 24.98 
non-
synonymous Cgc/Tgc R/C 
probably 
damaging 0.401 
22954273 982 0 0 0 1391 1 0 0.000359 24.98 
non-
synonymous Gcc/Acc A/T benign 0.401 
22954276 982 0 0 0 1391 1 0 0.000359 24.98 
non-
synonymous Atc/Gtc I/V 
possibly 
damaging 0.401 
22954334 981 1 0 0.000509 1392 0 0 0 24.98 
non-
synonymous cCg/cTg P/L benign 0.234 
22955174 981 1 0 0.000509 1392 0 0 0 24.98 non- aCg/aTg T/M possibly 0.234         
  
2
9
8
 
synonymous damaging 
22956327 979 3 0 0.001527 1391 0 0 0 24.94 
non-
synonymous Ccc/Tcc P/S unknown 0.039 
22956358 982 0 0 0 1391 1 0 0.000359 24.98 
non-
synonymous tCt/tTt S/F unknown 0.401 
22960795 981 1 0 0.000509 1392 0 0 0 12.49 splice-site   
probably 
damaging 0.234 
22962425 982 0 0 0 1391 1 0 0.000359 12.49 splice-site   
 
unknown 0.401 
22962514 981 1 0 0.000509 1392 0 0 0 24.98 
non-
synonymous cGc/cAc R/H 
possibly 
damaging 0.234 
22963782 982 0 0 0 1391 1 0 0.000359 24.98 
non-
synonymous Cgt/Agt R/S benign 0.401 
22963816 982 0 0 0 1385 7 0 0.002514 24.85 
non-
synonymous tAt/tGt Y/C benign 0.026 
22963869 976 6 0 0.003055 1377 15 0 0.005388 24.56 
non-
synonymous Ata/Gta I/V 
probably 
damaging 0.234 
22969154 978 4 0 0.002037 1387 3 0 0.001079 12.43 splice-site   
 
unknown 0.397 
22969215 982 0 0 0 1391 1 0 0.000359 24.98 
non-
synonymous cGg/cAg R/Q benign 0.401 
22969251 982 0 0 0 1391 1 0 0.000359 24.98 
non-
synonymous cGg/cAg R/Q 
possibly 
damaging 0.401 
22969353 982 0 0 0 1391 1 0 0.000359 24.98 
non-
synonymous tCt/tGt S/C 
probably 
damaging 0.401 
22990053 981 1 0 0.000509 1392 0 0 0 12.49 splice-site   
 
unknown 0.234 
22990087 975 7 0 0.003564 1371 21 0 0.007543 24.41 
non-
synonymous Ggc/Agc G/S benign 0.078 
22990190 981 1 0 0.000509 1392 0 0 0 24.98 non- gTc/gCc V/A benign 0.234 
  
2
9
9
 
synonymous 
22993010 982 0 0 0 1391 1 0 0.000359 12.49 splice-site   
 
unknown 0.401 
22993121 954 27 1 0.014766 1340 51 1 0.019037 23.3 
non-
synonymous gCc/gTc A/V 
possibly 
damaging 0.266 
22993158 981 1 0 0.000509 1392 0 0 0 12.49 splice-site   
 
unknown 0.234 
22997793 977 5 0 0.002546 1386 6 0 0.002155 12.38 splice-site   
 
unknown 0.783 
22999320 981 1 0 0.000509 1390 2 0 0.000718 12.47 splice-site   
 
unknown 0.778 
22999403 980 2 0 0.001018 1391 1 0 0.000359 24.94 
non-
synonymous aTg/aCg M/T benign 0.373 
22999408 981 1 0 0.000509 1392 0 0 0 24.98 
non-
synonymous Gag/Cag E/Q 
possibly 
damaging 0.234 
22999457 982 0 0 0 1391 1 0 0.000359 24.98 
non-
synonymous cGc/cAc R/H benign 0.401 
23000084 981 1 0 0.000509 1392 0 0 0 12.49 splice-site Cct/Gct P/A 
 
benign 0.234 
23000091 982 0 0 0 1390 2 0 0.000718 12.48 splice-site   
 
unknown 0.235 
23002876 982 0 0 0 1391 1 0 0.000359 12.49 splice-site   
 
benign 0.401 
23002888 982 0 0 0 1391 1 0 0.000359 24.98 
non-
synonymous Atg/Gtg M/V benign 0.401 
 
 
Output from SCOREASSOC for the analysis of Cyfip1 using the narrow category of variants and treating SCZ subjects as cases. The table shows 
genotype counts, frequencies, weights and effects for each variant. The weighted scores were calculated for each subject and the means compared. 
Mean scores unaffected = 1.904, cases = 2.415, *p = 0.0487) 
